https://www.biopharmawatch.com/news/AZTR/azitra-announces-q3-2025-results-business-updates2025-11-12T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q3-2025-financial-results-update2025-11-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-2-trial-results2025-10-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-positive-data-phase-1-2-trial-ide397-trodelvy2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-hengrui-positive-phase-1-data-ide849-sclc2025-09-07T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-q3-2025-results-novartis-merger2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-2025-financial-guidance-and-reports-results2025-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-q1-2025-financial-results2025-05-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-phase-2-trial-lti-03-ipf2025-10-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2025-financial-results-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-q3-20252025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q3-2025-financial-results2025-11-06T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-q3-2025-financial-results2025-11-10T21:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-jefferies-global-healthcare-conference-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-investor-conferences-20252025-08-20T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-bge-102-phase-1-trial-obesity2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-preclinical-data-apj-agonism-diabetic-obesity2025-06-21T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-expands-drug-discovery-platform2025-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-business-update-progress-h1-20252025-08-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-year-end-2024-financial-results2025-04-07T21:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-research-annamycin-pancreatic-cancer2025-11-12T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-phase-3-miracle-trial-acute-leukemia-meeting2025-10-30T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-expands-global-ip-portfolio-anamycin-patent2025-10-29T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-canadian-patent-annamycin2025-09-25T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-eu-patient-phase-3-miracle-trial-aml2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-warrant-exercise-6-million2025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-positive-aml-survival-data2025-08-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-webull-financial-webinar2025-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-q3-2025-results-update2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conference-participation2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inducement-grants-nasdaq-rule-56352025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-q3-2025-results2025-11-04T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-second-milestone-payment-kyowa-kirin2025-11-03T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-ash-2025-ziftomenib-data-presentation2025-11-03T14:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-30-million-milestone-ziftomenib-aml2025-10-24T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-esmo-2025-data2025-10-18T07:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-kin-launch-clinical-trial-aml2025-10-01T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-q3-2025-results-share-repurchase2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-positive-topline-phase-1-2-results-shingles-vaccine2025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-reports-q2-2025-financial-results2025-08-07T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-therapeutics-q1-2025-results-update2025-05-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-reschedules-q1-2025-results-release-and-call2025-05-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q3-2025-results2025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-q3-2025-financial-results-business-update2025-11-06T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-leadership-transition-plan2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-pdufa-date-lnth-2501-pet-imaging-kit2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-acceptance-mk-6240-alzheimers-imaging-agent2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-third-quarter-2025-earnings-call2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-ge-healthcare-licensing-agreement-pylaryfiy-japan2025-09-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-morgan-stanley-healthcare-conference-20252025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-acceptance-nda-psma-pet-imaging-agent2025-08-06T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-ptk7-target-aacr-nci-eortc2025-10-24T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-reports-q1-2025-financial-results2025-05-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-third-quarter-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-preliminary-q2-2025-results2025-01-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-q2-2025-financial-results2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-q3-2025-update2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-investor-conferences-20252025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-arid1b-cbp-ep300-updates2025-10-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-arid1b-degrader-progress-summit2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-citizens-life-sciences-conference2025-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-board-appointments2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-q1-2025-results-ayvakit-guidance2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-q4-2024-results2025-02-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-2025-outlook-growth-strategy2025-01-12T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-third-quarter-2025-results-update2025-11-13T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-q3-2025-financial-results-business-update2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-presentation-hc-wainwright-conference2025-08-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-acquisition-novartis-q1-2025-results2025-05-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-q3-2025-financial-results2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-denifanstat-posters-aasld-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/denifanstat-phase-3-acne-trial-results-china2025-10-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-investor-conferences-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-aasld-2025-presentation2025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-phase-1-trial-denifanstat-resmetirom2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-fierce-biotech-week-panel2025-09-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/positive-phase-3-results-denifanstat-acne-eadv-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-mash-summit-20252025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-first-quarter-results-20252025-05-13T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-closes-public-offering-senior-notes2025-09-29T12:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-pricing-euro-1-5-billion-senior-notes2025-09-15T21:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-q3-2025-financial-results2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-pth-renal-function-improvements-hypoparathyroidism2025-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-submits-maa-transcon-cnp-achondroplasia2025-10-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-endocrinology-rare-disease-data-asbmr-20252025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-2025-wells-fargo-conference2025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/fda-approves-skytrofa-growth-hormone-deficiency2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-ks101-apex-study-week-20-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-ksi-101-apex-study-results2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q2-2025-results-highlights2025-08-13T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-first-patient-arcevo-lsa-artizen-trial2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-stifel-2025-healthcare-conference2025-10-29T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-q3-2025-financial-results-teleconference2025-10-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-amds-persevere-protect-trials-eacts-presentation2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-morgan-stanley-healthcare-conference2025-09-05T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-participate-upcoming-investor-conferences2025-07-30T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-new-executive-committee-members-leadership-expansion2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-us-government-obesity-medicines-access2025-11-06T18:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-eloralintide-phase-2-results-weight-loss2025-11-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-new-european-manufacturing-facility2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-q3-2025-financial-results2025-10-30T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-inversion-puerto-rico-capacidad-manufactura2025-10-29T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-invests-1-2-billion-puerto-rico-manufacturing2025-10-29T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-q3-2025-financial-results2025-11-05T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-q3-2025-results-corporate-update2025-11-06T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-q3-2025-results-and-progress2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-financing-support-growth-sentry-trial2025-10-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2025-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-q3-2025-financial-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-data-asds-20252025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-q3-2025-financial-results2025-10-31T11:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-phase-3-results-upadacitinib-vitiligo2025-10-29T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-superiority-humira-rheumatoid-arthritis-study2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-acquires-gilgamesh-bretisilocin2025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-updated-indication-rinvoq2025-10-13T14:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-esmo-2025-targeted-therapies2025-10-13T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-q3-2025-financial-results-merger-divestment-plan2025-10-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-second-quarter-2025-financial-results2025-08-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-first-quarter-2025-results-divestment-plan2025-05-15T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q3-2025-financial-results2025-11-06T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q1-2025-financial-results-update2025-04-30T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q3-2025-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-presents-ap-sa02-idweek-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q3-2025-results2025-11-05T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-us-patent-endoxifen-formulations2025-04-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-smart-2-0-study-breast-cancer2025-04-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-2024-financial-results-update2025-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fourth-quarter-2024-results2025-03-20T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-metastatic-breast-cancer-endoxifen2025-03-11T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-congratulates-dr-tessa-cigler-cdc-grant2025-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-responds-ptab-ruling-patent-issuance2025-01-30T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-2024-accomplishments-outlook-20252025-01-23T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-abstracts-z-endoxifen-sabcs-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-q3-2025-financial-results-updates2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-d-boral-conference2025-05-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-q1-2025-financial-results2025-05-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-q1-2025-earnings-release-webcast2025-04-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-fireside-chat-november-20252025-10-30T17:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-q1-fy2026-results-corporate-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-investor-conferences-2025-ash2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-update-q3-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-049-ash-20252025-11-03T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-978-preclinical-data-acr-20252025-10-25T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fireside-chat-stifel-2025-forum2025-09-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-licenses-velinotamig-autoimmune-diseases2025-06-04T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-2025-asco-jefferies-conference2025-05-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-taiho-positive-results-rezilient1-trial2025-05-22T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-first-half-2025-results2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-phase-2-study-opaganib-darolutamide2025-07-01T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-reports-record-q3-2025-results-im8-growth2025-11-10T12:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q3-2025-financial-results-earnings-call2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-record-revenue-october-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-acquires-100-bitcoin-im8-reaches-100m-arr2025-10-31T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-dual-engine-revolution-manifesto2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-closes-44-million-equity-offering2025-10-28T18:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-48-million-equity-offering-im8-expansion2025-10-27T14:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-global-limited-public-offering2025-10-25T00:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-launches-daily-ultimate-longevity-supplement2025-10-08T12:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-q3-2025-results-financial-guidance2025-11-06T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q3-2025-results-business-updates2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-presentation-td-cowen-summit2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-september-2025-investor-conferences2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-closes-underwriters-option2025-08-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-public-offering-pricing2025-08-07T03:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-public-offering-20252025-08-06T20:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-hypoimmune-modified-islet-cells2025-08-04T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-positive-results-type-1-diabetes2025-06-23T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-ada-scientific-sessions-20252025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-q3-2025-financial-results-highlights-milestones2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-jefferies-2025-london-healthcare-conference2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-100-million-offering-common-stock2025-11-06T11:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-positive-data-phase-1-2-prism-trial-wet-amd2025-11-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-licensing-agreement-otsuka-pharmaceutical2025-10-31T03:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-employment-inducement-grants2025-10-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-chardan-genetic-medicines-conference2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-advances-4d-710-phase-2-funding-cystic-fibrosis-foundation2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-leadership-expansion-bla-readiness2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-felzartamab-asn-kidney-week-20252025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/health-canada-authorization-leqembi-lecanemab2025-10-26T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-licenses-c5ar1-antagonist-vanqua-bio2025-10-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-dapirolizumab-pegol-acr-convergence-20252025-10-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-iqlik-best-inventions-20252025-10-13T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-new-data-zorevunersen-dravet-syndrome2025-10-09T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-iqlik-launch-alzheimers-treatment2025-10-06T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-iv-maintenance-dosing-china2025-09-28T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-alzheimers-treatment-australia2025-09-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-regulatory-update-nusinersen-high-dose-regimen2025-09-23T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reschedules-q2-2025-results-release2025-08-13T22:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-fast-track-nrx-1002025-08-11T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-nrxp-dura-medical-acquisition-clearance2025-08-08T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-citizen-petition-benzethonium-chloride2025-08-04T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fireside-chat-btig-conference-20252025-07-29T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-nrxp-acquires-cohen-associates2025-06-26T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-files-cnpv-application-nrx-1002025-06-23T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-investor-partnership2025-06-16T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-hc-wainwright-conference2025-06-12T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-files-anda-preservative-free-ketamine2025-06-05T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-q3-2025-results-guidance-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-third-quarter-2025-earnings-call2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-investor-conferences-september-20252025-08-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-q1-2025-results2025-05-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-needham-healthcare-conference-20252025-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-participate-keybanc-healthcare-forum2025-03-07T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-fourth-quarter-2024-results-guidance2025-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-investor-conferences2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-first-quarter-fiscal-2026-results2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-nov-20252025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-conference-call-november-20252025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-q3-2025-financial-results2025-11-10T11:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-q3-2025-results-corporate-update2025-11-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-reports-revenue-growth2025-11-04T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q3-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-2101-abstracts-aes-20252025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-third-quarter-financial-results-november-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/medicare-advantage-plan-rewalk-7-exoskeleton2025-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ce-mark-approval-rewalk-7-exoskeleton2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-q2-2025-financial-results2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-almog-adar-cfo2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-expands-distribution-partnership-uae-gcc2025-08-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-closes-2-6-million-public-offering2025-06-26T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-2-6-million-public-offering2025-06-25T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-exoskeleton-medicare-coverage2025-06-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-q3-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-q1-2025-financial-results2025-05-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-q3-2025-results-business-update2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-ceo-transition-plan-growth2025-11-05T11:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-participate-investor-conferences2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-report-q2-2025-results-august-52025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-acquires-rev102-enpp1-inhibitor-hpp2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/mit-recursion-boltz-2-ai-model-binding-affinity2025-06-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/duncan-regional-hospital-bd-alaris-emr-interoperability2025-11-13T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-purewick-portable-solution-urinary-incontinence2025-11-12T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-fiscal-2025-financial-results2025-11-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-dividend-increase-54th-year2025-11-06T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-agility-study-revello-stent-pad2025-11-04T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-fda-clearance-ce-certification-enteric-panels2025-11-03T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-simplifies-at-home-hpv-testing2025-10-22T10:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-enabled-solutions-healthcare2025-10-20T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-manufacturing-excellence-broken-bow-anniversary2025-10-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-cfo-transition-plan2025-10-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-alphaledger-t12-fund-investment2025-10-29T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-update-ptsd-drug-development2025-10-23T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-bitcoin-purchase-strategic-growth2025-10-08T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-acquires-researchcoin-support-decentralized-science2025-10-06T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-closes-2-5-million-offering2025-10-01T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-fireblocks-strategic-agreement2025-09-29T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-cryptocurrency-treasury-strategy2025-09-16T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-japanese-patent-ptsd-drug2025-09-09T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards2025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q3-2025-financial-results-update2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-positive-phase-1-results-spy0032025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-upcoming-investor-conferences-november-20252025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-acr-convergence-20252025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-316-million2025-10-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-pricing2025-10-14T01:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-public-offering-common-stock2025-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-poster-presentations-uegw-20252025-10-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2025-financial-results2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-third-quarter-2025-financial-results2025-11-05T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/hifi-solves-consortium-publishes-study-pacbio2025-11-05T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-berry-genomics-regulatory-approval-china2025-11-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-revio-vega-advancements-lower-genome-cost2025-10-14T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-hifi-technology-south-korea-pangenome-project2025-10-13T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-hifi-sequencing-longevity-study2025-10-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-expands-partnership-seqwell-long-read-sample-prep2025-10-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-high-throughput-carrier-screening-assay2025-09-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-epicypher-partner-fiber-seq-workflow2025-09-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-regulatory-clearance-art100-uae2025-11-06T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-bites-ai-strategic-alliance2025-10-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-appoints-new-vp-and-board-member2025-10-21T19:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-h1-2025-results-business-update2025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-hyla-blood-sensor-us-elsoconference2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-hyla-blood-sensor-fda-submission2025-09-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspiratechnologies-expands-art100-lung-transplant2025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-patent-approval-art500-technology2025-08-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-secures-27-million-order-art100-systems2025-08-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q3-2025-results-update2025-11-13T02:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-snda-fda-filspari-fsgs2025-03-17T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-inducement-grants-nasdaq-rule-56352025-03-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-investor-conferences-march-20252025-02-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-q4-2024-financial-results2025-02-20T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-2025-outlook-update2025-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-jp-morgan-conference-20252025-01-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-ipo-submission-aspi2025-11-12T22:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-private-placement-convertible-notes2025-11-07T14:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quantum-leap-energy-engagement-uk-regulators2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-acquires-one-30-seven-assets2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-public-offering-pricing2025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-business-updates-october-20252025-10-13T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-institutional-investor-event-south-africa-20252025-10-10T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-purchase-order-enriched-barium-1372025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-executive-management-changes-october-20252025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-financial-results-q2-20252025-05-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-annual-general-meeting-results2025-03-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q2-2025-financial-results2025-08-08T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q1-2025-financial-results2025-05-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-reports-fiscal-q3-2025-results2025-08-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-q3-2025-results2025-11-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-q3-2025-results-update2025-11-05T21:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-biospace-best-places-to-work2025-11-04T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-jefferies-conference-20252025-11-03T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-scientific-conferences-20252025-10-09T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-share-repurchase-program2025-10-01T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-investor-conferences-20252025-08-28T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-settlement-firdapse-patent-litigation2025-08-26T23:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-modeyso-h3-k27m-glioma-sno-20252025-11-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/fda-approves-zepzelca-atezolizumab-combination-therapy2025-10-02T22:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-phase-4-data-xywav2025-09-22T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-q2-2025-financial-results2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-q3-2025-financial-results2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-annual-meeting-results-20252025-08-11T20:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-q2-results-pelareorep-plans2025-08-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-jefferies-global-healthcare-conference-20252025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-accepts-biomarin-palynziq-adolescents-pku2025-10-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-third-quarter-2025-results-update2025-10-27T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-q3-2025-financial-results-call2025-10-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-voxzogo-bone-health-asbmr-20252025-09-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-positive-phase-3-data-palynziq-adolescents-pku2025-09-06T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-participate-investor-conferences-september2025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-strong-q2-2025-results2025-08-04T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-ian-clark-board-directors2025-08-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-2025-revenue-surges-703-percent2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q3-2025-financial-results2025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-rezolve-ad-phase-2b-study-20252025-09-18T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-cld-401-sitc-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-investor-event-sitc-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-scientific-advisory-board-cld-4012025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-oncology-summit-boston2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-public-offering-august-20252025-08-21T22:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-public-offering-pricing2025-08-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q2-2025-results2025-08-08T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-fda-fast-track-cld-201-sarcoma2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-full-year-2024-results2025-03-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-q2-2025-results-bausch-acquisition-update2025-08-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-reports-q1-2025-results-business-update2025-05-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-announces-q4-2024-financial-results2025-03-19T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-presentation-oppenheimer-conference-20252025-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-q3-2025-results2025-10-23T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-q2-2025-results-dividend-guidance-update2025-07-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-pipeline-progress-q3-2025-results2025-10-30T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-reports-third-quarter-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/storm-pe-trial-results-cavt-anticoagulation2025-11-03T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/storm-pe-trial-cavt-superior-anticoagulation2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-investor-conferences-20252025-08-20T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-presents-canaccord-genuity-conference-20252025-07-30T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-storm-pe-trial-enrollment-completion2025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-q3-2025-financial-results2025-11-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-q2-2025-financial-results2025-08-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-reports-q3-2025-financial-results2025-11-12T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-q3-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q3-2025-financial-results2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-tender-offer-repurchase-shares2025-10-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-capital-return-plan2025-10-15T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-ker-065-asbmr-20252025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-healthcare-conferences-20252025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-fda-orphan-drug-designation-ker-065-dmd2025-08-20T13:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-prioritizes-clinical-advancement-of-ker-0652025-08-06T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-phase-3-renew-trial-elritercept2025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-return-375-million-excess-capital-stockholders2025-06-09T10:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-third-quarter-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/imprimisrx-leadership-changes-hrow2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-acquire-melt-pharmaceuticals2025-09-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-access-for-all-launch2025-09-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-investor-analyst-day-agenda-september-20252025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-pricing-250-million-offering-senior-notes2025-09-08T21:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-presents-hc-wainwright-ophthalmology-conference2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-hybrite-ctcl-therapy-advancement2025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-hybrite-ctcl-treatment2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-dr-ellen-kim-hybrite-clinical-trials2025-06-06T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-postpones-earnings-release-audit2025-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-report-q4-full-year-2024-results2025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-strengthens-balance-sheet-warrants-exercise2025-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-strengthens-balance-sheet-rights-offering2025-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-expands-dubai-sales-subsidiary2025-01-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-q1-2025-results-business-updates2025-05-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-q3-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-ash-2025-presentations2025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-xyngari-phase-3-trial-results2025-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-jefferies-london-healthcare-conference2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-cantor-global-healthcare-conference2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-results-business-update2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q2-2025-financial-results-conference-call2025-07-24T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-2026-first-quarter-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-q3-2025-results2025-10-22T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-cfo-dan-brennan-retires-jon-monson-succeeds2025-04-23T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-new-ceo-noam-band2025-04-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-reports-q2-2025-financial-results2025-08-08T10:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-second-quarter-2025-results-announcement2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/serb-pharmaceuticals-acquires-y-mabs-therapeutics2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-virtual-radiopharmaceutical-rd-update2025-05-28T10:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-gd2-sada-prit-trial-poster-anr-meeting2025-05-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-virtual-radiopharmaceutical-rd-update-may-20252025-05-13T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/naxitamab-danyelza-nccn-guidelines-update2025-05-07T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-presents-cd38-sada-aacr-20252025-04-27T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-closes-1-1-million-offering2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-registered-direct-offering2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-nasdaq-extension-compliance-notice2025-10-21T00:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-acquires-renal-anti-fibrotic-program-vectus2025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-investor-webinar-september-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-initiates-ind-preparation-xorlo-gout-program2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-completes-private-placement-1145002025-08-08T23:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-corporate-update-2025-20262025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-completes-private-placement-units2025-07-22T23:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-third-quarter-conference-call-november-20252025-10-08T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-aldo-denti-cco2025-10-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-retains-wellspect-healthcare2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-participate-investor-conferences2025-08-26T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-daniel-scavilla-ceo2025-07-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-prices-550-million-junior-subordinated-notes2025-06-05T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-matthew-garth-cfo2025-05-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q3-2025-results2025-10-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-post-hoc-analysis-tardive-dyskinesia-remission2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-osavampator-phase-2-study-results2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-reports-q3-2025-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-lava-amendment-purchase-agreement2025-10-17T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-extends-tender-offer-lava-therapeutics2025-10-02T20:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends2025-09-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-closes-tender-offer-hillevax2025-09-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-presentation-hc-wainwright-conference2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/mural-oncology-acquisition-xoma-royalty2025-08-20T12:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-closing-tender-offer-turnstone-biologics2025-08-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-lava-therapeutics-agreement2025-08-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-distribution-agreement-tianjin-merrill-youli2025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-share-repurchase-program-1-million2025-06-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launch-tea-pigment-health-products2025-05-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launch-postbiotic-hypoglycemic-ingredient-series2025-05-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-reverse-stock-split2025-05-15T10:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launches-broccoli-derived-sleep-health-products2025-05-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-nasdaq-delisting-notifications2025-05-02T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-apple-polyphenol-commercial-order2025-04-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-broccoli-nutritional-power-delivery-system2025-04-08T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-breakthrough-bio-manufacturing-tea-pigments2025-04-07T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-pipeline-business-updates-q3-20252025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-phase-2-data-vilastobart-sitc-20252025-11-07T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-sitc-40th-annual-meeting2025-11-07T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-inducement-grants-nasdaq-rule-56352025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-sitc-2025-presentations2025-10-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-phase-2-trial-efarindodekin-alfa2025-09-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-guggenheim-healthcare-conference-20252025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q3-2025-financial-results-update2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-public-offering-155-million2025-10-27T23:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-135-million-offering2025-10-24T04:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-public-offering-mavorixafor2025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-restructuring-business-operations2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-08-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-85-million-private-placement2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-60-million-financing-management-changes2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-positive-phase-2-trial-data-eha2025-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-q2-2025-results-update2025-11-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-q1-2025-results-update2025-08-13T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-reports-q3-2025-financial-results2025-11-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/burixafor-clinical-data-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-burixafor-phase-2-trial-update2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-present-upcoming-investor-conferences2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-reports-q3-2025-results-business-update2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-report-q3-2025-financial-results2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-appoints-tucker-kelly-cfo2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-10-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-investor-webinar-early-stage-ion-channel-programs2025-09-25T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-fiscal-q2-2026-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-secures-32-million-growth2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-schedules-q2-2026-financial-results-call2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-participate-roth-healthcare-conference2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-exercise-warrants-3-25-million2025-09-08T19:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/neuronos-fda-orphan-drug-designation-glioblastoma2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-hc-wainwright-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-lungfit-ph-distribution-agreements-japan2025-08-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q3-2025-financial-results-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-investor-conferences-november-20252025-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-lifesciences-wve-007-obesity-preclinical-data2025-11-05T01:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-positive-data-inlight-trial-wve-0072025-10-30T02:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-research-day-october-20252025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-lifesci-positive-update-restoration-2-trial-wve-0062025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q2-2025-financial-results-webcast2025-07-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-gempharmatech-service-contract2025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-investment-neologics-bioscience2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-reverse-stock-split-october-20252025-10-16T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-delisting-nasdaq2025-10-14T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-nasdaq-compliance-extension2025-10-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-offering2025-09-25T17:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-partners-hong-kong-web3-standardization2025-09-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-partners-wuxi-hospital-ai-healthcare2025-09-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-group-closes-offering2025-05-22T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-technology-offering-pricing2025-05-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-epic-study-imaavy-gmg2025-10-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/psoriasis-unmet-needs-oral-treatments2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-crohns-disease-remission2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-phase-2b-results-ulcerative-colitis2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-sjogren-disease-phase-2-results2025-10-24T22:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-long-term-results-psoriasis2025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/subcutaneous-amivantamab-head-neck-cancer-results2025-10-19T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-q3-2025-results-business-update2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-phase-2b-trial-repibresib-results2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-vyn202-program-update2025-07-02T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-update-vyn202-program2025-04-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-hc-wainwright-conference-20252025-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-march-investor-conferences2025-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-phase-1b-trial-vyn202-plaque-psoriasis2025-02-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-ce-mark-locket2025-05-27T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-engages-pcg-advisory-investor-relations2025-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-special-meeting-adjournment-20252025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-nasdaq-extension-compliance2025-08-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-q3-2025-results2025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/transition-bio-voyager-collaboration-tdp-43-als-ftd2025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-investor-conferences2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-alzheimers-program-apoe-targeting2025-07-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-presents-hc-wainwright-neuro-perspectives-conference2025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-alpl-blood-brain-barrier-aav-capsids2025-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-next-generation-cns-capsids-asgct-20252025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-preclinical-data-tau-targeting-gene-therapy2025-03-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-clinical-data-adhd-improvement2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-clinical-trial-results-pediatric-osa2025-09-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q2-2025-financial-results-update2025-08-19T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q2-2025-financial-results2025-08-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-management-expansion-growth2025-07-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-medicare-approval-vidasleep2025-07-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-acquisition-sleep-center-nevada2025-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q3-2025-financial-results-update2025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-new-scientific-advisory-board-appointments2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-innodia-symposium-easd-20252025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-september-investor-conferences2025-09-03T20:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-80-million-private-placement2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtvt-uspto-allowance-cadisegliatin-patent2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-catt1-phase-3-trial-cadisegliatin2025-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-hcw-home-series-20252025-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-appoints-cfo-reinitiates-phase-3-trial2025-05-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-q3-2025-results2025-11-06T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-phase-2-study-results-vtx32322025-10-22T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-investor-conferences-20252025-08-27T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-positive-phase-2a-results-vtx3232-parkinsons2025-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-jefferies-global-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-expands-sab-nlrp3-experts2025-04-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-phase-2-trial-vtx958-crohns-disease2025-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-acquisition-msd-approved-high-court2025-10-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-merck-acquisition-approval2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-phase-3-enhance-studies-ers-congress-20252025-09-16T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-june-2025-investor-conference2025-05-21T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-q1-2025-financial-results-update2025-04-29T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRNA/verona-pharma-amended-financing-oaktree-omerset2025-03-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-public-offering-100-million2025-11-11T02:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/telitacicept-phase-3-study-iga-nephropathy2025-11-08T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-participate-investor-conferences2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-jeremy-sokolove-cmo2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-inducement-grants-nasdaq-rule-5635c42025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/telitacicept-phase-3-gmg-data2025-10-29T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-webcast-phase-3-telitacicept-data-sjogrens2025-10-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-phase-3-iga-nephropathy-study-asn-20252025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-telitacicept-phase-3-study-lupus2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-phase-2-vp-315-basal-cell-carcinoma-data2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-positive-feedback-ema-approval-ycanth-eu2025-10-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-approval-ycanth-japan2025-09-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-hc-wainwright-conference-20252025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q2-2025-financial-results2025-08-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-strong-growth-ycanth-q2-20252025-07-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-amendment-collaboration-license-agreement-torii2025-07-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-jefferies-conference-20252025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-delisting-nasdaq2025-04-17T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-termination-merger-wind-down2025-04-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-business-update-q4-2024-results2025-03-27T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-qumulusai-merger-intent2025-03-18T12:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reverse-merger-termination-strategic-alternatives2025-02-28T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-oqory-promising-data-oqy-32582025-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-reverse-stock-split2025-01-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-iluzanebart-phase-2-update-alsp2025-06-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-merger-agreement-sanofi2025-05-21T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-q1-2025-results-updates2025-05-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-vg-3927-ad-pd-20252025-04-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-stifel-2025-cns-forum2025-03-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-guggenheim-conference-20252025-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-vg-3927-phase-1-trial-results2025-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-2024-achievements-2025-milestones2025-01-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-abstracts-obesityweek-20252025-10-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-pricing-public-offering2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-proposed-public-offering2025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fda-meeting-enobosarm-regulatory-clarity-obesity2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-reports-fiscal-2025-third-quarter-results2025-08-12T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-enobosarm-chronic-weight-loss-management2025-08-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-reverse-stock-split2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2025-q3-results-conference-call2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-participate-2025-btig-virtual-biotech-conference2025-07-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-positive-results-phase-2b-quality-study2025-06-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-third-quarter-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-debt-equity-exchange2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-q3-2025-financial-results-release2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-closes-3-45-million-offering2025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-3-45-million-offering-nasdaq2025-06-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-sells-hair-business-20-million2025-06-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-td-cowen-summit-20252025-11-10T12:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-atacicept-fda-application-iga-nephropathy2025-11-07T23:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-nasdaq-rule-56352025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-origins-phase-3-data-atacicept-igan2025-11-06T14:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q3-2025-results2025-11-05T12:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-investor-call-origins-update-november-20252025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-origins-atacicept-asn-kidney-week-20252025-10-17T13:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-investor-conferences-20252025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-pepinemab-immunotherapy-head-neck-cancer-asco-20252025-05-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-report-clinical-data-pepinemab-aacr-20252025-04-21T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-delists-common-stock-nasdaq2025-03-07T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-q3-2025-financial-results2025-11-06T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-presents-wells-fargo-healthcare-conference-20252025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-second-quarter-2025-financial-results2025-07-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-truist-securities-medtech-conference-20252025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-q1-2025-results-profitability-guidance2025-05-08T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-presents-bank-america-healthcare-conference-20252025-05-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-upcoming-investor-conferences2025-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-merger-cara-therapeutics2025-04-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-business-update-q3-2025-results2025-11-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-closes-common-stock-offering2025-10-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-common-stock-offering-pricing2025-10-26T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-presentation-thinkequity-conference-20252025-10-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-withdraws-cortigent-spin-off-date2025-10-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-emerging-growth-conference-20252025-09-24T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-spin-off-cortigent-neuromodulation2025-09-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-npm-139-semaglutide-implant-update2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-ceo-presentation-hc-wainwright-conference2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-business-update-equity-financing-q2-20252025-08-13T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-1-results-zika-vaccine2025-11-04T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-phase-1-trial-zika-vaccine-results2025-11-04T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investor-conferences-us-europe2025-10-27T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investor-meetings-healthcare-conferences2025-10-27T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-refinances-debt-pharmakon-advisors2025-10-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-refinances-debt-pharmakon-advisors-business-updates2025-10-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-q3-2025-financial-results-zusduri-launch2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-phase-3-utopia-trial-results-ugm-1032025-11-06T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-guggenheim-conference-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-third-quarter-2025-results2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/cms-assigns-j-code-for-zusduri-20262025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/zusduri-clinical-review-bladder-cancer2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-inducement-grants-nasdaq-rule-5635c42025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-investor-conferences-september-20252025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-launches-zusduri-q2-2025-results2025-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-zusduris-24-month-response-phase-3-trial2025-08-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-reports-q3-2025-results-progress2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-november-investor-conferences2025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-verekitug-ers-congress-20252025-09-30T08:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-stifel-2025-forum2025-09-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-vibrant-trial-results2025-09-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-trial-verekitug-copd2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/verekitug-potency-tslp-receptor-eaaci-congress2025-06-15T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-presents-verekitug-eaaci-20252025-06-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-aspire-phase-2b-study-results2025-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-arvo-2025-presentation2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-ubx1325-dme-vision-improvements2025-04-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-q1-2025-financial-results2025-04-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-virtual-investor-event-ubx13252025-03-23T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-yehia-hashad-board2025-03-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-employment-inducement-award2025-01-07T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UBX/unity-biotechnology-appoints-federico-grossi-cmo2025-01-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-expands-hla-coverage-precision-t-cell-therapy2025-11-05T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-clarifies-financials-capital-efficiency-low-cash-burn2025-11-03T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-engages-business-community-leaders-progress2025-10-29T16:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-updates-tvgn-489-long-covid-interest2025-10-15T19:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ai-initiative-t-cell-therapy-enhancement2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-tvgn-489-long-covid-viral-reservoirs2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-hhs-long-covid-impact-tvgn-4892025-09-19T19:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-cio-joins-startup-forum-databricks-tour-boston2025-09-10T15:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-5-year-revenue-forecast-liver-cancer-prevention2025-09-09T19:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-tvgn-489-clinical-product-valuation2025-09-08T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-private-placement-preferred-stock2025-06-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-business-combination-filing2025-06-03T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q3-2025-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-regains-rights-tsha-102-rett-syndrome2025-10-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-reveal-phase-1-2-trials-tsha-1022025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-inducement-grant-nasdaq-rule-56352025-10-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-q1-2025-financial-results2025-05-08T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-explores-strategic-alternatives2025-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-acquisition-by-novartis2025-09-09T05:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-phase-2-tranquility-trial-data-esc-20252025-08-31T14:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-q2-2025-results-business-highlights2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-phase-2-tranquility-trial-results2025-05-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-leerink-partners-conference-20252025-03-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-bio-guggenheim-conference-20252025-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRML/tourmaline-appoints-dr-paul-ridker-advisory-board2025-01-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-debt-equity-conversion2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regains-nasdaq-compliance2025-09-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-appoints-paul-tivnan-director2025-08-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-offshore-manufacturing-hiv-test2025-08-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-preclara-preeclampsia-testing-approval2025-08-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-cgm-sensor-trial-results2025-08-12T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-launches-cgm-ai-native-platform2025-07-24T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-profitability-inflection-point2025-07-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-investor-conferences-20252025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-dreams-grant-recipients2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-inducement-grants-nasdaq-rule-56352025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-appoints-maha-radhakrishnan2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-elevate-45-201-eu-authorization2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-q3-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-phase-2-covid-studies2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-appoints-john-leaman-and-key-executives2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-phase-2-covid-studies-ratutrelvir2025-08-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-q2-2025-financial-results2025-08-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-advances-antiviral-pipeline-regulatory-submissions2025-06-30T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-rigosertib-efficacy-rdeb-scc2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-fda-guidance-tivoxavir-marboxil2025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-q3-2025-results-business-update2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-clearance-pivotal-trial-amezalpat-hcc-china2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-4-6-million-offering2025-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-orphan-drug-designation-amezalpat-hcc2025-06-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-amezalpat-moa-data-aacr-20252025-04-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-orphan-drug-designation-tpst-1495-fap2025-04-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-explores-strategic-alternatives-oncology-assets2025-04-09T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q3-2025-results2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-response-unusual-market-action2025-10-24T18:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-warrant-incentive-operation2025-10-16T19:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-warrant-inducement-transaction2025-10-16T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-upcoming-congress-presentations2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-upcoming-presentations-esmo-idweek2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-12-esgct-presentation2025-10-06T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn12-esgct-presentation2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q2-2025-financial-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-q3-2025-financial-results-update2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-mypeak-1-phase-1b-2a-trial-results2025-11-08T16:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-tn-201-clinical-data-aha-20252025-11-04T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-hc-wainwright-conference-20252025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-october-investor-conferences2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-inducement-grants-nasdaq-rule-56352025-09-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-morgan-stanley-conference-20252025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-myclimb-study-esc-20252025-08-31T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-canaccord-genuity-conference-20252025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-third-quarter-2025-results2025-11-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-stifel-2025-healthcare-conference2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-collaboration-mgh-tnx-1500-trial2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presentation-bio-europe-20252025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-acr-20252025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-focus-study-avp-d2025-10-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-poster-acr-20252025-10-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-801-mpox-vaccine-data2025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-1500-update-japan-congress2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-world-vaccine-congress-20252025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-jefferies-conference-20252025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-bio-europe-20252025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-invited-life-sciences-innovation-forum-20252025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-advances-tzls-501-il-6r-monoclonal-antibody2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ectrims-presentation-foralumab2025-09-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/dod-grant-tiziana-life-sciences-intranasal-therapy-sci2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ceo-share-purchase2025-09-09T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-phase-2a-trial-foralumab-msa2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-report-first-quarter-2025-results2025-04-24T23:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-pluristyx-plurifreeze-cryopreservation-system2025-03-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-pluristyx-collaboration-cell-therapies2025-03-11T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-acquisition-future-pak2025-09-25T17:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-acquisition-completion-future-pak2025-09-25T17:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-court-approval-acquisition-future-pak2025-09-16T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-final-court-approval-acquisition-future-pak2025-09-16T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-shareholders-approve-acquisition-plan2025-09-12T15:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-shareholders-approve-acquisition-future-pak2025-09-12T15:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-egrifta-wrmc-availability-hiv-lipodystrophy2025-09-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-egrifta-wr-availability-hiv-lipodystrophy2025-09-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-vote-favor-arrangement-future-pak2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THTX/theratechnologies-shareholder-vote-arrangement-future-pak2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-q3-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-immuneonco-presentation-2510-nsclc-wclc-20252025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/immuneonco-imm2510-nsclc-clinical-trial-results2025-07-31T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-fda-clearance-axn-2510-ind-phase-1-trial2025-07-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-appoints-john-maraganore-board-role2025-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-appoints-jamie-freedman-cmo2025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-jefferies-global-healthcare-conference-20252025-05-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-immuneonco-investor-breakfast-2025-asco2025-05-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/imm2510-phase-2-trial-nsclc-enrollment-update2025-05-22T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-liquidation-thb335-update2025-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-liquidation-dissolution-plan2025-04-14T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-q4-2024-financial-results2025-03-27T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-phase-1-results-thb335-update2025-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-td-cowen-summit-participation2025-11-10T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-q3-2025-financial-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q3-20252025-10-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-phase-3-enhance-trial-briumvi2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/briumvi-six-year-data-relapsing-ms2025-09-24T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-data-presentations-ectrims-20252025-09-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-phase-3-trial-briumvi-enrollment-commenced2025-09-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-hc-wainwright-conference-20252025-09-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-share-repurchase-authorization2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-cantor-global-healthcare-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend2025-11-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-third-quarter-results-2025-outlook2025-11-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-q3-2025-earnings-conference-call-details2025-10-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/first-patient-enrolled-dubstent-diabetes-trial2025-09-11T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-presentation-morgan-stanley-healthcare-conference2025-08-26T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-barrigel-rectal-spacer-launch-japan2025-08-19T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-second-quarter-2025-earnings-call2025-07-17T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-acquires-biotronik-vascular-intervention-business2025-07-01T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-q3-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-inducement-grants-employees2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-positive-clinical-data-tern-701-cml-ash-meeting2025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-phase-2-trial-tern-601-obesity-results2025-10-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-webinar-tern-701-phase-1-data2025-08-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-phase-1-study-tern-6012025-06-23T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-june-investor-conferences2025-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-guggenheim-smid-cap-biotech-conference2025-01-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-appoints-gillian-andor-vp-clinical-operations2025-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q3-2025-financial-results-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-guggenheim-healthcare-innovation-conference2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-fda-agreement-pivotal-study-design2025-11-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-acr-convergence-2025-presentations2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-investor-conferences-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presentation-jefferies-conference2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presentation-asgct-20252025-04-28T20:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-needham-conference-20252025-03-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-third-quarter-2025-financial-results2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-william-plovanic-board-directors2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-board-update-betty-jo-rocchio2025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-inducement-grants-nasdaq-rule-5635c42025-08-08T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-participate-canaccord-genuity-conference2025-07-23T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-european-launch-ovitex-ingual2025-06-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-jeffrey-blizard-president2025-06-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-2-million-offering2025-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-participate-investor-conference-november-20252025-11-05T22:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-q3-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-third-quarter-2025-financial-results-webcast2025-10-28T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q3-2025-results-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-best-places-to-work-20262025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inducement-grants-nasdaq-rule-56352025-10-01T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-investor-conferences-20252025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-russell-3000-index-addition2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-appoints-william-conkling-cco2025-06-02T20:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-reports-q3-2025-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-third-quarter-fiscal-year-2025-results2025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-host-investor-day-november-20252025-08-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-participate-2025-wells-fargo-healthcare-conference2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-quarterly-dividend-increase2025-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-participate-bank-america-healthcare-conference-20252025-04-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesia-infection-negative2025-10-15T11:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/b-free-chronic-babesiosis-study-sxtp2025-10-09T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-webcast-hc-wainwright-conference2025-09-03T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharma-mount-sinai-phase-ii-trial-tafenoquine2025-08-19T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-q2-2025-results2025-08-13T20:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-tulane-research-agreement-tafenoquine2025-07-17T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-closes-10-million-offering2025-07-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-public-offering-pricing2025-07-15T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-arakoda-babesiosis-market-size2025-07-15T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-chmp-opinion-nirogacestat-desmoid-tumors2025-06-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-chmp-positive-opinion-mirdametinib2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-mirdametinib-nf1-pn-approval2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-regains-nasdaq-compliance2025-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-share-consolidation2025-02-21T17:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-participate-2025-jefferies-healthcare-conference2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-third-quarter-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-q3-2025-results-conference-call2025-10-21T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-september-investor-conferences2025-08-27T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-acquisition-sage-therapeutics2025-07-31T12:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-expiration-hsr-waiting-period-sage-acquisition2025-07-28T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-acquires-sage-therapeutics-neuropsychiatry2025-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2025-third-quarter-results2025-11-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/genesisx-robotic-navigation-fda-clearance2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-launch-synchrony-system-eu-fda-submission2025-10-15T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-cardiofocus-robotic-pfa-collaboration2025-10-13T11:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/erasmus-medical-center-genesis-robotic-system2025-09-22T11:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/first-us-commercial-robotic-hd-mapping-procedures2025-09-02T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-investor-conferences-september-20252025-09-02T11:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-technology-featured-hrx-20252025-08-28T11:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-q3-2025-financial-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-wedbush-securities-panel-20252025-10-02T11:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-closes-103-million-private-placement2025-08-26T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-ind-sl-325-inflammatory-bowel-disease2025-08-21T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-private-placement-103-million2025-08-05T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-leerink-partners-therapeutics-forum2025-07-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-participation-needham-conference-20252025-04-02T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2025-results-ceo-transition2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/tricare-west-expands-neurostar-tms-coverage-adolescents2025-11-12T15:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inducement-grant-nasdaq-rule-56352025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/new-york-medicaid-expands-tms-therapy-coverage2025-09-17T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neurostar-publication-jaacap-open-treatment-efficacy2025-07-30T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-next-gen-adc-innovation2025-11-12T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-exclusive-partnership-elite-dna-behavioral-health2025-10-30T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2025-financial-results-conference-call2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-presentation-canaccord-growth-conference2025-08-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reports-q3-2025-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-virtual-rd-day-november-20252025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-world-adc-conference-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-operational-restructuring-cash-runway2025-09-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-fda-collaboration-advancing-adc-standards2025-07-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-appoints-greg-chow-cfo2025-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-investor-conferences-may-20252025-05-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-fiscal-2026-second-quarter-results2025-11-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-announces-dividend-0-63-per-share2025-10-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-conference-call-fiscal-2026-results2025-10-21T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-cfo-transition-michael-tokich-karen-burton2025-08-06T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/cms-recognition-expanded-cpt-codes-sskn2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-q3-2025-financial-results-update2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-cofepris-clearance-theraclear-mexico2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-market-leadership-litigation-milestones2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/excimer-laser-promising-results-cutaneous-lymphoma-sskn2025-10-14T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/eczema-awareness-month-strata-skin-sciences-xtrac-laser2025-10-03T14:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-xtrac-laser-study-psoriasis2025-09-30T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/combination-therapy-vitiligo-strata-sskn2025-09-22T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-2-42-million-offering2025-09-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-elevate-360-growth-partnerships2025-09-04T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-first-telesurgery-ssii2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-reports-q3-2025-financial-results2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-upcoming-investor-conferences2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-us-regulatory-update-ssi-mantra2025-10-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-appoints-naveen-kumar-amara-cfo2025-09-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-first-pediatric-pyeloplasty-telesurgery2025-09-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-first-robotic-telesurgery-mantram-bus2025-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-intercontinental-robotic-cardiac-telesurgery2025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-stock-option-grant-cfo2025-11-12T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q3-2025-results-business-update2025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-healthcare-investor-conference2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-patent-antibody-wnt-pathway2025-05-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-q3-2025-financial-results-neffy2025-11-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/get-neffy-on-us-program-launch2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharma-neffy-presentation-acaa-meeting-20252025-11-03T19:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-q3-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-european-patent-decision-neffy2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-secures-loan-facility-neffy-commercialization2025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/neffy-epinephrine-nasal-spray-approval-japan2025-09-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/real-world-evidence-neffy-anaphylaxis2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-investor-conferences-september-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q3-2025-financial-results-update2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/pivotal-phase-3-data-tebipenem-hbr-cuti2025-10-21T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-tebipenem-hbr-idweek-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-gsk-pivot-po-phase-3-study-tebibenem-hbr2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-esther-rajavelu-ceo-appointment2025-04-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-neurothera-labs2025-10-24T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-sale-mitocarex-n2off-cancer-therapies2025-10-23T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-quantum-3d-protein-modeling-initiative2025-10-23T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-clearmind-patent-binge-behavior-disorders2025-10-20T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-miza-ventures2025-10-15T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-merger-termination-autotmax-agreement2025-10-06T10:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/n2off-shareholders-approve-scisparc-merger-mitocarex2025-09-29T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-autotmax-merger-approval2025-08-28T13:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-shareholders-approve-merger-automax2025-08-28T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-q3-2025-financial-results2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-partners-cm-sales-arkansas2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-third-quarter-2025-earnings2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-focusfactor-pharmacist-recommendation-2025-20262025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expansion-kroger-pricesmart-wakefern2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-new-england2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-leadership-changes-strategic-partnerships2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-partners-alabev-launch-focusfactor-beverages2025-09-17T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-closes-public-offering-4-375-million2025-08-27T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-pricing-public-offering2025-08-26T01:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q3-fy2025-financial-results2025-11-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-conference-call-november-20252025-11-03T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/cms-final-rule-2026-physician-fee-schedule-ultramist2025-11-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-q3-2025-revenue-results2025-10-06T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-strategic-debt-refinancing-jp-morgan2025-09-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-presentation-canaccord-conference-20252025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-dustin-libby-evp2025-06-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-updated-clinical-results-senti-202-ash-20252025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-present-chardan-genetic-medicines-conference2025-10-16T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-presentation-biojapan-20252025-10-06T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-medinvest-conference-presentation2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-presentation-hc-wainwright-conference-20252025-09-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-webull-webinar-20252025-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-phase-2-dose-selection-senti-2022025-08-12T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-q2-2025-results-phase-1-senti-202-update2025-08-07T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-phase-2-dose-senti-202-aml2025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-virtual-investor-conference2025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-strategic-review-shareholder-value2025-10-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-solnerstotug-esmo-2025-results2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-kol-event-solnerstotug-october-20252025-09-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-hc-wainwright-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-q2-2025-results-update2025-08-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-esmo-congress-20252025-07-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reverse-stock-split2025-06-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-participate-canaccord-genuity-conference2025-04-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-2024-financial-results-clinical-update2025-03-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-pico-snpwt-study-wound-dehiscence2025-10-27T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-ufc-partnership-extension2025-10-22T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-new-cpt-code-cartilage-repair-implant2025-10-09T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-allevyn-complete-care-dressing-data2025-10-03T15:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-coriograph-pre-op-services-shoulder2025-10-01T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-regneten-implant-updates2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-launches-centrio-prp-system2025-09-03T14:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-q-fix-knotless-anchor-launch2025-07-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-sponsors-players-wimbledon-20252025-06-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-trigen-max-tibia-nailing-system-launch2025-06-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-q3-2025-financial-results2025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-sil204-pan-kras-activity2025-09-30T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-regains-nasdaq-compliance2025-09-25T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-public-offering-pricing2025-09-11T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-positive-preclinical-data-sil2042025-09-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trials-sil2042025-09-04T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-presentation-hc-wainwright-conference2025-09-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-warrants-exercise-1-8-million2025-08-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-preclinical-data-sil2042025-07-31T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-reports-q3-2025-financial-results2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-ash-investor-event-december-20252025-11-03T14:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-niktimvo-ash-20252025-11-03T14:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-november-investor-conferences2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-third-quarter-2025-financial-results-conference-call2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-fda-approval-revuforj-npm1-aml2025-10-24T17:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-nccn-guidelines-aml2025-09-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q3-2025-financial-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-strategic-realignment-surgical-business2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-ceo-transition2025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-presentation-cantor-healthcare-conference-20252025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-launches-tissue-health-plus-pilot-program2025-07-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-regains-nasdaq-compliance2025-10-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-reverse-stock-split2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-extension-nasdaq-compliance2025-07-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-seclidemstat-inhibiting-lsd1-studies2025-07-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/decoy-therapeutics-langer-scientific-advisory-board2025-04-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/decoy-therapeutics-promising-antiviral-measles2025-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-merger-decoy-therapeutics-update2025-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-resumes-enrollment-phase-1-2-trial2025-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-decoy-merger-agreement2025-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-sls009-phase-2-data-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-warrant-exercise-31-million2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-jp-morgan-forum-20252025-10-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-sls009-esmo-20252025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-rd-day-october-2025-aml-trial-update2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-regal-trial-positive-recommendation2025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-phase-2-trial-sls009-aml-fda-guidance2025-07-15T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-100-million-share-repurchase2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-q3-2025-results-vykat-launch2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-november-conferences2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-q3-2025-financial-results2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-appoints-mark-hahn-board2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-public-offering-200-million2025-07-10T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alumis-merger-approval2025-05-13T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-iss-recommends-vote-for-alumis-merger2025-05-06T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alumis-merger-vote-20252025-05-01T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/alumis-acelyrin-amended-merger-agreement2025-04-21T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-limited-duration-stockholder-rights-plan2025-03-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-alumis-merger-strategic-rationale2025-03-04T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-concentra-biosciences-merger-update2025-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-receives-acquisition-interest-from-concentra2025-02-21T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/alumis-acelyrin-merger-immune-diseases2025-02-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRN/acelyrin-announces-phase-2-data-lonigutamab-ted2025-01-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-health-canada-approval-epsolay2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-q2-2025-results-and-updates2025-08-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-first-quarter-2025-results2025-05-23T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reverse-share-split2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-mayne-pharma-epsolay-twyneo-purchase-agreement2025-04-17T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-investor-conferences-20252025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-innovation-passport-sgt-0032025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-inducement-grants-nasdaq-rule-56352025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q3-2025-results-insPIRE-duchenne-update2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-scientific-meetings-20252025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-at-neuromuscular-study-group-meeting2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-licensing-agreement-kinea-bio-aav-slb1012025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-q3-2025-results-update2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-obesityweek-2025-nimacimab2025-11-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-nimacimab-phase-2a-data2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-phase-1b-nimacimab-easd-meeting2025-09-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-nimacimab-weight-loss-combination-therapy2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-completes-26-week-treatment-phase-cbeyond-study2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-kol-event-cbeyond-phase-2a-data2025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-investment-medical-conferences2025-08-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-q3-2025-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-investor-conferences-november-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-phase-1-data-nacfc-20252025-10-24T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-precision-cf-phase-2a-trial2025-10-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-nacfc-2025-presentation2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-appoints-caroline-stark-beer-cbo2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-phase-1-trial-sion-451-cystic-fibrosis2025-08-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-preclinical-data-cftr-correction2025-06-06T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-reports-financial-results-september-20252025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-november-20252025-10-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-announces-special-cash-dividend-20252025-04-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-appoints-general-john-keane-board2025-03-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q3-2025-results-and-guidance2025-11-10T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-third-quarter-2025-results2025-10-20T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-presents-morgan-stanley-healthcare-conference-20252025-08-26T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-present-canaccord-growth-conference-20252025-07-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-truist-securities-medtech-conference-20252025-06-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-goldman-sachs-conference-20252025-05-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-bofa-securities-2025-healthcare-conference2025-05-06T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-executes-loi-with-molecule-ai2025-10-10T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-enter-ai-pharmaceutical-market2025-10-09T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-q2-2025-update2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-4-25-million-private-placement2025-06-24T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-private-placement-425-million2025-06-20T19:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-reverse-stock-split-june-20252025-06-12T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-reverse-stock-split-nasdaq-compliance2025-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-george-scorsis-chairman-board2025-06-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-corporate-update-may-20252025-05-15T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHPH/shuttle-pharma-fda-orphan-drug-phase-2-trial2025-05-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-secondary-offering-common-stock2025-11-06T21:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-reports-strong-q3-2025-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-third-quarter-2025-earnings-release2025-10-21T21:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-progress-q3-2025-financial-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-participate-upcoming-investor-conferences2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-appoints-keith-gottesdiener-board-directors2025-09-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-phase-1-trial-sep-631-mrgprx22025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-jefferies-healthcare-conference2025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-corporate-overview-q4-2024-results2025-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-td-cowen-health-care-conference2025-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/omni-surgical-system-trusync-technology-glaucoma2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-third-quarter-2025-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-appoints-new-coo-cfo2025-11-06T21:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-investor-conferences-20252025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-third-quarter-2025-financial-results2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-tearcare-fee-schedule-announcement2025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-omni-surgical-system-review2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-omni-unitedhealthcare-coverage2025-09-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-tearcare-tfos-dews-iii-guidelines2025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-presentation-morgan-stanley-conference2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-hupo-2025-proteomics-data2025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-participate-november-investor-conferences2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-proteomics-genomics-precision-medicine-ashg-20252025-10-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-isaac-ro-board-directors2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-participate-morgan-stanley-healthcare-conference2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-q2-2025-financial-results2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-participate-canaccord-genuity-growth-conference2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-report-second-quarter-2025-results2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-q3-2025-results-corporate-update2025-11-05T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-gsk-phase-3-mario-study-resolution2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-positive-results-phase-1-scy-2472025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-sc247-timm-12-presentations2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-hc-wainwright-conference-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-resumes-patient-dosing-phase-3-mario-study2025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-present-preclinical-data-scy-247-escmid2025-04-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-appeal-nyse-delisting2025-04-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-engages-alliance-global-partners2025-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-kalocyte-erythromer-manufacturing2025-01-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-cancels-reverse-stock-split2025-01-17T20:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/mannkind-acquisition-scpharmaceuticals-revenue-growth2025-10-07T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/mannkind-acquires-scpharmaceuticals-patient-centric-leader2025-08-25T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-patent-allowances-scp-1112025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-q2-2025-financial-results-update2025-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-q2-2025-financial-results-announcement2025-07-31T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-participation-investor-conferences2025-05-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPH/scpharmaceuticals-financial-results-conference-call-20252025-03-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-reports-q3-2025-financial-results2025-11-13T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-arbli-losartan-formulary-expansion2025-11-04T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-launches-arbli-commercial-sales2025-10-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scientures-arbli-first-fda-approved-liquid-losartan2025-10-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-repayment-conversion-debentures2025-10-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-secures-gpo-agreements-arbli-expanding-market-access2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-expands-access-arbli-losartan-rebate-agreement2025-09-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-announces-3-9-million-offering2025-08-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-arbli-launch-quantities-shipment2025-08-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-secures-bridge-funding2025-07-24T21:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-distribution-dream-bowl-meme-coin2025-11-11T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-announces-exclusive-license-datavault-ai-tokenization2025-11-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-sponsors-dream-bowl-2026-shareholder-meme-coin2025-11-03T14:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-completes-first-tranche-oramed-warrant-repurchase2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-closes-initial-tranche-investment-datavault-ai2025-09-26T19:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-bitcoin-investment-datavault-ai2025-09-25T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-closes-200-million-bitcoin-transaction2025-09-25T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-biconomy-mou-cryptocurrency-strategies2025-09-24T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-signs-securities-purchase-agreement-bitcoin2025-09-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-semnur-denali-business-combination2025-09-22T19:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-reports-q3-2025-financials-business-update2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-dawn-bir-board2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-hc-wainwright-conference-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-appoints-dr-joseph-hulihan-cmo2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-sciences-simufilam-preclinical-study-tsc-epilepsy2025-08-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-simufilam-preclinical-data-tsc-alliance-meeting2025-06-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-appoints-bordey-enhance-preclinical-program2025-05-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-announces-retirement-of-cmo-and-new-svp2025-04-21T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presents-sab-142-data-at-ispad-conference2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-participate-investor-conferences-nov-dec-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-easd-presentations-sab-1422025-09-19T11:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presentations-easd-20252025-09-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-q2-2025-financial-results2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-oversubscribed-private-placement-175-million2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-q1-2025-financial-results-updates2025-05-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-full-year-2024-results2025-03-31T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-phase-1-results-sab-142-t1d-therapy2025-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inducement-grant-nasdaq-listing-rule2025-11-10T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-reports-fiscal-2026-results-business-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-virtual-investor-event-ersodetug-development2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-investor-conferences2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-fda-alignment-phase-3-trial-ersodetug2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-appoints-sunil-karnawat-cfo2025-08-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-btig-virtual-biotechnology-conference2025-07-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-obesityweek-2025-presentations2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-fda-review-extension-imcivree2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-imcivree-reimbursement-canada2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q3-2025-results-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-investor-conferences-20252025-08-27T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-fda-acceptance-setmelanotide2025-08-20T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q2-2025-results-report2025-07-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-brilaroxazine-presentation-neuroscience-20252025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-european-patent-brilaroxazine-pulmonary-fibrosis2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-spartan-capital-investor-conference2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-present-negative-symptom-data-brilaroxazine-cns-summit-20252025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-kol-webinar-alliance-global-partners2025-10-07T20:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-roth-healthcare-conference-20252025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-participate-lytham-partners-fall-2025-investor-conference2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-9-million-public-offering2025-09-19T01:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-proposed-public-offering2025-09-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-q2-2025-financial-results2025-08-14T20:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2025-financial-results-update2025-11-05T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-investor-conferences-november-20252025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2025-financial-results-webcast2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/daraxonrasib-fda-orphan-drug-designation-pancreatic-cancer2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-elironrasib-data-presentation2025-10-22T16:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-voucher-fda2025-10-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-leadership-additions-alan-sandler2025-09-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-phase-3-trial2025-09-10T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-q2-2025-business-update2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-priovant-positive-phase-3-valor-study-results2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-best-workplaces-bio-pharma-20252025-09-11T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-batoclimab-graves-disease-remission-data2025-09-03T17:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-priovant-investor-conference-brepocitinib-dermatomyositis2025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-strengthens-scientific-advisory-board-timothy-donahue2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-canaccord-forum-20252025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-q3-2025-financial-results-conference-call2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-expands-advisory-board-thierry-de-baere2025-10-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-panther-study-progress-first-procedure2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-presentation-investment-conference-20252025-09-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-expands-commercialization-efforts-renovocath2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-employment-inducement-grants2025-10-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-carsten-brunn-chairman2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-investor-conferences-september-20252025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-phase-3-aurora-trial-descartes-082025-05-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-hc-wainwright-bioconnect-conference2025-05-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q1-fiscal-year-2026-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q1-fiscal-2026-earnings-report2025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-participation-bank-america-healthcare-conference-20252025-09-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-launches-sleep-institute-global-priority2025-09-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/obstructive-sleep-apnea-77-million-us-adults-20502025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-innovation-leadership-red-dot-awards-patents2025-08-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-board-election-nicole-mowad-nassar2025-08-18T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-official-sleep-partner-lions-tour-20252025-05-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q3-2025-financial-results2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-100-million-offering2025-11-04T12:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-fda-feedback-ndv-01-nmibc2025-11-04T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-max-kates-clinical-advisory-board2025-10-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-regains-compliance-nasdaq-minimum-bid-price2025-09-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-mid-year-ceo-letter-shareholders2025-09-10T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q2-2025-results-ndv-01-data2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-yair-lotan-chair-cab2025-07-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-raj-pruthi-cmo-urology2025-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-investor-conferences-november2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2025-results-announcement2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-appoints-claire-mazumdar2025-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-updated-data-rly-2608-asco-20252025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-november-conferences2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-q3-2025-financial-results-guidance-update2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-third-quarter-2025-financial-results2025-10-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-novasign-partnership-bioprocessing-digitalization2025-07-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-2024-corporate-sustainability-report2025-05-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-william-blair-growth-conference2025-05-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-may-investor-conferences2025-05-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-sitc-2025-rp1-abstract2025-11-07T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fiscal-q2-2026-results-corporate-update2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fda-acceptance-bla-rp1-advanced-melanoma2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-acral-melanoma-data-esmo-20252025-10-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-update-type-a-meeting-fda2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fda-type-a-meeting-rp12025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fda-complete-response-rp1-melanoma2025-07-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-inducement-grants-nasdaq-rule-5635c42025-07-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-secures-us-patent-ai-drug-discovery2025-06-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-expedited-trial-predictive-oncology-merger2025-05-22T19:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-expedited-trial-lawsuit-predictive-oncology2025-05-22T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-launches-augusta-ai-precision-neurology-platform2025-05-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-amsterdam-umc-collaboration-blood-platelet-rna-diagnostics2025-05-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-nebul-partnership-accelerate-biomarker-discovery2025-04-22T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-biosymetrics-merger-ai-drug-discovery2025-04-09T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-update-predictive-oncology-agreement2025-04-04T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-completes-first-milestone-payment-predictive-oncology2025-03-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-progress-ash-2025-multiple-myeloma-lymphoma2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-phase-2-trials-factor-xi-antibodies2025-11-08T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-afrs-trial-results-fda-review2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-investor-conference-presentations2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-wins-2025-prix-galien-award2025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-q3-2025-results2025-10-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-eu-approval-cscc-treatment2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-esmo-2025-advances-oncology-pipeline2025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/db-oto-results-hearing-speech-perception-children2025-10-12T14:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-approval-adjuvant-cscc-treatment2025-10-08T18:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-investor-webinar-briefing2025-11-09T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-third-quarter-2025-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-standard-of-care-acute-wound-treatment2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avitamedical-recell-burns-australia2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-ceo-transition2025-10-16T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/cms-ntap-recell-access-non-burn-wounds2025-10-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-receives-ce-mark-recell-go-europe2025-09-14T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-reduces-hospital-stay-avita-medical2025-09-04T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-september-investor-conference-participation2025-08-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-q3-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-sale-north-american-royalties-crysvita2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-first-patient-dosed-aurora-study-gtx-1022025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q3-2025-update2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-inducement-grant-nasdaq-rule-56352025-10-24T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-evkeeza-approval-aifa-hofh2025-10-08T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-eric-olson-cbo2025-09-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-positive-data-phase-3-dtx401-gsdia2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-q3-2025-results-highlights2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-investor-conferences-november-20252025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-prestige-phase-2b-trial-azureprubart-food-allergies2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-public-offering-pricing2025-10-22T03:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-positive-topline-data-rpt9042025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPT/rapt-therapeutics-fda-clearance-ind-phase-2b-trial-rpt9042025-09-29T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-q3-2025-financials-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-investor-conferences-20252025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-td-cowen-summit-participation2025-09-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-announces-pricing-public-offering-common-stock2025-09-10T01:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-public-offering-common-stock2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-positive-results-rap-219-phase-2a-trial2025-09-08T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-investor-analyst-day-updates2025-06-02T18:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-participate-jefferies-goldman-sachs-conferences2025-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-q3-2025-results-update2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-obesityweek-2025-semaglutide2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-board-appointments2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-closes-60-million-private-placement2025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-chugai-collaboration-1-billion2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-3-million-offering2025-07-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-endo-2025-presentation-bioequivalence2025-07-14T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-chugai-research-agreement2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-q3-2025-financial-results-update2025-11-10T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-third-quarter-2025-financial-results2025-11-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-regulatory-update-amt-130-huntingtons-disease2025-11-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-upsized-public-offering-closure2025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-pricing-upsized-public-offering2025-09-26T03:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-200-million-public-offering2025-09-24T20:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-refinancing-debt-funding-amts-130-launch2025-09-24T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-positive-results-amd-130-huntingtons-disease2025-09-24T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-amt-191-phase-i-ii-data-fabry-disease2025-09-05T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-q3-2025-results2025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-corporate-update-october-20252025-10-31T23:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-unbuzzd-webinar-alcohol-metabolism2025-10-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-warrant-expiration-cvr-distribution2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-responds-to-allegations2025-10-14T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-whistleblower-reward-stock-manipulation2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-special-dividend-cvrs-litigation-settlement2025-10-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-phase-2-clinical-trial-update2025-10-02T11:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-dr-jack-antel-clinical-advisor-lucid-ms2025-10-01T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-agm-results-20252025-09-29T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-achieves-rapamycin-target-loadings2025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-update-q3-2025-results2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-syndrome-study-update2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-orphan-drug-designation-qrx0032025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-private-placement-financing2025-10-10T13:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video-fasanella-sisters2025-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-campaign-milestone2025-08-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-new-cfo-commercialization-strategy2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video-series2025-08-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-rebrand-aixcrypto-stockholder-meeting-november-20252025-10-28T03:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-bitgo-partnership-treasury-allocation2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-launches-c10-cryptocurrency-asset-treasury2025-10-13T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-leadership-changes2025-10-06T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-closes-41-million-pipe-financing2025-09-30T11:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/faraday-future-invests-41-million-in-qualigen-therapeutics2025-09-19T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-nasdaq-update-compliance-status2025-07-28T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-4-5-million-private-placement2025-07-28T16:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-granted-new-patents-covering-25-countries2025-07-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-nasdaq-deficiency-notification2025-05-19T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-investor-conferences-november-20252025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-business-update-q3-2025-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-micvo-data-presentation-esmo-aacr-nci-eortc2025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-appoints-alex-kane-investor-relations2025-10-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-inducement-grants-nasdaq-rule-56352025-09-30T20:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q3-2025-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-d-plex-1800-wins-biotech-breakthrough-award2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-phase-3-shield-ii-results-acs-20252025-09-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-presents-lytham-roth-conferences-20252025-09-17T12:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-gmp-inspection-success-d-plex18002025-09-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-participate-hc-wainwright-conference-20252025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-presentation-israel-controlled-release-society-conference2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-appoints-dr-nurit-tweezer-zaks-cmo2025-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q3-2025-financial-results-update2025-11-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-stifel-2025-healthcare-conference2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-qtorn-pitavastatin-dsap2025-11-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/fda-awards-funding-palvella-phase-3-selva-trial2025-10-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-expands-qtorin-development2025-09-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-rapamycin-venous-malformations2025-09-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-phase-2-toiva-trial-enrollment-complete2025-09-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-leadership-appointment-david-osborne2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-investor-conferences-20252025-08-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-japan-patent-modified-stilbenoid2025-07-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q3-2025-financial-results2025-11-13T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-acquires-xepi-financing2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-moms-against-molluscum2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-september-investor-conferences2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-wells-fargo-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q2-2025-financial-results-update2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-launches-zelsuvmi-topical-gel2025-07-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-merger-channel-therapeutics2025-07-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/channel-therapeutics-reverse-stock-split-merger-pelthos2025-06-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-respect-lm-trial-results-sitc-meeting2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-q3-2025-results-business-highlights2025-10-30T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-cnside-diagnostic-platform-launch2025-10-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-unitedhealthcare-cnsid-assay-agreement2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-cprit-advance-payment2025-09-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-cnside-diagnostics-accreditation2025-09-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-hc-wainwright-conference-20252025-09-02T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-compliance-nasdaq-listing-criteria2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-respect-lm-trial-results-reyobiq2025-08-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-stockholders-equity-compliance2025-08-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/alphaton-capital-closes-financing-ton-token-acquisition2025-09-25T18:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/alphaton-capital-launches-ton-digital-asset-strategy2025-09-03T16:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-fiscal-year-results-20252025-07-25T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-compliance-nasdaq-requirements2025-06-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-compedica-stock-exchange2025-06-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-preclinical-results-mesothelioma-port-72025-04-28T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-resumes-enrollment-port-6-adport-6012025-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-nasdaq-compliance-extension2025-02-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTG/portage-biotech-private-financing-completion2025-01-30T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-q3-2025-results-axiomer-study-initiation2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-cta-authorization-ax-0810-investor-event2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-participate-investor-conferences-october-20252025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-presentation-rna-editing-summit-20252025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-cta-submission-phase-1-study-ax-0810-ntcp2025-06-26T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-upcoming-scientific-presentations-asgct-tides2025-05-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-webcast-presentation-citizens-life-sciences-conference2025-05-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-general-meeting-shareholders-20252025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-be-smart-esophageal-cancer-study2025-10-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-engages-redchip-investor-relations2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-thinkequity-conference-20252025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-crown-medical-collections-bankruptcy2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-explores-crypto-treasury-strategy2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-stockholders-approve-proposals-september-20252025-09-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-virtual-roadshow-september-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-special-meeting-shareholders-20252025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-financial-results-june-20252025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-reports-q3-2025-results-regulatory-updates2025-11-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-phase-2-regeneration-trial-results2025-11-06T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-participate-upcoming-conferences2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-abstracts-asn-kidney-week-20252025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-fda-accelerated-approval-rilparencel2025-07-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-participate-hc-wainwright-kidney-conference2025-07-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-domestication-delaware2025-07-01T16:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-exclusive-distribution-agreement2025-11-13T09:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-distribution-agreement-getz-healthcare2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-exclusive-distribution-agreement-saudi-arabia2025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-tulsa-pro-canada-distribution-rights2025-11-10T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-busch-center-500th-tulsa-procedure2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-stifel-2025-healthcare-conference2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-record-revenue-q3-20252025-10-07T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/texas-prostate-dallas-medical-center-tulsa-program2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-lake-street-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-q3-2025-financial-results-update2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-strategic-business-update2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-incyte-jak2v617f-agreement2025-11-04T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-ash-2025-abstracts2025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-appoints-katina-dorton-board2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-upcoming-healthcare-conferences2025-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-citizens-life-sciences-conference2025-05-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-announces-presentations-aacr-annual-meeting-20252025-04-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-jefferies-global-healthcare-conference2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-q3-2025-financial-results2025-11-07T15:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-q3-2025-financial-results2025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-appoints-matthew-hawryluk-cbo2025-11-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-virtual-kol-event-wilsons-disease-strategy2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-participate-investor-conferences2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-public-offering-august-20252025-08-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-public-offering-pricing2025-07-31T01:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q3-2025-financial-results2025-11-04T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-ceo-transition-larry-wood2025-07-24T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/water-iv-trial-aquablation-therapy-prostate-cancer2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q2-2025-financial-results2025-07-21T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/aquablation-therapy-category-i-code-medicare-20262025-07-15T01:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-investor-conferences-may-june-20252025-04-29T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-aquablation-therapy-aua-20252025-04-24T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-nasdaq-rule-56352025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-investor-conferences2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-update-q3-2025-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-accelerated-development-relutrigine-fda-feedback2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-public-offering2025-10-17T03:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-ulixacaltamide-phase-3-results-essential-tremor2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-borescope-development-jet-engines2025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-ar-systems-fighter-pilots2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-conference-call-november-20252025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-fall-2025-conference2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-reports-q4-fy-2025-results2025-09-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-expands-facilities-backlog2025-06-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-leadership-additions-digital-asset-strategy2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-closes-private-placements-digital-assets2025-10-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-private-placements-athir-tokens2025-09-29T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-reverse-stock-split2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-every-cure-drug-repurposing-collaboration2025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-q2-2025-results-update2025-08-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-shareholder-letter-chemo-fx-expansion2025-07-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-yorkville-partnership-ai-drug-discovery2025-07-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/predictive-oncology-3d-organoid-models-labcorp2025-06-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POAI/court-denies-renovaro-motion-expedited-trial-july2025-05-27T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-reports-q3-2025-results2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-rezatapopt-pynacle-trial-update2025-10-24T15:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-rezatapopt-presentation-aacr-nci-eortc-20252025-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-investor-conferences-20252025-05-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-acquires-kokomodo-cultivated-cacao-agfoodtech2025-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-expansion-intellectual-property-3d-immune-cells2025-04-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-collaboration-hemafund-ukraine-radiation-preparedness2025-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-secures-3-5-million-investment-shareholder2025-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-secures-investment-enters-cacao-market2025-01-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q3-2025-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-guggenheim-healthcare-conference2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-board-appointment-slanix-alex2025-10-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-phase-1b-alzheimers-trial-update2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-showcase-preciad-trial-design2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-private-placement-financing2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-0-8-million-offering2025-07-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-fast-track-pmn310-alzheimers2025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-corporate-update-q3-2025-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-update-beacon-ipf2025-06-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-ats-2025-conference-data2025-05-21T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-strategic-realignment-workforce2025-05-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-ats-2025-conference-presentations2025-04-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-pln-101095-phase-1-data2025-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-stockholder-rights-agreement2025-03-13T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-viral-blocking-formulation-results2025-11-06T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-positive-preclinical-results-pl14-allergen-blocking2025-10-06T12:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-submits-pre-sub-fda-pl-14-allergy-blocker2025-09-19T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-intranasal-delivery-pl14-allergy-blocker-study2025-09-12T11:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-regains-nasdaq-compliance2025-08-14T12:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasdaq-listing-hearings-panel2025-07-15T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-intranasal-delivery-results-cns-therapeutics2025-06-12T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasdaq-delisting-notice2025-05-23T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-positive-preclinical-data-nasal-protection2025-05-21T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-q3-2025-results-business-update2025-11-12T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-deucrictibant-acaa-2025-presentation2025-11-10T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-present-clinical-data-acaa-2025-meeting2025-10-23T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-closes-201-2-million-public-offering2025-07-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-pricing-175-million-offering2025-07-23T01:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-public-offering-ordinary-shares2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-topline-data-update-rapide-3-study2025-07-10T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-clinical-trial-data-deucrictibant-hae-summit-20252025-06-27T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-deucrictibant-eaaci-congress-20252025-06-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-third-quarter-2025-financial-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-positive-fda-feedback-bx011-phage-cocktail2025-11-04T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-bx004-fda-feedback-update2025-10-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ceo-presentation-hc-wainwright-conference2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-bx004-phase-2b-trial-update2025-08-19T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-phase-1b-2a-bx004-cystic-fibrosis-results2025-07-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-phase-2-study-voquezna-eoe2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-investor-conferences-20252025-11-03T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q3-2025-results-update2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-voquezna-phase-3-study-results2025-10-25T13:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-highlight-voquezna-acg-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-appoints-sanjeev-narula-cfo2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-clarifies-shareholder-ownership-changes2025-08-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-q3-2025-financial-results-growth2025-11-06T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fireside-chat-jefferies-conference-20252025-10-30T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-third-quarter-2025-financial-results2025-10-23T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-2025-acaa-meeting-abstracts2025-10-20T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-g-and-a-expense-reduction-update2025-10-06T15:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fda-acceptance-leniolisib-apds-children2025-10-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-promoted-euronext-amx-index2025-09-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-hc-wainwright-conference-20252025-09-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-appoints-kenneth-lynard-cfo2025-09-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-investor-conference-august-20252025-08-04T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-q3-2025-results-clinical-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-11-1-million-offering2025-11-11T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-sitc-2025-immunotherapy-data2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-conference-call-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-sitc-2025-presentation2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-expedited-approval-pds0101-hpv16-cancer2025-10-29T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-head-neck-cancer-trial-results2025-09-18T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-versatile-002-phase-2-trial-results2025-08-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-q3-2025-financial-results-vax-24-update2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-fill-finish-manufacturing-north-carolina2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-advances-vax-31-infant-phase-2-study2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-q2-2025-results-vax-31-update2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-first-quarter-2025-financial-results-update2025-05-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-dr-olivier-brandicourt-board2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-positive-results-vax-24-infant-phase-2-study2025-03-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-webcast-conference-call-vax-24-results2025-03-30T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-report-fourth-quarter-full-year-2024-results2025-02-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-poster-presentation-pcs499-asn-kidney-week-20252025-11-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-secures-strategic-investment2025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-portfolio-business-update2025-07-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-pricing-public-offering2025-06-17T16:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-intact-therapeutics-license-gastroparesis2025-06-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-bio-international-convention-20252025-06-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-asco-2025-abstracts2025-05-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-dr-david-young-presentation-orphan-drug-congress2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-medinvest-conference-20252025-03-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-2025-bio-ceo-investor-conference2025-02-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-fireside-chat-healthcare-conferences2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-q3-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-phase-2-study-pcrx-201-osteoarthritis2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-license-agreement-amacathera2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-third-quarter-2025-financial-results2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-pcrx-201-gene-therapy-data2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-qilu-pharmaceutical-anda-filing2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-exparel-data-amcp-nexus-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-whiteoak-application-exparel2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-establishes-ibogaine-operations-africa2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-phase-iib-study-adjustment-disorder2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-investment-psylabs-35000002025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-presentation-hc-wainwright-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-corporate-update-august-20252025-08-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-psylabs-ibogaine-production2025-07-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-dr-garcia-romeu-scientific-advisory-board2025-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-q3-2025-financial-results-highlights2025-11-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-guggenheim-healthcare-innovation-conference2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-participate-chardan-genetic-medicines-conference2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-hc-wainwright-investment-conference-20252025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reverse-stock-split-20252025-07-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-uplift-d-study-update2025-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-investor-conferences-20252025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-sharon-skare-clinical-operations2025-10-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-phase-1b-pali-2108-crohns-disease2025-10-20T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-canadian-patent-pali-21082025-10-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-cancels-special-meeting-stockholders2025-10-09T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-closes-138-million-offering2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-pricing-120-million-offering2025-10-01T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-special-meeting-adjourned-quorum2025-09-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-positive-pali-2108-phase-1b-data2025-09-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-phase-1b-trial-pali-2108-fscd2025-09-05T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-leadership-succession-business-updates2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-private-placement-175-million2025-10-03T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-positive-results-ov329-gaba-inhibitor2025-10-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-business-updates-q2-2025-results2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-btig-virtual-biotech-conference2025-07-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-immedica-ganaxolone-royalties-agreement2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-media-event-june-20252025-06-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-needham-conference-20252025-04-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-acceptance-ons-5010-wet-amd2025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-resubmits-bla-ons-50102025-11-03T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-type-a-meeting-update2025-09-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-euretina-innovation-spotlight-20252025-09-03T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-type-a-meeting2025-09-02T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-update-ons-5010-lytenava2025-08-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-q3-2025-financial-results-update2025-08-14T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-ophthalmology-innovation-summit-20252025-07-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-virtual-investor-conference2025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-appoints-bob-jahr-ceo2025-07-01T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-q3-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-third-quarter-2025-financial-results-earnings-call2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-appoints-steven-boyd-board-directors2025-10-28T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-appoints-anne-messing-as-cco2025-08-04T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-launches-novel-blood-collection-device2025-07-10T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-40-million-stock-repurchase-program2025-03-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-november-investor-conferences2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-180-million-private-placement2025-09-17T05:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-positive-interim-phase-1-results-orka-0012025-09-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/orka-001-phase-2a-trial-clearance2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-promotes-laura-sandler-coo2025-07-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-jefferies-conference-20252025-05-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-phase-1-trial-orka-0022025-05-20T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inducement-grants-nasdaq-rule-5635c42025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-publication-cancer-research2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-investor-conferences-november-20252025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-eortc-nci-aacr-conference-20252025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-appoints-kevin-brodbeck-cto2025-08-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-q2-2025-financial-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-cms-payment-reform-20262025-11-03T18:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-inducement-grants-nasdaq-rule-56352025-10-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-update-second-phase-3-renu-study2025-09-25T20:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-investor-conferences-september2025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q2-fy2025-results2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-cms-skin-substitute-payment-reform2025-07-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-reports-q4-full-year-2024-results2025-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-cancels-earnings-call-acquisition-paratek2025-03-20T01:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPTN/optinose-preliminary-q4-2024-revenue2025-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-corporate-update-settlement-leadership-changes2025-08-18T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-discontinues-wet-amd-trials2025-03-31T04:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-coast-phase-3-trial-results2025-03-24T04:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-phase-2b-wet-amd-publication2025-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-half-year-results-business-updates2025-02-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-drug-product-ppq-campaign-completed2025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-coast-final-week-52-patient-visit2025-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-presentation-oppenheimer-healthcare-conference2025-02-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-wet-amd-data-macula-society-meeting2025-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPT/opthea-investor-days-new-york-australia2025-01-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-financing-private-placement-debt-settlement2025-09-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-ocuvex-terminate-merger-agreement2025-09-26T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-proteomedix-immunovia-pancreasure-license-agreement2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-ocuvex-merger-agreement2025-07-16T12:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-positive-decision-nasdaq-hearings-panel2025-06-16T12:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-reverse-stock-split-special-meeting-results2025-06-11T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-receives-nasdaq-delisting-notice2025-05-22T20:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-ocuvex-business-combination2025-04-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-proclarix-clinical-validation-danish-cohort2025-03-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-business-update-fxr-program-sale2025-03-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONVO/organovo-fxr-program-acquisition-eli-lilly2025-02-25T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMIC/singular-genomics-acquisition-deerfield-management2025-02-21T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/insourced-dialysis-service-line-outset-medical2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-2025-stifel-healthcare-conference2025-11-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-third-quarter-2025-results2025-10-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/northwest-kidney-centers-outset-medical-collaboration2025-09-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-presents-morgan-stanley-conference2025-08-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-q2-2025-results-revenue-growth2025-08-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-names-first-chief-nursing-officer2025-07-30T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-goldman-sachs-healthcare-conference-20252025-06-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-q3-2025-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-inducement-grants-nasdaq-rule-56352025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-investor-conferences-20252025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-phase-3-opera-02-trial-sabcs-20252025-10-30T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-phase-1b-2-trial-palazestrant-ribociclib2025-10-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-clinical-trial-agreement-pfizer2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-present-bio-europe-2025-vienna2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-chairman-acquires-shares2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-clinical-trial-ncp2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-funding-urcosimod-neuropathic-corneal-pain2025-07-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-presentation-bio-international-convention2025-06-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-gpcrs-summit-presentation-urcosimod2025-05-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/fda-fast-track-urcosimod-neuropathic-corneal-pain2025-05-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-long-term-stability2025-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-q2-2025-shareholder-update2025-08-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-southern-star-research-onp-002-phase-iia-trial2025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-drug-manufacturing-agreement-onp-0022025-07-16T12:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-completes-16-5-million-offering2025-07-02T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-public-offering-preferred-stock-warrants2025-07-01T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-presents-bio-convention-neurotrauma-symposium-20252025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-one-for-thirty-reverse-stock-split2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-phase-ii-concussion-drug-trial-australia2025-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-webinar-on-concussion-treatment-onp-0022025-05-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-participate-traumatic-brain-injury-conference2025-04-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q3-2025-results-business-update2025-11-06T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-investor-conferences2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-investor-conferences-20252025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-first-quarter-2025-results-release2025-05-07T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-participate-needham-healthcare-conference2025-04-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-reports-successful-2024-sets-stage-2025-catalysts2025-03-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-btig-conference-20252025-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-prices-29-million-equity-offering2025-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-appoints-dr-paul-billings-cmo2025-01-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCX/oncocyte-expands-vitagraft-kidney-market-opportunity2025-01-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-conferences-november-december-20252025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grant-nasdaq-rule-5635c42025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q3-2025-results2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-achieves-randomization-in-sol-r2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-participate-scientific-conferences-october-20252025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-underwritten-offering-common-stock2025-09-30T11:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-day-axpaxli-progress2025-09-30T10:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-day-september-20252025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-q3-2025-financial-results-update2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-financial-results-and-milestones-20252025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-participate-november-investor-conferences2025-11-05T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-110-million-financing-privosegtor-development2025-10-30T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-raises-110-million-for-privosegtor-development2025-10-30T08:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-late-stage-pipeline-eyecelerator-aao-20252025-10-14T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q3-2025-results2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-webcast-november-2025-business-updates2025-10-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-present-industry-investor-conferences-october-20252025-10-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-kwangdong-license-agreement-ocu4002025-09-15T10:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-participate-hc-wainwright-global-investment-conference2025-09-02T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-positive-scientific-advice-ema-ocu410st2025-08-13T10:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-20-million-offering-20252025-08-12T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-new-appointments-retina-advisory-board-leadership2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-expands-energy-digital-assets2025-04-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-patent-bispecific-antibodies-china2025-03-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-egfr-mutant-lung-cancer-fda-alignment2025-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCEA/ocean-biomedical-malaria-vaccine-research-funding2025-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-stifel-healthcare-conference-20252025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-participate-stifel-2025-healthcare-conference2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-q3-2025-financial-results-release2025-10-30T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-commercial-patients-genio-system-us2025-10-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-us-commercial-patients-genio-system2025-10-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-transparency-notification-vestal-point-capital2025-10-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-expansion-middle-east-genio2025-09-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-expands-middle-east-presence2025-09-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-upcoming-investor-conferences2025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-reports-q3-2025-results2025-11-10T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-business-update-call-november-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-terumo-30-million-agreements2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-virtue-sab-trial-enrollment2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-georgia-innovation-summit2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-clinical-data-hrx-20252025-09-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-clinical-data-publication2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-private-placement-common-stock2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-q3-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-expansion-phase-1-trial-sim05052025-10-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-hc-wainwright-conference-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-nc605-osteogenesis-imperfecta-preclinical-data2025-07-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-partnership-antibody-drug-conjugate2025-06-16T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-ligachembio-lnc74-asco-20252025-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-presents-needham-healthcare-conference2025-04-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-fda-q-submission-gen-2-sync-alzheimers-dementia2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-regulatory-approval-gen-2-sync-israel2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-difs-neurostimulation-alzheimers-dementia-improvements2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-dr-robert-rothstein-appointment2025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-maxim-growth-summit-20252025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-gen-2-sync-alzheimers-clinical-results2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-us-patent-halo-clarity-device2025-09-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-live-investor-webinar-september-92025-08-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-appoints-justin-van-fleet-cfo2025-08-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-reports-q3-2025-results2025-11-04T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-poster-presentation-highlights2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-appoints-juan-sanchez-board2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-hc-wainwright-investment-conference2025-09-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-phase-1b-nxp900-initiation2025-08-11T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp800-nxp900-update-ovarian-cancer2025-07-31T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-drug-drug-interaction-study2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-fda-meeting-aversafentanyl2025-10-28T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-return-gareth-sheridan2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-brand-institute-fentanyl-patch2025-10-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-files-provisional-patent-aversat-technology2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-presentation-noble-capital-markets-conference2025-10-08T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-present-microcap-rodeo-conference2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-quarterly-report-revenue-aversa-fentanyl2025-09-10T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-announces-warrant-exercise-6-432025-09-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-emerging-growth-conference-20252025-08-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-positive-phase-1-data-nexiguran-amyloidosis2025-11-10T20:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-lonvoguran-ziclumeran-positive-data2025-11-08T22:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q3-2025-results-updates2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-update-magnitude-trials-nexiguran2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-nasdaq-rule-56352025-10-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-nexiguran-phase-1-trial-data-presentation2025-09-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-q3-2025-financial-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-peter-soukas-cmo2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-rule-56352025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-dan-dearen-board-directors2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-presentation-hc-wainwright-conference2025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-raymond-cohen-board-directors2025-07-31T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-combined-financings-58-million2025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-new-medical-coverage-michigan2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-third-quarter-2025-results2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-q3-2025-results-update-call2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-fda-clearance-functional-dyspepsia-treatment2025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-participate-lytham-partners-fall-2025-conference2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-new-medical-policy-coverage-700k-lives2025-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-achieves-milestone-fap-ibs-guidelines2025-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-roger-dansey-board2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-nx-1607-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-ash-annual-meeting-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-investor-conferences2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-250-million-offering2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-daybreak-pivotal-study-bexobrutideg-cll2025-10-22T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-nx-1607-esmo-congress-20252025-10-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-q3-2025-financial-results-update2025-10-09T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-gs-6791-preclinical-data-eadv-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-q2-2025-financial-results-guidance2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-cms-reimbursement-epilepsy-rns-system2025-08-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-strategic-cfo-transition2025-06-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-secures-75-million-debt-financing2025-06-04T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-nautilus-study-results-20252025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-update-tariff-status2025-04-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-rns-system-data-2025-aan-meeting2025-04-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-presentation-aan-20252025-04-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-sidoti-small-cap-conference-20252025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-fda-clearance-onerf-trigeminal-nerve-ablation-system2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-q3-fy2025-results-revenue-growth2025-08-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-third-quarter-fiscal-results-20252025-07-31T16:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-receives-notice-of-allowance-for-patent2025-07-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-patient-seizure-freedom-onerf-ablation-system2025-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-appoints-emily-johns-general-counsel2025-06-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medinvest-conference-20252025-05-29T17:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKGN/nkgen-biotech-funding-compliance-reporting-obligations2025-07-16T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-third-quarter-2025-financial-results2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-november-investor-conferences2025-10-30T17:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-poster-presentation-acr-convergence-20252025-10-22T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-hcw-home-series2025-07-23T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-appoints-shawn-rose-cmo-autoimmune-focus2025-06-06T12:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-april-investor-conference2025-04-01T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q3-2025-financial-results-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-conferences-november2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-phase-1-study-nmra-8982025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-nmra-215-weight-loss-preclinical-results2025-10-27T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-host-virtual-rd-day-october-272025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-strategic-review-maximize-stockholder-value2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-stockholder-rights-plan2025-10-27T20:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-affirms-bnc210-trial-update2025-10-20T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-fiscal-year-end-2025-results2025-09-29T20:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-presentation-hc-wainwright-conference2025-08-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-presentation-ascp-2025-annual-meeting2025-05-27T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-first-quarter-2025-business-updates2025-05-20T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-review-2024-highlights-2025-plans2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-therapeutics-nasdaq-opening-bell-20252025-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q3-2025-financial-results2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-financing-roluperidone-phase-3-trial2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-jefferies-london-healthcare-conference-20252025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-jefferies-london-healthcare-conference2025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-investor-conferences-november-20252025-11-03T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-healthcare-royalty-agreement-funding2025-10-31T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-royalty-monetization-agreement2025-10-31T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-clinical-updates-jnj-1900-nbtxr32025-10-24T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-updates-jnj-1900-clinical-program2025-10-24T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-field-evaluation-unit-buck-institute2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q3-2025-financial-results2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-september-investor-conferences2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-agreement-allen-institute-alzheimers-research2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-goldman-sachs-conference-20252025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-rule-56352025-11-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-corporate-update-q3-20252025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-medical-meeting-investor-conferences-november2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-stifel-2025-forum2025-09-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-ema-marketing-authorization-obicetrapib2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-broadway-trial-alzheimers-biomarkers2025-07-30T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-positive-alzheimers-data-broadway-trial2025-06-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-showcases-cancer-detection-solutions-medica-20252025-11-12T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-attend-garps-20252025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-attend-2025-maxim-growth-summit2025-10-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-pancreatic-cancer-biomarker-study-results2025-10-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-colorectal-cancer-screening-presentation2025-09-30T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-launch-coloalert-switzerland2025-09-23T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-coloalert-registration-uk2025-09-02T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-swiss-approval-coloalert2025-08-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-follow-on-offering-20252025-08-04T14:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-care-cooperation-agreement2025-07-23T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-investor-healthcare-conferences2025-11-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-myrisk-cancer-test-expansion2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-2025-nsgc-conference-advancements2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q3-2025-financial-results2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/genesight-results-depression-treatment-analysis2025-10-31T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-adds-f8-fxn-genes-foresight-panel2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sophia-genetics-liquid-biopsy-collaboration2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-precise-mrd-clinical-data-lancet-oncology2025-09-04T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/genesight-test-improves-depression-response-rates2025-09-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-proxy-statement-acquisition-details2025-09-23T23:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-q2-2025-financial-results-update2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-announces-securities-issue2025-05-19T19:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-explores-strategic-alternatives2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-phase-3-artistry-7-trial-update2025-03-25T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-q4-2024-results-clinical-milestones2025-03-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-presents-td-cowen-conference-20252025-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-cfo-transition-20262025-11-12T21:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q3-2025-financial-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-q3-2025-financial-results-release2025-10-08T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-moonlight-bio-t-cell-therapies2025-10-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-operational-restructuring-costs-profitability2025-09-22T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-signs-platform-license-agreement-adicet-bio2025-08-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-strategic-license-agreement-anocca-tcr-t-therapy2025-07-31T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-positive-phase-2b-results-met-097i2025-09-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-next-generation-obesity-portfolio-easd-20252025-09-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-september-investor-conferences2025-08-27T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-reports-q2-2025-results-progress2025-07-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-goldman-sachs-healthcare-conference-20252025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-positive-phase-1-data-amylin-candidate-met-233i2025-06-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-research-obesity-portfolio-ada-20252025-06-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTSR/metsera-present-bank-america-2025-healthcare-conference2025-05-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-new-board-members2025-03-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-acquisition-preferred-stock-dr-smith2025-02-13T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-appoints-evelyn-dan-board2025-02-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTNB/matinas-biopharma-nyse-noncompliance-notice2025-01-10T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q2-2025-financial-results2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-call-august-20252025-07-28T21:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-appoints-rajesh-asarpota-cfo2025-06-25T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-appoints-bernd-brust-ceo2025-06-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-2024-sustainability-report2025-05-21T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-postpones-earnings-release2025-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-mcrc-clinical-data2025-10-25T09:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-colorectal-cancer-data2025-10-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-petosemtamab-aacr-nci-eortc-conference2025-10-14T18:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-abstract-petosemtamab-aacr-conference-20252025-10-13T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-presents-2025-wells-fargo-healthcare-conference2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-q2-2025-results-business-update2025-08-07T19:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-q2-2025-financial-results2025-08-07T19:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRUS/merus-present-canaccord-genuity-growth-conference2025-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/day-one-biopharmaceuticals-acquire-mersana-therapeutics2025-11-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-third-quarter-2025-conference-call2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-business-update-q2-2025-results2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-reverse-stock-split2025-07-24T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-emile-phase-1-data-asco-20252025-06-02T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-investor-conferences2025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-business-update-q1-2025-results2025-05-15T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-restructuring-plan-emi-le-breast-cancer2025-05-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRSN/mersana-therapeutics-emile-presentations-asco-20252025-04-23T14:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-kathryn-penkus-corzo-board-appointment2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-ash-2025-mt-601-presentations2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-first-patient-ots-program2025-10-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-hc-wainwright-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-phase-1-apollo-study-update2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-fireside-chat-canaccord-conference2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-cellipont-collaboration-mt-6012025-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-lymphodepletion-mar-t-cells2025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-mar-t-cells-webcast2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-canaccord-genuity-conference2025-04-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-new-data-dll3-targeting-mp07122025-11-12T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-phase-1-2a-trial-mp0533-ash-20252025-11-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-sitc-2025-data-presentation2025-11-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-q3-2025-results-clinical-progress2025-10-30T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-h1-2025-financial-results2025-08-25T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-appoints-martin-steegmaier-cso2025-08-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-orano-med-preclinical-data-mp07262025-06-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-positive-data-phase-1-2a-trial-mp05332025-06-11T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-operational-efficiencies-cash-runway2025-06-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-investor-conferences-20252025-05-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-q3-2025-financial-results2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-fireside-chat-leerink-conference2025-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-update-clinical-programs2025-01-12T16:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-presentation-jp-morgan-conference-20252025-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-contract-research-development-award-20252025-11-06T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-enrollment-mn-001-clinical-trial2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-atherosclerosis-therapeutic-approach2025-10-30T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-presentation-ld-micro-conference-20252025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-completes-enrollment-combat-als-trial2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-combat-als-poster-presentation-symposium2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-shareholder-update-key-developments2025-09-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-presentation-hc-wainwright-conference-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-combat-als-trial-enrollment2025-08-26T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-signs-standby-equity-purchase-agreement2025-07-31T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-q3-2025-financial-results2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-new-data-copper-balance-wilson-disease2025-11-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-abstract-accepted-aasld-liver-meeting-20252025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-135-million-offering2025-09-24T03:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-alxn1840-copper-balance-wilson-disease2025-09-24T03:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-alxn1840-ana-2025-presentation2025-09-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-abstract-accepted-ana-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-expanded-access-program-mnpr-1012025-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-russell-3000-2000-inclusion2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-presentation-jefferies-global-healthcare-conference2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-phase-3-icon-1-trial-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-launches-al-mann-scholarship-diabetes2025-11-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-reports-q3-2025-financial-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-third-quarter-financial-results-call-20252025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fda-review-afrezza-children-diabetes2025-10-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-appoints-dr-ajay-ahuja-cmo2025-09-29T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-investor-conferences-september-20252025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-expansion-united-therapeutics-collaboration2025-08-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-wrapsody-trial-results2025-11-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-24-month-efficacy-results-wave-trial2025-11-03T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-q3-2025-results-guidance-update2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-pentax-c2-cryoballoon-technology2025-10-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q3-2025-results-announcement2025-10-03T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-scout-milestone-750000-patients2025-10-01T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-embosphere-ce-mark-knee-osteoarthritis2025-09-12T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/first-patient-enrolled-merit-medical-wrapsody-registry2025-08-18T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-prelude-wave-launch-snapfix-technology2025-08-07T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-autonomous-robotic-knee-surgery2025-07-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRM/zimmer-biomet-acquires-monogram-technologies2025-07-14T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRM/monogram-technologies-q1-2025-financial-results2025-05-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-offering-pricing2025-11-05T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-q3-2025-results-sonelokimab-data2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-velas-phase-3-results-sonelokimab2025-09-28T16:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-q2-2025-update2025-08-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-capital-markets-day-april-20252025-04-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-secures-500-million-financing-clinical-updates2025-04-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-initiates-new-clinical-trials-sonelokimab2025-01-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q3-2025-financial-results-update2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/lorundrostat-asn-kidney-week-20252025-11-07T23:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-investor-conferences2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-phase-2-explore-ckd-trial-asn-kidney-week-20252025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-phase-2-explore-osa-trial2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-launch-htn-trial-lorundrostat-hypertension2025-09-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-upsized-public-offering2025-09-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-pricing-public-offering2025-09-03T01:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-public-offering-common-stock2025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-growth-initiatives-new-leadership2025-10-14T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-nyse-compliance-notification2025-10-14T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-dawood-sayed-board2025-09-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-revenue-increase-q2-20252025-08-14T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-q2-2025-results-call2025-08-13T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-jason-papes-sales-marketing2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-eric-hines-ceo2025-08-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-compuflo-sales-painless-center2025-07-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-appoints-shanth-thiyagalingam-board2025-05-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-reports-revenue-business-update-q1-20252025-05-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-investor-conferences-20252025-11-12T20:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-second-quarter-results-20252025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-second-quarter-results-november-20252025-10-03T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-declares-quarterly-dividend2025-10-03T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-laboratories-strategic-financing-plan2025-08-18T18:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-fy25-results2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-third-quarter-2025-update2025-11-12T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-etrapamil-nasal-spray-psvt2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-etriapamil-aha-20252025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-conference-presentation-20252025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-public-offering-20252025-07-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-proposed-public-offering2025-07-11T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-fda-acceptance-cardamyst-response2025-07-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-fda-response-cardamyst-etripamil2025-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-q3-2025-results-pipeline-prioritization2025-11-11T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-mgx-001-hemophilia-a-preclinical-data2025-11-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-q2-2025-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-appoints-laurence-reid-board-directors2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-advancements-next-gen-genome-editing-asgct-20252025-05-14T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-present-scientific-meetings-20252025-05-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-publication-nature-communications-cast-systems2025-03-13T10:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-td-cowens-45th-health-care-conference2025-02-11T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-affordable-access-zepbound-wegovy2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-mgx-0024-avian-flu-defense2025-05-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-entry-high-growth-pouch-industry2025-04-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-expands-diabetes-market-diabetinol2025-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-launches-peachesrx-womens-telehealth2025-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-advances-avian-flu-research2025-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-h1n1-h5n1-research-advancement2025-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-exclusive-distribution-agreement-dermytol2025-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ME/23andme-sale-agreement-ttam-research-institute2025-06-13T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ME/23andme-voluntary-delist-nasdaq-deregister-sec2025-05-27T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ME/regeneron-acquires-23andme-court-supervised-sale2025-05-19T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-fda-meeting-rexlemestrocel-opioid-cessation2025-11-04T23:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-net-revenues-increase-q2-20252025-10-19T23:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-j-code-medicare-medicaid-services2025-10-03T01:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-cell-therapy-us-origin-tariffs2025-09-26T05:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/successful-launch-ryoncil-meso2025-09-15T01:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-convertible-notes-50-million2025-09-04T01:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/banner-year-mesoblast-fda-approval-ryoncil2025-08-29T00:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-20252025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/successful-commercial-launch-of-ryoncil2025-07-18T00:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-reports-q3-2025-results-update2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-stifel-2025-healthcare-conference2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-presentation-hc-wainwright-conference2025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-second-quarter-2025-financial-results2025-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-appoints-eric-risser-ceo2025-08-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-sagard-royalty-purchase-agreement2025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-goldman-sachs-healthcare-conference-20252025-06-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-q1-2025-financial-results-release2025-05-06T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-investor-conference2025-05-01T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q3-results-20252025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-third-quarter-2025-financial-results-release2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-closes-exosome-diagnostics-acquisition2025-09-15T21:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-q2-2025-results-acquisition-bio-techne2025-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-michael-holder-management-change2025-07-03T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q1-2025-results2025-05-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-q4-full-year-2024-results2025-02-26T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-fourth-quarter-full-year-2024-results2025-02-12T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-2024-revenues-2025-guidance2025-01-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-update-epieffect-randomized-controlled-trial2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-participate-upcoming-investor-conferences2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-comments-cy-2026-medicare-physician-fee-schedule2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-record-revenue-third-quarter-20252025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-third-quarter-2025-results-conference-call2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launches-epiexpress2025-10-06T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-sponsor-attend-sawc-fall-symposium2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-record-q2-2025-results2025-07-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-vaporox-strategic-collaboration2025-07-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-third-quarter-2025-financial-results2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-expands-gmp-manufacturing-facility-nexobrid2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-30-million-offering-ordinary-shares2025-09-29T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-nexobrid-approval-australia2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-nexobrid-european-burns-association-congress2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-presents-hc-wainwright-investment-conference2025-08-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-q2-2025-results-update2025-08-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/medi-wound-escharex-phase-ii-data-wound-closure2025-08-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-positive-interim-analysis-sknjct-0032025-03-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-phase-2-clinical-design-uae-bcc2025-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-update-sknjct-003-phase-2-study2025-02-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-standby-equity-agreement-delisting-tsxv2025-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-mash-cirrhosis-data2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-equity-awards-nasdaq-rule-56352025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q3-2025-financial-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-new-data-mash-program-aasld-20252025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-morgan-stanley-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-q3-2025-financial-results2025-11-11T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2025-q3-financial-results2025-10-28T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-raises-7-6-million-growth-capital2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-time-healthtech-companies-20252025-09-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/deepview-system-european-burns-association-congress2025-09-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-submission-fda-deepview-system2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/deepview-system-british-burn-association-conference2025-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-stanley-micek-coo2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-q3-2025-financial-results-updates2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-carb-x-funding-ser-1552025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-idweek-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-fda-feedback-ser-155-phase-22025-09-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-hc-wainwright-conference-20252025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-leadership-transition2025-07-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-asco-20252025-05-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-q3-2025-financial-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-november-investor-conferences2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-stifel-2025-forum2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-upsized-public-offering2025-09-25T01:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-proposed-public-offering2025-09-22T20:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-canvuparatide-phase-2-trial-results2025-09-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-2-trial-results-canvuparatide2025-09-19T20:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-1-trial-mbx-4291-obesity2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-andreas-moraitis2025-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-orphan-drug-designation-mb-1012025-07-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-regains-compliance-nasdaq-requirement2025-03-05T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-sale-fixed-assets-exit-facility2025-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-regains-nasdaq-compliance2025-02-11T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-closes-8-million-public-offering2025-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-public-offering-pricing2025-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBIO/mustang-bio-reverse-stock-split2025-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-endovascular-robotic-system-release2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-system-debut-symposium2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-logistics-partner-liberty-system2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-final-closing-preferred-investment-options2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-patent-japan-global-ip-portfolio2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-fda-clearance-liberty-robotic-system2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-preferred-investment-options-exercise2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-fda-clearance-liberty-system-conference2025-09-09T12:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-q3-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-asn-kidney-week-20252025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-investor-conferences-20252025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-appoints-herve-hoppenot-chairman2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-oversubscribed-private-placement-150-million2025-09-11T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-positive-phase-1-results-mze7822025-09-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-appoints-misbah-tahir-cfo2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-jefferies-2025-conference2025-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-trial-progress-aacr-20252025-10-27T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-nsclc-trial-results2025-10-23T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-private-placement-funding-phase-ii-trial2025-10-13T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-digital-asset-treasury-strategy2025-10-07T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-phase-2-trial-grant2025-09-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-101-phase-2-trial-nsclc2025-09-11T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-abstract-poster-presentation-2025-iaslc2025-09-05T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-interim-clinical-data-publication2025-08-27T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-european-patent-telomere-targeting-agents2025-08-13T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-phase-3-trial-update2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-clinical-plan-lyr-210-enlighten-22025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-15-million-offering2025-06-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYRA/lyra-therapeutics-enlighten-2-phase-3-trial-results2025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q3-2025-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-acquires-lyl273-car-t-cell-therapy2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-phase-1-2-ronde-cel-ash-meeting2025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-phase-3-car-t-cell-trial-aggressive-lymphoma2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-september-investor-conferences2025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-private-placement-funding2025-07-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-hcw-home-series-participation2025-06-23T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-phase-1-2-lyl314-data2025-06-17T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-strengthens-leadership-team2025-06-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2025-financial-results2025-11-05T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-public-offering-private-placement2025-10-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-offering-common-stock2025-10-16T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-fda-accelerated-approval-lx20062025-10-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-fda-breakthrough-therapy-lx20062025-07-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-partnership-advance-cardiac-rna-therapeutics2025-06-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-80-million-financing-genetic-medicines2025-05-27T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-jefferies-2025-conference2025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-hfpef-data-aha-20252025-11-08T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-benefits-patient-populations-ahead-of-sessions-20252025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-pilavapadin-phase-3-development2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-roundtable-chronic-pain-policy2025-10-08T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-update-fda-zynquista2025-09-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/pilavapadin-dpn-pain-reduction-easd-neurodiab2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-pilavapadin-clinical-data-presentations2025-09-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-tender-offer-delisting-nasdaq2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-shareholders-tender-shares-xoma-royalty2025-11-10T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-egm-rescheduled-november-20252025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-reports-q2-2025-results-corporate-update2025-08-13T20:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-therapeutics-full-waiver-rvo-payment-obligation2025-04-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-evaluation-strategic-options-shareholder-value2025-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LVTX/lava-doses-first-patient-phase-1-lava-1266-study2025-01-10T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-q3-2025-financial-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nomlabofusp-friedreichs-ataxia-study2025-09-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-conference-call-nomlabofusp2025-09-28T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-public-offering-20252025-07-31T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-public-offering-pricing2025-07-30T03:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-public-offering2025-07-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nonclinical-data-nomlabofusp-friedreichs-ataxia2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-fda-recommendations-nomlabofusp2025-06-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-q3-2025-financial-results-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-bio-pharma-award-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-preclinical-data-certepetide-adc2025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-catalent-adc-license-agreement2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-cendifox-trial-results2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-warpnine-ilsta-trial-enrollment-update2025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-q3-2025-results-business-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-inducement-grants-nasdaq-listing-rule-5635c42025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/alcon-acquires-lensar-merger-agreement2025-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-fourth-quarter-full-year-2024-results2025-02-19T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-upcoming-investor-conferences2025-11-12T21:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-third-quarter-2025-earnings-announcement2025-10-09T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-presents-bank-america-healthcare-conference-20252025-05-05T20:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-present-needham-virtual-healthcare-conference2025-04-01T19:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-spartan-capital-conference-20252025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-q4-2025-priorities-lb-100-acquisition-plans2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-board-appointments-cfo2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-corporate-update2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-1-5-million-offering2025-07-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-5-million-private-placement2025-07-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-us-patent-stem-cell-therapy-aging-frailty2025-11-12T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-third-quarter-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-dr-joshua-hare-npr-interview-hlhs-therapy2025-10-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-participate-roth-healthcare-conference-20252025-10-06T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/george-paletta-elected-longeveron-board2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-attend-alliance-regenerative-medicine-meeting2025-09-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-leadership-updates2025-09-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-presents-hc-wainwright-investment-conference2025-08-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-positive-results-phase-2a-lp-10-oral-lichen-planus2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-delisting-nasdaq-capital-market2025-06-20T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-us-patent-diagnostic-technology2025-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-collaboration-cook-myosite-lp-3102025-06-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-phase-2a-data-lp-310-oral-lichen-planus2025-05-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-lp-10-oral-lichen-planus-presentation2025-04-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-positive-phase-2a-results-lp-310-oral-lichen-planus2025-04-22T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-phase-2a-trial-lp-310-oral-lichen-planus2025-04-08T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIPO/lipella-pharmaceuticals-podcast-michael-chancellor2025-03-31T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-third-quarter-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-participate-november-investor-conferences2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-investor-day-december-20252025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-sq-innovation-fda-approval-lasix-onyu2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-closes-convertible-senior-notes-offering2025-08-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-pricing-convertible-senior-notes-offering2025-08-12T03:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-investor-conferences-20252025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-financial-results-september-20252025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-commercial-manufacturing-partner2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-polypeptide-collaboration-peptide-manufacturing2025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-industry-events2025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-inducement-grant-nasdaq-rule-56352025-09-23T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-contract-pharma-conference2025-09-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q3-2025-financial-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-vizz-commercial-availability2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-investor-medical-conferences2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-fda-approval-vizz-presbyopia-treatment2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-nmpa-submission-lnz100-presbyopia2025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-thea-license-agreement-lnz100-canada2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-lotus-pharmaceutical-license-agreement2025-05-09T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-q3-2025-results-highlights2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-ash-annual-meeting-20252025-11-03T16:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q3-2025-results2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-morgan-stanley-conference-20252025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-carlos-santos-cfo2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-5-year-survival-data-asco-20252025-06-03T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-oncologic-hematologic-developments-asco-eha-asgct2025-05-22T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-event-asco-20252025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-reports-q3-2025-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-precise-sg100k-proteomics-collaboration2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q2-earnings-call-20252025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotech-sale-somalogic-illumina2025-06-23T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-proteomics-roundtable-webcast-series2025-05-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-new-product-innovations-aacr-20252025-04-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q3-2025-results-business-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-november-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-579-preclinical-data-acr-meeting2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-eadv-ers-congresses2025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-brian-adams-appointment2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-public-offering-250-million2025-06-27T03:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-activates-clinical-trial-site-uab2025-11-04T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-phase-1-1b-trial-update2025-09-08T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-presentation-update-hc-wainwright-conference2025-08-29T12:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-dr-james-lee-advisory-board2025-06-11T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-updated-interim-data-pas-004-asco-20252025-06-02T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-preclinical-data-pas-004-inhibits-ets22025-05-20T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q3-2025-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-fda-designation-hsv1-kb8012025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-fda-approval-vyjuvek-label-update2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-presents-cantor-global-healthcare-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-kb707-oncology-update2025-08-21T16:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-vyjuvek-approval-japan-deb2025-07-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/jeune-positive-results-phase-1-kb304-wrinkles2025-07-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-q3-results-updates-on-krro-1102025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-participate-investor-scientific-conferences-september-20252025-09-02T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-q2-2025-financial-results-updates2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-receives-ema-orphan-drug-designation-krro-1102025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-appoints-loic-vincent-cso2025-04-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-full-year-2024-financial-results2025-03-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/krro-110-orphan-drug-designation-aatd2025-03-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-present-td-cowen-health-care-conference2025-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-jefferies-conference-20252025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q3-2025-results2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-orphan-drug-designation-kpl-387-pericarditis2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-investor-conferences-september2025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q2-2025-financial-results2025-07-24T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-phase-2-3-trial-kpl-387-recurrent-pericarditis2025-06-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-carly-pearce-life-disrupted-campaign2025-04-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/largest-real-world-study-wearable-defibrillators-kmts2025-11-10T14:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-ace-pas-trial-results-aha-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-stifel-2025-conference2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-appoints-timothy-moran-chief-business-officer2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-cardiac-recovery-system-hfsa-20252025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-dr-elizabeth-kwo-appointment2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-q1-fiscal-2026-results2025-09-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-top-workplaces-20252025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-reports-strong-financial-results-q3-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-cytogam-cmv-kidney-transplant-trial2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-q3-financial-results-november-20252025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-present-stifel-2025-healthcare-conference2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-participate-september-investor-conferences2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fda-approval-plasma-collection-center-houston2025-08-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-announces-q2-results-20252025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-global-operations-products-availability2025-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-expands-specialty-bracing-portfolio2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-participate-upcoming-conferences2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q3-2025-financial-results2025-10-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-fda-approval-3p-pediatric-plating-platform2025-10-28T20:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q3-2025-revenue-guidance2025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-verteglide-first-procedures-eos2025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-my01-distribution-agreement2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-appoints-kelly-fischer-board2025-08-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-chase-phase-2b-trial-results2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-presentation-hc-wainwright-conference2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-appoints-todd-bazemore-ceo2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-q2-2025-results-and-update2025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-presents-hc-wainwright-ophthalmology-conference2025-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-kol-event-kpi-012-pced-treatment2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-presentation-jefferies-global-healthcare-conference2025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-fda-clearance-ind-phase-2a-trial2025-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-financing-parkinsons-trial2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-names-jean-fallacara-brand-ambassador2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-launch-pre-orders2025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-chris-webber-nugevia-ambassador2025-08-19T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-mnd-launch2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-jotrol-advancement2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-regains-nasdaq-compliance2025-07-10T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-pwr-launch2025-06-30T19:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-glo-launch2025-06-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-preclinical-safety-profile-jade1012025-11-08T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-participate-upcoming-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-new-data-jaDE101-asn-kidney-week-20252025-10-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jadebiosciences-jade201-autoimmune-diseases2025-10-07T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-135-million-private-placement2025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-phase-1-trial-jade1012025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-q2-2025-financial-results-update2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-investor-conferences-20252025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-appoints-brad-dahms-cfo2025-07-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q3-2025-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-investor-conferences-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-30-million-offering2025-09-19T04:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-public-offering-briquilimab2025-09-18T20:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-corporate-reorganization-cost-cutting2025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-briquilimab-update-csu2025-07-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-briquilimab-eaaci-congress-20252025-06-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-reports-q3-2025-financial-results2025-11-06T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-third-quarter-2025-financial-results-call2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-webcast-revolution-clinical-program-vyd23112025-10-28T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-us-ind-clearance-vyd2311-covid2025-10-06T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-paul-b-bolno-to-board2025-09-24T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-kristie-kuhl-communications-officer2025-09-17T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/spear-study-group-long-covid-antibody-study-design2025-09-04T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-participate-upcoming-investor-conferences2025-08-27T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-closing-57-5-million-public-offering2025-08-22T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-announces-50-million-public-offering2025-08-21T03:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-temporary-suspension-euronext-paris2025-11-13T07:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-temporary-trading-halt-euronext-paris2025-11-13T07:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-public-offering-phase-3-trial-funding2025-11-12T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-launch-public-offering-125-million2025-11-12T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/assemblee-generale-mixte-inventiva-novembre-20252025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/combined-general-meeting-november-2025-documents2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-at-the-market-offering-iva2025-10-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-new-atm-program-100-million2025-10-14T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-acquisition-concentra-biosciences2025-07-21T11:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-therapeutics-wind-down-operations2025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/galaxies-lung-201-results-belrestotug-dostarlimab2025-05-13T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/galaxies-lung-201-results-itos2025-05-13T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/galaxies-lung-201-results-belrestotug-dostarlimab-itos2025-05-13T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-financial-results-q1-20252025-04-29T21:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-reports-q1-2025-financial-results2025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITOS/iteos-preclinical-data-eos-215-aacr-20252025-03-26T15:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-q4-2024-results2025-02-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/johnson-johnson-acquires-intra-cellular-therapies2025-01-13T11:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-settles-caplyta-patent-litigation2025-01-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ITCI/intra-cellular-therapies-jp-morgan-conference-20252025-01-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-third-quarter-2025-financial-results2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-rally-mf-phase-2-trial-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-conferences-20252025-10-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-upsized-public-offering-250-million2025-10-21T04:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-public-offering-common-stock2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-update-hematology-portfolio-objectives2025-10-20T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-phase-1b-trial-data-asn-kidney-week-20252025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-fda-national-priority-voucher-bitopertin-epp2025-10-16T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-nda-bitopertin-epp2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-third-quarter-earnings2025-10-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-ai-advanced-imaging-ion-system2025-10-08T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-real-time-surgical-insights-da-vinci-52025-09-12T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-demonstrates-telesurgery-capabilities2025-07-16T13:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/vessel-sealer-curved-fda-clearance2025-07-10T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitives-da-vinci-5-surgical-system-ce-mark2025-07-02T13:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/dan-larson-robotic-surgery-success-story2025-05-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-ceo-transition-announcement-20252025-05-15T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-fda-clearance-da-vinci-single-port2025-05-01T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-americas-growth-leaders-20262025-11-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-reports-third-quarter-2025-results2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-third-quarter-2025-financial-results-call2025-10-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-board-transition-anthony-vuoto-retires-joe-kiani-appointed2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-participate-wells-fargo-healthcare-conference-20252025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-fda-clearance-mridium-3870-infusion-pump2025-05-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-first-quarter-2025-financial-results2025-05-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-first-quarter-2025-financial-results-call2025-04-28T13:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-third-quarter-2025-financial-results2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-nasdaq-listing-compliance2025-09-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-second-quarter-2025-financial-results2025-07-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-dame-trial-first-patient-enrolled2025-06-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-preliminary-results-q1-20252025-04-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-strategic-vision-call-april-20252025-04-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-phase-1-2-trial2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-financial-results-q3-2025-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-meeting-opgx-lca5-advancement2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-23-million-offering2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-inducement-grant-nasdaq-rule-56352025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-gma-spotlight-gene-therapy2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-chardan-genetic-medicines-conference-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-present-october-2025-conferences2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-positive-pediatric-data-opgx-lca5-trial2025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-q3-2025-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-new-beta-islet-program-type-1-diabetes2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-presentation-chardan-conference2025-10-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-hc-wainwright-conference-20252025-08-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-eular-2025-presentations2025-05-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-asgct-2025-presentations2025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-fireside-chat-preclinical-programs2025-04-15T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q3-2025-results2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-nsclc-clinical-data2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-third-quarter-2025-financial-results-webcast2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-inducement-grants-nasdaq-rule-56352025-10-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-conference-presentations2025-08-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-amtagvi-health-canada-approval-advanced-melanoma2025-08-18T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-financial-results-q2-20252025-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-participation-investor-conferences2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-preclinical-data-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-phase-3-results-cylembio-keytruda-esmo-20252025-10-20T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-update-pre-bla-meeting-fda2025-09-29T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-esmo-2025-abstract-presentation2025-09-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-q2-2025-financial-results-business-highlights2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/iobiotech-cylembio-keytruda-phase-3-trial-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-participation-cowen-jefferies-conferences2025-05-20T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-postpones-2025-annual-meeting2025-06-20T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-energy-3-trial-results2025-05-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-enpp1-deficiency-publication-impact2025-04-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-participate-needham-healthcare-conference2025-03-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-enpp1-deficiency-pivotal-program-update2025-03-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-td-cowen-conference-20252025-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INZY/inozyme-pharma-inz-701-enpp1-deficiency-presentation-chop-20252025-02-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-q3-2025-results-business-update2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-maxim-growth-summit-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-phase-2-mindful-trial-results-alzheimers2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-cordstrom-manufacturing-success2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-carepctrial-results2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-minful-trial-findings-video-release2025-07-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q3-2025-results-and-clinical-highlights2025-11-05T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-sitc-presentation2025-10-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-appoints-dr-holcomb-board2025-09-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-dr-jennifer-buell-car-tcr-summit2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-appoints-dr-terese-hammond2025-09-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q2-2025-results2025-08-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-corporate-update-q2-20252025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-inkts-solid-tumor-therapy2025-07-15T12:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-complete-remission-testicular-cancer2025-07-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-q3-2025-financial-results2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-clinical-update-decoy202025-09-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-hc-wainwright-conference-20252025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-additional-sale-private-placement2025-07-01T12:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reverse-stock-split2025-06-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-phase-1b-2-trial-decoy20-tislelizumab2025-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-dr-newman-cytokine-summit2025-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-q3-2025-results-business-highlights2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-inb-100-phase-1-trial-expansion-ohio-state2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-inb-619-b-cell-depletion-autoimmune2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-inb-200-four-years-remission-glioblastoma-trial2025-06-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-phase-1-inb-200-gbm-data2025-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-preclinical-data-inb-619-asgct-20252025-05-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-isct-2025-gamma-delta-t-cell-manufacturing2025-05-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-present-clinical-preclinical-data-gamma-delta-t-cell-platform2025-04-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-corporate-updates-financial-results-q2-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-batoclimab-six-month-remission-graves-disease2025-09-03T16:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-next-phase-growth-leadership-changes2025-04-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-positive-results-batoclimab-mg-cidp-studies2025-03-19T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-investor-webcast-batoclimab-results2025-03-18T20:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-reports-financial-results-q3-20242025-02-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-announces-450-million-private-placement2025-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-q3-2025-financial-results-updates2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-discusses-overall-survival-data-phase-2a-trial2025-09-26T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-175-million-offering-sanofi2025-09-25T04:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-public-offering-sanofi-investment2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-appoints-dr-thomas-schall-chairman-board2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-closes-25-million-private-placement2025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-clinical-supply-agreement-lilly-atebimetinib2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-imm-529-fda-approval-phase-2-trial2025-11-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-clinical-trial-update-imm-529-travelan2025-10-31T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-q1-fy26-sales-growth2025-10-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-shareholder-update-projects-progress2025-10-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-partners-with-investorhub2025-08-27T02:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-fy25-global-sales-exceed-projection2025-07-17T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-travelan-highest-sales-history2025-04-10T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-calmino-ibs-treatment-launch2025-03-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-clinical-proof-of-concept-tcr-bispecifics2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-amie-krause-chief-people-officer2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/anzu-cel-prame-cell-therapy-esmo-20252025-10-20T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-venkat-ramanan-cfo2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-q2-2025-financial-results-update2025-08-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203-prame-cell-therapy-asco-20252025-05-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203-asco-2025-presentation2025-04-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-q3-2025-financial-results-business-update2025-11-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-webcast-ovarian-cancer-immunotherapy2025-11-10T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-immunotherapy-ovarian-cancer2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-ovarian-cancer-treatment2025-11-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-third-quarter-2025-conference-call2025-11-06T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-ovation-3-study-update2025-11-04T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovation-3-advanced-ovarian-cancer2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-2-ovation-2-sitc-presentation2025-10-23T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-rd-day-ovation-3-study-advanced-ovarian-cancer2025-10-20T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-present-placcine-technology-vaccine-conferences2025-10-17T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-appoints-chief-commercial-officer-nxc-201-launch2025-11-12T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nxc-201-ash-2025-presentation2025-11-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-guggenheim-healthcare-conference-20252025-10-14T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-ash-2025-abstract-presentation2025-10-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-presents-piper-sandler-conference2025-10-01T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nexicart-2-enrollment-milestone2025-09-18T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/nancy-chang-joins-immix-biopharma-board2025-09-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-goose-capital-investment2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-stifel-2025-healthcare-conference2025-08-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-other-serious-diseases-strategy2025-08-06T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/eftisarc-neo-phase-ii-results-ctos-20252025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-rd-tax-incentive-france2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q1-fy262025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/primary-endpoint-met-eftisarc-neo-phase-ii-immp2025-10-20T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-esmo-congress-2025-nsclc-treatment2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-fda-project-optimus-completion2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-tacti-004-phase-iii-update-nsclc2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-phase-ii-trial-neoadjuvant-efti-breast-cancer2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-eftisarc-neo-phase-ii-ctos-20252025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-positive-fda-feedback-efti-head-neck-cancer2025-08-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-q3-2025-results-progress-2026-launch2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-third-quarter-2025-results-webinar-conference2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-new-vp-marketing-transplant-assay-launch2025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-reports-kidney-transplant-immune-reset-therapy2025-10-06T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-kidney-transplant-conferences2025-09-24T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-positive-strategic-update2025-09-08T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-enrolls-first-patient-graftassuredx-trial2025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-participate-nyc-investment-conferences-september-20252025-08-26T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-q2-2025-results-graftassuredx-launch2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-release-q2-2025-results-needham-conference2025-08-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-investor-conferences-november-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-data-hepatitis-b-aasld2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q3-2025-financial-results-update2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q2-2025-financial-results-call2025-07-31T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-2025-jefferies-global-healthcare-conference2025-06-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-hiv-functional-cure-croi-20252025-03-10T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-timothy-pigot2025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-q2-2025-results2025-08-14T20:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-david-mcintyre-cfo2025-04-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-expansion-senior-leadership-team2025-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-appoints-mark-iwicki-ceo-growth2025-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-acquisition-concentra-biosciences2025-07-01T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGMS/igm-biosciences-strategic-update-autoimmunity-pipeline2025-01-09T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-positive-phase-2a-data-inf904-hidradenitis-csu2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-guggenheim-healthcare-conference2025-10-21T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-regains-compliance-nasdaq-minimum-bid-price2025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-september-investor-conferences2025-08-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-q2-2025-results-business-update2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-report-second-quarter-2025-results2025-07-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-nasdaq-deficiency-notice-minimum-bid-price2025-07-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-vilobelimab-phase-3-trial-outcome2025-05-28T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participate-investor-conferences-20252025-05-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-third-quarter-results-november-20252025-11-05T15:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-therapy-results2025-09-29T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-neutralize-aki-trial-update2025-09-24T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-hc-wainwright-conference-20252025-09-04T22:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-health-economic-study2025-09-02T12:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-neutralize-aki-trial-enrollment-milestone2025-08-06T12:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-4-4-million-offering2025-07-31T19:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-new-ceo-management-changes2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-preliminary-sales-results-q3-20252025-10-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-new-ceo-olivier-te-boekhorst2025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-bank-debt-refinancing2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-ceo-succession-planning2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-virtual-annual-meeting-20252025-06-05T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-radnet-acquisition-vote-recommendation2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-reports-q1-2025-financial-results2025-05-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-microsoft-collaboration-mammography-solutions2025-04-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-appoints-mark-koeniguer-cco2025-04-08T14:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-fourth-quarter-full-year-2024-results2025-03-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-ramsoft-partnership-ai-mammography-solutions2025-03-05T19:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/koios-medical-icad-partner-breast-cancer-detection-ecr-20252025-02-26T19:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-ai-research-ecr-20252025-02-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICAD/icad-pre-announces-estimated-q4-2024-revenue2025-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-q2-2025-results2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-fda-clearance-cusa-clarity2025-11-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-2025-financial-results2025-10-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-2025-results-call2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-neurosurgical-portfolio-cns-meeting2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-appoints-new-cmo2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-leadership-presentation-conferences2025-08-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-acclarent-aera-pediatric-registry2025-07-02T20:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-veithsymposium-2025-presentations2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-q3-2025-financial-results-business-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-phase-3-trial-results-kidney-week-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-q3-financial-results-november-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-autologous-vein-comparison2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-60-million-oversubscribed-offering2025-10-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-ukraine-combat-results2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-expansion-intellectual-property-bioengineered-esophagus2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-ctev-coronary-bypass-graft-preclinical-data2025-09-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-patients-outcomes-publication2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-business-update-fq1-2026-results2025-09-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-conference-participation-investor-webinar2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fda-breakthrough-device-aortic-stenosis2025-06-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-patent-granted-ecg-assessment2025-06-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-signs-first-myovista-insights-customer2025-05-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-ceo-andrew-simpson-emerging-growth-conference-822025-05-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-investor-webinar-may-14-20252025-05-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-adds-key-advisors-scientific-board2025-05-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-launch-myo-vista-insights-platform2025-05-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-sitc-2025-presentation2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-q3-2025-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-fast-track-wtx-1242025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-sitc-2025-poster-presentations2025-10-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-kidneycan-summit-20252025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-bio-international-convention-20252025-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-jefferies-conference-20252025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-q2-2025-financial-results2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-acquisition-xoma-royalty2025-08-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLVX/hillevax-reports-2024-financial-results2025-03-28T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-delisting-notification-nasdaq2025-05-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-new-day-diagnostics-partnership2025-05-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-reverse-stock-split2025-03-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HEPA/hepion-pharmaceuticals-9-million-public-offering2025-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-immune-checkpoint-inhibitor-sitc20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-preclinical-data-tce-program-sitc-20252025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-participates-virtual-investor-segment2025-10-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-participate-maxim-growth-summit-20252025-10-16T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-poster-presentations-sitc-20252025-10-16T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-virtual-investor-tcell-engager-program2025-09-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-congratulates-wugen-equity-financing2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-trbc-pembrolizumab-immune-checkpoint-inhibitor2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-positive-results-tcell-engager-study2025-09-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-second-generation-immune-checkpoint-inhibitor2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2025-earnings-call2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-expands-distribution-agreement-fisher-scientific2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-stephen-denelsky-board2025-09-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-ceo-succession-plan-appointment-directors2025-07-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-john-duke-board-appointment2025-06-02T20:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q3-2025-financial-results-update2025-11-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-phase-3-trial-pirfenidone-pneumoconiosis2025-10-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hydronidone-phase-3-results-aasld-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hc-wainwright-conference-20252025-09-05T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-appoints-dan-weng-board2025-08-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-first-dosing-phase-1-trial-f230-pah-china2025-06-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-public-offering-closure2025-05-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-pricing-public-offering2025-05-23T00:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-public-offering-common-stock2025-05-22T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-q3-2025-results-revita-momentum2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-q3-2025-financial-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-rjva-002-preclinical-results-obesity2025-10-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-60-million-offering2025-09-26T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-weight-loss-maintenance2025-09-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-expands-board-of-directors2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-closes-23-million-public-offering2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-20-million-public-offering2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-enrollment-update-gtb-3650-phase-1-trial2025-10-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-centurion-bahamas-summit-20252025-10-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-hc-wainwright-conference-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-advances-cohort-3-gtb-3650-phase-1-trial2025-08-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-appoints-new-board-member2025-06-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-advances-gtb-3650-phase-1-trial2025-05-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-ipf-study-interim-results2025-09-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-presentation-hc-wainwright-conference2025-09-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-webull-financial-webinar-20252025-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-ceo-participates-virtual-investor-segment2025-07-31T17:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-virtual-investor-conference-20252025-07-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-study-gr-0621-ipf-enrollment-complete2025-07-01T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-gr0621-inflammation-fibrosis-data2025-05-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-virtual-investor-closing-bell-series2025-05-21T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-q2-2026-financial-results-update2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-abstract-accepted-svin-meeting2025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-secures-funding-fda-review-gtx-1042025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-strive-on-trial-results-20252025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-us-patent-iv-dosing-regimen-gtx-1042025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-presentation-hc-wainwright-conference2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-gtx-104-fda-review2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-q3-2025-results-highlights2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-upcoming-healthcare-investor-conferences2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-ada-poster-presentations-accg-26712025-06-20T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-reports-q3-2025-financial-results2025-11-05T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-participate-fireside-chat-hc-wainwright-conference2025-09-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-appoints-eric-groen-executive-team2025-07-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-fireside-chat-citizens-conference-20252025-05-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-pricing-offering-common-stock2025-03-25T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-fda-approval-pathway-olvi-vec2025-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-newsoara-positive-phase-1b-2-data-olvi-vec2025-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-q3-2025-results2025-11-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-third-quarter-earnings-release2025-10-16T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-launches-anthem-elbow-fracture-system2025-10-14T20:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-jury-verdict-life-spine2025-08-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-leadership-transitions-q2-2025-sales-results2025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-durapro-navigation-system-launch2025-07-15T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-share-repurchase-program2025-05-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-private-offering-senior-notes-acquisition-merus2025-11-10T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-fireside-chat-jefferies-conference-london2025-11-05T17:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-ash-20252025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-tender-offer-merus-shares2025-10-21T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-endometrial-cancer-data2025-10-18T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-darzalex-sales-q3-20252025-10-14T10:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-acquires-merus-late-stage-pipeline2025-09-29T05:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-stock-units-warrants-grant-employees2025-09-25T23:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-q3-2025-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-highlight-gb3226-program-ash-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-reports-full-year-2024-financial-results2025-03-19T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-participate-upcoming-investor-conferences2025-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-mrt-8102-preclinical-data-aha-20252025-11-08T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q3-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-mrt-6160-acr-convergence-20252025-10-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-novartis-collaboration-degraders-immune-diseases2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-phase-1-study-mrt-8102-inflammation2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-science-publication-molecular-glue-degraders2025-07-03T18:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-austria-expansion2025-10-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-expansion-belgium2025-10-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-portugal-flamingo-01-trial2025-09-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-trial-ireland2025-09-18T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-glsi-100-fda-fast-track2025-09-10T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/noble-capital-markets-initiates-research-coverage-glsi2025-08-20T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-internal-clinical-operations2025-08-19T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-romania-expansion2025-08-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-ceo-interviews-update2025-08-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-update2025-04-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-financial-results-update-november-20252025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-reports-financial-results-business-update-20252025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-new-data-glpg5101-ash-20252025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-board-changes-business-development-focus2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-board-changes-strategic-focus2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/glpg3667-differentiation-tyk2-inhibitors-acr-20252025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-glpg3667-acr-convergence-2025-data2025-10-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-cell-therapy-activities-reduction2025-10-21T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wind-down-cell-therapy-business2025-10-21T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-novel-therapies-symposium-2025-ecnp2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-global-pivotal-program-plans2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-ind-hold-response-fda2025-06-20T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-presentation-ascp-20252025-05-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-pricing-150-million-public-offering2025-02-05T01:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-announces-public-offering2025-02-03T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-executive-leadership-transitions2025-10-13T20:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-inducement-grants-nasdaq-rule-56352025-09-18T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-preclinical-trial-oily-drug-delivery2025-10-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-new-product-development-agreement-melbourne-health2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-technology-us-product-launches-nutraceuticals2025-09-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-preclinical-trial-gel-based-antihistamine2025-09-05T15:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-agreement-idt-australia-manufacturing-facility2025-07-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-expands-us-operations-healthy-extracts-partner2025-06-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-sportsgel-sponsor-pickleball-tour-australia-new-zealand2025-02-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-launches-sportsgel-distribution-agreement-wpic2025-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-appoints-matthew-jones-head-sports-performance2025-01-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-third-quarter-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-ceo-transition2025-10-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-ctlnp-delivery-system-data-q2-2025-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reverse-stock-split2025-07-18T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-inducement-grant-nasdaq-rule-56352025-07-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-presentation-jefferies-conference-20252025-05-28T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-reports-business-highlights-q1-2025-results2025-05-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-needham-conference-20252025-04-02T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/generation-bio-td-cowen-conference-20252025-02-24T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-shareholders-vote-november-20252025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-appoints-dr-usman-latif-advisory-team2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-participate-q3-virtual-investor-summit2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reports-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-expands-clinical-advisory-team-hirsh2025-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-exhibit-adces-20252025-07-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-repurchases-series-a-warrants2025-07-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-continuous-blood-glucose-monitor-results2025-06-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-reverse-stock-split-nasdaq-requirements2025-06-12T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-q3-2025-results-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-neuroscience-2025-presentation2025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-attend-2025-maxim-growth-summit2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-virtual-kol-event-gt-02287-parkinsons2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-gt-02287-parkinsons-phase-1b-study2025-10-06T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-drug-discovery-innovation-programme-20252025-09-23T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-gt-02287-phase-1b-extension-study2025-09-18T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-phase-1b-dosing-extension2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-btig-conference-20252025-07-24T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-navigate-trial-results-aasld-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-hc-wainwright-mash-conference2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-q2-2025-financial-results-update2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-new-credit-line-20252025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-kol-event-belapectin-mash-cirrhosis2025-06-10T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inducement-grants-nasdaq-rule-5635c42025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-pioneer-trial-data-ash-20252025-11-03T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-q3-2025-highlights2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-q3-2025-results-call2025-10-22T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-preclinical-data-esmo-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-investor-meetings-20252025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-q3-2025-financial-results2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-investor-conferences-november-20252025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/new-four-year-data-pombiliti-opfolda-iciem2025-09-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-approval-pombiliti-opfolda-japan2025-06-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/new-analysis-pombiliti-opfolda-muscle-nerve2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reports-q3-2025-financial-results-business-update2025-11-10T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-phase-2-trial-fg-3246-mcrpc2025-09-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-sale-china-astrazeneca-220-million2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-presents-hc-wainwright-investment-conference2025-08-27T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-approval-sale-china-astrazeneca2025-08-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-positive-fda-feedback-roxadustat-lr-mds2025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-reverse-stock-split-20252025-06-12T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reports-q3-2025-results-corporate-update2025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-present-bio-europe-20252025-10-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-present-2025-thinkequity-conference2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presentation-2025-cell-gene-meeting2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibroblast-cells-therapeutic-advantages2025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-positive-ind-updates-psoriasis-treatment2025-09-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-bone-marrow-organoid-advancements2025-09-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presentation-hc-wainwright-conference2025-08-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-multipotent-cells2025-07-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q2-2025-financial-results2025-08-14T10:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-announces-results-annual-meeting2025-06-03T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-launch-pedmarqsi-germany2025-02-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-urica-therapeutics-phase-3-trials-dotinurad2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-urica-therapeutics-crystalys-financing2025-10-01T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-update-nda-cutx-1012025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-hc-wainwright-conference-20252025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-q2-2025-financial-results2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-sale-checkpoint-therapeutics2025-05-30T14:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/partex-fortress-biotech-ai-collaboration2025-03-17T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q3-2025-results-and-corporate-developments2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-participation-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-third-quarter-2025-financial-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-inducement-grants-nasdaq-rule-5635c42025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-announces-pricing-public-offering2025-10-15T02:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-public-offering-common-stock2025-10-14T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-phase-3-duravyu-dme-trials2025-10-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-q3-2025-results-updates2025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-awards-nasdaq-rule-56352025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-sle-acr-convergence-20252025-10-26T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-appoints-kamal-adawi-cfo2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-investor-conferences-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-q3-2025-financial-results-update2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-acquisition-qol-medical2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-eversana-gimoti-access-expansion2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-gimoti-patent-fda-orange-book2025-08-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-gimoti-patent-exclusivity-20382025-08-06T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-gimoti-patent-allowance-20362025-07-09T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVOK/evoke-pharma-td-incidence-metoclopramide-ddw-20252025-04-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-2026-financial-calendar2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-evx-01-data2025-11-07T22:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-q3-2025-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-expands-rd-pipeline-ai-designed-cancer-vaccine2025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-raises-7-2-million-cash-runway-20272025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-appoints-dr-helen-tayton-martin-ceo2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-results-evx-012025-10-17T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-esmo-congress-20252025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-craig-hallum-conference-20252025-11-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q3-2025-financial-results2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-participate-2025-wells-fargo-conference2025-08-20T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-fda-acceptance-et-600-nda2025-07-08T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-addition-russell-indexes2025-06-27T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-fda-approval-khindivi-hydrocortisone-solution2025-05-28T21:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-investor-conferences-20252025-05-14T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-agreement-acquired-roche2025-09-18T05:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-inducement-grants-nasdaq-listing-rule-56352025-09-05T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-investor-conferences-september-20252025-08-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-q2-2025-financial-results-updates2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETNB/89bio-participate-goldman-sachs-healthcare-conference2025-06-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-clear-outcomes-data-aha-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-inducement-grants-nasdaq-rule-5635c42025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-q3-2025-financial-results-update2025-11-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-appoints-john-harlow-cfo2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-jefferies-global-healthcare-conference-20252025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-hosts-virtual-kol-event-statin-intolerance2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-clear-outcomes-aha-scientific-sessions-20252025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-nominates-esp-2001-preclinical-development-candidate2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-pricing-public-offering-common-stock2025-10-08T01:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-present-cell-20252025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-reports-strong-quarterly-performance2025-11-10T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-cellipont-partnership-ovarian-cancer2025-11-06T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-presentation-cell-gene-meeting2025-10-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-ceo-panel-ipsc-summit2025-09-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-aacr-conference-20252025-09-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-operational-update-20252025-09-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-presentation-hc-wainwright-conference2025-09-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-nasdaq-compliance2025-07-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-advisory-board-expansion2025-06-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-q3-2025-business-updates2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-announces-us-patent-eras-00152025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-upcoming-conferences-november-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-morgan-stanley-healthcare-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-ind-clearance-eras-40012025-06-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-investor-conferences-june-20252025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-clinical-advancement-rastargeting-franchise2025-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-presents-bank-america-health-care-conference2025-05-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-participate-upcoming-investor-conferences2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-inducement-grants-nasdaq-rule-56352025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-kol-event-ulcerative-colitis-november-20252025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-leadership-corporate-updates2025-10-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q3-2025-financial-results2025-11-04T21:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-positive-data-resolve-trial-eosinophilic-esophagitis2025-09-29T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-public-offering-80-million2025-09-24T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-70-million-offering2025-09-23T02:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-proposed-public-offering2025-09-22T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/resolve-trial-results-eosinophilic-esophagitis-eprx2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-investor-conferences-20252025-07-22T21:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-doses-first-patient-phase-2b-eo-e-trial2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-annual-meeting-results2025-06-02T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-q3-fiscal-2025-results2025-06-16T22:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-strategic-alternatives-review2025-04-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-voluntarily-delist-nyse-otcqx2025-03-28T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENZ/enzo-biochem-nyse-non-compliance-notice2025-01-14T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-phase-2-trial-results2025-10-23T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-phase-2-eb613-nams-20252025-10-16T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-positive-pk-data-oral-glp2-tablet2025-09-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-positive-effects-asbmr-20252025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-clinical-data-september-conferences2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-q2-2025-financial-results2025-08-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-fda-agreement-bmd-eb613-phase-3-study2025-07-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/opko-enterabio-oral-glp2-tablet-2025-espen-congress2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/opko-enterabio-endo-2025-presentation2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTO/entero-therapeutics-appoints-richard-paolone-ceo2025-02-14T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTO/entero-therapeutics-secures-loan-appoints-board-members2025-02-07T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-iia-allocetra-acr-convergence-20252025-10-28T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-kol-webinar-knee-osteoarthritis-insights2025-09-29T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-strategic-roadmap-positive-phase-iia-results2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-patent-allocetra-osteoarthritis2025-09-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-positive-data-allocetra-knee-osteoarthritis2025-08-18T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-ii-knee-osteoarthritis-webinar2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-phase-ii-topline-data-announcement-20252025-07-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-allocetra-eular-congress-20252025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-presentation-israeli-biomed-2025-conference2025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-allocetra-osteoarthritis-oarsi-20252025-04-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2025-results2025-11-06T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-conference-call-q3-2025-results2025-10-24T20:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-sells-dr-comfort-business-60-million2025-10-08T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-time-change-baird-2025-conference2025-09-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-participate-upcoming-investor-conferences2025-08-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-second-quarter-2025-results-conference-call2025-07-08T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-reports-q3-2025-results-bioenvelope-sale2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-third-quarter-2025-financial-results2025-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-presents-ld-micro-main-event-xix-conference2025-10-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-appoints-guido-neels-board-directors2025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-bioenvelope-sale-boston-scientific2025-10-01T12:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-biologic-envelopes-cied-stabilization2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-exhibit-elupro-antibiotic-eluting-bioenvelope2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-participate-upcoming-investor-conferences2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-robust-growth-elupro-market-adoption2025-08-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-el002-7p-trial-results-sitc-20252025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-sitc-2025-presentation2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-phase-2-amplify-7p-trial-results2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-phase-1-trial-eli-002-7p-pancreatic-cancer2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-inducement-grants2025-09-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-7p-trial-results2025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-amplify-201-phase-1-data2025-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q2-2025-financial-results2025-08-07T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-eli-002-phase-2-study-update2025-08-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-virtual-kol-event-eli-0022025-06-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-50-million-offering2025-11-12T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-phase-2-bestow-trial-results-tegoprubart2025-11-06T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-guggenheim-conference-20252025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-ix-congress-20252025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-cantor-global-healthcare-conference-20252025-08-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-q2-2025-results2025-08-14T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-conference-call-tegoprubart-kidney-transplantation2025-07-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-upcoming-conference-schedule2025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-positive-results-phase-3-study2025-10-28T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-fiscal-3rd-quarter-2025-results2025-08-08T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-bloom-burton-conference-20242025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-cfo-transition2025-04-04T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-15-million-private-placement2025-02-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-q3-2025-results-updates2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-edit-401-poster-presentation-aha-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-proof-of-concept-edit-401-esgct-20252025-10-09T15:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-esgct-congress-presentation-investor-conferences2025-10-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-nominates-edit-401-lead-candidate2025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-webinar-lead-in-vivo-candidate2025-08-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-investor-conferences-september-20252025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-targeted-lipid-nanoparticle-delivery2025-06-12T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-eha-2025-congress-presentation2025-05-14T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-reports-third-quarter-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-presents-jefferies-global-healthcare-conference-london2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-participate-ubs-global-healthcare-conference2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-announces-q3-2025-financial-results2025-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-secures-euro36-million-credit-facility-eib2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/focal-one-prostate-cancer-awareness-campaign2025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/focal-one-hifu-innovation-award-edap2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-hifu-reimbursement-prostate-cancer-france2025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-reports-strong-q2-2025-hifu-results2025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-euro-credit-facility-growth-expansion2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-participate-canaccord-genuity-forum2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-q3-2025-results-webinar2025-10-23T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inducement-grant-nasdaq-listing-rule2025-10-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/ecor-gammacore-nvns-improves-post-concussion-symptoms2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-reimbursement-approval-gammacore-belgium2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-truvaga-plus-best-relaxation-gadget2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-board-changes-cuneo-errico2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-partners-greg-buttle-truvaga-plus2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q3-2025-results-business-highlights2025-11-05T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conferences2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-phase-1-2-achieve-trial-data2025-10-06T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-brian-posner-board2025-10-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-orphan-drug-designation-dyne-2512025-09-29T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-fda-breakthrough-dyne-251-dmd2025-08-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-public-offering-closure2025-07-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-200-million-offering2025-07-01T01:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-dr-sullivan-retirement2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q3-2025-financial-results2025-10-29T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-survey-biological-threats-preparedness2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-opioid-poisoning-awareness-naloxone2025-09-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-29-million-orders2025-09-19T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-17-million-contract-tembexa2025-09-15T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-acam2000-contract-modification2025-09-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-cyfendus-anthrax-vaccine-contract2025-09-02T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-naloxone-awareness-campaign2025-08-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-ceo-engage-investors-maxim-growth-summit2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-bva-technology-medaxiom-transforum-fall-252025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-fda-cleared-bva-analyzer-hfsa2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-next-gen-bva-analyzer-hfsa-meeting2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-blood-volume-analysis-covid-sepsis-study2025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-presentation-hc-wainwright-conference2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-mid-year-update-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-nasdaq-closing-bell-ceremony-replay2025-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-fda-clearance-blood-volume-analyzer2025-08-07T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-blood-volume-analysis-technology-expansion2025-07-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-q3-2025-results2025-11-06T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-secures-license-for-sp162025-09-29T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-hc-wainwright-conference-20252025-09-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-halneuron-phase-2b-trial-enrollment2025-08-07T17:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-sidoti-conference-20252025-06-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-nasdaq-compliance2025-04-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-dt-818-dosing-plans-20262025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-appoints-justin-gover-board2025-09-10T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2025-cantor-global-healthcare-conference2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-progress-genetac-programs-q2-20252025-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-friedreich-ataxia-dosing-trial2025-06-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2025-jefferies-global-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-2025-rbc-healthcare-conference2025-05-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-phase-1-data-dt-168-fuchs-dystrophy2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-phase-1-data-fuchs-dystrophy-eyecelerator2025-04-21T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-prader-willi-syndrome-program2025-11-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-upcoming-conferences2025-10-30T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-201-preclinical-results2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-2025-jefferies-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-epilepsy-rd-day-20252025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-101-study-results2025-05-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-rd-day-20252025-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-expands-scientific-advisory-board2025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-healthcare-conferences-march-20252025-02-24T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-jefferies-global-healthcare-conference-20252025-11-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alphatau-radioactive-material-license-new-hampshire2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-first-patient-pancreatic-cancer-trial2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-participate-investor-conferences-september-20252025-08-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-announces-q2-2025-results-corporate-update2025-08-11T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-jefferies-global-healthcare-conference2025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-appoints-nadav-kidron-board-directors2025-05-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-closes-36-9-million-offering-oramed-alliance2025-04-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q3-financial-results2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-investor-conferences-november2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-claseprubart-2025-aanem2025-10-29T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-license-agreement-dnth2122025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-288-million-offering2025-09-11T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-upsized-public-offering2025-09-10T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-claseprubart-phase-2-magic-trial-results2025-09-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q3-2025-financial-results2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-board-executive-leadership-updates2025-11-06T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-fda-review-extension-tividenofusp-alfa-mps-ii2025-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q1-2025-results-bla-submission2025-05-06T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-phase-1-2-study-hunter-syndrome2025-02-06T16:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-worlsymposium-2025-presentations2025-01-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-q3-2025-results2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-emrosi-phase-3-results-derm2025-10-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-october-2025-investor-conferences2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-emerging-growth-conference-20252025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-nasdaq-closing-bell-august-112025-08-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-announces-q2-2025-results2025-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-expands-emrosi-coverage2025-07-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-phase-3-vitesse-trial-completion2025-11-12T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbvt-vitesse-phase-3-trial-completion2025-11-12T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-guggenheim-healthcare-conference-20252025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-guggenheim-healthcare-conference2025-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-appoints-kevin-trapp-cfo2025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DBVT/dbv-technologies-appoints-kevin-trapp-cco2025-11-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-acquires-mersana-therapeutics2025-11-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-ojemda-tovorafenib-sno-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-third-quarter-2025-results2025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-q3-2025-financial-results2025-10-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-second-quarter-2025-results2025-07-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-appoints-michael-vasconcelles-head-research-development2025-06-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-first-quarter-2025-results2025-04-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-launch-dare-to-play-sildenafil-cream2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-q3-2025-financial-results-conference-call2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-gates-foundation-funding-assessment2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-funding-smart-drug-delivery-device2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-funding-preeclampsia-research2025-09-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-q2-2025-financial-results-update2025-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-rosy-wellness-sildenafil-cream-campaign2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-webinar-sildenafil-cream2025-07-21T17:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-maple-hcm-data-presentation-20252025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-q3-2025-financial-results-update2025-11-05T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-investor-conferences-november-20252025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-upcoming-presentations-hcm-sessions-20252025-10-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-third-quarter-results-november-20252025-10-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inducement-grants-nasdaq-listing-rule2025-10-17T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-aficamten-hfsa-20252025-09-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-communications-grant-program-20252025-09-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-present-stifel-2025-forum2025-09-23T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/bio-green-med-acquisition-fitters-sdn-bhd2025-09-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-q2-2025-financial-results2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-preclinical-data-plogosertib-biliary-tract-cancer2025-08-04T22:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-comments-stock-price-volatility2025-07-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-amendment-exchange-agreement2025-07-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-plogosertib-fibrolamellar-carcinoma-data2025-07-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-announces-stock-split2025-07-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-pharmaceuticals-private-placement-offering2025-06-20T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCC/cyclacel-regains-nasdaq-compliance-minimum-bid-price2025-06-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q3-2025-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-presents-jefferies-global-healthcare-conference-london2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-presents-canaccord-growth-conference-20252025-07-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-second-quarter-2025-results-conference-call2025-07-21T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-positive-news-outpatient-payment-barostim2025-07-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-present-william-blair-growth-stock-conference2025-05-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-signs-mou-singapore-biowaste-solutions2025-10-27T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-skyline-signature-series-presentation-october-20252025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-secures-exclusive-medical-waste-recycling-technology2025-09-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-commitment-shareholders-patients-stock-activity2025-08-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-dr-sherman-fda-maggot-license2025-07-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-update-research-studies-education-institutes2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-lab-supply-medifly-therapy-mena-region2025-06-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-ipo-over-allotment-option2025-05-08T17:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-ivf-media-facility-certification2025-05-05T16:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-closing-initial-public-offering2025-05-05T16:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-q3-2025-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-immunoscape-collaboration-cell-therapy2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-leadership-transition-growth-strategies2025-09-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-fireside-chat-cantor-conference2025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-cue-102-glioblastoma-trial2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-phase-1-trial-cue-101-pembrolizumab2025-07-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-cue-101-update-hawaii-summit2025-07-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-fda-feedback-pre-ind-cue-4012025-06-24T20:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-jefferies-london-healthcare-conference2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-q3-2025-financial-results-update2025-11-06T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-cx-801-phase-1-data-sitc-20252025-11-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-appoints-rachael-lester-cbo2025-10-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-september-investor-conferences2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-cx-2051-phase-1-update2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-growth-leaders-20262025-11-12T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-muse-micro-analyzer-award-20252025-11-06T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-investor-conferences-20252025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-flow-cytometry-access-initiative2025-10-29T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-expands-european-presence-amsterdam2025-10-15T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-full-spectrum-cell-analysis-conferences2025-09-10T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-piper-sandler-conference-20252025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2025-results2025-11-03T21:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-launches-advancead-tx-atopic-dermatitis2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-investor-conferences-20252025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/tissuecypher-risk-insights-acg-20252025-10-26T19:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-risk-stratification-fall-conference2025-10-24T08:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2025-financial-results-conference-call2025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/derek-maetzold-ceo-of-the-year-cstl2025-10-01T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-top-workplaces-20252025-09-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-americas-greatest-companies-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-q2-2025-results-strategic-update2025-08-14T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-2025-shareholder-meeting-results2025-06-30T22:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-board-reconstitution-shareholders2025-05-30T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-director-nominations-goodwood2025-05-26T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-appoints-anna-biehn-ceo2025-04-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-management-cease-trade-order2025-04-01T23:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSCI/cosciens-biopharma-delay-year-end-reporting2025-03-19T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-20252025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-phase-1-trial-data-ash-20252025-11-03T14:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-guggenheim-healthcare-conference2025-10-31T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-ciforadenant-esmo-20252025-10-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-appoints-david-moore-board2025-10-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-ind-approval-soquelitinib-china2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-eular-20252025-06-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-q3-2025-financial-results-corporate-updates2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-fda-registration-path-neflamapimod-dementia2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-appoints-david-quigley-board2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-emerging-growth-conference-presentation2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-phase-2b-trial-neflamapimod-dementia2025-10-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-appoints-matthew-winton-as-cbo2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-roth-healthcare-conference2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-dementia-lewy-bodies-ana-conference2025-09-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-investor-conferences-september-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-business-update-q3-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-positive-phase-1-data-ctx3102025-11-08T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-ctx460-preclinical-data-aatd2025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-esgct-2025-presentation2025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-sirius-phase-2-srsd107-thromboembolic-disorders2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-aha-scientific-sessions-20252025-09-09T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-investor-conferences-september-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-time-most-influential-20252025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-phase-1-data-update-ctx3102025-06-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-q3-2025-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-limited-edition-spinach-green-apple-products-fall2025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2025-q3-earnings-call2025-10-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-launches-sourz-spinach-multipacks2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-expands-peace-naturals-switzerland2025-07-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2025-annual-meeting-results2025-06-23T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-td-cowen-consumer-conference-20252025-06-02T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-november-2025-inducement-grants2025-11-10T21:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q3-2025-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-neuroendocrine-tumor-research-nanets-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-fda-approval-palsonify-acromegaly2025-09-25T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-fda-orphan-drug-designation-atmelnant-cah2025-08-21T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-q3-2025-financial-results-guidance-update2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-defencath-innovative-technology-designation2025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-q3-2025-results-guidance2025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-completes-enrollment-phase-iii-respect-trial2025-09-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-investment-talphera-niaid2025-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-acquisition-melinta-therapeutics-leadership2025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-participate-investor-conferences2025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-acquires-melinta-therapeutics2025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-q3-2025-results-business-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-investor-conferences-november-20252025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-positive-data-ras-mutated-mcrc-trial2025-07-29T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-dr-roger-sidhu-appointment-crdf-004-update2025-06-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-positive-data-onvansertib-paclitaxel-trial2025-06-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-second-patent-onvansertib-mcrc2025-04-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q3-2025-financial-results-update2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-investor-conferences-20252025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-public-offering-pricing2025-10-31T06:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-proposed-public-offering2025-10-30T20:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-crb-701-esmo252025-10-18T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-crb-701-esmo-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-piper-sandler-symposium2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-esmo-2025-kol-event2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/fda-fast-track-corbus-pharmaceuticals-crb-7012025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-fourth-quarter-full-year-2025-release2025-11-04T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-share-repurchase-program-increase2025-09-17T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-third-quarter-2025-results2025-08-27T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-participate-wells-fargo-healthcare-conference2025-08-14T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-2024-sustainability-report2025-05-20T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-participate-william-blair-conference2025-05-08T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-barbara-carbone-board2025-04-30T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-participate-upcoming-investor-conferences2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/paris-hilton-collaborates-collegium-pharmaceutical-adhd2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-report-q3-2025-financial-results2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-poster-presentations-aacap-nei-conferences2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-nasdaq-opening-bell-anniversary2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-present-nine-posters-painweek-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-q2-2025-financial-results2025-08-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-public-offerings-20252025-11-12T04:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-phase-3-trial-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q3-2025-results2025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-ash-meeting-20252025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-kras-poster-presentation-20252025-10-24T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-fda-breakthrough-designation-bezuclastinib2025-10-20T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-inducement-grants-nasdaq-rule-56352025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-participation-citi-biopharma-conference2025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-extinguishes-convertible-note-yorkville2025-07-22T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-filing-registration-statement-merger-z-squared2025-06-26T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/monarch-snap-biosciences-licensing-agreement2025-05-28T12:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-nexgenai-india-hub-launch2025-04-17T12:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-therapeutics-geartm-cell-therapy-platform2025-03-11T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-nexgenai-nuburu-partnership-innovation2025-03-07T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-nexgenai-arketyp-valu-partnership2025-02-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-marketleverage-ai-affiliate-marketing-partnership2025-02-20T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-private-placement-investment2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-nih-sbir-award-influenza-program2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-noble-capital-markets-conference2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-13-million-offering2025-09-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-cdi-988-norovirus-conference2025-09-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-fda-ind-clearance-cdi-988-norovirus-study2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-hc-wainwright-conference-20252025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-q2-2025-financial-results2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-phase-1-results-cdi-9882025-08-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-ct-95-ct-202-sitc-20252025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-q3-2025-results2025-11-05T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-investor-conferences-20252025-10-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-sitc-40th-annual-meeting2025-10-06T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-inducement-grant-nasdaq-rule-56352025-10-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-ctim-76-trial-presentation-asco-20252025-06-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-appoints-dr-karen-chagin-cmo2025-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-q3-2025-results-update2025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-rademikibart-ers-congress-20252025-09-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presentations-ers-congress-20252025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-terminates-adr-program-and-lists-on-nasdaq2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-investor-conferences-september-20252025-08-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-asthma-education-expansion2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-appoints-jim-schoeneck-board2025-07-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-btig-virtual-biotechnology-conference2025-07-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-public-offering-250-million2025-11-12T01:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-public-offering-ads2025-11-11T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-investor-conferences-20252025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ox2r-agoinst-update-q3-20252025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-morgan-stanley-conference-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-q2-2025-results2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ind-clearance-orx1422025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-reports-q4-2024-financial-results2025-03-21T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-inducement-grants-nasdaq-rule-56352025-03-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/jazz-pharmaceuticals-acquire-chimerix-oncology-portfolio2025-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-fda-acceptance-dordaviprone-h3-k27m-glioma2025-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-jonestrading-precision-medicine-symposium2025-01-29T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMRX/chimerix-speak-white-house-cancer-moonshot-forum2025-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-q3-2025-financial-results-update2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-preclinical-data-ctx-10726-sitc-20252025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-november-investor-events2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-pricing-public-offering2025-08-13T02:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-proposed-public-offering2025-08-12T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-jefferies-global-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-patent-publication-depression-treatment2025-11-12T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-phase-i-ii-trial-alcohol-use-disorder2025-11-10T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-nasdaq-notification-stockholders-equity2025-11-06T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-ip-protection-meai-depression-south-korea2025-11-05T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-meai-cocaine-addiction-patent2025-10-31T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-ceo-dr-adi-zuloff-shani-webinar2025-10-28T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-appoints-gifford-global-impact2025-10-27T13:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-nebokitug-aasld-2025-presentations2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-hc-wainwright-conference-20252025-08-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-q2-2025-financial-results-corporate-update2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-nebokitug-phase-2-data-bsg-live-20252025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-positive-fda-feedback-nebokitug-phase-32025-06-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-new-patents-nebokitug-psc2025-06-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-nebokitug-clinical-data-conferences2025-04-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-reports-q3-2025-results-and-updates2025-11-06T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-investor-conferences-20252025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-adam-villa-ashley-jones2025-10-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-presents-data-asn-kidney-week-20252025-10-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-susan-altschuller-cfo2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-clym116-preclinical-data-ig-an-therapeutic2025-09-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-webcast-clym116-igan-opportunity2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-euretina-congress-20252025-08-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-xipere-approval-canada2025-07-23T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-strategic-alternatives-scs-platform2025-07-17T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-summit-meeting-presentations2025-06-17T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-fireside-chat-stifel-ophthalmology-forum2025-05-21T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-phase-3-program-update2025-05-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-arvo-2025-presentations2025-05-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-fireside-chat-citizens-conference2025-05-01T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLSD/clearside-biomedical-fireside-chat-needham-conference2025-04-01T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-third-quarter-2025-update2025-11-13T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-rare-pediatric-designation-iopofosine2025-10-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-preclinical-data-aacr-conference2025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-raises-5-8-million2025-10-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-ema-cma-iopofosine2025-10-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-aacr-pediatric-cancer-conference2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-evestia-partnership-tnbc-trial2025-09-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-itm-actinium-225-supply-agreement2025-09-11T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-oppenheimer-summit-20252025-09-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-q3-2025-financial-results2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-emerging-growth-conference-presentation2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-participate-maxim-growth-summit2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-cnmau8-ectrims-2025-data2025-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-preclinical-data-cnm-au8-parkinsons-disease2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presentation-hc-wainwright-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-present-canaccord-growth-conference-20252025-08-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-regulatory-update-fda-meeting-neurofilament-analysis2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-financial-results-q3-20252025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-q3-2025-results-business-update2025-11-07T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-ash-2025-eti-cel-advancements2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-development-update-eti-cel-ash-20252025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-q3-financial-results-november-20252025-10-31T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-rd-day-lasme-cel-potential-b-cell-leukemia2025-10-16T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-rd-day-lasme-cel-potential-unmet-need2025-10-16T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-q3-2025-financial-results-update2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-appoints-terri-lawver-as-cco2025-11-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-upcoming-investor-conferences2025-11-07T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-phase-2-results-cold-urticaria-sd2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-csu-phase-2-data2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-phase-1-trial-cdx-622-results2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-chronic-spontaneous-urticaria-eadv-20252025-09-17T09:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-presents-morgan-stanley-healthcare-conference2025-09-09T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-phase-2-barzolvolimab-eosinophilic-esophagitis-results2025-08-19T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-reports-q3-2025-results-update2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-names-bryan-downey-cco-ctxt-1301-launch2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-phase-3-results-ctxt-1301-adult-adhd2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-ct-1301-aacap-podium-presentation2025-10-23T20:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/fda-accepts-cingulate-cth-1301-adhd-nda2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-exclusive-manufacturing-partnership-bend-bio-sciences2025-09-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-management-team-update2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-submits-nda-ctx-1301-fda2025-08-06T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-fda-waiver-ctxt-1301-approval2025-07-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-sitc-chs-114-biomarker-data2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-q3-2025-financial-results-update2025-11-06T21:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/arvind-sood-joins-coherus-oncology2025-11-06T18:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-investor-conferences-20252025-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-poster-sitc-20252025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-strategic-transformation-cancer-therapeutics2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-phase-2-study-zervimesine-alzheimers2025-11-13T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-30-million-offering-zervimesine2025-09-02T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-30-million-offering2025-08-28T00:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-regains-nasdaq-compliance2025-08-26T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-data-aaic-20252025-07-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-alzheimers-study2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-bond-003-cohort-c-results2025-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-completes-enrollment-pivot-0062025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-executive-leadership-investor-conferences2025-08-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-q2-2025-financial-results-business-updates2025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-jury-verdict-no-royalties-ani-pharmaceuticals2025-07-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-goldman-sachs-healthcare-conference2025-06-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-2025-rbc-capital-markets-conference2025-05-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-nmibc-research-fellowship-20252025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-bond-003-cretostimogene-data-aau-20252025-04-26T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-biodefense-initiative-veterans2025-10-30T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-warrants-exercise-agreements2025-10-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-shareholder-letter-20252025-10-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-nobel-laureates-regulatory-t-cells2025-10-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-fda-fast-track-designation-celz-201-ddt2025-08-13T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-type-1-diabetes-patent2025-07-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-immcelz-heart-failure2025-07-11T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-fda-clearance-expanded-dose-escalation-trial2025-03-20T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-ivf-access-initiative2025-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-q3-2025-results-corporate-update2025-11-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-third-quarter-2025-financial-results-webcast2025-11-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-stifel-2025-healthcare-conference2025-11-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-update-viktoria-1-trial-pik3ca-mutant-cohort2025-10-18T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-updated-data-esmo-2025-gedatolisib-darolutamide2025-10-18T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/gedatolisib-phase-3-viktoria-1-trial-results2025-10-18T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-viktoria-1-trial-esmo-congress-20252025-09-22T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-gedatolisib-nda-submission-fda-review2025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-corporate-update-q3-2025-results2025-11-06T21:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-november-investor-conferences2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-cd388-eswi-conference-20252025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-phase-2b-data-id-week-20252025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-eswi-influenza-conference-20252025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-fda-breakthrough-therapy-cd388-influenza2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-barda-award-cd388-manufacturing-development2025-10-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDTX/cidara-therapeutics-phase-3-anchor-trial-cd3882025-09-25T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-stockholders-approve-gho-ampersand-transaction2025-01-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-reminds-stockholders-vote-transaction-gho-ampersand2025-01-22T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-recommends-stockholders-vote-for-gho-ampersand-transaction2025-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDMO/avid-bioservices-investor-presentation-gho-ampersand2025-01-08T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-125-million-offering2025-10-16T11:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-pfizer-collaboration-cemsidomide-elranatamab2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-phase-1-results2025-09-20T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-biogen-ind-acceptance2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-1-trial-cemsidomide-ims-meeting2025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-march-investor-conferences2025-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-forum2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-reports-third-quarter-2025-financial-results2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/erica-rogers-joins-ceribell-board2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-conference2025-07-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-report-q2-2025-financial-results2025-07-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-files-complaints-against-natus-medical2025-07-07T20:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-participate-william-blair-growth-conference2025-05-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-q3-2025-financial-results2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-investor-conferences-november2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-cr-001-sitc-2025-presentation2025-11-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-appoints-jan-pinkas-cso2025-07-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-merger-glycomimetics-private-placement2025-06-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-jefferies-conference-20252025-05-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-appoints-david-lubner-board2025-04-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-appoints-new-ceo-and-leadership-team2025-04-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q3-2025-financial-results-update2025-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-deramiocel-study-biomedicines2025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-deramiocel-regulatory-update2025-09-25T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-responds-fda-complete-response-letter-deramiocel2025-09-09T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-phase-1-exosome-vaccine-trial2025-08-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-fda-type-a-meeting2025-08-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-webinar-deramiocel-dmd2025-07-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-esophageal-varices-resolution2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-h1-2025-financial-results-clinical-update2025-08-28T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-phase-2a-enrollment-milestone2025-07-30T11:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-public-offering-15-million2025-07-28T16:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/uclas-study-piclidenoson-vascular-dementia2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-phase-iia-pancreatic-cancer-study-bio-20252025-06-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-raises-175-million-phase-3-trials2025-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/fda-approval-namodenoson-pancreatic-cancer2025-04-17T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-announces-3-million-offering2025-04-14T18:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-685m-future-revenues-partnerships2025-04-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-q3-2025-results-and-highlights2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-glp-toxicology-studies-cmp-syngap-012025-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-oversubscribed-private-placement-syngap1-treatment2025-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-translational-data-syngap1-urea-cycle-disorders2025-05-16T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-preclinical-data-asgct-20252025-04-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-reports-full-year-2024-financial-results2025-03-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-appoints-industry-veterans-board2025-03-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-participate-upcoming-investor-conferences2025-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q3-2025-financial-results2025-11-13T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-immunotherapy-sitc-20252025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-jefferies-conference-20252025-11-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-bali-pulendran2025-10-16T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-130-million-loan-trinity-capital2025-10-14T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-positive-data-can-3110-glioblastoma2025-10-14T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sitc-2025-annual-meeting2025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-phase-3-trial-can-2409-prostate-cancer2025-09-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-carl-h-june2025-09-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-third-quarter-2025-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-investor-conferences-november-december2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-rese-cel-acr-convergence-20252025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-appoints-steve-gavel-cco2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reset-pv-data-esgct-20252025-10-09T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-public-offering-pricing2025-06-11T13:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-rese-cel-data-eular-20252025-06-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-q3-2025-results-corporate-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-q2-2025-financial-results-update2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-plinabulin-clinical-study-ici-failure2025-07-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-phase-2-study-pembrolizumab-plinabulin-docetaxel2025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-poster-presentation-2025-asco2025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2024-annual-report2025-03-27T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-2024-financial-results-clinical-highlights2025-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-sells-equity-seed-therapeutics-plinabulin-trials2025-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-reports-q3-2025-financial-results2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-q3-fy2025-financial-results-report2025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-presentation-morgan-stanley-healthcare-conference2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-canaccord-genuity-conference-20252025-08-07T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-new-400-million-credit-agreement2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-fda-clearances-pns-products2025-07-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-clinical-update-20252025-06-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPTH/bio-path-holdings-expands-global-patent-portfolio2025-02-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPTH/biopath-holdings-phase-1b-trial-update-bp10022025-02-12T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-q3-2025-financial-results2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-japanese-patent-thermostem2025-10-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-appoints-crystal-romano-global-operations2025-10-22T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-maxim-growth-summit-20252025-10-15T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-ceo-lance-alstodt-interview-big-biz-show2025-10-07T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-registered-direct-offering2025-10-06T18:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-q2-2025-results-conference-call2025-08-05T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-benzinga-show-bRTX-100-update2025-06-18T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-q3-2025-results-update2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-serenity-at-home-study-results2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-nasdaq-closing-bell-october-20252025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-regains-nasdaq-compliance2025-09-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-serenity-at-home-phase-3-trial-results2025-09-10T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-hc-wainwright-conference-20252025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-serenity-trial-update2025-08-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-q3-2025-financial-results2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-clywedog-merger-metabolic-autoimmune-diseases2025-09-30T13:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-strategic-focus-immunology-inflammation2025-01-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-update-bdc-4182-cash-runway-20272025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-kol-conference-call-bdc-3042-phase-1-results2025-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/boltbody-isacs-preclinical-results-aacr-20252025-04-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-bdc-3042-phase-1-results-aacr-20252025-04-25T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-march-conferences2025-02-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-q3-2025-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-presentation-aacr-nci-eortc-20252025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-goldman-sachs-healthcare-conference2025-06-05T20:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-portfolio-prioritization-runway-extension2025-05-23T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-needham-virtual-healthcare-conference2025-04-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-leerink-global-healthcare-conference2025-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-robert-doebele-cmo-appointment2025-02-03T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q3-2025-results-business-update2025-11-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q3-2025-financial-results-update2025-11-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-innovation-series-day-november-20252025-10-28T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-hosts-rd-day-november-11-20252025-10-28T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q3-2025-results-conference-call2025-10-27T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-public-exchange-offer-curevac-shares2025-10-22T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-public-exchange-offer-curevac2025-10-22T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-ai-day-october-20252025-09-23T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-hosts-second-ai-day-october-20252025-09-23T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-100-million-offering2025-11-06T05:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-public-offering-november-20252025-11-05T21:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-bb301-clinical-trial-results-fda-fast-track2025-11-03T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-appoints-sharon-mates-board2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-phase-1b-2a-update-bb-301-opmd2025-11-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-full-year-2025-results-update2025-09-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-operational-updates2025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-positive-results-bb-301-opmd2025-03-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-targeted-rna-seq-leukemia2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-report-q3-2025-financial-results2025-10-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-ashg-2025-conference2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-participate-hc-wainwright-home-event2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-closes-10-million-public-offering2025-09-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-10-million-offering2025-09-16T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-chromoanagenesis-cancer-research2025-09-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/cms-preliminary-payment-determination-ogm-cpt-code2025-09-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-present-hc-wainwright-investment-conference2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-q2-2025-results-business-progress2025-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-jefferies-london-healthcare-conference2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-preclinical-advances-bmf-650-icovamenib2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-q3-2025-results-highlights2025-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-poster-presentations-obesityweek-20252025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-bmf-650-phase-i-trial2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-citi-biotech-fireside-chat2025-10-21T23:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-public-offering-pricing2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-positive-results-phase-ii-covalent-1112025-10-06T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-inducement-grant-nasdaq-rule-56352025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-corporate-update-clinical-milestones2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-closes-4-5-million-private-placement2025-10-10T21:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-sanyo-seiko-partnership-symphony-platform2025-10-09T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-q2-2025-update2025-08-07T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-abstract-presentation-saem-20252025-04-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-warrant-inducement-transaction2025-04-07T21:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-expands-cdmo-services-market-demand2025-11-06T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-henry-schein-marketing-agreement-ibs-test2025-10-16T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-first-quarter-fiscal-2026-results2025-10-15T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/gary-huff-appointed-biomerica-board2025-10-08T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-launches-ai-infoods-ibs-navigator2025-09-09T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/uae-approves-biomerica-fortel-kidney-test-home-use2025-09-03T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/uae-approves-biomerica-fortel-ulcer-test-home-use2025-08-14T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/infoods-ibs-cpt-code-biomerica2025-07-02T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/scott-madel-joins-biomerica-as-cco2025-06-26T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-q3-2025-financial-results-update2025-11-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-sells-xepi-license-pelthos-therapeutics2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-closes-purchase-us-assets2025-10-23T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-participate-lytham-partners-fall-2025-conference2025-09-26T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-engages-lytham-partners-investor-relations2025-09-23T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-phase-3-study-ameluz-completion2025-09-16T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-phase-2b-study-acne-vulgaris2025-08-25T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-appoints-george-jones-cco2025-08-11T20:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-q3-2025-financial-results-update2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-november-2025-financial-results2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-conditional-marketing-authorization-tinlarebant2025-11-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-deutsche-bank-adr-investor-conference2025-10-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-participate-maxim-growth-summit-20252025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-nmpa-priority-review-tinlarebant-stargardt2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-dragon-trial-completion-tinlarebant2025-09-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-private-placement-financing-275-million2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-investor-conferences-20252025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-investor-conferences2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-q3-2025-results-update2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-jefferies-conference-20252025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/servier-black-diamond-licensing-agreement-bdtx-49332025-03-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-host-live-investor-webinar-october-82025-09-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-phase-2-trial-bezisterim-long-covid2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-closes-12-million-public-offering2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-pricing-public-offering2025-08-08T00:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-age-deceleration-alzheimers-conference2025-07-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-appoints-industry-veterans-to-board2025-07-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-aging-neurodegeneration-conference2025-07-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-sunrise-pd-trial-atmrd-congress2025-06-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-phase-2-sunrise-pd-trial-presentation2025-06-24T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-clinical-trial-bezisterim-long-covid2025-05-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-approval-cta-phase-3-serenta-trial-fap2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-symposium-fap-mechanisms-chemoprevention-trial-issues2025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-interim-results-june-20252025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-enrolment-first-patients-serenta-trial-fap2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-adr-ratio-change-effective2025-07-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-filing-cta-phase-3-serenta-trial-fap2025-07-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-annual-general-meeting-results2025-06-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-serenta-phase-3-study-fap2025-06-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-new-data-acaa-highlight-hae-burden-pediatric-patients2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-inducement-grants-nasdaq-rule-56352025-11-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-presentation-jefferies-conference-20252025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-q3-2025-financial-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-pediatric-hae-data-acaa-meeting-20252025-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-acquires-astria-therapeutics-hair-portfolio2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-sale-european-orladeyo-business2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-anti-cancer-activity-sitc-20252025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-anti-cancer-activity-bria-ots2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-dsmb-positive-recommendation-phase-3-study2025-10-22T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-clinical-sites-phase-3-study2025-10-21T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-collaboration-msk-accelerator-breast-cancer2025-10-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-3-clinical-biomarker-data-esmo-20252025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-preclinical-data-sitc-20252025-10-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-bria-ots-mechanism-action-validation2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-nci-grant-bria-pros-prostate-cancer2025-08-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-reports-q3-2025-results2025-11-12T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-first-patient-phase-3-trial2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-q3-2025-update-financial-results-call2025-11-06T00:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-phase-3-cardiamp-hf-ii-trial-enrollment2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-regains-compliance-nasdaq-listing-requirements2025-10-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-positive-consultation-pmda-cell-therapy2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-announces-12-million-public-offering2025-09-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-cardiamp-trial-results-improved-exercise-tolerance2025-09-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-ceo-peter-altman-hc-wainwright-conference-20252025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-cart-tech-partnership-heart3d-imaging2025-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q3-2025-financial-results-update2025-11-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-fda-designation2025-10-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-investor-conferences2025-08-27T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-goldman-sachs-conference-20252025-06-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-asco-20252025-06-01T17:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-aacr-20252025-04-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-mecbotamab-vedotin-survival-sarcomas2025-11-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-q3-2025-financial-results2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-ozuriftamab-vedotin-opscc-ipvs-conference2025-10-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-phase-1-trial-ba3182-esmo-20252025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-present-clinical-data-mecbotamab-vedotin-sitc-20252025-10-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-regulatory-update-ozuriftamab-vedotin-opscc2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-q2-2025-financial-results-progress2025-08-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-upcoming-presentation-esmo-tat-asia-20252025-07-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-ba3182-esmo-20252025-07-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-investor-conferences-20252025-11-03T21:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-q3-2025-financial-results2025-10-28T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-third-quarter-2025-results2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-presentation-bank-america-conference2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/acoramidis-reduces-mortality-attr-cm-populations2025-11-08T15:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-november-investor-conferences2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-presents-attribute-cm-data-aha-20252025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-q3-2025-financial-results2025-10-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-positive-phase-3-encaleret-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-phase-3-encaleret-results-october-29-20252025-10-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-phase-3-results-bbp-418-lgmd2i-r92025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-inducement-grants-nasdaq-rule-56352025-10-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/acoramidis-reduces-cardiovascular-outcomes-attr-cm2025-09-28T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-acquires-gaba-a-receptor-modulator-azd73252025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q3-2025-financial-results2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-november-20252025-10-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-mental-illness-awareness-week2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-psych-congress-20252025-09-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-rd-day-cns-pipeline2025-07-21T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-nasdaq-opening-bell2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-upcoming-investor-conferences2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-q3-2025-financial-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-fda-review-timeline-avance-nerve-graft2025-08-25T10:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-canaccord-genuity-conference2025-07-29T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-goldman-sachs-healthcare-conference2025-05-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-alzheimers-trial-results2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-presentation-alzheimer-europe-conference2025-10-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-successful-once-daily-tablet-anavex3-712025-10-02T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-phase-2-results-anavex3-71-schizophrenia2025-10-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/oral-blarcamesine-phase-iiib-iii-alzheimers-trial2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-hc-wainwright-conference-20252025-09-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-autophagy-mechanism-publication2025-08-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-alzheimers-prevention-study2025-08-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-fiscal-2025-q3-results2025-08-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-third-quarter-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-investor-conferences-20252025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-completes-enrollment-lotus-trial-avtx-0092025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-leadership-expansion-appointments2025-10-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalon-therapeutics-appoints-kevin-lind-board2025-09-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-q2-2025-financial-results-business-updates2025-08-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-appointment-of-rita-jain-to-board2025-06-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-announces-third-quarter-results-20252025-11-12T22:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/fda-approves-anteris-duravr-thv-paradigm-trial2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-duravr-thv-positive-outcomes-small-annuli2025-10-28T22:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-duravr-thv-clinical-outcomes-tct-20252025-10-27T12:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-european-regulatory-clearance-paradigm-trial2025-10-15T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-special-meeting-adjourned2025-09-19T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-postpones-stockholders-meeting2025-09-11T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateapharma-q3-2025-financial-results-update2025-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateas-bemnifosbuvir-ruzavir-hcv-treatment-data2025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-virtual-hcv-kol-panel-november-20252025-10-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-morgan-stanley-conference-20252025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-q2-2025-financial-results-call2025-07-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateapharma-advancement-global-phase-3-hcv-program2025-06-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-q3-2025-results-update2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-jazz-pharmaceuticals-global-settlement2025-10-22T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-grant-inducement-awards-nasdaq-rule-56352025-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-five-years-sleep-research2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-lumryz-world-sleep-2025-data2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-valiloxybate-license2025-09-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVDL/avadel-pharmaceuticals-investor-conferences-20252025-08-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-appoints-brent-rice-cco2025-09-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-firmonertinib-phase-1b-study-egfr-nsclc2025-09-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-q2-2025-financial-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/furvent-phase-3-firmonertinib-nsclc-data-20262025-07-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-announces-pricing-75-million-offering2025-07-02T03:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrivent-investor-event-firmonertinib-nsclc2025-06-20T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-q3-2025-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-hc-wainwright-conference-20252025-09-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-public-offering-pricing2025-05-15T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-investor-conferences-20252025-05-01T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-teresa-bitetti-appointment2025-04-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/positive-data-phase-1-trial-bel-sar-nmibc-eau-congress2025-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-piper-sandler-conference-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-third-quarter-2025-results-update2025-11-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-phase-3-efzo-fit-study-ers-congress-20252025-09-30T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-phase-3-efzo-fit-study-results2025-09-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inducement-grants-nasdaq-rule-56352025-09-05T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-added-russell-indexes2025-06-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-phase-2-efzo-connect-study-findings2025-06-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-investor-conferences-may-june-20252025-05-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-bell-potter-conference-20252025-11-12T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-msa-symposium2025-11-10T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q1-fy26-cash-flow-report2025-10-31T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-positive-data-ath434-phase-2-trial2025-10-09T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-2025-parkinsons-congress2025-10-02T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-phase-2-data-ana-meeting2025-09-15T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-raises-20-million-strategic-placement2025-09-08T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-biotech-showcase-presentation2025-09-02T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q4-fy25-cash-flow-report2025-07-30T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-positive-data-ath434-msa2025-07-28T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-q3-2025-results-business-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-reverse-stock-split2025-09-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-ath-1105-phase-1-trial-results2025-08-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-ath-1105-phase-1-trial-data2025-05-13T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-2024-financial-results-pipeline-updates2025-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-announces-leadership-transition2025-10-28T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-real-world-study-sympazan-clobazam2025-09-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-present-new-data-sympazan-ana20252025-09-10T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-participate-hc-wainwright-lake-street-conferences2025-09-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-q2-2025-financial-results2025-08-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-participate-alliance-global-partners-showcase2025-05-19T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-q1-2025-results-webcast2025-05-05T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-participate-iaccess-alpha-conference-20252025-03-20T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-q3-2025-financial-results2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-positive-phase-1b-data-abi-43342025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-investor-conference-participation2025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-hsv-inhibitor-abi-5366-data-iusti2025-10-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-pricing-175-million-equity-financing2025-08-08T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-positive-results-abi-53662025-08-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-phase-1a-data-abi-6250-hdv2025-08-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-genital-herpes-data-presentation2025-07-26T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-phase-1b-abi-1179-trial2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-third-quarter-2025-results2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-preclinical-data-arv-393-ash-20252025-11-03T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-participate-investor-conferences2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-third-quarter-2025-financial-results-webcast2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-arv-806-preclinical-data-aacr-nci-eortc-20252025-10-24T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-arv-806-presentation-aacr-nci-eortc-20252025-10-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/vepdegestrant-veritac-2-trial-results2025-10-20T08:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-vepdegestrant-esmo-congress-20252025-10-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-arv-102-positive-phase-1-data-mds-20252025-10-05T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-autoimmune-disease-data2025-11-12T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-q3-2025-financial-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-virtual-event-allonk-data2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-investor-conferences-november-20252025-10-30T20:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-refractory-ra-lead-indication2025-10-16T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-cantor-healthcare-conference-20252025-08-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-jefferies-global-healthcare-conference2025-05-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-phase-1-2-data-allonk-rituximab-b-nhl2025-05-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-business-update-q3-20252025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-fabp3-cancer-publication2025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-appoints-mark-spring-cfo2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-expanded-clinical-data-art26-12-art27-132025-10-15T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-closes-2-million-public-offering2025-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-public-offering-20252025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-public-offering2025-09-29T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-positive-phase-2-cares-data2025-09-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art12-11-efficacy-depression-anxiety2025-09-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-integument-infant-phase-2-study-zoryve-cream2025-11-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-inducement-grants-nasdaq-rule-56352025-11-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-safety-efficacy-seborrheic-dermatitis2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/free-to-be-me-campaign-arcutis2025-10-30T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-strategy-sustainable-growth-q3-2025-results2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-present-investor-conferences2025-10-27T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-atopic-dermatitis-conference-20252025-10-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/fda-approves-arcutis-zoryve-cream-atopic-dermatitis-children2025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-ipo-closing2025-05-12T21:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-ipo-pricing-announcement2025-05-08T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-q3-2025-financial-results-business-update2025-10-30T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-vyvgart-data-aanem-mgfa-20252025-10-29T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-2025-aanem-mgfa-meeting-data2025-10-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-extraordinary-general-meeting-november-20252025-10-03T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-investor-conferences-september-20252025-08-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-adapt-seron-study-results-vyvgart2025-08-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-rd-webinar-argx-119-september-20252025-08-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-monica-seles-myastenia-gravis-awareness2025-08-12T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aqst-q3-2025-financial-results-business-update2025-11-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-leadership-expansion-growth2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fireside-chat-piper-sandler2025-11-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-acaa-meeting-20252025-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q3-2025-results-conference-call2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-patent-broadening2025-10-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-fda-update2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-september-investor-conferences2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-85-million-offering2025-08-14T10:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-funding-anaphylm-launch2025-08-14T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/xphozah-tenapanor-patient-satisfaction-serum-phosphate-reduction2025-11-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-jefferies-global-healthcare-conference-20252025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-ceo-participate-wedbush-asn-2025-conference2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-q3-2025-financial-results-update2025-10-30T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-ibrela-acg-2025-meeting2025-10-28T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-abstracts-american-society-nephrology-kidney-week2025-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-third-quarter-2025-financial-results-call2025-10-13T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-appoints-sue-hohenleitner-cfo2025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-participate-investor-conferences2025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-executive-leadership-changes2025-08-04T20:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-q3-2025-financial-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-upcoming-investor-conferences-november-20252025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-fda-510k-ayons-power-liposuction2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-virtual-kol-event-ayon-launch2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-inducement-grant-nasdaq-rule-56352025-08-07T20:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-participate-canaccord-growth-conference2025-07-30T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-launch-renuvion-china2025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q3-2025-results-clinical-update2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-clinical-update-acesot-1051-trial2025-10-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-2-dose-atrn-119-combination-therapies2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-eortc-nci-aacr-conference-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-hc-wainwright-conference-20252025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-reports-apr-1051-clinical-data-hpv-hnscc2025-06-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-hpv-head-neck-cancer-trial2025-03-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-q3-2025-financial-results2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-update-fda-meeting2025-09-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-leadership-appointments2025-06-17T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-govorestat-insPIRE-trial-results2025-05-18T11:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-late-breaking-abstract-pns-20252025-05-09T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-files-form-12b-25-sec2025-03-31T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-appoints-todd-baumgartner-cro2025-03-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-5-year-gale-data-syfovre-geographic-atrophy2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-stifel-2025-healthcare-conference2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-third-quarter-2025-results2025-10-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/new-data-reinforcing-efficacy-of-empaveli2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-conference-call-october-20252025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-investor-conferences-20252025-08-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/fda-approves-apellis-empaveli-c3g-ic-mpgm-treatment2025-07-28T23:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-abstracts-asrs-meeting-syfovre2025-07-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-nasdaq-listing-announcement2025-10-16T16:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-nasdaq-listing-update2025-10-16T16:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-advances-clinical-development-aplm2025-10-15T16:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-company-operational-update2025-10-14T01:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-reports-2024-financial-results-clinical-updates2025-04-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-launxp-agreement-vebreltinib2025-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pipeline-progress-q3-2025-results2025-11-10T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-positive-phase-1-results-apg3332025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-upcoming-conferences2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering-345-million2025-10-10T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pricing-300-million-offering2025-10-09T01:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering2025-10-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-apg777-eadv-2025-presentation2025-09-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-stifel-2025-forum2025-09-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-phase-2-apex-trial-results2025-07-07T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-q3-2025-results2025-11-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-phase-3-alzheimers-program-progress2025-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-3-4-million-stock-offering2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-closes-6-million-stock-offering2025-10-15T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-biomarker-data-buntanetap-alzheimers2025-10-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-appoints-mark-guerin-cfo2025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-buntanetap-pharmacokinetics-publication2025-09-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-presents-hc-wainwright-investment-conference2025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-pricing-public-offering-common-stock2025-11-13T03:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-reports-q3-2025-results-and-milestones2025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-september-investor-conferences2025-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-inducement-grant-new-employee2025-08-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-ema-product-development-coordinator-pilot-vonaprument2025-08-07T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-phase-3-archer-ii-trial-completion2025-07-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-appoints-dr-clark-amd-trial-advances2025-06-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-jefferies-global-healthcare-conference2025-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-q3-2025-financial-results2025-11-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-hyalofast-pma-filing2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-inducement-grants-nasdaq-rule-56352025-09-05T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-hyalofast-phase-iii-study-results2025-07-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-second-quarter-2025-financial-results2025-07-16T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-jefferies-global-healthcare-conference2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2025-financial-results2025-11-07T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2025-results-conference-call2025-10-24T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-new-day-trial-results-aao-20252025-10-16T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-investor-conferences-20252025-08-25T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-new-day-trial-results-iluvien-dme2025-07-23T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-leerink-partners-therapeutics-forum-20252025-07-02T10:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-preclinical-data-cortrophin-gel2025-06-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-phase-2-trial-rosnilimab-results2025-11-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-announces-q3-2025-financial-results-business-update2025-11-04T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-participation-november-investor-conferences2025-11-04T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-positive-phase-2b-trial-rosnilimab-ra2025-10-29T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-phase-2b-rosnilimab-acr-convergence-20252025-10-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-separation-biopharma-royalty-assets-20262025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-overview-anb033-virtual-event-october-142025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-positive-rosnilimab-data-phase-2b-trial-ra2025-06-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-q3-2025-financial-results2025-10-30T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-tentative-approval-beclomethasone-inhaler2025-10-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-launches-brekiya-dhe-autoinjector-migraine-cluster-headaches2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-third-quarter-2025-results-webcast2025-09-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-bla-submission-biosimilar-xolair2025-09-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-bimatoprost-ophthalmic-solution2025-09-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-sodium-oxybate-solution2025-09-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-risperidone-injectable-suspension2025-09-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-refinancing-credit-agreement-offering-notes2025-07-21T11:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-aspirin-analysis-aha-scientific-sessions-20252025-11-09T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-presents-new-analyses-reduce-it-aha-20252025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-q3-2025-financial-results2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-supports-fda-revision-fenofibrate-labeling2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-third-quarter-2025-financial-results-conference-call2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-hls-therapeutics-ccc-20252025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-epa-mechanistic-insights-esc-20252025-08-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-analyses-esc-2025-vascepa2025-08-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/new-analyses-reduce-it-esc-congress-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-tct-2025-presentations2025-10-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-highlight-nerve-sensing-platform-maxim-summit2025-10-16T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-patent-nerve-targeted-therapies2025-10-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-segment-release2025-10-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-glp-study-sensing-rf-ablation-system2025-09-29T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-abstract-cirse-20252025-09-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-virtual-investor-segment2025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-pain-reduction-study2025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-presentation-hc-wainwright-conference2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-european-patent-catheter-technology2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-presentation-military-health-symposium-20252025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-2025-financial-results-clinical-update2025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-closing-5-million-private-placement2025-06-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-phase-ii-trial-al0012025-05-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-reverse-stock-split2025-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-qmenta-ai-imaging-phase-ii-trials2025-05-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-phase-ii-trial-al001-alzheimers2025-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALZN/alzamend-phase-ii-trial-al001-mdd2025-03-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-q3-2025-financial-results-update2025-11-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-q3-2025-results-sitc-presentation2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx2004-preclinical-data-phase-1-trial-progress2025-10-23T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-phase-2-aspen-06-trial-sitc-20252025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-barbara-klencke-interim-cmo2025-09-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-investor-conferences-september-20252025-08-29T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-phase-1-trial-alx2004-egfr-tumors2025-08-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-jefferies-2025-conference2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-q3-20252025-11-12T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-reports-results-business-update-20252025-11-12T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-court-ruling-avt06-eylea2025-11-10T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/uk-high-court-rules-alvotech-avt06-eylea-biosimilar2025-11-10T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-marketing-authorizations-gobivaz2025-11-06T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q3-2025-earnings-announcement2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-impact-phase-2b-trial-data-lancet2025-11-11T13:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-liver-fibrosis-aasld-20252025-11-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-q3-2025-financial-results-business-updates2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-participate-investor-conferences2025-11-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-reclaim-phase-2-trial-pemvidutide-aud2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-phase-2b-impact-data-pemvidutide-mash-aasld-20252025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-christophe-arbet-engels-cmo2025-09-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-linda-richardson-cfo2025-09-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-participate-november-investor-conferences2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-reports-q2-2025-results-and-corporate-update2025-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-lumus-phase-2b-trial-esk-001-sle-enrollment2025-07-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-promotes-sanam-pangali-chief-legal-officer2025-07-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-presentation-jefferies-global-healthcare-conference2025-05-29T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-completes-enrollment-phase-3-esk-0012025-05-29T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-merger-acelyrin-completed2025-05-21T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-stockholders-approve-merger-acelyrin2025-05-13T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-2-data-stenoparib2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-ceo-presents-biomarkers-precision-medicine-20252025-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-fda-fast-track-stenoparib-ovarian-cancer2025-08-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-q2-2025-update-clinical-progress2025-08-15T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-licensing-agreement-drp-platform2025-07-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-jeff-ervin-cfo-appointment2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-australian-patent-acceptance-stenoparib2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-doses-second-patient-phase-2-trial2025-06-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-board-changes2025-06-11T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-research-collaboration-indiana-biosciences2025-06-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-investor-conferences-20252025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q3-2025-results-update2025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-alpha3-trial-poster-ash-20252025-11-03T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-alpha3-trial-cema-cel-lymphodepletion2025-08-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-phase-1-data-allocation-3162025-06-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-agreement-acquired-concentra-biosciences2025-04-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-business-update-q4-2024-results2025-03-12T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLK/allakos-phase-1-trial-results-ak006-csu2025-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-liver-meeting-20252025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-q3-2025-financial-results2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-investor-conferences-20252025-11-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-third-quarter-2025-results2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-inducement-grants-nasdaq-rule-56352025-10-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-pevifoscorvir-sodium-approval2025-10-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-hc-wainwright-liver-conference-20252025-10-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-liver-meeting-2025-abstracts2025-10-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-preclinical-presentations-hbv-meeting-20252025-09-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-hc-wainwright-conference-20252025-09-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-q1-2025-financial-results2025-05-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-expands-biopharma-service-portfolio2025-04-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-enable-medicine-single-cell-spatial-atlas2025-04-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-super-study-cancer-immunophenotyping2025-04-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-biosciences-pheno-cycler-fusion-cancer-equity2025-04-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKYA/akoya-reports-fourth-quarter-2024-financial-results2025-03-17T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ph1-adc-data-sitc-20252025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-abstract-sitc-meeting-20252025-11-04T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-scientific-advisory-board-dr-hurvitz2025-10-30T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-corner-launch2025-10-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-2-5-million-offering2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-files-patents-immuno-oncology-adc-platform2025-10-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-sitc-presentation-20252025-10-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-preclinical-data-ph1-adc2025-09-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-hc-wainwright-conference-20252025-09-05T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-efruxifermin-aasld-20252025-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-acquired-novo-nordisk-5-2-billion2025-10-09T10:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-morgan-stanley-conference-20252025-08-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-efruxifermin-harmony-trial-results2025-08-14T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-q2-2025-results-business-update2025-08-08T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKRO/akero-therapeutics-histoindex-easl-20252025-05-11T07:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q3-2025-financial-results2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/vadadustat-post-hoc-analysis-asn-kidney-week-20252025-11-06T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-investor-conferences-november-20252025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-inducement-grants-nasdaq-rule-56352025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-vafseo-update-non-dialysis2025-10-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-asn-kidney-week-2025-presentations2025-10-20T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-launches-a-perfusctm-3d-cell-culture-platform2025-09-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-ip-offering-6-56-million2025-03-07T17:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-upmc-abstract-advanced-ovarian-cancer2025-11-10T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-sitc-presentation-20252025-11-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-european-patent-ampligen-long-covid2025-11-03T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-2025-maxim-growth-summit2025-10-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-approval-20392025-09-25T18:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-patent-japan-cancer-therapy2025-09-25T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-interferon-alpha-tumor-growth2025-09-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-conference-poland2025-09-04T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-ceo-corner-segment-release2025-08-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-q2-2025-financial-results-update2025-08-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-q3-2025-financial-results2025-11-12T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-healingmaps-partnership2025-09-05T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-clear-platform-launch2025-08-26T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-commercial-agreement-fda-cleared-bna-platform2025-07-14T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-added-russell-microcap-index2025-06-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-objective-measurement-alzheimers2025-06-20T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-acquires-evoke-neuroscience2025-05-06T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-warrant-exercise-funds2025-02-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-nvidia-connect-program2025-02-11T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-mitapivat-data-ash-20252025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-q3-2025-results-business-update2025-10-30T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-positive-chmp-opinion-thalassemia2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-third-quarter-2025-financial-results-webcast2025-10-16T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-update-pdufa-goal-date-pyrukynd-thalassemia2025-09-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-approval-thalassemia-saudi-arabia2025-08-04T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-appoints-dr-jay-backstrom-board-directors2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-goldman-sachs-healthcare-conference-20252025-05-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-nasdaq-delisting-notice2025-05-14T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-insolvency-proceedings-filing2025-05-13T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-afm24-response-rates-aacr-20252025-04-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-abstracts-asco-20252025-04-23T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-receives-nasdaq-deficiency-notice2025-04-21T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-afm24-abstract-aacr-20252025-03-25T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AFMD/affimed-present-leerink-partners-healthcare-conference-20252025-03-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grants-nyse-american2025-05-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-aegis-capital-conference-20252025-05-19T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-first-quarter-2025-results-update2025-05-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-nyse-american-compliance-plan2025-04-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-appoints-rob-bancroft-ceo2025-04-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-ceo-transition2025-03-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-leerink-global-healthcare-conference2025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reverse-stock-split2025-02-24T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital-treasury-shares2025-10-29T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-2025-financial-results-update2025-09-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-appoints-bny-mellon-as-depositary-bank2025-09-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-shareholders-approve-resolutions-annual-meeting2025-06-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q1-2025-financial-results2025-06-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-gabab-pam-candidate-anti-tussive-activity2025-06-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-positive-gabab-pam-chronic-cough-data-presentation2025-06-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-completes-screening-artemis-trial-ixo-vec2025-09-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-inducement-grants-nasdaq-rule-56352025-09-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-q2-2025-results-pipeline-highlights2025-08-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-hc-wainwright-ophthalmology-conference2025-08-06T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-biotechnologies-2025-rbc-ophthalmology-conference2025-03-31T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-investor-conferences-20252025-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q3-2025-financial-results2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-morgan-stanley-conference-20252025-08-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-flatiron-integration-clonoseq2025-07-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-clonoseq-mrd-assessment-asco-eha-20252025-05-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-q3-2025-financial-results-update2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-fda-approval-yield-enhancement-process2025-04-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-statement-on-tariffs2025-04-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-raymond-james-conference-20252025-02-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-ceo-big-biz-show2025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-partners-genomind-precision-medicine-testing2025-10-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-business-update-fda-eop2-meeting-ad042025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-nasdaq-extension-compliance2025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-senate-support-clinical-trial-endpoints2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-q2-2025-financial-results-update2025-08-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-eop2-fda-meeting-success2025-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-regains-nasdaq-compliance2025-07-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-pct-patent-application-20452025-07-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-manufacturing-agreements-cambrex-thermo-fisher2025-06-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-licensing-agreement-third-arc-bio2025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-phase-2-muzastotug-keytruda-colorectal-cancer2025-10-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-expands-safebody-collaboration-exelixis2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-adg126-csco-meeting-20252025-09-05T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-appoints-axel-hoos-executive-advisor2025-09-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-investor-conferences-september-20252025-08-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-six-months-2025-financial-results2025-08-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-regulatory-update-muzastotug-fda-meeting2025-07-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-conjugatebio-partner-develop-antibody-drug-conjugate2025-07-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-sanofi-investment-muzastotug2025-07-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-fda-updated-data-elraglusib2025-09-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-public-offering-20252025-09-11T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-public-offering-15-million2025-09-10T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-public-offering2025-09-09T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-clinical-trial-advanced-pancreatic-cancer2025-08-06T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-ewing-sarcoma-phase-1-trial2025-07-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-2-trial-results2025-06-24T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-trial-asco-20252025-06-20T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-russell-index-inclusion2025-06-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-2-data2025-06-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q3-2025-financial-results-update2025-11-06T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-november-healthcare-conferences2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-rd-day-2025-new-york2025-09-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-ati-2138-eadv-20252025-09-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2a-trial-results-ati-21382025-07-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-leadership-transition2025-07-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-russell-indexes-inclusion2025-06-30T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-hc-wainwright-conference-20252025-06-26T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-present-jefferies-2025-london-healthcare-conference2025-11-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q3-2025-results-corporate-update2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-appoints-catherine-mummery-chair-cab2025-10-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/aci-19626-tdp-43-pet-tracer-nature-communications2025-10-24T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/aci-35-030-phase-1b-2a-trial-results2025-09-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-pipeline-focus-operational-efficiencies2025-09-04T07:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-phase-2-trial-results-parkinsons2025-04-02T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-ad-pd-2025-symposium2025-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-update-q3-20252025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-nda-milestones2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q3-2025-results-conference-call2025-10-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-erik-atkisson-appointment2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-fda-voucher-cytisinicline2025-10-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-new-hire-inducement-awards2025-10-02T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-smoking-cessation2025-09-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-promotes-craig-donnelly-coo2025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-dr-mark-rubinstein-cmo2025-09-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-fda-acceptance-cytisinicline-nda2025-09-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHL/achilles-therapeutics-voluntary-nasdaq-delisting2025-02-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-phase-3-trials-ulcerative-colitis2025-11-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-abtect-trial-results-ulcerative-colitis2025-10-06T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-abtect-trial-results-safety-data2025-10-05T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-acceptance-late-breaking-abstract-ueg-20252025-09-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ueg-presentation-20252025-09-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-first-half-2025-financial-results2025-09-08T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reports-q3-2025-results-corporate-update2025-11-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-abstracts-aasld-20252025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-reacquires-china-rights-imdusiran2025-06-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-clinical-trial-data-easl-20252025-05-07T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-present-imdusiran-ab-101-easl-congress-20252025-04-23T06:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/genevant-arbutus-patent-infringement-modena2025-03-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABUS/arbutus-board-changes-lindsay-androski-ceo2025-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-q3-2025-results2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-appoints-george-golumbeski-chairman2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-stifel-healthcare-conference2025-11-04T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-investor-conferences-20252025-08-26T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-pTau217-assay-utility2025-07-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-jcr-collaboration-alzheimers-therapy2025-07-15T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-aaic-2025-cost-savings-sabirnetug2025-07-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-reports-q3-2025-results2025-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-employee-inducement-grants2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-j-code-zevaskyn2025-10-30T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-james-gow2025-10-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-ab0-503-fda-rdea-pilot-program2025-10-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-children-hospital-colorado-zevaskyn2025-10-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-investor-conferences-september-20252025-08-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-inducement-grant-nasdaq-rule-56352025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-obesityweek-2025-data2025-11-04T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-investor-conferences-november2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-obesityweek-2025-presentation2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-fda-protocol-amendment-phase-3-hero-trial2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-stifel-2025-forum2025-09-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q2-2025-results-pipeline-updates2025-08-13T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-lisaftoclax-ash-20252025-11-04T01:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-olverembatinib-ash-20252025-11-04T01:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-investor-conferences-november-20252025-10-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-2025-interim-financial-results2025-08-20T23:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-glora-4-phase-iii-study-lisaftoclax2025-08-17T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-evercore-china-biotech-summit2025-08-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-btig-conference-20252025-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-tradipitant-glp1-nausea-vomiting-results2025-11-17T23:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-second-winds-film-blood-cancer2025-11-14T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-robert-huffines-jacqueline-wright-board2025-11-17T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-onclarity-hpv-assay-who-prequalification2025-11-17T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/ziihera-phase-3-results-her2-targeted-agent2025-11-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-positive-topline-data-neladalkib-advanced-nsclc2025-11-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-rezlidhia-five-year-data-publication2025-11-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-inhibits-structural-damage-psa2025-11-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-gateway-labs-philadelphia-opening2025-11-19T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-financial-results-september-20252025-11-19T13:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-financial-results-20252025-11-20T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-nine-month-2025-financial-results2025-11-20T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-pharma-gobivaz-approval-europe2025-11-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-advanz-pharma-gobivaz-market-authorization2025-11-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-q3-2025-financial-results2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-evercore-isi-healthcare-conference2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-piper-sandler-healthcare-conference-20252025-11-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-evercore-healthcare-conference2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-lecanemab-data-ctad-conference2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-december-investor-conferences2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-piper-sandler-healthcare-conference-20252025-11-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-application-depression-treatment2025-11-20T11:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-q3-2025-results-corporate-updates2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-humana-cnsid-assay-coverage2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-ibogaine-supply-breakthrough2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-presents-noblecon21-emerging-growth-conference2025-11-20T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-piper-sandler-healthcare-conference-20252025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-q3-2025-results-corporate-update2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-2-thio-101-study-romania2025-11-20T13:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-investment-conferences-20252025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-mink-215-anti-tumor-activity2025-11-20T16:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-noblecon21-investor-conference2025-11-20T14:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-atev-positive-results-veithsymposium2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-gt-02287-neuroscience-20252025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-hrec-approval-phase-1-2-cywc628-trial2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-positive-data-cmv-vaccine-program2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-fda-clearance-focal-one-hifu2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-fda-approved-alcohol-use-disorder-trial2025-11-20T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-q3-2025-financial-results-update2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-participate-benchmark-investor-conference2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fites-cf602-erectile-dysfunction-patent-brazil2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receptor-ai-collaboration-cancer-therapeutics2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-december-20252025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-corporate-updates2025-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-agreements-22-5-million-financing2025-11-21T05:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-announces-stock-repurchase-plan-100-million2025-11-21T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-litigation-tesaro-gsk2025-11-21T08:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquires-lava-therapeutics2025-11-21T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/b-free-chronic-babesiosis-study-open-enrollment2025-11-21T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-otsuka-launches-nexletol-japan2025-11-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-evercore-healthcare-conference-20252025-11-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-rule-5635c42025-11-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-ateganosine-clinical-program-sitc-20252025-11-21T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-positive-pas-004-pk-data2025-11-21T17:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-reports-long-term-survival-trends-gbm-trial2025-11-24T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-warrant-exercise-20-million2025-11-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-positive-six-month-data-knee-osteoarthritis2025-11-24T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-avt03-marketing-authorization-europe2025-11-24T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-approval-avt03-biosimilar-prolia-xgeva2025-11-24T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-hematology-investor-event2025-11-24T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-ash-2025-hematology-pipeline-advancements2025-11-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-vby329-rsv-antibody-development2025-11-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-advances-veterinary-partnerships-biofit-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-evercore-healthcare-conference2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-piper-sandler-conference-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-investor-conferences-december-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-piper-sandler-conference-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-phase-1-trial-update2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-piper-sandler-conference2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-helios-3-axpaxli-npdr2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-december-investor-conferences2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-investor-conferences2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-december-investor-conferences2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-fda-ind-clearance-phase-2-study2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-dlb-ctad-conference2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-completes-senior-notes-tender-offer2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-good-supply-vaping-products-quebec2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-good-supply-vapes-quebec-launch2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-piper-sandler-conference-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-vepdegestrant-sabcs-20252025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-participation-upcoming-investor-conferences2025-11-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-evercore-healthcare-conference2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-fda-leqembi-subcutaneous-application2025-11-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-azetukalner-aes-2025-data2025-11-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-presents-piper-sandler-conference2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-investor-conferences-december2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-8-35-million-offering2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-nasal-foralumab-phase-2-trial-accepted2025-11-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-participate-evercore-healthcare-conference2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-chronic-spontaneous-urticaria-eu2025-11-25T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-phase-2a-data-rap-219-seizures2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-upcoming-conference-participation2025-11-25T13:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-sil204-toxicology-studies-phase-2-3-trial2025-11-25T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-phase-2-results-lyme-vaccine2025-11-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-2-results-lyme-vaccine2025-11-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-therapy-medicare-reimbursement-20262025-11-26T06:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-therapy-medicare-reimbursement-increases2025-11-26T06:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-bank-of-america-transparency-declarations2025-11-26T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-transparency-notifications-bank-of-america2025-11-26T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/fda-priority-review-sonrotoclax-mcl-treatment2025-11-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVLT/scilex-closes-second-tranche-investment-datavault-ai2025-11-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-piper-sandler-conference-20252025-11-26T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-participate-evercore-healthconx-conference2025-11-26T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-evercore-healthcare-conference2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquire-patents-endoscopy-systems2025-11-26T12:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-participate-citi-2025-global-healthcare-conference2025-11-26T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-participate-piper-sandler-conference-20252025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-citi-2025-healthcare-conference2025-11-26T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-investor-webinar-december-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/enlivex-closes-212-million-private-placement2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-warrant-inducement-transaction2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-participate-piper-sandler-healthcare-conference2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-piper-sandler-conference-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-investor-conferences-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-evercore-healthcare-conference-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-curevac-exchange-offer-update2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-exchange-offer-curevac-shares-expiration2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-blarcamesine-ctad-conference-20252025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-piper-sandler-healthcare-conference-20252025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-presents-evercore-healthcare-conference-20252025-11-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-pipeline-presentation-noblecon212025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-emperor-total-artificial-heart-ismcs-20252025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-piper-sandler-conference2025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-presents-piper-sandler-healthcare-conference2025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-board-transition-christina-rossi2025-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/emory-hospital-adopts-liberty-endovascular-robotic-system2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-announces-payoff-outstanding-debt2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-strategic-growth2025-11-26T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-reverse-stock-split2025-11-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MURA/mural-oncology-acquisition-xoma-royalty2025-11-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-custom-integration-pipeline2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-virtual-investor-closing-bell-series2025-11-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lawsuit-stock-manipulation-w52025-11-26T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-ph80-menopausal-hot-flashes-findings2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-evm401-patent-allowance2025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-pristina-recon-dl-mammography2025-11-26T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-participation-december-investor-conferences2025-11-26T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-consolidates-operations-france2025-11-26T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-consolidate-operations-france2025-11-26T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-webinar-french-shareholders-december-20252025-11-27T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-fiba-award-20252025-11-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-available-france-official-journal2025-11-28T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-voting-rights-november-20252025-11-28T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-general-assembly-vote-results-november-20252025-11-28T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-shareholders-meeting-results-november-20252025-11-28T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inducement-grants-nasdaq-rule-56352025-11-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-recommendation-reimbursement-skyrizi-colitis2025-11-28T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/skyrizi-positive-reimbursement-canada-ulcerative-colitis2025-11-28T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-regulatory-update-tradipitant-motion-sickness2025-11-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-evercore-healthcare-conference-20252025-11-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-launch-ai-bph-module-rsna-suo2025-11-28T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inducement-grant-nasdaq-rule-56352025-11-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-nasdaq-notification-letter2025-11-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-public-offering-60-million2025-11-28T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-piper-sandler-healthcare-conference-20252025-11-28T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-stock-manipulation-lawsuit2025-11-28T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-acquires-family-beginnings-clinic2025-11-28T18:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/deephealth-next-gen-imaging-ai-rsna-20252025-11-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-next-generation-signa-mri-technology2025-11-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-rsna-2025-innovation2025-11-30T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-verida-launch-ai-spectral-ct2025-11-30T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-blueseal-horizon-helium-free-mri-platform2025-11-30T16:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q3-2025-financial-results2025-12-01T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-agm-december-20252025-12-01T09:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-phase-3-atogepant-migraine-data2025-12-01T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/deephealth-breast-suite-launch-ai-cancer-detection2025-12-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-phase-3-dragon-trial-results2025-12-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ind-clearance-ide034-bispecific-adc2025-12-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-board-transition2025-12-01T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-alzheimers-candidates-ctad-20252025-12-01T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-sells-complement-inhibitor-adx-0972025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-participate-piper-sandler-healthcare-conference2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fda-fast-track-cln-0492025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-regains-nasdaq-compliance2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-biosciences-piper-sandler-conference-20252025-12-01T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-evercore-healthcare-conference2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-proteograph-platform-genetic-signals-drug-targets2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-tessera-develop-tsra-196-gene-therapy2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-respect-phase-1-results-sabcs-20252025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-plasma-ptau-alzheimers-trials2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-evercore-healthcare-conference2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-va-contract-functional-abdominal-pain2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-webcast-phase-1-btx-degrader-bexobrutideg2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-apoc3-ionis-nature-conference-20252025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-public-offering2025-12-01T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q2-fy26-results2025-12-01T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-secures-investment-and-new-ceo2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-evercore-healthcare-conference-20252025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-piper-sandler-conference-20252025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-phase-3-zervimesine-alzheimers-ctad2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-phase-1b-ficerafusp-alfa-data-esmo-asia2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-ceo-transition-succession-plan2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-rare-kidney-disease-pipeline2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVM/adverum-tender-offer-lilly-expiration2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-biogen-presentations-2025-aes-meeting2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-fda-breakthrough-olesarsen-severe-hypertriglyceridemia2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-notice-allowance-xp-8121-patent2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-frank-leonard-ceo-appointment2025-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bmy-ash-2025-hematology-pipeline-data2025-12-01T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-appoints-carolyn-bonner-cfo2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dyadic-brig-bio-animal-free-alpha-lactalbumin-agreement2025-12-01T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-appoints-margaret-dugan-cmo2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-ceo-letter-shareholders2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-noble-capital-markets-conference-20252025-12-01T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-presentations-2025-aes-meeting2025-12-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-webinar-tupelo-phase-1b-2-trial2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-appoints-nick-tressler-cfo2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-closes-novo-nordisk-agreement-zaltenibart2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-bloom-phase-2-study-fragile-x2025-12-01T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-appoints-richard-hoffman-general-counsel2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-21-cfr-part-11-compliance-software-xcelligence-rtca-esight2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-reverse-stock-split2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-enters-gerd-device-market-acquisition2025-12-01T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-collaborate-texas-biomed-influenza-study2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-fda-rare-pediatric-disease-sgt-2122025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-presentation-iaccess-alpha-conference2025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-participate-evercore-healthcare-conference2025-12-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-piper-sandler-conference-20252025-12-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-breast-cancer-sabcs2025-12-01T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-launches-lymphir-cancer-immunotherapy2025-12-01T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-phase-3-data-european-headache-congress2025-12-01T17:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inducement-grants-nasdaq-rule-56352025-12-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-inducement-grants-nasdaq-listing-rule-5635c42025-12-01T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-sale-coflex-assets-companion-spine2025-12-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-inducement-plan-grants2025-12-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inducement-grants-nasdaq-rule-56352025-12-01T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/2025-sabcs-breast-cancer-index-test-utility2025-12-02T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-phase-3-argus-trial-data-20252025-12-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-pari-european-patent-molbreevi-nebulizer2025-12-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-innovation-webcast-rd-leadership2025-12-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engens-detalimogene-fda-manufacturing-pilot-program2025-12-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-fda-breakthrough-therapy-plozasiran2025-12-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-fda-breakthrough-therapy-zilganersen-alexander-disease2025-12-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMI/owens-minor-investor-conferences-december-20252025-12-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-appoints-dr-winer-advisory-board2025-12-02T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-fda-type-c-meeting-scheduled2025-12-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/doctorbox-adds-mainz-biomed-coloalert2025-12-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-albuterol-sulfate-aerosol2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-futurevision-advisory-council2025-12-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-nine-month-2025-results-cdmo-growth2025-12-02T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/who-approval-olastrocel-celz-2012025-12-02T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-fda-approval-trial-locally-recurrent-prostate-cancer2025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-winnie-harlow-vitiligo-awareness-campaign2025-12-02T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-nvidia-imaging-solutions-rsna-20252025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-ai-powered-care-aes-20252025-12-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-signatera-datasets-sabcs-20252025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-aws-strategic-collaboration-ai-platform2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-appoints-lucile-blaise-global-head-commercialization2025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDY/aurigene-phase-1-study-aur112-lymphoid-malignancies2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-grants-40th-us-patent2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-2-phase-3-data-sabcs-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-corporate-update-call-december-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-appoints-alicia-secor-board2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-manufacturing-upscaling-nasal-spray-platform2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-spinout-il-6-asset2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-briquilimab-asthma-study-results2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-dr-petra-kaufmann-cmo2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reveal-1-results-glp-1-weight-maintenance2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-closes-60-million-offering2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-dlb-biomarker-data2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-positive-results-pedmark-japan2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTYX/ventyx-clinical-corporate-updates2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-evercore-healthcare-conference-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-virtual-fireside-chat-titan-partners2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-acquires-sommaplast-oral-dosing-packaging2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-fourth-quarter-fiscal-2025-results2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-phase-1-trial-results-janz007-mcrpc2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNMD/mindmed-new-employee-inducement-grants-december-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-innovation-update-ashp-20252025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-december-2025-conferences2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-webinar-preliminary-data-etesian-study2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-leadership-presentation-citi-2025-conference2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fda-approval-cyclosporine-ophthalmic-emulsion2025-12-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-study-atogepant-migraine-results2025-12-02T04:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-eclipse-study-atogepant-migraine-relief2025-12-02T08:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-pharmacological-effect-csad-conference-20252025-12-02T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-positive-preclinical-data-pegph202009-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-roche-phase-1-clinical-trial-enhanze-technology2009-01-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-presents-jp-morgan-healthcare-conference2009-01-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-grant-cdmo-business2023-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-nasdaq-compliance-update2023-11-03T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/eib-considering-extension-financial-facility-scini2023-10-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-q3-2023-financial-results2023-10-31T12:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-bio-europe-20232023-10-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-showcase-cgmp-biologics-cdmo-cphi-barcelona-20232023-10-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-1-33-million-offering2023-09-19T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-psoriasis-nanoabs-preclinical-results2023-09-13T20:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-investment-conferences-20232023-09-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-03-ipf-study2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-fda-clearance-phase-2-trial-lti-03-ipf2025-11-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-03-ipf-data-publication2025-09-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-ipf-summit-20252025-08-14T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-financing-agreements-21-million2025-07-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/ailerons-positive-phase-1b-trial-results-lti-032024-05-15T21:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/ailerons-upcoming-investor-conferences2024-05-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/ailerons-20-million-offering-closed2024-05-03T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/zircon-x-study-tlx250-cdx-clinical-decision-making2025-11-19T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-participate-ubs-jefferies-healthcare-conferences2025-11-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/tlx250-cdx-included-in-international-guidelines2025-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-doses-first-patient-solace-trial-bone-pain2025-10-22T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-206m-revenue-fy-2025-guidance-upgraded2025-10-14T06:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/cms-grants-tpt-status-gozellix2025-09-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-first-patient-phase-3-bipass-trial-prostate-cancer2025-09-09T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-presents-morgan-stanley-hc-wainwright-conferences2025-08-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-2025-half-year-results-commercial-performance2025-08-21T00:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-h1-2025-results-investor-webcast-notification2025-07-29T22:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-morgan-stanley-healthcare-conference2021-08-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-ubs-genomics-summit2021-08-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q2-2021-financial-results2021-08-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-bio-rad-patent-agreement2021-07-27T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-chromium-x-series-launch2021-07-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-visium-assay-ffpe-tissues2021-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-june-investor-conferences2021-05-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-bofa-securities-2021-conference2021-04-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launch-simpligraft-simplimax-wound-care2024-04-30T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-record-revenue-20232024-04-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-fourth-quarter-results-20232024-03-21T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-increases-credit-facility-midcap-financial2024-03-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-present-td-cowen-conference2024-02-26T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-investor-conferences-20242024-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-acquires-nanoss-production-operations2023-10-23T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-nasdaq-ipo-closing2021-10-18T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-ipo-pricing-announcement2021-10-14T02:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-new-employee-stock-options2024-10-02T11:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-grants-inducement-plan2024-10-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-investor-conferences-september-20242024-09-03T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q2-2024-financial-results2024-08-06T22:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adct-lot7-phase-1b-trial-updates2025-12-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-reverse-stock-split2024-11-29T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-announces-private-placement2024-11-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-open-letter-shareholders2024-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-nasdaq-extension-compliance2024-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1-ttx-mc138-trial-update2024-10-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1-trial-ttx-mc1382024-10-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-study-ttx-mc138-metastatic-cancer2024-09-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-nih-grant-ttx-mc1382024-09-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/catalent-brainstorm-partnership-nurown-als-therapy2020-10-23T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/catalent-brainstorm-partnership-nurown-therapy2020-10-23T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/catalent-brainstorm-partnership-nurown-manufacture2020-10-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-present-scientific-conferences-september2020-09-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-appoints-anthony-waclawski-regulatory-affairs2020-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-nurown-exosome-treatment-covid-19-ards2020-07-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-sme-status-ema2020-06-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-financial-results-q1-2020-update2020-05-07T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-leases-cleanroom-facility-tel-aviv2020-05-07T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-nurown-immunomodulation-neurology2020-05-04T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-labs-piper-sandler-conference-20252025-11-25T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-update-aml2025-11-13T13:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-virtual-investor-event-ash-20252025-12-03T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/first-us-commercial-sale-komzifti-kura-oncology2025-12-02T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/komzifti-nccn-guidelines-aml2025-11-25T22:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/komzifti-fda-approval-npm1-mutated-aml2025-11-13T15:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-hc-wainwright-conference-20202020-08-31T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-grant-cpg-1018-adjuvant-capacity-covid-192020-08-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-announces-q2-2020-financial-results2020-08-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/trisalus-acquires-dynavax-sd-101-oncology-program2020-08-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-report-q2-2020-financial-results2020-07-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-medigen-collaboration-covid19-vaccine2020-07-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-appoints-new-board-members2020-07-21T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-mount-sinai-universal-influenza-vaccine2020-07-16T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-phase-1-trial-medicagos-covid-19-vaccine2020-07-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presentation-american-society-hematology-20172017-12-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-q3-2017-financial-results2017-11-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presents-sitc-32nd-annual-meeting-cowen-io-next-summit2017-11-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-q3-2017-financial-results-conference-call2017-11-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presentation-cantor-fitzgerald-conference2017-09-22T15:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-pricing-public-offering-common-stock2017-09-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-aurigene-ca-170-update-esmo-20172017-09-11T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-presentation-baird-2017-healthcare-conference2017-09-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-ca-170-poster-esmo-20172017-08-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-florbetaben-f18-ctad-2025-presentation2025-11-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-hcwainwright-hbv-conference2023-10-12T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-abstracts-aasld-20232023-10-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-business-update-q3-20232023-10-05T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-barda-funding-antibody-platform2023-10-03T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-1-trial-hiv-vaccine2023-09-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-investor-healthcare-conferences-september-20232023-08-29T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-sasha-damouni-ellis2023-06-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-inducement-grants-nasdaq-rule-5635c42018-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-board-changes-elizabeth-anderson2018-11-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-three-november-conferences2018-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-q3-2018-financial-results-business-update2018-10-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-third-quarter-2018-financial-results-conference-call2018-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-new-data-idweek-chest-20182018-10-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-patent-protection-japan-20332018-10-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-fda-approval-arikayce-mac-lung-disease2018-09-28T21:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/convert-study-alis-ntm-lung-disease2018-09-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-q4-2022-financial-results-2023-objectives2023-03-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-conference-call-svb-cash-holdings2023-03-11T16:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-data-sgo-20232023-02-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-financial-report-20222023-02-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-participate-february-investor-conferences2023-01-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-balstilimab-mss-crc-asco-gi2023-01-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-participate-b-riley-2023-virtual-oncology-conference2023-01-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-data-asco-gi-presentation2022-12-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-balstilimab-advanced-sarcoma2022-11-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-criminal-investigation-update2024-12-13T00:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-pika-rabies-vaccine-application-pakistan2024-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-deutsche-bank-health-care-conference2009-05-15T13:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-presents-bank-america-healthcare-conference-20092009-05-12T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-present-sequire-investor-summit-puerto-rico2023-04-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launch-minimed-780g-system-instinct-sensor2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-pre-ind-submission-sublingual-aspirin2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-expands-okaidx-testing-cancer-detection2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-fda-approval-trial-recurrent-prostate-cancer2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-canadian-patent-stem-cell-treatment2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-long-covid2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-new-data-ash-2025-blood-cancers2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-investor-event-pioneer-trial-data2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-receipt-anda-ketafree2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-fda-type-c-meeting-20252025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-snda-ameluz-pdt-sbcc-treatment2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-james-izanec-vp-clinical-development2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-patent-mpar-overdose-technology2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-synthetic-halneuron-ip-filing2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-iovera-results-chronic-low-back-pain2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-new-data-aipac-003-phase-ii-sabcs-20252025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-q2-2025-financial-results2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-cancels-conference-call-svb-deposit-access2023-03-13T00:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-2-peninsula-trial-results2023-07-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-fda-review-extension-transcon-cnp-achondroplasia2025-11-25T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/cosibelimab-results-esmo-congress-20242024-09-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-presentation-hc-wainwright-conference2024-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-cosibelimab-fda-acceptance2024-07-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/gc-cell-checkpoint-therapeutics-cancer-research2024-07-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-12-million-offering2024-07-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cryoablation-superior-drug-therapy-af2020-08-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-first-quarter-financial-results-20212020-08-25T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-appoints-kevin-lofton-director2020-08-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-fy2021-q22020-08-24T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evolut-tavr-updated-labeling-bicuspid-as2020-08-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-financial-results-q1-fy20212020-08-11T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquires-companion-medical-smart-insulin-pen2020-08-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-interstim-micro-neurostimulator2020-08-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-orphan-drug-designation-sclc2023-09-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-lung-cancer2019-09-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-biotech-strength-potential2019-08-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-jaypirca-cll-sll-indication2025-12-03T17:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CKPT/checkpoint-therapeutics-fda-approval-unloxcyt2024-12-13T23:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/approach-trial-transcon-cnp-achondroplasia-results2025-11-17T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/fda-accepts-karyopharm-snda-xpovio-multiple-myeloma2020-07-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-nci-partnership-xpovio-research2020-07-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-xpovio-q2-2020-sales-update2020-07-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-inducement-grants-nasdaq-rule-5635c42020-07-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-xpovio-phase-2b-sadal-study-results2020-06-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-fda-approval-xpovio-dlbcl2020-06-22T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-eha-2020-presentation-selinexor-eltanexor2020-06-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-selinexor-phase-1-2-glioblastoma-study2020-06-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-positive-phase-3-boston-data-asco-20202020-05-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-elites-study-interstim-micro-system2020-08-20T14:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-surgery-fda-clearance2025-12-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-milestone-achievements-biotech-growth2019-08-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-cancer-treatment2019-05-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-breakthroughs2019-05-30T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapies-cancer-treatment2019-05-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gnpx-gene-therapy-programs2019-04-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-ceo-discusses-partnerships-and-developments2017-09-19T18:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-pre-nds-meeting-health-canada-april-20262025-12-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-presentations-sabcs-20252025-12-04T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-positive-interim-phase-1-data-bge-1022025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-new-use-patents-aramchol-rezdiffra-mash2025-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nu-q-nets-sepsis-detection-france2025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nuq-assay-detection-sepsis-france2025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-strategy-sustainable-growth2025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-academy-launch-education-platform2025-12-04T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endras-taeus-liver-matches-mri-pdff-performance2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-advances-starlight-1-trial-phase-ii2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-new-plasmid-preps2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-presentation-sachs-forum-20262025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-tender-results-senior-notes-2026-20272025-12-04T12:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-fda-clearance-omnipod-5-enhancements2025-12-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-releases-skintuition-report-20252025-12-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-asco-20262025-12-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-mesenchymal-drift-chronic-diseases2025-12-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-appoints-spencer-stiles-president-coo2025-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-wins-injunction-merck-keytruda-germany2025-12-04T18:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/fda-lifts-partial-hold-tradipitant-motion-sickness2025-12-04T21:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-presentation-dawson-james-conference-20232023-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/eazy-testing-aditxtscore-covid-19-monitoring2021-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-appoints-dolly-tyan-senior-vp-clinical-development2021-01-29T14:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-secures-financing-scale-aditxtscore2021-01-26T13:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxtscore-immune-monitoring-launch-february-20212021-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-signs-distribution-agreement-todos-medical2020-12-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-present-ld-micro-conference-20202020-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxtscore-covid19-event-dr-drew2020-11-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-appoints-anthony-voorhies-business-development2020-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-secures-clia-certification-and-launches-covid-19-test2020-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q3-2022-results2022-10-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-updates-sleep-society-meetings2022-09-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-wells-fargo-conference-20222022-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-appoints-ezgi-yagci-vp-investor-relations2022-08-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-stock-offering-pricing2022-08-12T01:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q2-2022-results2022-08-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-new-independent-directors2022-08-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-fda-approval-full-body-mri-compatibility2022-07-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-presentation-lake-street-conference-20192019-09-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-presentation-dougherty-conference2019-09-03T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q2-2019-update2019-08-13T20:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-intellisight-conference-20192019-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/interim-results-phase-1b-dm199-chronic-kidney-disease2019-06-19T20:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-presentation-craig-hallum-conference-20192019-05-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-scientific-advisory-board-kidney-disease2019-05-21T12:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q1-2019-financials-update2019-05-06T12:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/tac-stim-performance-improvements-air-force2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-human-health-innovation-conference2021-06-15T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-jefferies-conference-20212021-05-27T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-buyback-equity-spin-off-hanxin-subsidiary2021-05-07T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q1-2021-financial-results2021-05-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fda-approval-morphine-sulfate-injection2021-05-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q1-2021-earnings-call2021-04-29T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-needham-conference-20212021-04-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fda-approval-dextrose-injection2021-03-29T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-third-quarter-2025-results2025-11-14T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-needham-conference-20212021-04-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q4-2020-financial-results2021-03-25T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-svb-leerink-conference-20212021-02-18T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-appoints-william-forbes-cdo2021-02-01T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q3-2020-financial-results2020-11-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-key-talent-hiring2020-10-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-presents-piper-sandler-healthcare-conference2025-11-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-nasdaq-notification-mvp2023-08-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-share-consolidation2023-07-27T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-nasdaq-notification-minimum-bid-price2023-03-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-covid-19-catalogue-inclusion2022-12-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-partnership-lian-ou-health2022-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-authorized-international-branch2022-03-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-fiscal-year-2021-results2022-01-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-strategic-alliance-jiangxi-imm2022-01-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-inducement-grants-nasdaq-rule-56352025-12-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-dr-lori-kunkel-appointment2024-04-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-90-million-financing-updates2024-03-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q4-2023-financial-results2024-03-14T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-anniversary2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-march-investor-conferences2023-02-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-ocs-heart-fda-advisory-panel-postponement2020-09-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-ipo-closing-additional-shares2022-02-08T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-pricing-initial-public-offering2022-02-04T06:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-third-quarter-2016-results2016-11-02T11:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-ceo-transition-damien-mcdonald2016-11-02T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-credit-suisse-healthcare-conference-20162016-10-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-conference-call-q3-2016-results2016-10-04T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-participation-eacts-annual-meeting2016-09-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-launches-next-gen-icd-crt-d-devices2016-09-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-growth-new-facility-adoptions-bva-analyzer2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-capital-efficiency-q3-20252025-11-14T19:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-piper-sandler-conference-20252025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-partners-akeso-ivonescimab2022-12-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-dr-cesano-appointment2022-11-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-financial-results-q3-20222022-11-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ridinilazole-idweek-20222022-10-20T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-dr-robert-booth2022-10-03T20:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-100-million-rights-offering2022-08-09T17:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-lab-capabilities-expansion2025-12-03T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-completes-clinical-study-hyla-blood-sensor2025-11-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-appoints-executives-global-sales-board2025-10-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/paul-mann-returns-ceo-aspi2025-12-02T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quarterly-update-call-november-20252025-11-17T21:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-public-offering-common-stock2025-10-14T20:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-q3-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-q2-2025-results-call2025-08-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-phase-2-data-silevertinib2025-12-03T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-silevertinib-webcast-phase-2-results2025-12-02T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-inducement-grants-new-employees2025-11-17T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-phase-1b-meeting2025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/crest-2-study-carotid-artery-stenting-benefits2025-11-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-piper-sandler-healthcare-conference-20252025-11-19T21:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/prostact-global-phase-3-first-patient-dosed2025-12-08T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-oppenheimer-summit-20252025-12-08T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-atalanta-1-cell-therapy-data-ash-20252025-12-08T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-development-plan-ash-20252025-12-08T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-eti-cel-nhl-response-rate-ash-20252025-12-08T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-inducement-grants-nasdaq-rule-56352025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-inducement-grants-nasdaq-rule-5635c42025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inducement-grants-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-inlexzo-gemcitabine-nmibc-study-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inducement-grants-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-phase-1b-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards-december-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-ipo-closing2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-warrant-inducement-5-million2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-closes-10-million-offering2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/gallop-oncology-lyt-200-phase-1b-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-amx0114-als-lumina-trial-data2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/zorevunersen-dravet-syndrome-aes-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-bcr-abl1-panel-2025-ash-meeting2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-private-placement-warrant-inducement2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-seizures-data-analysis2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-acquires-mural-oncology2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/freenome-perceptive-capital-business-combination2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cretostimogene-potential-backbone-therapy-nmibc2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-adipose-distribution-presentation-cvct-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-advancing-rare-disease-therapies2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-clinical-trials-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-bexobrutideg-phase-1-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/bezuclastinib-summit-results-nonadvanced-systemic-mastocytosis2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-agreement-monetize-equity-biocon-biologics2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-clonoseq-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-rally-mf-phase-2-trial-data2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APTO/aptose-tuspetinib-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-ficerafusp-alfa-data-phase-1b2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-preclinical-data-arv-393-glofitamab-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-enozertinib-esmo-asia-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-ultramist-healogics-gpo2025-12-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-phase-2-3-trial-update-als2025-12-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-enrollment-completion2025-12-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-deliver-trial-results2025-12-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-updated-bexmab-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-nomination-committee-2026-agm2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-end-of-phase-2-fda-deupirfenidone-ipf2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-sale-toulouse-site-sandoz2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/sonrotoclax-data-ash-2025-b-cell-malignancies2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ash-2025-ascentage-pharma-lisaftoclax-data2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-phase-2-data-sls009-aza-ven-aml-mr-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-positive-phase-2-nxc-201-results-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-100-million-offering2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-access-clinical-program-aleniglipron2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-pirtobrutinib-phase-3-study-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-ronde-cel-clinical-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/lynozyfic-linvoseltamab-multiple-myeloma-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/hemgenix-long-term-durability-safety-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-updated-data-phase-1b-study-r289-lower-risk-mds2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-data-inc033989-myelofibrosis-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-inca033989-breakthrough-therapy-fda2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conference-call-deliver-trial2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/yescarta-safety-efficacy-quality-life-benefits-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-evorpacept-phase-2-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-pm359-cgd-clinical-data-publication2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-epkinly-phase-3-data-follicular-lymphoma2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-china-national-reimbursement-drug-list-updates2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/onco-innovations-nasdaq-cross-listing-equity-offering2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/hympavzi-reduced-bleeds-hemophilia-a-b2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-positive-data-alloha-phase-1-trial2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-pociredir-sickle-cell-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/kite-bicistronic-car-t-cell-therapies-phase-1-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/kite-anito-cel-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-oncoc4-gotistobart-sqnsclc-trial-results2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-new-data-evx-04-cancer-vaccine-ash-meeting2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-data-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-takeda-rusfertide-ash-20252025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-ash-2025-presentation2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-casgevys-first-data-children-5-11-ash-meeting2025-12-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-dor-target-cancer-therapy2025-12-08T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cretostimogene-grenadenorepvec-nmibc-data2025-12-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-collaboration-brain-tumors2025-12-08T13:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-abstract-hep-dart-20252025-12-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-abstracts-naclc-lung-cancer2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-baird-biotech-discovery-series2025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-gene-editing-hscs-fusogen-technology2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/caldolor-injection-j-code-reimbursement-update2025-12-08T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-jp-morgan-healthcare-conference2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/positive-phase-1b-2-results-rec-4881-tupelo-trial2025-12-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lingo-android-glucose-monitor2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-expands-leadership-ambassador-jamie-mccourt2025-12-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-positive-data-phase-1-inlight-trial2025-12-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-ss-mantra-fda-submission2025-12-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-ash-2025-leadership2025-12-08T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-showcase-aav-slb101-cardiac-gene-therapy2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-presents-sab-142-at-atted-asia-conference2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-fda-clearance-smart-comfort-cpap-therapy2025-12-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-aes-wrap-up-best-in-class-potential-epilepsies2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-fda-pre-submission-meeting-pl-142025-12-08T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-discontinues-phase-2b-bx004-trial2025-12-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-accelerates-nda-submission-axpaxli2025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-virtue-sab-ici-meeting2025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-bexobrutideg-phase-1-trial-ash-20252025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEUP/neuphoria-iss-recommends-white-proxy-card2025-12-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/carolyn-bertozzi-returns-lilly-board2025-12-08T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-phase-3-trial-vax-312025-12-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-kyowa-combination-data-ziftomenib-venetoclax-azacitidine2025-12-08T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-cln-049-ash-meeting2025-12-08T15:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-first-quarter-2026-dividend2025-12-08T19:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-participate-virocon-20252025-12-08T17:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/jim-lang-elected-halozyme-board-directors2025-12-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-fda-fast-track-st-503-sfn-treatment2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-varian-theranostics-ebrt-collaboration2025-12-11T09:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-pricing-550-million-financing2025-12-11T06:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-2025-rd-update-ash-data-review2025-12-11T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-amends-at-the-market-offering-agreement2025-12-11T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-ffrct-analysis-cost-savings2025-12-11T08:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-appoints-jon-resnick-ceo2025-12-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-late-breaking-preclinical-data-bbo-10203-sabcs2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-enrollment-phase-2-3-trial-darovasertib2025-12-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-exercise-warrants-68-million2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/fda-renews-canalevia-ca1-approval-jagx2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-orders-high-performance-nmr-systems-europe2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-fda-clearance-cable-free-ecg2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-water-tower-research-fireside-chat2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-ctdna-research-sabcs-20252025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/tukysa-first-line-maintenance-therapy-her2-positive-breast-cancer2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-2-results-chikungunya-vaccine2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-share-repurchase-program-20252025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-telomere-targeting-approach-nsclc2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-fda-clearance-da-vinci-sp-indications2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DLHC/dlh-reports-fiscal-2025-fourth-quarter-results2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-ipf-study-results2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-hero-trial-prader-willi-syndrome2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-preliminary-data-setmelanotide-pws2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-december-2025-inducement-grants2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-fda-response-ser-2522025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-positive-ragistomig-phase-1-data-esmo-io2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-18-million-offering-lymphir-launch2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-inducement-grant-new-employee2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-inducement-awards-nasdaq-rule-56352025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-phase-3-trial-results2025-12-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1510-esmo-2025-data2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-wyss-center-3d-multiomics-technology2025-12-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-wyss-center-biologie-spatiale2025-12-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-announces-10-million-cash-dividend2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-phase-3-sunrize-study-results2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-expands-cnside-assay-california2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-scientific-advisory-board-radiotherapeutics2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-fda-fast-track-kt-6212025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-jp-morgan-2026-conference2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-micropulse-glaucoma-retreatment-study2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-ima203cd8-prame-cell-therapy-data-esmo-io-20252025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-izicopan-international-name2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ceo-transition-orexin-strategy2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-phase-1a-study-results-crb-913-obesity2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-dublin-3-phase-3-study-plinabulin-docetaxel2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-positive-phase-2-data-parkinsons-disease2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-new-treatment-center-texas2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/broadwood-partners-opposes-staar-surgical-alcon-sale2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-refinancing-convertible-notes2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-partial-repurchase-convertible-senior-notes-20272025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/fda-priority-review-opdivo-hodgkin-lymphoma2025-12-11T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-pipeline-progress-outlook-investor-day-20252025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-setmelanotide-pws-trial-results2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-new-us-patent-emp-012025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/redecans-amped-live-resin-vapes-launch2025-12-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-acsl5-preclinical-data-lx98512025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-application-fibroblast-platform2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-year-2025-financial-results-call2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launches-nanoss-strata-synthetic-bone-graft2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-present-two-posters-sabcs-20252025-12-11T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-corporate-update-financing2025-12-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-designation-endoxifen-dmd2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-arakoda-expansion-20262025-12-11T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-quarterly-dividend-increase-20252025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-relutrigine-nda-filing-20262025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-intranasal-naloxone-hydrogel-advancement2025-12-11T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-phase-2-results2025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-leadership-insider-buying-trial-data-signals-potential2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-upgrade-myvista-insights-platform-launch2025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-strategic-restructuring-plan2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-antigen-spreading-AMPLIFY-7P-trial2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-advances-optical-genome-mapping-amp-20252025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-egyptian-drug-authority-authorization2025-12-11T13:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-hep-dart-20252025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-smart-infusion-pump-emr-integration2025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-european-patent-molbreevi-liquid-formulation2025-12-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-appoints-sean-salmon-board2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-104-phase-3-trial2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-partners-vugene-ai-drug-discovery2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-water-institute-launch-education2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-acceptance-clinical-data-abstract-asco-20262025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-lumee-technology-presentation-linc-20262025-12-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-senior-notes-offering2025-12-11T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-acquires-vlx-1005-hit-treatment2025-12-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-emrosi-clinical-trial-results2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-new-ceo-development-phase2025-12-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-announces-public-offering-pricing2025-12-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staars-go-shop-process-alcon-merger2025-12-11T14:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-first-patients-dual-energy-platform2025-12-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-acquisition-proposal-silvercape-investments2025-12-11T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-issues-second-tranche-bonds-eur-10-million2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-2026-financial-calendar2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/otr-therapeutics-zealand-pharma-collaboration-metabolic-diseases2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-private-placement-update2025-12-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-inducement-grants-nasdaq-elvn2025-12-11T21:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-jp-morgan-conference-20262025-12-11T22:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-positive-phase-1-breast-cancer-vaccine2025-12-11T23:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-uplizna-generalized-myasthenia-gravis2025-12-11T23:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-public-offering-pricing2025-12-12T05:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-merus-tender-offer-completion2025-12-12T06:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-investor-conference-20262025-12-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/revuforj-revumenib-best-new-drug-scrip-awards-20252025-12-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-preclinical-data-sabcs-20252025-12-12T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-54th-year2025-12-12T15:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-inluriyo-imlunestrant-ember-3-study-results2025-12-12T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approves-akeega-brca2-mcspc2025-12-13T01:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-uplighted-studies-update-efgartigimod-sc2025-12-15T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-integrates-cac-mid-60-sbf-120-euronext2025-12-15T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-joins-cac-mid-60-sbf-120-indices2025-12-15T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-acquires-spectrawave-advancing-coronary-imaging2025-12-15T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-concludes-legacy-doj-matter2025-11-20T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-participate-piper-sandler-healthcare-conference2025-11-19T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-amcp-nexus-2025-sublocade-evidence2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-q3-2025-financial-results-guidance2025-10-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-participate-stifel-2025-healthcare-conference2025-10-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-third-quarter-2025-financial-results-webcast2025-10-16T21:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/rapid-induction-sublocade-improves-retention-opioid-treatment2025-10-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-proposes-new-corporate-structure-us-domiciliation2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-q2-2025-financial-results-guidance-raise2025-07-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-cancellation-london-listing-nasdaq-maintained2025-07-25T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-virtual-kol-event-neuroimmunology2025-07-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-new-cfo-appointment2025-06-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jefferies-conference-20252025-05-28T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-business-update-q1-2025-results2025-05-13T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-leerink-partners-conference-20252025-03-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-naji-gehchan-appointment2025-01-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jp-morgan-healthcare-conference-20252025-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-leadership-growth-appointments2024-12-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-private-placement-funding2025-11-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-addresses-false-report-sale-securities2025-11-07T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-positive-preclinical-data-atr-01-ichthyosis-vulgaris2025-10-20T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-participate-dermatologic-rare-disease-panel2025-10-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-nyse-american-non-compliance-notice2025-10-03T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-presentation-hc-wainwright-conference-20252025-09-04T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-first-patient-phase-1-2-trial-atr-042025-08-27T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-reverse-stock-split2025-08-11T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-schedules-third-quarter-2025-financial-results2025-11-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-presentation-hc-wainwright-conference-20252025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-sale-lavie-bio-icl-completion2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-generative-ai-foundation-model-completion2025-06-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-innovation-authority-grant-fill-finish-capabilities2025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-six-month-2025-financial-results2025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-pc111-disease-modifying-therapy-pemphigus-sjs-ten2025-07-29T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-pc111-award-italian-dermatology2025-06-26T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-funding-cdmo-growth-bio-convention-20252025-06-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-acquisition-pincell-clearance2025-06-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-q1-2025-financial-results2025-05-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-announces-annual-financial-results-20242025-05-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-pincell-webinar-pc111-rare-skin-diseases2025-05-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-adjourns-annual-meeting-stockholders2025-06-24T15:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-first-patient-renew-trial-lti-03-ipf2025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-ats-2025-conference-lti-03-ipf2025-05-19T21:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-q1-2025-results-business-update2025-05-15T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-presentation-citizens-conference-20252025-04-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-abstract-accepted-ats-20252025-04-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-patents-lti-03-respiratory-diseases2025-04-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-2355-ipf-pasc-f-publication2025-04-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-avadel-bid-counteroffer-lundbeck2025-11-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/lundbeck-bids-for-avadel-pharmaceuticals2025-11-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-narcolepsy-program-phase-iii2025-11-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-spin-out-oncology-business2022-11-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/managing-multigenerational-post-pandemic-workforce2022-08-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-oncology-asco-22-nemvaleukin2022-06-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/kinaset-ceo-robert-clarke-asthma-patients2022-01-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/biopharma-clinical-report-2q20212021-07-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-lybalvi-fda-approval-schizophrenia-drug2021-06-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-participate-evercore-healthcare-conference2025-11-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-acquires-elektrofi-drug-delivery-expansion2025-11-18T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/fda-approves-darzalex-faspro-high-risk-smoldering-multiple-myeloma2025-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-pricing-convertible-senior-notes-offering2025-11-07T04:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-2025-financial-guidance-q3-results2025-11-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-third-quarter-2025-results2025-10-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-opens-tms-yokohama-japan2025-11-21T20:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/zircon-x-study-tlx250-cdx-impact-clinical-decision-making2025-11-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/opalescence-trial-tlx250-cdx-breast-cancer2025-11-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-solace-trial-bone-pain-treatment2025-10-23T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-injunction-parse-biosciences-atac-products2025-03-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-5000-plex-gene-panel2024-05-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q1-2024-financial-results2024-04-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-visium-hd-spatial-assay2024-03-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-expands-xenium-menu-cell-segmentation-immuno-oncology2024-03-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-begins-commercial-shipments-gem-x-products2024-03-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-td-cowen-conference-20242024-02-20T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-gem-x-technology2024-02-07T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ind-submission-ide574-cancer2025-12-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-december-2025-investor-events2025-11-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-positive-phase-2-data-darovasertib2025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-managed-access-program-del-zota-dmd442025-11-19T14:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-acquisition-novartis-ag2025-10-26T18:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-investor-conference-participation2025-10-16T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-positive-pre-bla-meeting-fda-del-zota2025-10-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-explore44-data-wms-congress2025-10-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-upsized-public-offering2025-09-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-public-offering-common-stock2025-09-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-del-zota-disease-progression-reversal2025-09-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-launches-collagenx-surgical-wound-closure2025-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-hc-wainwright-conference-20252025-09-04T13:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-cg-annual-growth-conference-20252025-08-06T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-q2-2025-financial-results-announcement2025-08-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-fda-clearance-phase-3-trial-primec-als2025-11-24T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-investor-webinar-december-20252025-11-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-alzheimers-biomarkers-reduction2025-10-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-alzheimers-trial-results2025-09-10T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-private-placement-premium2025-09-04T13:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-live-podcast-als-science-commercialization2025-07-22T13:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-primec-commercial-manufacturing-scale-up2025-05-07T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-shareholder-letter-clinical-progress2025-04-24T14:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-nasdaq-extension-compliance2025-12-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-4-million-offering2025-10-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-int230-6-clinical-results-ebio-medicine2025-10-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-invincible-4-update2025-09-10T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-fireside-chat-hc-wainwright-conference2025-09-02T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-regains-nasdaq-compliance2025-08-12T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/fda-review-nurown-evidence-treatment-effectiveness2025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-nurown-als-survival-data2025-06-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-manufacturing-partnership-minaris-nurown-phase-3b2025-05-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCLI/brainstorm-fda-clearance-phase-3b-trial-nurown-als2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-appoints-dr-michel-janicot2025-11-17T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-study-ttx-mc1382025-10-14T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-acquires-polynoma-funding2025-10-08T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-dr-phillip-zamore-appointment2025-05-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-trial-update2025-05-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-trial-progress2025-05-01T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-special-meeting-adjournment2025-04-21T21:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-lotis-7-update-webcast2025-12-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2025-financial-results-call2025-11-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-november-investor-conferences2025-10-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-60-million-private-placement2025-10-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-cantor-global-healthcare-conference-20252025-08-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-esophageal-precancer-detection-data2025-12-09T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-genomeweb-best-places-to-work2025-11-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-participate-canaccord-forum2025-11-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-conference-call-november-20252025-10-29T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-maxim-growth-summit-20252025-10-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-john-palumbo-board-appointment2025-09-25T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-appoints-danielle-scelfo-market-access2025-09-16T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-public-offering-closure2025-09-11T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-public-offering-pricing2025-09-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-participate-evercore-healthcare-conference2025-11-19T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-exclusive-license-vaxart-oral-covid-vaccine2025-11-05T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-third-quarter-2025-financial-results-conference-call2025-10-22T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-phase-1-2-trial-shingles-vaccine2025-10-21T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-participate-2025-wells-fargo-healthcare-conference2025-08-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/dynavax-stockholders-elect-director-nominees-20252025-06-11T16:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-kol-investor-event-ampreloxetine2025-11-20T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-investor-conferences-december-20252025-11-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-ampreloxetine-symposium-presentation2025-10-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-yupelri-copd-chest-20252025-10-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-hc-wainwright-conference-20252025-09-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-phase-3-cypress-study-enrollment-completed2025-08-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-q2-2025-financial-results2025-07-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-stifel-2025-healthcare-conference2025-11-05T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-collaboration-framework2025-10-01T22:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-hetlioz-insomnia-study-publication2025-09-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-september-2025-investor-conferences2025-08-28T22:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-virtual-investor-conference-20252025-03-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-at-roth-conference-20252025-03-10T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-patent-allowances2025-03-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-abstract-accepted-isalxix-symposium2025-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-3-5-million-offering2025-02-25T17:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-warrant-exercise-5-8-million2025-02-13T18:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-fda-guidance-miracle-trial-aml2025-02-13T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-approval-miracle-phase-3-trial2025-02-11T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participates-in-virtual-investor-segment2025-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-phase-3-trial-update2025-01-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-q3-2025-financial-results-webcast2025-11-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-appoints-joe-todisco-board-directors2025-10-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-announces-private-placement-financing-29-million2025-09-08T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-nephro-crrt-trial-enrollment-milestone2025-08-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-piper-sandler-conference-20252025-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-jefferies-conference-20252025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-investor-conferences2025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-btig-conference-20252025-07-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-hcw-home-series2025-06-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-third-quarter-earnings-release-date2025-03-20T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/nrlb-withdraws-labor-claim-neogen2025-02-18T21:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-igenity-bchf-bovine-heart-health2025-01-21T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-mda2-quantitative-salmonella-assay2025-01-16T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-participate-upcoming-investor-conferences2025-01-07T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-second-quarter-earnings-release-change2025-01-02T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-petrifilm-bacillus-cereus-count-plate2024-12-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-participate-piper-sandler-healthcare-conference2024-11-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-q3-2025-results-update2025-11-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-announces-top-line-results-am-001-study-aramchol2025-11-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-top-line-results-oncology-moa-studies2025-11-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-digital-asset-management-strategy2025-08-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-biomarker-signature-aramchol-expansion-potential2025-05-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ayvakit-efficacy-eha-eaaci-20252025-06-12T23:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-q1-2025-financial-results2025-04-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-needham-conference-20252025-03-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-mast-cell-therapies-2025-aaaai2025-02-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-jp-morgan-conference-20252024-12-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ash-2024-ayvakit-advancements2024-12-07T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-signal-aa-phase-2a-trial-enrollment-completed2025-10-21T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-participate-2025-wells-fargo-healthcare-conference2025-08-28T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-adrien-sipos-interim-cmo2025-06-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-fda-fast-track-bempikibart-alopecia-areata2025-04-30T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-transparency-update-equity-financing2025-07-31T17:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-strategic-update-woori-io2025-07-30T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-acquires-woori-io-glucose-monitoring2025-07-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-appoints-dr-andreas-niethammer-cmo-vaximm2025-07-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-security-token-offering-roadmap2025-07-09T15:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-bcm-europe-taekwondo-token-launch2025-05-22T12:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/darnatein-presents-bmp-conference-20252025-05-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-tyra-300-proof-of-concept-data2024-10-24T23:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-q2-2023-results-highlights2023-08-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-preclinical-data-tyra-200-symposium2022-10-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-september-2022-investor-conferences2022-09-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-2021-jefferies-london-conference2021-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-announces-ipo-closing-and-underwriters-option2021-09-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-divests-clinical-services-business-audax-private-equity2024-08-16T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-launches-responsible-supplier-program2023-06-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-rebrands-tao-synergies-taox2025-06-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-tao-acquisition-crypto-strategy2025-06-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-crypto-strategy-ai-token-tao2025-06-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-special-committee-value-creation2024-12-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-5-million-financing2024-09-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-collaboration-lsu-health-spinal-cord-injury2024-07-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-fda-ind-bryostatin-1-ms-trial2024-06-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-dea-cannabis-reclassification-benefits2024-05-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-regains-nasdaq-compliance2024-04-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-increases-stake-psilocybin-drug-discovery2024-04-09T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-inducement-grants-nasdaq-rule-56352025-12-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/european-commission-approves-brinsupribrensocatib-ncfb2025-11-18T16:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-global-day-of-good-20252025-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-present-november-december-2025-investor-conferences2025-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-science-top-employers-20252025-10-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-phase-3-aspen-study-presentation-chest-20252025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-third-quarter-2025-financial-results-conference-call2025-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-first-sale-nuq-cancer-assays-clinical-use2025-11-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-first-sales-contract-nuq-cancer-tests2025-11-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-q3-2025-financial-results-update2025-11-13T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-schedules-q3-2025-earnings-call2025-11-10T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-donates-nuq-vet-cancer-tests-hope-dogs2025-10-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-pricing-public-offering-common-stock2025-10-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-15-6-million-offering2025-12-09T14:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-reports-q3-2025-results-update2025-11-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-dor-targeting-mdscs-ash-meeting2025-11-03T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inclusion-russell-indexes2025-07-01T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-acquisition-kineta2025-06-30T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-phase-3-trial-ifx-2-0-keytruda-mcc2025-06-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-inducement-grants-nasdaq2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-appoints-christopher-martin-board2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-new-cfo-michael-noffi2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-investor-conferences-20252025-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-sevasemten-wms-congress-20252025-10-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-jefferies-global-healthcare-conference2025-11-11T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-launch-charged-aerosol-detector-empower-software2025-11-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q3-2025-financial-results2025-11-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-rd-day-december-20252025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-q3-2025-financial-results2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-investor-conferences-20252025-10-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-conference-call-q3-2025-results2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-vatiquinone-crl-fda2025-08-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-novartis-acquisition-agreement2025-04-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-2025-oppenheimer-summit2025-04-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-phase-1b-trial-farabursen-adpkd2025-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-leerink-partners-2025-conference2025-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-oppenheimer-conference-20252025-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-adpkd-farabursen-updates2025-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-investor-conferences-20242024-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-acceptance-denifanstat-acne-nmpa2025-12-10T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-inducement-grants-nasdaq-5635c42025-12-09T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q3-2025-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-investor-conferences-20252025-11-12T22:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-participate-scientific-conferences-ksi-1012025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-presentation-american-chemical-society-20252025-08-19T19:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-investor-rd-day-july-20252025-07-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-ksi-101-presentation-iois-20252025-06-25T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-2025-jefferies-conference2025-05-30T02:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-regains-nasdaq-compliance2024-10-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-extraordinary-general-meeting-20242024-09-11T02:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSB/lakeshore-biopharma-fy-2024-financial-results2024-08-16T02:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cash-dividend-q3-fy20262025-12-04T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-q2-fiscal-2026-financial-results2025-11-18T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-q2-fy2026-financial-results2025-11-05T22:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-symplicity-spyral-coverage-finalized2025-10-28T23:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/spyral-htn-on-med-results-blood-pressure-reductions2025-10-26T22:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-brainsense-adaptive-deep-brain-stimulation2025-10-09T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-surgery-study-gynecology2025-10-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-builds-6-billion-facility-alabama2025-12-09T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-adverum-acquisition-tender-offer-expiration2025-12-09T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-improves-survival-cll-sll2025-12-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-progress-breast-cancer-symposium-20252025-11-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-phase-3-ash-20252025-11-24T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-attend-morgan-stanley-conference2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-strategic-review-infant-formula-business2025-11-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-attend-jefferies-consumer-conference2025-11-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend2025-10-29T16:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-third-quarter-2025-financial-results-release2025-10-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/opill-chill-collaboration-launch2025-10-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-attend-barclays-consumer-staples-conference2025-08-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-biopharm-complete-response-mrd-patient2025-06-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-transition-nasdaq-otc-markets2025-03-21T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-bio-pharm-outsourcing-initiatives-reducing-burn-rate2025-03-18T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-acquires-ophthalmic-pharmaceutical-company2025-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-bio-pharm-ceo-cancer-progress-panel-european-forum2025-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-achieve-clinical-trial-cohort-a-completion2025-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-achieve-clinical-trial-patient-dosing-completion2025-02-10T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tc-bio-pharm-ads-ratio-change2025-02-05T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCBP/tcbp-h5n1-proof-of-concept-studies2025-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-water-tower-research-chat-20252025-12-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-who-approval-liraltagene-autoleucel2025-11-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-patent-20252025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-data-transfer-agreement-cleveland-clinic2025-11-05T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-spartan-capital-conference-20252025-10-23T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-chinese-patent-breast-cancer-vaccine2025-10-20T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-trial2025-10-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-results-sabcs-20252025-09-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-inc-reverse-stock-split2025-12-02T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-2a-data-vanoglipel-mash-aasld-20252025-11-07T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-preclinical-data-da-1726-obesityweek-20252025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-poster-presentation-vanoglipel-aasld-20252025-10-27T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-obesityweek-20252025-10-20T15:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-presentation-hc-wainwright-liver-conference2025-10-14T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-present-upcoming-investor-industry-conferences2025-08-26T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-trial-da-1726-obesity-8-weeks2025-08-06T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-third-quarter-2025-financial-results2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-sentry-trial-enrollment-completion2025-09-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-acclaim-1-phase-1-gene-therapy-data2025-11-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-adds-clinical-trial-site-acclaim-lung-cancer2025-11-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patent-reqorsa-gene-therapy-pd-l1-antibodies2025-11-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-10-million-offering-nasdaq2025-10-28T16:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-positive-preclinical-data-reqorsa-gene-therapy2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-september-investor-conferences2025-09-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-gene-therapy-lung-cancer2019-09-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-pipeline-update-clinical-progress2025-12-03T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-nvidia-connect-program2025-11-20T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-gdnf-weight-loss-therapy-study2025-10-27T12:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-fda-orphan-drug-ht-kit2025-10-21T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-expands-ai-initiative-nvidia-platform2025-10-08T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ceo-presentation-bio-europe-20252025-10-07T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-patent-expansion2025-09-24T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-shareholder-update-ht-001-ht-kit2025-09-16T13:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ema-submission-ht-001-cancer2025-09-10T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-whole-genome-sequencing-genetic-signals2025-11-12T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-webcast-upcoming-investor-conference2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-protein-prep-precision-ngs-proteomics2025-11-10T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-responds-chinese-ministry-commerce-updates2025-11-05T22:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-5-base-solution-multiomic-discovery2025-10-15T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-constellation-mapped-read-technology-genedx-pilot2025-10-15T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-third-quarter-2025-financial-results2025-10-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-advances-personalized-cancer-care-partnerships2025-09-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-q3-2025-results-release2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-com701-phase-1-trials-esmo-20252025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-present-sitc-20252025-10-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-research-single-cell-genomics-2025-conference2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-hc-wainwright-investment-conference2025-08-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-q3-2025-financial-results2025-11-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-third-quarter-2025-results2025-11-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-acquires-quantum-computing-bio-data-company2025-10-23T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-board-changes-strategic-decision2025-09-16T11:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-regains-nasdaq-compliance2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-warrant-amendments-registration-filing2025-08-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-covid-19-vaccine-development2020-03-24T15:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eczema-market-growth2020-01-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-acne-eczema-asthma-research2020-01-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-emerging-markets-report2019-12-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eczema-therapy-market2019-12-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-adds-dr-adam-friedman-advisory-board2019-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-initial-public-offering2019-02-20T22:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-third-quarter-2024-results-update2024-11-08T15:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-cross-license-agreement-mannkind2024-05-29T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-pur3100-clinical-results-migraine2024-05-15T14:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-piper-sandler-healthcare-conference-20252025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-fda-approval-epkinly-lymphoma2025-11-18T17:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-migraine-career-catalyst-award-recipients-20252025-11-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NLSP/nls-pharmaceutics-kadimastem-equity-financing2025-06-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-closes-18-2-million-offering2025-11-12T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-upsized-public-offering2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-abj-mathew-center-biopreservation2025-11-20T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-investor-conferences-nov-dec-20252025-11-17T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-sale-savsu-subsidiary2025-10-07T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-invests-in-pluristyx2025-07-28T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q2-2025-financial-results-update2025-07-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-earnings-call-update2025-05-08T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-webinar-s-aureus-bacteremia2025-11-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-cgmp-manufacturing-facility-los-angeles2025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-phase-2a-disarm-study-results2025-10-22T16:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-structural-biology-publication2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-hc-wainwright-conference-20252025-09-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-positive-topline-data-phase-1b-2a-disarm-study2025-05-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-preclinical-data-crac-channel-inhibitor-pah2025-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-auxora-preclinical-data-asn-kidney-week-20252025-11-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-telperian-ai-collaboration-clinical-trials2025-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-hc-wainwright-investment-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-hc-wainwright-kidney-conference-20252025-07-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-phase-2-kourage-trial-auxora-aki2025-06-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-symposium-vicenza-course-aki-crrt-ebpt2025-06-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-strategy-endoxifen-breast-cancer2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/insilico-atossa-endoxifen-glioblastoma-study2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-endoxifen-duchenne-muscular-dystrophy-opportunity2025-11-17T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-third-quarter-2025-update2025-11-12T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-recast-trial-update2025-10-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-maxim-growth-summit-20252025-10-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-appoints-mark-daniel-cfo-commercial-readiness2025-10-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-carpo-trial-auxora-expansion2023-08-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-relisting-nasdaq2023-06-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-merger-graybug-vision2023-03-20T20:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/graybug-name-symbol-change-calciMedica2023-03-20T17:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/graybug-calimedica-merger-agreement2022-11-21T23:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-financial-results-september-20222022-11-10T21:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-investor-day-sustainable-growth-strategy2025-12-09T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-credeliotm-cat-eua-new-world-screwworm2025-11-21T18:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-participate-upcoming-investor-conferences2025-11-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-expands-credelio-labels-lyme-disease-ticks2025-10-27T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-credelio-fda-eua-new-world-screwworm2025-10-24T21:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-host-investor-day-december-9-20252025-10-16T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-third-quarter-2025-financial-results2025-10-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-fda-approves-zenrelia-label-update2025-09-23T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-innovation-credilio-quattro-blockbuster-status2025-09-08T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-east-africa-growth-accelerator-socio-economic-value2020-02-17T14:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-presentation-pcr-platform-ai-integration2025-12-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-tuberculosis-test-adoption-implementation2025-11-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-clinical-evaluations-fda-submission2025-11-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-q3-2025-results2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-jv-announcement-saudi-arabia2025-11-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-maxim-group-spac-transaction-india2025-11-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-ai-business-unit-co-dx-primer-ai2025-11-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-third-quarter-2025-earnings-release2025-10-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-launch-ivd-products-india2020-01-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-expansion-ghana2019-10-29T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-zdc-launch2019-10-10T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-liquid-biopsy-conference-corfu2019-10-03T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-launch-vector-control-products-opma2019-09-19T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-lgc-expand-license-agreement-coprimer2019-09-04T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-presentation-rodman-renshaw-conference-20192019-08-28T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q2-2025-financial-results-im8-growth2025-09-13T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-fourth-quarter-full-year-2024-results2025-03-06T03:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-collaboration-mayo-clinic-supplements2024-12-20T03:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-space-experiment-aging-longevity-iss2024-12-06T03:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-december-2025-investor-conferences2025-11-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-appoints-kristian-humer-cfo2025-11-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-new-employment-inducement-grants2025-11-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-executives-share-purchases-1-45-million2025-11-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/cantor-fitzgerald-reiterates-overweight-rating-prenetics2025-11-14T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk5211-clinical-trial-hip-fracture2015-09-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q2-2015-financial-results-update2015-08-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-phase-2-trial-vk28092015-07-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-agreement-monetize-equity-stake-biocon2025-12-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-participate-upcoming-investor-conferences2025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-on-antibiotic-prices-and-scarcity-europe2025-11-20T19:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-reveals-antibiotic-access-issues-europe2025-11-20T19:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-highlights-urgent-reforms-antibiotic-access-vtrs2025-11-20T00:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/study-reveals-price-decrease-cost-increase-shortages-vtrs2025-11-20T00:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/european-study-shows-declining-prices-rising-costs2025-11-20T00:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/european-study-falling-prices-rising-costs-shortages2025-11-19T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-thinkequity-conference-20242024-10-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-report-q2-2021-results2021-08-11T20:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-otsuka-joint-venture-iv-solutions2025-05-01T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-introduces-new-infusion-devices-fda-clearance2025-04-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-fda-clearance-plum-duo-infusion-pump2023-08-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-plum-360-best-in-klas-smart-pump2023-02-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-acquires-smiths-medical2022-01-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-recalls-amino-acid-injection2021-09-03T19:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-new-york-supreme-court-judgment2025-11-04T17:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-talicia-investment-partnership2025-10-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-talicia-middle-east-deal2025-10-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-wins-ny-supreme-court-appeal-kukbo2025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-legal-costs-award2025-08-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-talicia-licensing-payments2025-08-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-positive-fda-feedback-rhb-204-crohns-disease2025-07-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-china-commercial-insurance-list2025-12-08T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-zorevunersen-dravet-syndrome-aes-20252025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-leqembi-data-ctad-conference-20252025-12-03T23:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-submits-new-drug-application-leqembi-japan2025-11-28T00:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-dayra-collaboration-oral-macrocyclic-peptides2025-11-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stoke-dravet-syndrome-study-publication2025-11-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ibuprofen-approval-mexico2025-10-01T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/tabuk-launches-vibativ-antibiotic-saudi-arabia2025-09-29T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-vizient-contract-vibativ-starter-pak2025-08-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q2-2025-results-update2025-07-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-presentation-german-equity-forum-20202020-11-16T14:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-german-equity-forum-20202020-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-q3-2020-results-talicia-growth2020-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-q3-financial-results-webcast2020-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-patent-allowance-opaganib-rhb-1072020-11-04T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-talicia-phase-3-acg-20202020-10-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-production-expansion2020-10-15T05:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-manufacturing-partnerships2020-10-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-covid19-collaboration2020-10-14T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-1154-phase-3-trial-update2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-2401-obesityweek-presentation2025-11-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presents-hc-wainwright-investment-conference2025-09-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-virtual-rd-event-lpcn-1154-postpartum-depression2025-06-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-filing-new-drug-submission-tlando-canada2025-06-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-enhanced-leo-system-protein-analysis2025-12-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-upcoming-investor-conferences2025-11-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-licenses-ai-designed-novobody-duo-molecules2025-11-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/ai-spatial-biology-biomarker-discovery-melanoma2025-11-04T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-reimbursement-coverage-rewalk-7-exoskeleton2025-12-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/unitedhealthcare-medicare-advantage-approval-rewalk-72025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-ltd-reports-q3-2025-results2025-11-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/fda-extends-review-tlando-lpcn2017-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-usppto-decision-interference-clarus2017-09-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-fda-advisory-meeting-tlando2017-09-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presentation-ladenburg-thalmann-conference-20172017-09-19T19:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-presentation-rodman-renshaw-conference-20172017-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-fda-acknowledgement-tlando-nda-resubmission2017-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-resubmits-nda-lpcn-1021-hypogonadism2017-08-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q2-20172017-08-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-endometriosis-drug-discontinued-failure2025-07-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-layoffs-new-jersey-workforce-cuts2025-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/mercks-singulair-linked-mental-health-issues2024-11-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/roivant-sells-dermavant-to-organon-deal-value-1-2b2024-09-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/humira-biosimilars-launch-us2023-07-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/fda-weekly-review-daewoong-novavax-preceptis2022-08-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-international-womens-day-holiday2022-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/merck-spinout-organon-launch-global-womens-health2021-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/biopharma-leadership-changes-october-20232018-09-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-participate-evercore-isi-healthcare-conference2025-11-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-participate-industry-investor-conferences-november2025-10-29T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-vidofludimus-calcium-ectrims-20252025-09-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-vidofludimus-calcium-patent-allowance2025-09-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-positive-data-phase-2-emphasis-trial2025-06-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-phase-3-ensure-trials-enrollment-completed2025-06-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-upsized-public-offering-200m2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-pricing-public-offering-common-shares2025-11-12T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-proposed-public-offering-common-shares2025-11-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/fda-complete-response-biohaven-vyglxia-spinocerebellar-ataxia2025-11-05T01:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-phase-2-3-trial-parkinsons-disease2025-05-29T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-trap-degrader-innovation-rd-day2025-05-28T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-oncology-program-updates-20252025-05-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-positive-phase-1-results2025-06-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-phase-1-results-webcast2025-06-16T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-investor-conferences-june-20252025-05-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q1-2025-financial-results2025-05-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-poster-presentations-ddw-20252025-05-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-phase-1-trial-spy0032025-03-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-acquisition-concentra-biosciences2025-06-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-preclinical-data-eo-1022-aacr-20252025-04-25T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-discontinues-eo-3021-advances-eo-10222025-03-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-investor-conferences-march-20252025-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-updates-adr-programs-milestones2025-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-nominates-eo-1022-her3-adc2024-12-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELEV/elevation-oncology-preclinical-data-20242024-12-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-appoints-carl-haney-chief-rd-officer2025-06-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-joe-sta-romana-chief-customer-officer2024-12-02T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/haleon-eroxon-launch-fda-cleared-gel-ed2024-09-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLN/centrum-silver-memory-benefits-older-adults2024-01-24T19:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-first-quarter-dividend2025-12-09T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-citi-global-healthcare-conference-20252025-11-24T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-present-evercore-healthconx-conference2025-11-24T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-imdelltra-small-cell-lung-cancer2025-11-19T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-repatha-cuts-cardiovascular-risk-trial-results2025-11-08T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-repatha-phase-3-data-aha-20252025-10-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2025-third-quarter-results2025-10-29T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-investor-scientific-conferences2020-09-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-preclinical-covid-vaccine2020-09-04T14:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-supply-agreement-israel2020-08-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-phase-1-2-covid-19-vaccine2020-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q2-2020-financial-results-update2020-08-10T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-appoints-lance-kurata-clo2020-08-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-public-offering-20202020-07-31T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-public-offering-173-million2020-07-29T04:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-public-offering-common-stock2020-07-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-david-hastings-cfo-appointment2025-12-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q3-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-stifel-2025-healthcare-conference2025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-chest-2025-abstracts2025-10-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-phase-2a-river-trial-ers-congress-20252025-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-september-conferences2025-08-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-cryoablation-rsna-20252025-12-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-patent-allowance-china-cryoablation2025-12-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecures-prosense-cancer-treatment-approval-switzerland2025-11-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-nasdaq-minimum-bid-price-notification2025-11-14T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-q3-2025-results-report2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-promotes-shay-levav-coo-commercial-traction2025-11-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecures-cryoablation-system-nsclc-survival-rate2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-tme-fall-summit-breast-cancer2025-10-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-maxim-growth-summit-20252025-10-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/university-wisconsin-wins-abbott-big-ten-blood-competition2025-12-07T01:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-ensure-max-protein-shakes2025-12-04T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acquires-exact-sciences-cancer-diagnostics2025-11-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-heartmates-holiday-movie-hallmark2025-11-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-third-quarter-2025-results-guidance2025-10-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/diabete-et-prejuges-campagne-abbott2025-10-15T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-third-quarter-earnings-conference-call2025-09-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-completes-acquisition-xenotherapeutics2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-securityholders-approve-acquisition-xenotherapeutics2025-10-06T22:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-acquired-xenotherapeutics2025-07-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-corporate-update-financial-results-20242024-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-terminates-phase-2-study-masofaniten-enzalutamide2024-11-01T01:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-masofaniten-esmo-20242024-09-13T22:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPIX/essa-pharma-presentation-2024-cantor-conference2024-09-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-clinical-trial-updates-haduvio2020-10-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-chemoglo-hazardous-drug-testing2025-12-04T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-cell-analyzer-configurations2025-12-03T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-surgiphor-surgical-wound-irrigation-europe2025-11-24T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-regains-compliance-nasdaq2024-01-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-15-million-private-placement-nasdaq-listing2021-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-pyxis-es-system-dod-medication-safety2017-03-01T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-rights-offering-expiration2022-08-02T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-appoints-dr-maky-zanganeh-co-ceo-president2022-07-26T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-upcoming-investor-conferences2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-allucent-fda-ind-application-ptsd2025-11-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-installation-art100-system2025-03-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-showcase-amsect-conference-20252025-03-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-ceo-update-respiratory-care2025-03-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-nasdaq-notification-minimum-bid-requirement2025-03-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-2024-financial-results2025-03-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-hyla-blood-sensor-results2025-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-positive-results-bloodstream-infections2025-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-oxygenation-indicator-hyla-sensor2025-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-art100-advanced-features-support2025-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-life-support-systems-deployment2025-01-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-patent-japan-dual-lumen-cannula2025-12-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-cml-data-ash-20252025-11-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-soho-2025-annual-meeting2025-08-25T23:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-public-offering-closure2025-06-16T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-public-offering-pricing2025-06-13T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-phase-1-trial-data2025-06-13T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-nol-preservation-plan2025-08-15T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-capital-restructuring-growth2025-08-08T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reschedules-q2-2025-earnings-call2025-08-08T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-settlement-mylan-cinvanti-aponvie2025-05-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-appoints-mark-hensley-coo2025-04-28T23:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q4-2024-results2025-02-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/darioiq-launch-ai-integration-hypertension2025-12-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-digital-health-platform-blood-pressure-improvements2025-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-new-client-target-exceeded-20252025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-study-cost-savings-digital-health-platform2025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-significant-reduction-medical-costs2025-11-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-third-quarter-2025-results-conference-call2025-11-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-signs-new-employer-clients-value-based-care2025-10-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-onestep-strategic-collaboration-fall-risk-assessment2025-10-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-strategic-review-unsolicited-inquiries2025-09-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-phase-1-trial-update2024-09-28T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-phase-1a-data-presentation2024-09-18T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-investor-conferences-june-20242024-05-29T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-elvn-001-proof-of-concept-data2024-03-28T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-ccs-medical-partnership2017-07-24T13:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-fda-clearance-android-devices2017-07-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-first-choice-uk-diabetes2017-07-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-18-million-offering2025-12-10T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-expands-lymphir-distribution-turkey-gcc2025-12-04T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-ash-annual-meeting-20252025-11-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-launch-verix-ai2025-11-21T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-mckesson-distribution-agreement-lymphir2025-10-20T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-eversana-commercialization-agreement2025-10-16T13:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-named-patient-programs2025-10-07T13:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-closes-9-million-offering2025-09-10T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-bank-america-conference-20252025-11-24T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-fastest-growing-company-20252025-11-19T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-citi-global-healthcare-conference2025-11-18T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-epidiolex-aes-20252025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-present-phase-3-results-ziihera2025-12-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-citi-2025-healthcare-conference2025-11-18T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-ted-love-board2025-10-28T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-third-quarter-results-november-20252025-10-22T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-live-investor-webinar-november-20252025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q3-2025-results2025-11-13T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-chapter-11-assets-sale2025-05-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-fda-510k-clearance-wave-system2025-03-21T18:52:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-2024-results2025-01-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q3-results-call-20242024-10-25T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-fda-clearance-accelerate-arc-system2024-09-30T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-wave-pre-clinical-trial-success2024-08-08T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-third-quarter-2025-financial-results2025-11-14T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-participation-scientific-conferences2025-11-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-positive-topline-results-ozekibart-chondrosarcoma2025-10-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-leadership-changes2025-04-01T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-phase-1-trial-ozekibart-colorectal-cancer2025-01-21T22:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-loan-agreement-oxford-finance2025-01-13T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-piper-sandler-healthcare-conference-20252025-11-18T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-inducement-grants-nasdaq-rule-56352025-10-31T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-mercedes-benz-organ-transportation-network-italy2025-09-22T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-september-investor-conferences2025-08-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-fda-ide-approval-next-gen-ocs-heart-trial2025-08-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-breast-cancer-findings2025-12-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-private-placement-equity-securities2025-12-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-immune-complete-response-tnbc-update2025-11-18T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-fda-type-c-meeting-gbm-paxalisib2025-10-27T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-pd-l1-degrader-agreement2025-10-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-tumor-reduction-paxalisib-tnbc2025-10-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-ai-driven-therapy-dipg-dmg2025-10-01T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-her2-positive-breast-cancer2025-09-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-2-million-private-placement2025-08-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-trial-results2025-07-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-anal-cancer-data2025-10-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-shareholder-meeting-nevada-jurisdiction2025-10-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pancreatic-cancer-study-update2025-09-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-goblet-study-update-us-expansion2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-mcrc-regulatory-pathway2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-safety-data-update2025-09-02T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-investor-conferences-september-20252025-08-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-voluntary-delisting-tsx2025-08-08T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-phase-3-trial-vosoritide-achondroplasia2016-12-12T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-q3-2016-financial-results2016-10-27T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-vosoritide-data-ashg-20162016-10-19T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/uk-regulatory-agency-approves-biomarin-bmn-270-study2016-10-13T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-patent-interference-update2016-09-21T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-ema-validation-brineura-cerliponase-alfa2016-09-15T12:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-ssieme-2016-presentations2016-09-08T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-update-brineura-cerliponase-alfa-cln2-disease2016-09-06T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-review-q2-2018-results2018-07-19T18:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-william-blair-conference-20182018-06-05T15:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q1-2018-financial-results2018-05-09T20:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-eccmid-2018-data-release2018-04-21T07:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-convertible-notes-offering2018-03-23T06:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-full-year-results-20172018-02-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-q4-earnings-call-20182018-02-08T22:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXDX/accelerate-diagnostics-ce-ivd-milestone-revenue-growth2018-01-10T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-global-healthcare-conference-20202020-09-01T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-q2-2020-financial-results2020-08-05T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-canaccord-40th-annual-growth-conference2020-07-28T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-public-offering-pricing2020-05-26T22:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-proposed-public-offering-common-stock2020-05-26T11:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-positive-results-ocs-liver-protect-trial2020-05-26T11:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-first-patient-treated-study-pelareorep2018-12-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-presentation-ash-20182018-12-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-rita-laeufle-cmo2018-11-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-phase-2-study-pelareorep-keytruda2018-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-2018-q3-financial-results-update2018-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-presentation-sitc-20182018-11-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-conference-call-q3-results2018-11-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-ash-annual-meeting2018-11-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-at-the-market-facility2018-10-25T00:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/bausch-health-acquires-durect-corporation-liver-disease2025-09-11T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-larsucosterol-phase-2b-results-publication2025-01-28T15:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-sells-alzet-product-line-lafayette-instrument2024-11-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-inducement-grants-nasdaq-rule-56352025-12-05T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-ad-study-rezpegaldesleukin-acaa-20252025-11-08T22:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-jefferies-conference-20252025-10-30T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-q3-financial-results-call2025-10-28T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-investor-conferences-september-20252025-09-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/japanese-pharmas-ma-us-eu2025-12-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/fda-probing-patient-death-takeda-therapy2025-11-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/top-biopharma-companies-hiring-november-20242025-11-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/biospace-2026-best-places-to-work2025-11-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/regulatory-jobs-biopharma-hiring2025-10-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-partners-innovent-cancer-assets2025-10-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/q3-earnings-novo-buys-akero-takeda-exits-cell-therapy2025-10-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-nabla-ai-partnership-early-pipeline2025-10-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/oncology-job-opportunities-growth2025-10-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRRX/durect-corporation-healthcare-conferences-20232010-09-07T22:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-raises-1-4-billion-20252025-10-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-nyse-underwriting-approval2025-10-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-tim-ledwick-interim-cfo2025-09-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-securities-appoints-brian-parsley-board2025-09-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-american-bitcoin-nasdaq-debut2025-09-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-files-2-billion-shelf-registration2025-08-28T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-crypto-advisory-board-expansion2025-08-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-quarterly-dividend-20252025-12-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-synchrony-prefillable-syringe-launch-cphi2025-10-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-third-quarter-2025-conference-call2025-10-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-participate-investor-conferences-september-20252025-08-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-robert-mcmahon-cfo-appointment2025-07-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-annual-financial-results-march-20242024-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-exclusive-license-agreement-motixafortide-asia2023-10-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-motixafortide-phase-2-trial-results2023-09-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-q2-2023-results-and-updates2023-08-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-genesis-phase-3-trial-data-publication2023-04-17T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-participate-investor-conference2025-11-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-completes-enrollment-duchenne-gene-therapy2025-10-30T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-november-20252025-10-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presentation-american-academy-ophthalmology-20252025-10-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-completes-enrollment-pivotal-trials-wet-amd2025-10-06T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presentation-world-muscle-society2025-09-29T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-positive-data-rgx-121-mps-ii-trial2025-09-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/precigen-syros-zhiyi-agile-capital-raises2022-07-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/biotech-gender-equality-tipping-point2021-04-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/2021-biotech-ipos-roaring-start2021-01-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRS/ash-2020-crispr-vertex-sickle-cell-cure2020-12-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-q4-2024-results-update2025-03-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-100-million-pipe-financing2025-03-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-special-meeting-stockholders-approval2025-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-td-cowen-healthcare-conference-20252025-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-appoints-david-dornan-cso2025-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-proxy-statement-special-meeting-20252025-02-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-adc-portfolio-sale-pipe-financing2024-12-19T23:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-q3-2024-financial-results2024-11-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AADI/aadi-bioscience-precision1-trial-update2024-08-20T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-phase-1-trial-rgx-314-wet-amd2018-02-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-enhances-gene-therapy-manufacturing-capabilities2018-01-23T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-avexis-expansion-license-agreement-sma2018-01-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-year-end-2017-update2018-01-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-ind-active-phase-i-ii-trial-rgx-1212017-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-presents-piper-sandler-healthcare-conference2025-11-19T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-investor-event-tct-conference-october-20252025-10-08T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-shruthi-narayan-president-promotion2025-08-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-second-quarter-2025-earnings-call2025-07-01T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-ron-squarer-board-directors2025-12-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-piper-sandler-healthcare-conference-20252025-11-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-public-offering-closing-nuvl2025-11-24T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-fda-acceptance-zidesamtinib-nsclc2025-11-19T21:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-public-offering-common-stock2025-11-19T04:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-arros-1-trial-zidesamtinib-presentation-20252025-11-04T22:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-piper-sandler-healthcare-conference2025-11-18T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-wolfe-research-healthcare-conference2025-11-04T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-325-million-private-placement-financing2025-10-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-oxford-symplify-study-galleri-test-edcc2025-10-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-pathfinder-2-results-galleri-cancer-detection2025-10-18T10:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/samsung-grail-collaboration-galleri-test-asia2025-10-16T13:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-galleri-data-esmo-edcc-20252025-09-23T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-december-investor-conferences2025-11-18T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-pricing-public-offering-25-million2025-11-11T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-proposed-public-offering2025-11-10T23:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-bla-submission-accelerated-approval-ino-31072025-11-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-inducement-grant-2022-plan2025-10-31T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-stephens-biotechnology-conference2025-10-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/clinical-proof-of-concept-dmabs-nature-medicine2025-10-21T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-q3-2025-results-update2025-11-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-rhcollagen-distribution-north-america2025-10-27T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-collagen-bioink-study-results2025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/first-humanized-3d-bioprinted-skin-model-collplant2025-10-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-positive-results-dermal-filler2025-09-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-expands-vergenixstr-distribution-europe2025-09-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-presentation-biofabrication-conference-20252025-09-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-participate-hc-wainwright-conference-20252025-08-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-settlement-stockholder-derivative-actions2023-06-23T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-phase-2-trial-hpv-cancers2018-12-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-technology-clinical-trials-20192018-11-27T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-phase-1-trial-preparation2018-11-27T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dna-monoclonal-antibody-trial-results2018-11-27T02:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-dmab-platform-preclinical-results-clinical-trial-20192018-11-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-leadership-appointments-commercialization2018-11-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-q3-2018-results2018-11-08T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-investment-conferences-20182018-11-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-closes-35-million-direct-offering2021-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-35-million-ads-offering2021-02-12T04:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-tender-offer-results2025-11-20T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-appoints-eliot-forster-chairman-board2023-09-12T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-therapeutics-worlsymposium-20232023-02-21T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q3-2022-results2022-11-14T12:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-appoints-dr-shmuel-ben-zvi2022-06-30T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-fireside-chat-june-30-20212021-06-28T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-deficiency-letter-nyse-american2019-08-30T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-strategic-alternatives2019-08-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/shlomo-yanai-resigns-chairman-protalix-biotherapeutics2019-08-13T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q2-2019-conference-call2019-07-29T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bioappoints-eyal-rubin-cfo2019-07-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bright-trial-phase-iii-completion2019-06-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/protalix-bio-therapeutics-new-ceo-dror-bashan2019-05-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-defiance-study-esmo-20252025-10-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-private-placement-digital-assets2025-10-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-private-placement-winklevoss-capital2025-10-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-q2-2025-financial-results2025-08-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-sirexatamab-colorectal-cancer-update2025-06-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-virtual-fireside-chat-december-20252025-12-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-presentation-jefferies-global-healthcare-conference2025-11-17T22:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-q3-2025-results-business-update2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/dr-robert-hawes-bartlett-obituary-ctso2025-10-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-showcase-cardiac-surgery-data-eacts-20252025-09-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-drugsorb-atr-regulatory-update2025-09-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-webinar-sepsis-septic-shock2025-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-presentation-hc-wainwright-conference2025-09-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-merck-pfizer-collaboration-trx5182018-07-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presentation-jmp-conference-20182018-06-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-dkn-01-aacr-20182018-04-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-public-offering-closing2018-03-27T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-public-offering-pricing2018-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-public-offering-common-stock2018-03-22T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-presentation-needham-conference-20182018-03-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPTX/leap-therapeutics-dkn-01-update-aacr-20182018-03-14T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-q4-2024-revenue-report2025-01-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-rights-offering-begins2024-12-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-investor-meetings-jp-morgan-conference2024-12-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-piper-sandler-healthcare-conference-20242024-11-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-enrollment-milestone-hybrite-ctcl-trial2025-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-recent-accomplishments-q3-2025-results2025-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-expands-european-medical-advisory-board-ctcl2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-closes-7-5-million-public-offering2025-09-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-pricing-public-offering-7-5-million2025-09-26T11:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-appoints-tomas-philipson-strategic-advisor2025-09-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-thermovax-ebola-vaccine-stability2025-09-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-presentation-hc-wainwright-conference-20252025-09-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/fda-grants-soligenix-orphan-drug-designation-behcets-disease2025-08-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-kombucha-product-sales-agreement-qingshengyuan2025-12-10T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-next-gen-tea-pigment-digestive-health-products2025-11-25T14:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-cooperation-agreement-apple-series-health-products2025-09-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-weight-managing-compounds-ai-drug-rd2025-09-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-nasdaq-compliance-letter2025-08-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-launches-ai-powered-drug-research-development2025-07-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-distribution-agreement-weight-loss-products2025-07-21T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-nasdaq-compliance2025-07-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-announces-breakthrough-order-gut-health-products2025-07-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-expansion-project-update2022-09-30T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-q3-2025-results-business-updates2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-third-quarter-2025-financial-results2025-11-06T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-papzimeos-long-term-results-rrp2025-10-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-125-million-financing2025-09-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-virtual-fireside-chats-cantor-hc-wainwright2025-08-25T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-fda-approval-papzimeos-therapy2025-08-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-rrp-awareness-day-20252025-04-16T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-full-year-2024-results-business-updates2025-03-19T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-full-year-2024-results-call2025-03-13T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-us-marketing-authorization-transfer-sanofi2025-11-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-site-consolidation-cost-reduction-strategy2025-10-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-sanofi-partnership-nuvaxovid-eu-transfer2025-10-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-progress-sanofi-agreement2025-09-30T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-approval-japan-takeda-payment2025-09-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-2025-2026-fda-approval2025-08-27T20:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-innovative-treatment-ctcl2025-12-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-present-thinkequity-conference-20242024-10-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-hc-wainwright-conference-fireside-chat2021-03-08T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-takeda-covid-19-vaccine-trial-japan2021-03-01T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-takeda-license-agreement-covid-vaccine-japan2021-02-26T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-completes-enrollment-prevent-19-trial2021-02-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gavi-mou-covax-supply-1-1-billion-doses2021-02-18T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-conference-call-fourth-quarter-results2021-02-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-sk-bioscience-collaboration-covid-19-vaccine2021-02-16T01:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-swiss-government-covid-vaccine-agreement2021-02-04T22:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-rolling-review-covid-vaccine-authorization2021-02-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-fiscal-third-quarter-2025-results2025-11-17T13:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-declares-dividend-distribution2025-11-17T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-shareholder-letter-insulin-program-investment-growth2025-10-23T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-investment-alpha-tau-collaboration2025-04-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-shareholder-letter-20252025-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-joint-venture-accelerate-oral-insulin2025-02-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-restructuring-scilex-debt2024-10-07T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-update2024-06-26T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-stock-buy-back-program2024-06-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-launches-custom-tools-digital-pcr-ngs-panels2024-11-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-mcgill-university-microbiome-research2024-11-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-q3-2024-growth-outlook-increased2024-11-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-meningitis-encephalitis-panel2024-11-04T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-approval-qiastat-dx-meningitis-panel2024-11-04T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-approval-qiastat-dx-mini-panel-respiratory-infections2024-10-29T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-mini-panel2024-10-29T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-updates-phase-1b-study-r289-lower-risk-mds2025-12-07T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-piper-sandler-healthcare-conference2025-11-26T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-jefferies-global-healthcare-conference2025-11-12T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q3-2025-results2025-10-29T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-r289-phase-1b-mds-trial-update2025-10-08T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inducement-grants-nasdaq-rule-56352025-10-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-participate-september-investor-conferences2025-08-26T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-sabcs-20252025-11-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-participate-stephens-biotechnology-chat2025-11-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-lung-cancer-aacr-conference2025-10-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-efficacy-data-pcf-retreat2025-10-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-nsclc-data-aacr-conference2025-10-13T17:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-preclinical-data-prostate-cancer2025-10-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-prostate-cancer-summit-20252025-07-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-atnm-400-prostate-cancer-efficacy-snmm-meeting2025-06-23T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-iomab-act-trial-enrollment-utsw2025-05-06T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-ata-annual-meeting-20242024-10-14T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-preliminary-financial-results-20242024-10-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-nasdaq-listing2024-10-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-participate-roths-healthcare-conference2024-10-08T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-delisting-nasdaq-sec-deregistration2025-12-05T16:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-corporate-updates2025-03-31T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-hc-wainwright-conference-20252025-02-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-oppenheimer-conference-20252025-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-strategic-restructuring-pipeline2024-12-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-evercore-healthconx-conference-20242024-11-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-engineered-macrophages-liver-fibrosis2024-11-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-preclinical-data-gpc3-car-m-therapy-hcc2024-11-08T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARM/carisma-therapeutics-q3-2024-results-business-highlights2024-11-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-inducement-award-nasdaq-listing-rules2025-10-31T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-first-quarter-fiscal-2026-results2025-10-28T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-transformation-leadership-appointments2025-10-20T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-cyberknife-melbourne-launch2025-10-08T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-university-wisconsin-madison-mou-advance-radiotherapy2025-09-30T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-launches-advanced-radiotherapy-solution2025-09-26T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-host-analyst-event-astro-meeting-20252025-09-11T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-completes-last-visit-phase-3-trial-acne2025-03-04T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-nuclear-medicine-advisory-board-iomab-b2018-07-17T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-webcast-actimab-a-mrd-trial-july-20182018-07-09T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-new-clinical-trial-actimab-a-mrd-aml2018-06-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-sierra-trial-enrollment-update2018-06-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-update-snmmi-annual-meeting2018-06-25T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-phase-1-trial-actimab-a-clag-m2018-06-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-bioequity-europe-conference-20182018-05-08T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-dr-jeffrey-chell2018-05-01T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-strengthens-clinical-team2018-04-18T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-awe-technology-showcase-aacr-20182018-04-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-present-jp-morgan-healthcare-conference2014-12-16T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-brean-capital-2014-life-science-conference2014-11-10T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-q1-fiscal-2015-results2014-10-29T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-financial-results-q1-fiscal-20152014-10-08T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-signs-exclusive-radiation-therapy-contract2014-09-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-financial-results-fy-2014-guidance2014-08-21T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presentation-morgan-stanley-healthcare-conference2014-08-19T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-financial-results-q4-fiscal-20142014-08-07T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presentation-goldman-sachs-conference-20142014-06-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-presentation-goldman-sachs-healthcare-conference-20142014-05-28T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-q4-2019-financial-results2020-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inducement-grants-nasdaq-rule2020-02-21T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-investor-conferences-march-20202020-02-20T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-q4-2019-results-announcement2020-02-19T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-kristin-yarema-cco2020-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-2020-milestones-jp-morgan-conference2020-01-12T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-tab-cel-ebv-ptld-results-ash-20192019-12-09T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-evercore-isi-healthconx-conference2019-11-26T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-investor-conference-schedule2025-11-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-nalu-medical2025-10-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-investor-day-20252025-09-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-farapulse-fda-approval2025-07-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-conference-call-q2-2025-results2025-07-01T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/advantage-af-trial-results-farapulse-system2025-04-24T20:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-darzalex-faspro-phase-3-results-multiple-myeloma2025-12-09T12:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-treatment-free-remissions-multiple-myeloma2025-12-06T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-inlexzo-gemcitabine-bladder-cancer-study-results2025-12-05T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approval-caplyta-lumateperone-mdd2025-11-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acxp-health-holland-grant-dna-pol-iiic-inhibitors2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-publication-nature-communications-dna-pol-iiic2025-11-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-new-data-dna-pol-iiic-inhibitor-antibiotics-idweek-20252025-10-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-2025-financial-results-call2025-10-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-australian-patent-dna-polymerase-iiic-inhibitors2025-10-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-positive-opinion-ema-ibezapolstat-cdi-children2025-09-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-regains-nasdaq-compliance2025-09-03T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-reverse-stock-split2025-07-31T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-acquisition-social-proxy-private-placement2024-08-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-acquires-the-social-proxy-ai-web-data2024-06-05T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-to-acquire-the-social-proxy2024-03-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-nasdaq-notification-minimum-bid-price2023-10-20T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-business-operations-israel2023-10-20T20:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-rd-day-december-20252025-12-09T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-ingrezza-review-tardive-dyskinesia2025-11-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-investor-conferences-20252025-11-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-update-phase-2-nbi-10707702025-11-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-kinect-4-analysis-ingrezza-efficacy2025-10-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q3-2025-financial-results2025-10-07T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-mike-sibley2025-10-06T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-ingrezza-huntingtons-disease-data2025-10-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-long-covid-data2025-12-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-second-quarter-results-november-20252025-11-07T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-oncology-trial-australia2025-10-07T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-pricing-public-offering2025-09-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-hemopurifier-patents-long-covid-cac2025-09-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-dsmb-recommendation-advance-trial2025-07-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquires-mural-oncology2025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-financial-results-conference-call-20202020-02-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-public-offering-pricing2020-02-12T00:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-public-offering-shares2020-02-10T21:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-inducement-grants-nasdaq-rule-5635c42019-12-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-business-update-investor-conference2019-11-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-third-quarter-2019-results2019-11-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-appoints-mark-thierer-board2019-10-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-investor-webinar-aes-2025-data2025-12-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAB/ymabs-reports-q1-2025-financial-results2025-05-13T10:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-cfo-transition2025-11-26T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-second-quarter-conference-call-20252025-07-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-phase-2-data-burixafor-multiple-myeloma-ash-20252025-12-08T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-350-million-public-offering2025-12-10T02:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-250-million-offering2025-12-08T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-inlight-trial-wve-007-obesity-data2025-12-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-revenue-growth-q3-20252025-11-19T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-q3-2025-financial-results2025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-manufacturing-day-event2017-10-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-participate-cjs-securities-conference2017-06-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-ecr-exhibit-20172017-02-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-imaging-investor-conferences-20172017-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-novartis-immunology-acquisition-strategies2025-11-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-new-products-dim-analysts-eye-kidney-portfolio2025-11-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/mid-cap-biopharma-ma-opportunities2025-10-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/biospace-40-under-40-winners-impact-industry-grit2025-10-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-enlaza-autoimmune-disease-pact2025-09-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/fda-leadership-changes-drug-pricing-negotiations2025-08-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-vx993-trial-failure-q2-earnings2025-08-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/biotechs-to-watch-q2-2025-earnings2025-07-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-participate-maxim-group-2022-conference2022-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-q3-financial-results-update2022-02-10T21:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-q3-2022-financial-results2022-02-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-jefferies-london-healthcare-conference2021-11-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-phase-2a-trial-ph94b2021-10-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-ph94b-preclinical-data-anti-anxiety2021-10-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-advances-palisade-phase-3-program-ph94b2021-09-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-baird-global-healthcare-conference2021-09-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q1-2023-update2023-05-09T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-partnership-enable-injections2023-05-08T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-inducement-grants-nasdaq-rule-56352023-05-04T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-webcast-q1-2023-results2023-05-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-arvo-2023-presentations2023-04-20T17:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-appoints-tony-casciano-cco2023-04-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-q3-2025-financial-results-update2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VINC/vincerx-pharma-merger-oqory2024-12-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-year-2025-results-conference-call2025-12-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-presents-sarcopenia-cachexia-conference-20252025-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-james-meyers-board2025-11-26T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-private-placement-financing-50-million2025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-present-stephens-investment-conference-november-20252025-11-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPC/universe-pharmaceuticals-regains-nasdaq-compliance2022-11-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIGL/vigil-neuroscience-investor-conferences-november-20242024-11-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-delisting-notification-nasdaq2024-12-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-q3-2024-financial-results-corporate-update2024-11-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-activmab-update-project-deals-sitc-presentation2024-11-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-pepinemab-immunity-clinical-benefit-sitc2024-11-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-signal-ad-trial-pepinemab-alzheimers-update2024-10-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCNX/vaccinex-exercise-warrants-6-2-million2024-09-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-shares-to-police-association2025-12-11T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-dr-curtis-patton-yale-honor2025-12-09T19:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-recognized-njbiz-power-list-20252025-12-08T19:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-phase-2-results-chikungunya-vaccine-children2025-12-10T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-secures-regulatory-approval-uni-gold-hiv-test2025-11-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-epicapture-prostate-cancer-test2025-11-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-nasdaq-notice-compliance2024-11-27T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-merger-agreement-ke-sdn-bhd2024-08-19T20:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-nasdaq-compliance2024-01-25T21:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-reverse-stock-split-20232023-12-28T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-board-appointments2023-10-16T20:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTNP/titan-pharmaceuticals-sale-proneura-assets2023-07-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-q2-2025-financial-results-progress2025-08-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-acquires-dual-car-t-programs-factor2025-11-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/novo-nordisk-thermo-fisher-wegovy-demand2023-08-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/week-in-review-novo-nordisk-novavax-nektar-lawsuit2023-08-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/ultragenyx-sued-henrietta-lacks-family-hela-cells2023-08-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-cuts-88-jobs-san-diego-layoffs2023-06-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-grant-program-innovation2023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/importance-of-validated-processes-in-mrna-production2023-04-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/ai-potential-in-pharmaceutical-industry2023-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/sonoma-thermo-fisher-jobs-seattle-plainville2022-08-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-q4-2024-financial-results2025-03-29T01:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-preclinical-data-sitc-20242024-11-05T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-strategic-restructuring-portfolio2024-10-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-positive-data-tidal-01-trial2024-08-14T20:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSBX/turnstone-biologics-presentation-bank-america-conference2024-05-08T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-proposed-public-offering2025-12-11T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-lifts-clinical-hold-mypeak-1-trial2025-12-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-positive-data-ridge-1-trial2025-12-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-piper-jaffray-conference2015-11-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-stifel-2015-healthcare-conference2015-11-04T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2015-earnings-call2015-10-13T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-conference-presentations2015-08-26T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-wedbush-pacgrow-conference-20152015-07-28T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-cowen-conference-20152015-02-27T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q2-2025-results2025-08-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-spinout-il6-asset2025-12-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-irina-ishak-general-counsel2025-12-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-fibromyalgia-treatment2025-11-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-sale-acute-care-interventional-urology-oem-businesses2025-12-09T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-presentation-jefferies-global-healthcare-conference2025-11-14T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-evercore-healthconx-conference2024-11-25T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/THRD/third-harmonic-bio-investor-conferences-november2024-11-07T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-closes-public-offering-747-million2025-12-11T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-upsized-public-offering-650-million2025-12-10T04:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-announces-proposed-public-offering2025-12-09T11:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-phase-1-data-tern-701-cml-ash-meeting2025-12-08T19:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-jefferies-conference-20252025-11-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-deloitte-fast-500-20252025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-q3-2024-financial-results-update2024-11-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-guggenheim-healthcare-conference-20242024-10-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-closes-100-million-private-placement2024-08-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-100-million-private-placement2024-08-06T11:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-levosimendan-patent-ph-hfpef2024-04-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-kol-event-levosimendan-phase-3-level-study2024-04-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-ceo-passing-changes-board2024-08-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-russell-indexes-membership2024-07-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-dia-2024-panel-participation2024-06-17T20:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-pivotal-milestones-telomir-12024-05-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-preclinical-data-telomir-12024-04-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-preclinical-data-presentation2024-04-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-collaboration-argenta-osteoarthritis2024-03-29T20:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-preclinical-data-global-longevity-conference2024-03-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-ai-telomir-1-potential2024-03-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-piper-sandler-37th-healthcare-conference2025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-inducement-grants-nasdaq-rule-56352025-11-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-q3-2025-financial-results2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-kol-event-alloha-phase-1-trial2025-12-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-q3-2023-results-phase-1-data2023-11-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-presentation-hawaii-summit2023-06-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-tcr-t-library-phase-1-2-trial-asco2023-05-25T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-asco-2023-poster-presentation2023-04-26T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-appoints-dr-robert-hofmeister2023-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-investor-conferences-april-20232023-03-29T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-participate-upcoming-investor-conference2025-11-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-q3-2025-results2025-11-13T18:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-chmp-positive-mirdametinib-nf1-pn2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SWTX/springworks-therapeutics-chmp-advies-mirdametinib-nf1-pn2025-05-24T23:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-nasdaq-notification-bid-price-deficiency2024-10-07T20:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-reverse-stock-split2023-10-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-nasdaq-extension2023-05-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/sxt-pharmaceuticals-convertible-promissory-note2022-03-15T02:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-4-1-million-offering2022-01-20T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-update-impala-avail-clinical-studies2019-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-optima-clinical-study-results-molgradex-ntm2018-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-evercore-healthconx-conference-20182018-11-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-q3-2018-results-business-update2018-11-07T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-third-quarter-2018-financial-results-conference-call2018-11-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-completes-enrollment-molgradex-impala-study2018-10-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-enrollment-update-molgradex-clinical-studies2018-09-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-pap-foundation-partnership2018-08-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-piper-sandler-healthcare-conference-20252025-11-24T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-phase-1-trial-stro-0042025-12-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-showcases-xtrac-theraclearx-teracilad-20252025-12-09T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-q3-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-bank-america-cns-conference-20252025-12-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-63-per-share2025-07-30T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-declares-dividend-0-57-per-share2025-05-07T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-announces-pricing-75-million-public-offering2025-12-05T03:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-phase-2-advanced-2-trial-update2025-12-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-positive-results-tara-002-trial2025-11-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-advanced-2-trial-data-presentation2025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-q2-2025-results2025-07-31T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-upcoming-healthcare-investor-conferences2025-11-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-q2-2025-financial-results2025-08-07T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/pompano-veterinary-oncology-sensus-healthcare-srt2024-12-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q3-2024-financial-results2024-11-18T01:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-third-quarter-2024-conference-call2024-10-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-sells-srt-system-providence-swedish-hospital2024-09-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q2-2024-conference-call2024-08-01T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-srt-100-veterinary-use-tel-aviv2024-05-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-first-srt-100-vision-sale-asia2024-05-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-srk-015-sma-europe-congress2020-02-06T12:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-corporate-update-rd-priorities-20202020-01-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-gilead-fibrosis-collaboration-milestone2020-01-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-added-to-nasdaq-biotechnology-index2019-12-19T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-topaz-phase-2-trial-srk-015-sma2019-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-q3-2019-results-business-progress2019-11-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-presentation-jefferies-london-conference2019-11-08T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-srk-015-world-muscle-society-congress2019-10-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-appoints-george-nomikos-vp-medical-research2019-09-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-upcoming-healthcare-conferences2019-09-04T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inducement-grants-nasdaq-rule-5635c42023-01-31T23:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q4-2022-revenue-report2023-01-09T18:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-jp-morgan-conference-20232023-01-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-fda-accepts-srp-9001-application2022-11-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-evercore-healthconx-conference2022-11-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q3-2022-results2022-11-02T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/fda-committee-recommends-praluent-approval2015-06-09T22:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-elixa-study-results-lixisenatide2015-03-19T06:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-regeneron-odyssey-long-term-trial-results2015-03-15T15:14:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-mannkind-global-licensing-agreement-afrezza2014-08-11T05:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/first-ever-dengue-vaccine-efficacy-asia2014-07-10T23:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-regeneron-positive-results-dupilumab-study2014-07-09T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-positive-phase-3-results-toujeo2014-06-14T17:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q3-2025-results-business-update2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q1-2025-financial-results-update2025-05-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/neurothera-labs-acquires-quantum-bio-data-company2025-12-02T14:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-distribution-ten-states2025-11-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-reports-q3-2025-results2025-11-14T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-senti-202-phase-1-trial-results2025-12-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-fda-rmat-designation-senti-202-aml2025-12-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-conference-call-senti-202-data-ash-20252025-12-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-phase-1-senti-202-study-ash-meeting2025-11-13T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-participate-jp-morgan-healthcare-conference2025-12-10T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-assets-microsafe-group2020-02-27T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-q3-fy2020-financial-results2020-02-14T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-maxim-group-strategic-opportunities2020-01-23T21:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-closes-public-offering2019-11-29T21:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-public-offering-1-6-million2019-11-26T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-public-offering-common-stock2019-11-26T00:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-management-changes2019-10-01T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-regains-nasdaq-compliance2019-07-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-receives-positive-feedback-phase-2-3-trial2025-12-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-errors-sp-capq-platform-merger2025-11-19T19:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-decoy-merger-completion2025-11-13T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-biomimetic-innovations-osstic-update2025-12-10T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-piper-sandler-conference-20252025-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-announces-passing-board-member-harris2025-12-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-piper-sandler-conference-20252025-11-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-nasdaq-compliance-extension2024-11-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-andelyn-biosciences-licensing-agreement2025-11-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/lilly-sangamo-licensing-deal-1-4b2025-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-pfizer-hemophilia-gene-therapy-termination2025-01-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-fabry-gene-therapy-fda-approval2024-10-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-genentech-deal-alzheimers-1-9b2024-08-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-hemophilia-gene-therapy-financial-challenges2024-07-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/novartis-biogen-scrap-gene-regulation-partnerships-sangamo2023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/clinical-trial-updates-labor-day-weekend2022-09-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/clinical-trial-updates-covid-19-eua-cyton-dyn2022-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-sanofi-scd-program-update2022-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-piper-sandler-conference-20252025-11-18T21:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-ventures-launch-biotech-innovation2024-11-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCPX/scorpius-holdings-q3-2024-results2024-11-14T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-brexafemme-nda-transfer-gsk2025-11-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-federal-funding-collaboration-hackensack-johns-hopkins2025-11-17T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-closes-5-million-private-placement2023-05-16T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-private-placement-announcement2023-05-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-blinkrx-collaboration-arbli-launch2025-12-10T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-participate-iaccess-alpha-investment-conference-20252025-12-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-exercise-warrants-20-million2025-11-25T19:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-dream-bowl-2026-meme-coin-distribution2025-11-21T20:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-layoffs-75-percent2025-02-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/roche-returns-camonsertib-repare-therapy2024-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/roche-repare-1-2b-deal-cancer-therapy2022-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/aacr-bms-repare-investisbio-data2022-04-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/canada-biotech-talent-growth2021-08-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/valence-repare-ai-precision-oncology2021-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/bms-repare-65-million-collaboration2020-05-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-secures-funding-synthetic-lethality2017-06-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-reports-third-quarter-results-business-highlights2025-11-13T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-presents-sage-547-data-aan-20162016-03-03T21:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-cowen-health-care-conference-20162016-02-29T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-q4-2015-results2016-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-presentation-leerink-conference-20162016-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-public-offering-pricing2016-01-07T02:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-therapeutics-jp-morgan-conference-20162016-01-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAGE/sage-updates-phase-3-status-trial-results2015-12-15T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-q3-2025-results-and-business-highlights2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-descartes-08-phase-2-trial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-inducement-grant-nasdaq-rule-5635c42025-10-09T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q2-2025-financial-results-update2025-08-06T20:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q2-2025-financial-results2025-07-30T20:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-ndv-01-phase-2-data-presentation2025-12-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q3-2025-results2025-11-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q2-2025-financial-results2025-07-31T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-poster-presentation-nhia-20222022-03-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inducement-grant-nasdaq-rule-56352022-02-14T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-triferic-dialysate-approval-south-korea2022-01-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-triferic-avnu-approval-south-korea2022-01-13T13:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-presentation-hc-wainwright-bioconnect-20222022-01-07T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-fda-feedback-phase-2-trial2021-12-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-fpc-heparin-interaction-study2021-11-16T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q3-2021-update2021-11-15T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-june-20222022-08-15T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-5-million-offering2022-07-29T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-public-offering-5-million2022-07-26T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-phase-1b-clear-study-results2022-07-22T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-revtx-99b-allergic-rhinitis2022-05-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-conference-call-update2022-04-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-phase-2b-study-results2022-03-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-casdatifan-kidney-cancer-merck-challenge2025-06-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/checkpoint-inhibitors-at-a-crossroads2025-05-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/tigit-therapeutics-esmo-20242024-10-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/gilead-expands-arcus-collaboration-320m-investment2024-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/gilead-arcus-phase-ii-upper-gi-cancers2023-11-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/biopharma-companies-stock-investments2023-09-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/asco-gilead-arcus-cancer-immunotherapy-scrutiny2023-06-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-gilead-amend-phase-iii-nsclc-trial2022-11-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/iteos-gsk-anti-tigit-candidate-future2022-05-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-ceo-shaun-bagai-presentation-agp-showcase2025-11-19T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-third-quarter-2025-financial-results2025-11-13T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-fda-approval-rvo-treatment2025-11-19T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-approval-eu-adjuvant-cscc-treatment2025-11-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-piper-sandler-conference-20252025-11-24T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investor-conferences-december-20252025-11-24T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-clinical-response-seizures2025-12-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RENB/renovaro-biosciences-biosymetrics-merger-ai-biomarkers2025-02-26T18:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-evercore-healthcare-conference-20252025-11-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QLGN/qualigen-therapeutics-rebrands-aixcrypto-holdings2025-11-16T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-bla-submission-imsidolimab-gpp2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-releases-cvr-kintara-safety-endpoint2025-12-15T12:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-proposed-public-offering2025-12-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-transfer-ind-breast-cancer-vaccine2025-12-15T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-z-endoxifen-updates-sabcs-20252025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-biopharma-opaganib-results-cll2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-bd-max-system-with-new-viasure-assays2025-12-15T21:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-1-8-million-offering-equity-financing2025-12-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-conference-call-rezolve-aa-results2025-12-15T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-jp-morgan-conference-20262025-12-15T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-jp-morgan-healthcare-conference-20252025-12-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-transformation-plan-operational-efficiency2025-12-15T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-quarterly-cash-dividend2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-fireside-chat-december-20252025-12-15T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-150-million-private-placement2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-global-rollout-hba1c-testing-solution2025-12-15T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-withdraws-public-offering2025-12-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-inducement-grants-nasdaq-rule-5635c42025-12-15T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-distribution-maine-pennsylvania2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-fda-meeting-renu-knee-osteoarthritis2025-12-15T21:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-jp-morgan-conference-20262025-12-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-phase-2-clinical-study-bcc2025-12-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-presentation-jp-morgan-healthcare-conference2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-private-placement-45-million2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-phase-1-2-trial-outcomes2025-12-15T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-q2-2026-results-business-update2025-12-15T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fda-510k-submission-myovista-wavecg-device2025-12-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-calls-tranche-a-warrants-december-20252025-12-15T22:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-mrt-2359-phase-1-2-results2025-12-15T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GBIO/xoma-acquires-generation-bio-merger-agreement2025-12-15T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/roxadustat-orphan-drug-designation-mds2025-12-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-1-7-million-offering-nasdaq2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-fda-acceptance-cutx-101-nda2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-arbitration-decision-servier2025-12-15T21:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-arbitral-decision-servier-dispute2025-12-15T21:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-presentation-jp-morgan-20262025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-servier-arbitration-cellectis2025-12-15T22:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-pfizer-immune-receptor-agreements2025-12-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-ii-data2025-12-15T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-appoints-mohamad-tabrizi-cbo2025-12-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-licenses-tnx-4900-neuropathic-pain2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-jp-morgan-conference2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-mrt-2359-enzalutamide-cancer2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-stock-options-inducement-grants-nasdaq2025-12-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presentation-jp-morgan-conference-20252025-12-18T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-cypath-lung-test-american-cancer-society2025-12-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-influenza-co-primers-analysis-h3n22025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-partnering-investor-meetings-jpmorgan-20262025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-public-offering-100-million2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-adapt-trial-enrollment-completion2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-level-study-assessment2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-shareholders-nomination-board2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CG/acentra-health-appoints-meghan-harris-board-directors2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-phase-1-study-accg-2671-obesity2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-positive-results-phase-1-wp1066-trial2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-phase-2-alzheimers-trial2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-wins-excellence-award-20252025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-jp-morgan-healthcare-conference2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-presentation-jp-morgan-conference2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sabs-positive-phase-1-results-sab-142-t1d2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-phase-2a-sgx302-results-psoriasis2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-present-jp-morgan-healthcare-conference2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-phase-2-breast-cancer-update2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-yarrow-merger-agreement2025-12-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-influenza-co-primers-analysis2025-12-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-positive-interim-data-4d-710-phase-1-trial2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/extended-release-buprenorphine-reduces-opioid-use2025-12-17T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-signs-lungfit-ph-distribution-agreements2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-expands-rewalk-distribution-internationally2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-record-sales-fda-clearance-prosense2025-12-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-tapi-global-license-agreement-resmetirom2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-investor-events-20262025-12-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-regains-nasdaq-compliance2025-12-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-business-review-20252025-12-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-clinical-business-update-brensocatib-ins11482025-12-17T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-nyse-compliance-plan-acceptance2025-12-17T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-positive-interim-data2025-12-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-phase-1-sab-142-results2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-astrazeneca-royalties-agreement2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-wins-2025-award-precision-therapy2025-12-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-presents-jp-morgan-healthcare-conference-20262025-12-17T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approval-rybrevant-faspro-johnson-johnson2025-12-17T23:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-year-2025-results-clinical-progress2025-12-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-update-phase-1b-sgt-210-darier-disease2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-launch-genio-therapy-netherlands2025-12-17T06:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-genio-launch-netherlands2025-12-17T06:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-phase-1b-study-nxp900-osimertinib-nsclc2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-closing-bell-nasdaq2025-12-17T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-acquisition-renergen-approvals2025-12-17T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-presents-jp-morgan-healthcare-conference-20262025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-jp-morgan-conference-20262025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-jp-morgan-conference-20262025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-convertible-bonds-sale-108-million2025-12-17T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-jp-morgan-conference-20262025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-jp-morgan-healthcare-conference-20262025-12-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-presents-jp-morgan-healthcare-conference-20262025-12-17T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-us-patent-female-sexual-dysfunction2025-12-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-presentation-jp-morgan-healthcare-conference2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/celz-adapt-trial-enrollment-completed2025-12-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-nmpa-approval-myorzo-aficamten-china2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-decisiondx-um-prame-study2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-jp-morgan-healthcare-conference-20262025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-debt-refinancing-growth-package2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-cdmo-agreement2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-phase-3-trial-atebimetinib-pancreatic-cancer2025-12-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-jp-morgan-2026-conference2025-12-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-jp-morgan-2026-healthcare-conference2025-12-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ecco-2026-abstracts2025-12-17T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLUE/impactful-ma-deals-20252025-12-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-participate-investor-conferences-20262025-12-17T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-european-commission-approval-minjuvi-follicular-lymphoma2025-12-17T16:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staars-stockholders-vote-alcon-merger2025-12-17T15:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-palisade-3-fasedienol-results-social-anxiety2025-12-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-regulatory-approval-swoop-india2025-12-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-clinical-trials-award-advanced-prostate-cancer2025-12-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-jp-morgan-healthcare-conference2025-12-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-files-pma-supplement-ige-indication2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-invest-250-million-manufacturing-expansion2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-participate-jp-morgan-healthcare-conference2025-12-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-launches-gobivaz-biosimilar-simponi-europe2025-12-22T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-launches-gobivaz-simponi-europe2025-12-22T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/destiny-endometrial02-phase-3-trial-enhertu2025-12-22T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/enhertu-breakthrough-therapy-designation-breast-cancer2025-12-22T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/precision-medicine-update-tlx-china-phase-3-study2025-12-22T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-voting-rights-december-20252025-12-22T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-launches-blaze-trial-immunotherapy-resistance2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inducement-grants-nasdaq-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bms-agreement-us-government-affordability-access-medicines2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/samsung-biologics-acquires-human-genome-sciences-gsk2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-agreement-us-government-access-medicines2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-inducement-grants-nasdaq-listing-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-us-government-agreement-lower-drug-costs2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-ipo-registration-diabetes-business-minimed2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-fda-approval-myqorzo-obstructive-hcm2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-nasdaq-biotechnology-index2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-convertible-bonds-issuance2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-bob-marshall-chairman-board2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-inducement-grants-nasdaq-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-jp-morgan-healthcare-conference-20262025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-annual-meeting-adjournment2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-acquisition-executive-chairman2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-private-placement-tcgx2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-lowers-medicine-costs-us-government2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-precision-oncology-alliance-welcomes-providence-swedish2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-acquire-amicus-therapeutics-4-8-billion2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-private-placement-gamma-delta-t-cell-engager2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-public-offering-pricing2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-fda-update-belapectin-funding2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-tebipenem-hbr-nda-resubmission-fda2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fiscal-year-2025-results2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-update-msd-collaboration-gonorrhea-vaccine2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-inducement-grants-nasdaq-rule-56352025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-pemvidutide-impact-phase-2b-results2025-12-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-included-in-sp-smallcap-6002025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-sephience-approval-japan2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-declares-quarterly-dividends2025-12-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-launches-rezenopy-naloxone-nasal-spray2025-12-22T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-nasdaq-extension-compliance2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lawsuit-stock-manipulation2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-jp-morgan-healthcare-conference2025-12-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-positive-update-imp761-phase-i-study2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-symvess-long-term-safety-efficacy-results2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-updates-strategy2025-12-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/first-patient-dosed-alpaccca-trial-firmonertinib2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/ateapharma-completes-enrollment-phase-3-trial-hcv2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-acquires-nicotinamide-riboside-patents2025-12-22T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-resubmits-bla-molbreevi-autoimmune-pap2025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-participate-jp-morgan-healthcare-conference2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-licenses-assembly-biosciences-herpes-programs2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-appoints-senior-executives-commercialization2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-livechain-acquire-humanyze-note2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-presentation-jp-morgan-conference-20262025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-landmark-nature-study-alzheimers-disease2025-12-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-bla-acceptance-veligrotug2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-presents-jp-morgan-healthcare-conference-20262025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-approval-ekterly-japan-hereditary-angioedema2025-12-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-zugo-cel-update-autoimmune-hematologic2025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-present-jp-morgan-healthcare-conference-20262025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-eb612-long-acting-pth-tablet2025-12-22T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ceo-2025-shareholder-letter2025-12-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-impact-proenzymes-pancreatic-cancer2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-q2-fiscal-2026-results-announcement2025-12-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-appoints-jack-stover-board2025-12-22T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-regains-compliance-nasdaq-minimum-bid-price2025-12-22T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-volt-pfa-system-fda-approval-afib2025-12-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DVAX/sanofi-acquire-dynavax-hepatitis-b-shingles-vaccine2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/fda-approves-agios-aqvesme-thalassemia-treatment2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-update2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-appoints-andrew-einhorn-board2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-fy-2025-financial-results-update2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-fiscal-year-2025-update2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reverse-split-ads-ratio-change2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-acquires-acera-surgical2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-nasdaq-extension2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-appoints-leaders-board-directors2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORGO/organogenesis-initiates-blas-for-renu-knee-arthritis2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-jp-morgan-healthcare-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/fda-approves-edwards-sapien-m3-mitral-valve-system2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-healthcare-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-botensilimab-balstilimab-ovarian-cancer-results2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-cta-acceptance-alstars-trial-als2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-2026-q2-results-report2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-approval-cobenfy-first-class-therapy-schizophrenia2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-january-2026-events2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-inducement-awards-december-20252025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-jp-morgan-healthcare-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-jp-morgan-conference-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-fda-qualification-bmd-osteoporosis2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-gmp-manufacturing-aktx-1012025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-expanding-ip-strategy2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-agreements-capital-structure-growth2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-expand-ovarian-cancer-trial2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-announces-survival-data-phase-2a-trial2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-regulatory-update-brilaroxazine-schizophrenia2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBLG/bone-biologics-rhnell-1-shelf-life-extension2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopercompanies-appoints-walter-rosebrough-director2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-investor-webinar-january-20262025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-participate-jp-morgan-healthcare-conference2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-cms-medicare-payment-rate-infoods-ibs-test2025-12-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-therapeutics-gilead-acquisition-rp-34672025-12-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-edg-7500-cirrushcm-phase-2-results2025-12-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-phase-2-update-bhv-7000-depression2025-12-24T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-nda-resubmission-tebipenem-hbr-fda2025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-psilocybin-phase-iib-trial-approval2025-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-announces-2-5-million-placements2025-12-19T15:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-partnership-cube-group-solana-digital-assets2025-12-19T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-zasocitinib-phase-iii-psoriasis-data2025-12-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-financing-announcement-20252025-12-19T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-medical-coverage-policy-milestone2025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-publication-journal-inflammation-immunomodulatory-effects2025-12-19T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-ceo-donates-shares-fire-department2025-12-19T16:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fy-2025-financial-results2025-12-19T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-first-tranche-convertible-bonds2025-12-19T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-nasdaq-opening-bell-20252025-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-reverse-merger-abl2025-12-19T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-teva-avt06-sale-agreement-20262025-12-19T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-teva-us-settlement-avt06-biosimilar-eylea2025-12-19T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-regulatory-update-fda-response2025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-bempedoic-acid-acc-recommendation-20252025-12-19T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-brazilian-patent-sexual-dysfunction2025-12-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reverse-stock-split2025-12-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-january-20262025-12-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-ceo-comments-cms-withdrawal-skin-substitutes2025-12-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-termination-roosevelt-resources2025-12-26T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-quarterly-dividend-announcement2025-12-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-lockup-extension-20262025-12-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-ask-pharm-license-agreement-an90252025-12-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-yartemlea-approval-conference-call2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inducement-grants-nasdaq-rule-56352025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-employment-inducement-grants2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-earnings-conference-call-20262025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-ceo-comments-cms-withdrawal-lcds2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-reverse-stock-split2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-termination-notice-roosevelt-resources2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/fda-review-inovios-bla-ino-3107-rrp2025-12-29T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-positive-ema-advice-phase-3-trial-vcn-012025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-ema-approval-phase-iii-trial2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-annual-safety-report-intranasal-foralumab-fda2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-20-million-offering2025-12-29T12:57:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tnx-4800-lyme-disease-updates2025-12-29T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/neffy-epinephrine-nasal-spray-approval-china2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-presents-sachs-neuroscience-forum2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-fda-breakthrough-ulixacaltamide-essential-tremor2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-explores-revenue-generating-opportunities2025-12-29T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-private-placement-financing2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-6-million-securities-purchase-agreement2025-12-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-portfolio-prioritization-update2025-12-29T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-il-6-antibody-production2025-12-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-fda-approval-motiva-implants2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-acquires-halda-therapeutics-cancer-treatment2025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-investor-conference-20262025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-phase-3-regal-trial-update-gps-aml2025-12-29T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-phase-3-orbit-cosmic-results-setrusumab2025-12-29T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-phase-3-orbit-cosmic-results-setrusumab2025-12-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRM/medirom-partners-world-proof-human-japan2025-12-29T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/babesia-infection-chronic-fatigue-study-nc-state2025-12-29T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-jp-morgan-conference-20262025-12-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-distribution-agreement-miplyffa-npc2025-12-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-sponsor-mash-tag-2026-conference2025-12-29T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-australian-patent-codx-pcr-platform2025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-exclusive-distribution-ai-analyzer2025-12-29T14:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WOK/work-medical-ai-blood-analyzer-approval2025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-sells-majority-stake-pocono-pharmaceutical2025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-startup-health-alzheimers-moonshot-participation2025-12-29T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-dr-soon-shiong-influential-oncology-20252025-12-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVM/celsci-reports-fiscal-2025-results2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-patent-issuance2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-rebuilding-anticoagulation-therapy2025-12-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-2025-clinical-advances-20262025-12-29T16:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-presents-jp-morgan-healthcare-conference2025-12-29T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-rd-transformation-innovation2025-12-16T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-participate-jp-morgan-healthcare-conference2025-12-16T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-aa-phase-2b-study-rezpegaldesleukin-alopecia2025-12-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-ppd-phase-3-study-enrollment-milestone2025-12-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-biosciences-inbrx-106-ozekibart-updates2025-12-16T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-fiscal-year-2025-results2025-12-23T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-conference-20262025-12-23T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-present-2026-jp-morgan-healthcare-conference2025-12-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-jp-morgan-conference-20252025-12-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-present-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-participate-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-jp-morgan-conference-20262025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-ramp-203-update-kras-g12c-trial2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-presents-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-private-placement-12-4-million2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-presentation-jp-morgan-healthcare-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-dr-olga-nissan-vp-business-development2025-12-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-us-market-entry-trump-order2025-12-30T12:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-capital-allocation-update-im8-focus2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-allucent-phase-1-clinical-development2025-12-30T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-takeda-royalty-sharing-transaction2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-appoints-dan-moorhead-cfo2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-phase-3-data-update-vilobelimab-pyoderma-gangrenosum2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-private-placement-funding2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/phase-1-2-study-tividenofusp-alfa-hunter-syndrome2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-nda-submission2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-closes-980-million-credit-facility2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-european-patent-nerve-targeted-therapies2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-webcast-conference-call-q4-2025-results2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-japanese-patent-pali-21082025-12-30T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-7-million-direct-offering2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-invests-10-million-digital-assets2025-12-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-opioid-technology2025-12-30T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-participation-jp-morgan-healthcare-conference2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-ceo-elected-azbio-board2025-12-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-restructures-convertible-notes2025-12-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-nasdaq-opening-bell-20262025-12-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reverse-stock-split2025-12-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-2025-shareholder-letter2025-12-30T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-sells-hong-kong-subsidiary2025-12-30T15:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-present-jp-morgan-2026-conference2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-appoints-john-kenny-board-directors2025-12-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-jp-morgan-healthcare-conference-20262025-12-30T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-letter-shareholders-20252025-12-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-gatc-health-40-million-spv-ozuriftamab-vedotin2025-12-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-fda-axs-05-alzheimers-agitation-review2025-12-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-fda-pre-nda-meeting-ax12-narcolepsy2025-12-31T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-ceo-letter-20252025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-jp-morgan-conference-20262025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-focus-study-subgroup-analyses2025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-complete-response-letter-relacorilant2025-12-31T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-presentation-jp-morgan-conference-20262025-12-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-files-ind-application-cyps317-psoriasis2025-12-31T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-expands-european-network-with-medsell2025-12-31T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-regains-nasdaq-compliance2025-12-31T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-present-jp-morgan-healthcare-conference2025-12-31T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-manufacturing-partnership2025-12-31T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-usda-approval-befrena-canine-dermatitis2025-12-31T19:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-nasdaq-extension-compliance2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-gatc-health-ozuriftamab-vedotin-trial2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-inducement-grants-nasdaq-rule-56352026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-research-genome-wide-pathways-gout-update2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-private-placement-10-million2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-secures-term-loan-facility-100-million2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-focus-study-subgroup-analyses2026-01-01T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presentation-jp-morgan-healthcare-conference-20262026-01-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-spect-business-sale-shine-technologies2026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-oncology-dermatology-ip-platform2026-01-02T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-jp-morgan-healthcare-conference-20262026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-appoints-jason-litten-cmo2026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-nasal-spray-flu-protection2026-01-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-achondroplasia-investor-webinar-january-20262026-01-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-fourth-quarter-2025-results2026-01-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-quarterly-dividend-q1-20262026-01-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-fy-2026-financial-guidance2026-01-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-jp-morgan-conference-20262026-01-02T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-engages-njs-foresight-bio-advisory2026-01-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-appoints-kasowitz-llp-counsel2026-01-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-fourth-quarter-2025-earnings-report2026-01-02T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-employee-inducement-grant2026-01-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-inducement-grants-nasdaq-rule-56352026-01-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-trial-representation-clinical-research2026-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/clinical-readouts-h1-20262026-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-leadership-transition-growth2026-01-05T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-founder-purchase-ads2026-01-05T06:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-palsonify-update-phase-2-results2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-nasdaq-notification-late-filing-report2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-closes-private-placement2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-new-employee-inducement-grant2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-nasdaq-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-ind-status-gh0012026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-fourth-quarter-2025-results-conference-call2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-fourth-quarter-2025-earnings-call2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-fda-grant-canalevia-ca12026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ON/innocan-pharma-anticipates-nyse-listing-offering2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-jp-morgan-healthcare-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVO/evotec-appoints-dr-sarah-fakih-evp-communications2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-board-changes-leadership-roles2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-participation-jp-morgan-conference2026-01-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPH/prophase-labs-update-convertible-debt-capital-structure2026-01-05T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-2026-pipeline-strategy2026-01-05T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-nmra-511-phase-1b-results-alzheimers-agitation2026-01-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-product-agreement-extension-20262026-01-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-skye-bioscience-nimacimab-enhanze-obesity2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presentation-jp-morgan-healthcare-conference-20262026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/redhill-rhb-102-gi-indications-glp-1-therapy2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-voluntary-warrant-exchange-update2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-first-phasix-hernia-prevention-case-greece2026-01-05T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-advocacy-scholars-summit-20262026-01-05T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/permanent-j-code-zusduritreatment-access2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-presentation-jp-morgan-conference2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-fda-designations-tara-0022026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-financial-results-q4-full-year-20252026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-presentation-jp-morgan-healthcare-conference2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-vykat-xr-study-results2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-acquires-xeglyze-head-lice-treatment2026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-submits-ct-ng-self-test-colli-pee-fda-review2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-appoints-robert-dempsey-ceo2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-jp-morgan-healthcare-conference-20252026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-jp-morgan-healthcare-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/baylor-college-medicine-multi-antigen-targeted-t-cells2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-biotech-showcase-2026-skinject-phase-22026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-lunatus-partnership-vizz-middle-east2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-presents-jp-morgan-healthcare-conference2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JBIO/jade-biosciences-2026-objectives-strategy-pipeline2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-us-commercial-launch-graftassuredx2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-plans-marketing-authorization-israel2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-hydronidone-approval-pathway2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-2026-strategic-outlook2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-olvi-vec-lung-cancer-trials-interim-data2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-presentation-jp-morgan-healthcare-conference2026-01-05T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-fda-lifts-clinical-hold-gh0012026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-participate-jp-morgan-healthcare-conference2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-phase-1-results-january-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-jp-morgan-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-palsonify-launch-atmelnant-trial-results2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-jp-morgan-conference-20262026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-leadership-appointments2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-fda-breakthrough-device-lvo-stroke2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/fiona-sharp-appointed-cfo-biodexa-pharmaceuticals2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-jp-morgan-healthcare-conference2026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-fda-breakthrough-therapy-pemvidutide-mash2026-01-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-presents-jp-morgan-healthcare-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-presentation-jp-morgan-conference-20262026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-positive-preclinical-results-fsdc-therapy2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABR/caring-brands-exclusive-license-emesyl2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYOJ/ryojbaba-shareholder-letter-2025-highlights-2026-priorities2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-jp-morgan-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-presents-jp-morgan-healthcare-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-jp-morgan-conference-20262026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WW/weight-watchers-glp1-platform-wegovy-pill2026-01-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-expands-collaboration-novo-nordisk-wegovy-pill2026-01-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jp-morgan-2026-conference2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-appoints-hyunsu-jung-ceo2026-01-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-phase-3-indigo-trial-obexelimab-results2026-01-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-mollo-xmg-cannabis-beverages-dry-january2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-fast-track-designation-alzheimers2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-presentation-jp-morgan-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-protagonist-rusfertide-nda-polycythemia-vera2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-jp-morgan-conference-20242026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launches-21-gene-fetal-focus-nipt2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-jp-morgan-2026-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-participate-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-global-regulatory-submissions-influenza-vaccine2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-ind-clearances-cr-001-cr-0032026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-appoints-sung-lee-board2026-01-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-neurocare-therapy-depression-ptsd2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-phase-1b-trial-da-1726-results2026-01-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-appoints-alon-dayan-board-directors2026-01-05T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-libre-assist-app-feature-diabetes-food-decisions2026-01-05T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-acquisition-liquid-biopsy-diagnostics2026-01-05T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-preclinical-results-pl14-allergen-blocking2026-01-05T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-ngc-cap-interim-analysis2026-01-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-achieves-ibogaine-production-milestone2026-01-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-2025-highlights-review2026-01-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-submits-pre-market-approval-module-fda2026-01-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-tagmokitug-pharmacology-publication2026-01-05T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-manufacturing-agreement-pathmuscle2026-01-05T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-limited-2026-clinical-commercial-roadmap2026-01-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-first-half-2026-outlook2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-leadership-appointments2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-8-million-offering2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-leads-rare-disease-genomics-20252026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-jp-morgan-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-fda-acceptance-ind-coya-302-ftd2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q4-2025-results-announcement2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-jp-morgan-healthcare-conference-20242026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-jp-morgan-healthcare-conference-20262026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-health-canada-approval-redeemplo-fcs2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-results-tafasitamab-dlbcl-trial2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-participate-jp-morgan-healthcare-conference2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-telomir-1-tumor-growth-reduction2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-fast-track-designation-ml-007c-ma2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-acquisition-liquid-biopsy-technology-investment2026-01-05T15:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-sung-lee-board-appointment2026-01-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-ceo-speak-jp-morgan-healthcare-conference2026-01-05T21:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-fourth-quarter-earnings-conference-call2026-01-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-presents-jp-morgan-healthcare-conference-20262026-01-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-jp-morgan-conference-20262026-01-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presentation-jp-morgan-healthcare-conference2026-01-06T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-altaur-trial-asco-gi-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-subcutaneous-formulation-china-approval2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-presents-jp-morgan-healthcare-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-jp-morgan-conference-20242026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-conference-call-onward-data-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-presents-jp-morgan-healthcare-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-bmb-101-phase-2-results-announcement2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-inducement-grants-nasdaq-rule-56352026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-participation-january-2026-conference2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-present-jp-morgan-healthcare-conference2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-wind-down-cell-therapy-activities2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-medsteer-phase-2-study-cyc-1262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-conference-call-phase-1b-trial2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-public-offering-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-employee-inducement-awards2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-board-changes-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-44th-jp-morgan-healthcare-conference2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-jp-morgan-conference-20262026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-appoints-oliver-engert-ca-officer2026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-inducement-grants-nasdaq-56352026-01-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-fda-breakthrough-therapy-designation2026-01-06T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-present-biotech-showcase-jp-morgan-conference2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-ceo-amir-reichman-bio-manufacturing-roundtable2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-unravel-collaboration-neurological-damage-therapy2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-clinical-update-diabetes-gene-therapy2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-2025-earnings-conference-call2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-company-update-development-milestones-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-presentation-jp-morgan-healthcare-conference-20262026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-2025-accomplishments-upcoming-milestones2026-01-07T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-board-development-phase-32026-01-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-acquisition-renergen2026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-receives-18-million-payment-scilex-holdings2026-01-07T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-presents-jp-morgan-healthcare-conference-20262026-01-07T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-jp-morgan-healthcare-conference2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-phase-3-ycanthe-vp-102-common-warts2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-fda-priority-review-atacicept-igAN2026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-phase-3-thrive-3-trial-choline-chloride2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-woda-launch-access-program-revuforj2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLRX/salarius-pharmaceuticals-changes-name-decoy-therapeutics2026-01-07T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-jp-morgan-healthcare-conference-20262026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-appoints-new-chair-and-director2026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-phase-3-sunrize-study-insights-hyperinsulinism2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-phase-3-program-epilepsy-portfolio2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-leadership-appointment-vimal-patel2026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-strategic-investment-crohns-colitis-foundation2026-01-07T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-jp-morgan-conference-20262026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-jp-morgan-conference-20262026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-2026-guidance-revenue-ebitda-growth2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presentation-jp-morgan-healthcare-conference2026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-2026-milestones2026-01-07T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-conference-call-strategic-change-focus2026-01-07T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-positive-phase-1-data-mrt-81022026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-partners-anthropic-ai-research-development2026-01-07T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-conference-participation-jpm-week2026-01-07T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-ceo-letter-shareholders-20252026-01-07T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FGEN/fibrogen-rebrands-kyntra-bio-focus-oncology-rare-diseases2026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-jp-morgan-healthcare-conference-20262026-01-07T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-jp-morgan-conference-20262026-01-07T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-pipeline-commercial-overview-jp-morgan-conference2026-01-09T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investors-jp-morgan-healthcare-conference-20262026-01-09T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-investors-jp-morgan-healthcare-conference2026-01-09T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-inducement-grant-nasdaq-56352026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-jp-morgan-conference-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-everett-cunningham-ceo-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-inducement-grants-nasdaq-rule-56352026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-launch-update-2025-revenue2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-q1-fiscal-2026-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/octave-bioscience-kirk-stockwood-appointment2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-sales-increase-december-quarter2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-delivery-order-anthrax-vaccine2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-2026-strategy-catalysts2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-leadership-appointments2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-2025-revenue-estimates2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presentation-jp-morgan-conference-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-reports-fourth-quarter-full-year-2025-revenues2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-kb407-coral-1-update2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-eversense-365-twiist-aid-launch2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-preliminary-q4-2025-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-presents-phase-2-revert-ipf-data2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-preliminary-sales-results-q4-20252026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-2026-outlook2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-second-quarter-fiscal-2026-earnings-report2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-appoints-mark-wilson-chief-legal-officer2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-taltz-zepbound-phase-3b-trial-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/visby-engages-quest-labcorp-consumer-access-sti-test2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-ip-strategy-update2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-phase-1-clinical-trial-agent-7972026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-jp-morgan-healthcare-conference-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-komodo-health-partnership-rare-disease-dataset2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-abstracts-2026-asco-gastrointestinal-symposium2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q4-2025-financial-results-release2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-jp-morgan-conference-update2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-lara-ramsburg-chief-officer2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-cifi-long-read-3c-method2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-ceo-transition-barbara-weber-retirement2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-public-offering-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-biotech-showcase-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/namsa-acquires-labcorp-medical-device-testing-assets2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VEEV/veeva-biomarin-strategic-partnership2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-webcast-acquisition-cdmo-assets2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-clinical-data-asco-gi-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-advances-clinical-trials-evorpacept-alx20042026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-q4-2025-revenue-record2026-01-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-presentation-jp-morgan-healthcare-conference-20262026-01-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-agreement-lower-medicine-costs-us2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-reports-2025-revenue-outlook-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-corporate-updates-milestones2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-2026-program-defining-year2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-business-update-jp-morgan-healthcare-conference2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-neuroscience-innovation-forum-20262026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q4-2025-revenue-milestones2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-progress-outlook-20262026-01-09T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-fda-type-a-meeting-amts-1302026-01-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-2026-outlook-advancing-pipeline2026-01-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-jp-morgan-2026-conference2026-01-09T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-2025-achievements-2026-priorities2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-expands-mash-pipeline-ervogastat-license-agreement2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-2026-strategic-priorities-jp-morgan-conference2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-global-bioinnovation-forum-nxt-41x-program2026-01-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-strategic-initiatives-20262026-01-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHA/athira-pharma-name-change-leonabio-lona2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-regulatory-update2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-vascepa-therapies-elevated-triglycerides2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-registered-direct-offering-over-28-million2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-relief-chronic-pain2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-jp-morgan-conference-20262026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-2026-strategic-priorities2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-pivot-006-phase-3-data-timeline2026-01-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-phase-2-results-timing-update2026-01-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-change-jurisdiction-nevada2026-01-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-biotech-showcase-20262026-01-09T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-fda-alignment-pfs-primary-endpoint2026-01-09T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-poc-study-pain-relief-pancreatic-cancer2026-01-09T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-corner-2025-progress2026-01-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-launches-ng-tube-comfort-program2026-01-09T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-preliminary-2025-revenue-guidance2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-lilly-ai-drug-discovery-collaboration2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-private-placement-80-8-million2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APVO/aptevotherapeutics-secures-60-million-equity-line2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-lilly-tunelab-livedesign-partnership2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-appoints-maria-sainz-board-directors2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZR/kezar-regulatory-update-zetomipzomib-autoimmune-hepatitis2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-fourth-quarter-full-year-2025-results2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-acquires-vivasure-medical-limited2026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-clinical-studies-data-locks-20262026-01-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-closing-public-offering2026-01-09T16:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-updated-presentation-time-jp-morgan-conference2026-01-09T16:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-biobeat-collaboration-wearable-defibrillator2026-01-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-fda-acceptance-vyvgart-seronegative-gmg2026-01-13T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-global-oncology-leadership-jp-morgan-conference2026-01-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-strengthens-balance-sheet-cash-runway-20282026-01-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-nasdaq-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-update-2026-outlook2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-business-updates2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-regains-nasdaq-compliance2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-earnings-call-february-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-employee-inducement-grants-nasdaq-rule-56352026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inducement-grant-nasdaq-rule-56352026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-arpit-dave-chief-digital-officer2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-virtual-2026-annual-meeting-shareholders2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-virtual-fireside-chat-titan-partners2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-nasdaq-notification-minimum-equity-non-compliance2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-inducement-grants-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-preliminary-results-q4-2025-revenue-guidance-q1-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-inducement-grant-new-employees2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-fda-orphan-drug-sgt-2122026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-reports-preliminary-fourth-quarter-full-year-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-phase-2-trial-abcl635-menopause2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-european-commission-approval-spinraza-high-dose2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-update-2025-2026-priorities2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-2025-results-commercial-growth2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-preliminary-results-q4-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/us-saudi-biotech-alliance-summit-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-commercial-progress-program-updates-2026-milestones2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATEC/atec-theradaptive-partnership-regenerative-technology2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/cosara-regional-conferences-distributor-relationships2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-fda-clearance-minimed-go-smart-mdi-system2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/ai-driven-immuno-oncology-initiative-10x-genomics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-advance-research-diagnostic-applications2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-study-autoimmune-disease-diagnostics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-manufacturing-scale-up-entolimod2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-phase-1-study-update-cid-1032026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-vivasure-acquisition-haemonetics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-platform-scalability-t-cell-pipeline-expansion-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-mark-bezjak-vice-president2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-atezolizumab-anal-cancer2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-bge-102-phase-1-data-hscrp-reduction2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-preliminary-revenue-q4-full-year-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-preliminary-fourth-quarter-full-year-2025-revenue2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-hifi-sequencing-sudc-research2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMDA/omada-health-preliminary-revenue-q4-fy-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-collaboration-n-lorem-esperare-precision-therapies2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-jp-morgan-conference-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-preliminary-results-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-2026-milestones2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-q4-2025-results2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-corporate-name-change-mgx-therapeutics2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-cnm-au8-fda-meeting-biomarker-data2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-operational-highlights-20252026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/syncardia-hydrix-development-collaboration-emperor-heart2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q4-2025-results-guidance-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-upcoming-milestones-jp-morgan-healthcare-conference2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-2025-milestones-2026-priorities2026-01-13T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-2026-priorities2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-phase-3-study-ap-sa022026-01-13T12:42:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-strategic-investment-partnership-oramed2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-invests-110-million-us-pharmaceutical-supply-chain2026-01-13T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-lifeward-strategic-transaction2026-01-13T12:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-leadership-depression-acnp-20262026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-donald-zurbay-board2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/xtl-biopharmaceuticals-acquires-neuronos-autism-market2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-tivoxavir-marboxil-ind-application2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-preliminary-revenue-q4-20252026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquires-patents-endoscope-market2026-01-13T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-q4-2025-financial-highlights2026-01-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SAVA/cassava-simufilam-phase-3-results-alzheimers-publication2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-pre-jp-morgan-update-2025-growth-outlook2026-01-13T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-secures-loan-facility-horizon-finance2026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-lg-chem-exparel-asian-markets2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-webcast-ocu410-phase-2-trial-data2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-2026-objectives-strategy2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-outlook-pas-004-clinical-programs2026-01-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/zycubo-fda-approval-menkes-disease2026-01-13T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-expands-ai-immunology-autoimmune-diseases2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-record-fourth-quarter-revenues-20252026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-complete-resolution-lung-metastasis2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-access-ad-initiative-alzheimers-disease2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-appoints-james-hassard-cfo2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-announces-ceo-succession2026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-nsclc-checkpoint-inhibitors2026-01-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-mrd-risk-stratification-ai-model2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-strategic-priorities-global-pipeline-progress2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-acnp-2026-presentations2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-reports-q4-2025-results-and-2026-outlook2026-01-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/tropion-lung17-phase-3-trial-datroway-nsclc2026-01-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-positive-preclinical-results-cannabinoid-absorption2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-syncardia-cruxx-medtech-podcast-launch2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-supports-decentralized-transplant-monitoring2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-partnership-refuah-health-center-femaseed2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-preliminary-2025-financial-results2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-cardiotoxicity-assessment2026-01-13T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-shareholder-update-20262026-01-13T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-explores-investment-opportunities-high-growth-sectors2026-01-13T13:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-2026-update-shareholder-feedback2026-01-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-preliminary-fourth-quarter-full-year-2025-revenue2026-01-13T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-50-percent-enrollment-maveric-trial2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-achievements-business-objectives-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-financing-phase-2b-halneuron2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-accelerates-outlook-2026-pivotal-trial-unblinding2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-strategic-priorities-2026-milestones2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-2-trial-data2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-billion-cell-atlas-ai-drug-discovery2026-01-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-preliminary-financial-results-q4-fy20252026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-acquires-neuronos-autism-market2026-01-13T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-positive-data-adapt-trial2026-01-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-q4-2025-financial-results-release2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDRX/surescripts-goodrx-partnership-price-transparency2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-new-data-acnp-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPCE/neuropace-fy-2025-results-outlook-20262026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/definium-therapeutics-new-nasdaq-ticker-dftx2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-oncology-leadership-jp-morgan-conference2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSCR/oscar-health-2025-earnings-conference-call2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-global-access-commitment-agreement2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-mrd-testing-breast-lung-colon-cancer2026-01-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-lifenet-health-collaboration-drug-discovery2026-01-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-jp-morgan-conference-20242026-01-13T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-erica-wheeler-cervical-cancer-screening2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-business-pipeline-updates-jp-morgan-conference2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-dynamo-series-smart-stretcher-launch2026-01-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-business-pipeline-updates-jp-morgan2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-nasal-vaccine-delivery-castlevax-phase-ii-trial2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-2025-guidance-2026-outlook2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-preliminary-q4-2025-net-sales-guidance2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-appoints-dr-orrin-devinsky-head-clinical-strategy2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-participate-lytham-partners-2026-summit2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-inducement-grants-20262026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-50-million-financing2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-2026-outlook-neuromuscular-cardiac-pipeline2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q4-2025-revenue2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-2025-revenue-guidance-and-milestones2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-fda-review-extension-filspari2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-positive-results-nsclc2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPAA/minovia-therapeutics-new-us-patents-mitochondrial-therapy2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-upsized-public-offering-15-million2026-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-shawn-bevec-svp-investor-relations2026-01-14T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-patterson-dental-partnership-renewal2026-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-patent-rezenopy-naloxone-spray2026-01-14T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-strategic-milestones2026-01-14T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-launches-make-it-vizzable-campaign2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/saudi-fda-accelerated-approval-anktiva-nsclc2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/saudi-fda-approval-immunitybio-anktiva-bladder-cancer2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-validates-platform-precision-tdp43-discovery2026-01-14T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-patent-alto-207-depression2026-01-14T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-present-sequire-investor-summit-20262026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-private-placement-nasdaq2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-53-growth-medicare-advantage-membership2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-launches-otc-enfit-syringes2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-updated-guidance-2025-20262026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-expands-sls009-clinical-program-europe2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-participate-alphanorth-capital-event-20262026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSPT/sl-bio-horizon-space-acquisition-business-combination2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-expands-europe-distribution-engagement2026-01-14T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/emjx-ceo-eric-jackson-fireside-chat-treasury-strategy2026-01-14T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-approval-nrx-100-ketamine2026-01-14T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-public-offering-pricing2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-partnership-refuah-health-femaseed-access2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-john-mcadory-yujun-wu2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-aml-data-ash-meeting2026-01-14T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-difs-neurostimulation-adhd-study2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-present-results-pancreatic-cancer-study-aacr-20262026-01-14T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-preliminary-fourth-quarter-full-year-2025-results2026-01-14T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-trial-cmnd-1002026-01-14T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/emergency-care-holdings-acquires-philips-emergency-care2026-01-14T15:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDY/dr-reddys-launches-olopatadine-hydrochloride-ophthalmic-solution2026-01-14T13:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAT/j-star-signs-mou-with-pssb-battery-resins2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-nasdaq-extension-compliance-bid-price2026-01-14T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OR/os-therapies-filing-form-s1-os-animal-health2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-broad-spectrum-antivirals-influenza-wave2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-jpm26-yeztugo-hiv-numbers2026-01-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-analyst-coverage-valuation-zacks2026-01-14T16:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-record-q4-2025-revenues2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-secures-50-million-loan-facility2026-01-14T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-monotherapy-phase-3-study-results2026-01-14T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/big-pharma-manufacturing-job-opportunities-20262026-01-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-gemini-presentation-aki-crrt-20262026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-patent-application-ad042026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-preliminary-results-q4-full-year-20252026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-aacr-2026-pancreatic-cancer-study2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-virtual-investor-ceo-connect-ash2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-expands-sls009-europe2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-reverse-stock-split2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-upsized-public-offering2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-strategic-milestones-20262026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-ox2r-against-neuropsychiatric-indications2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/ajovy-reduces-migraine-days-children-adolescents2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-reports-q2-fiscal-2026-results2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-debt-management-convertible-notes-offering2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONQ/katie-arrington-joins-ionq-as-cio2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/saudi-fda-approves-immunitybio-anktiva-bladder-cancer2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-tdp43-discovery-neurodegenerative-disease2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-alto-207-patent-depression2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/mount-sinai-first-metro-new-york-tulsa-pro2026-01-15T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-positive-phase-2-data-ocu410-gene-therapy2026-01-15T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-fda-clearance-encor-encompass-breast-biopsy-system2026-01-15T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eu-regulatory-inflection-ht-0012026-01-15T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-preliminary-financial-update-20252026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-penumbra2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-reverse-stock-split2026-01-15T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-present-real-world-data-apsard-20262026-01-15T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-forward-phase-3-trial-axs-14-fibromyalgia2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-ind-submission-gtb-55502026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staarsurgical-broadwood-cooperation-agreement2026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-sales-momentum-20252026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-system-contrast-study-enrollment2026-01-15T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-imagevue-dr50-plus-launch2026-01-15T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-closes-141m-collaboration-zydus-lifesciences2026-01-15T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-veterinary-cancer-care-mast-cell-tumor-testing2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABP/abpro-abp-102-jp-morgan-healthcare-conference2026-01-15T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-expands-hsa-fsa-access-tru-niagen2026-01-15T13:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-pancreatic-cancer-impact2026-01-15T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-ai-initiative-tcm-supply-chain2026-01-15T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-vs-austedo-vmat2-occupancy-comparison2026-01-15T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-clean-balance-sheet-steps2026-01-15T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-sidoti-conference-20262026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-submission-ketamine-suicidal-depression2026-01-15T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-prices-550-million-convertible-notes2026-01-16T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTV/asp-ultra-gi-cycle-ce-mark-approval2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-global-innovation-strategy-jp-morgan-conference2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-reverse-stock-split2026-01-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-special-meeting-results-20262026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-fourth-quarter-2025-results2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-closing-public-offering2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-sales-momentum-113-million-revenue2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CASI/casi-pharmaceuticals-approval-clinical-trial-cid-1032026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-vs-austedo-vmat2-occupancy2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/zydus-lifesciences-acquires-agenus-biologics-facilities2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-eu-regulatory-inflection-ht-001-trial2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-positive-phase-2-data-ocu410-geographic-atrophy2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-webcast-conference-call-q4-2025-results2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-preliminary-update-fourth-quarter-full-year-20252026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABP/abpro-abp-102-celltrion-jpmorgan-conference2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-warrant-exercise-4-64-million2026-01-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-offering-17-6-million2026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-inducement-grants-nasdaq-rule-56352026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-pali-2108-ibd-conferences-20262026-01-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-invests-in-opendoor-technologies2026-01-16T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-launches-lumee-tissue-oxygen-monitoring2026-01-16T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-2025-annual-meeting-date2026-01-16T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-lock-up-agreement2026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-acnp-meeting-20262026-01-16T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-sponsors-symposium-veterinary-meeting-expo2026-01-16T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-real-world-data-delivery-1-5m-patients2026-01-16T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-bought-deal-financing2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-cd19-car-nk-therapy-waldenstrom-lymphoma2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-advances-bcg-naive-nmibc-program2026-01-16T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/protagonist-decision-rusfertide-takeda2026-01-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-topline-results-epcoritamab-phase-3-trial2026-01-16T18:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/first-us-patient-dosed-bipass-phase-3-study2026-01-17T09:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/next-gen-alzheimers-treatment-candidates2026-01-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-continued-sales-growth2026-01-19T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/genflow-biosciences-directorate-change2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/harbour-biomed-acquires-spruce-biosciences-stock2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/fda-acknowledges-rexlemestrocel-l-back-pain-efficacy2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-employment-inducement-grants-january-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-fda-approval-nexplanon-extension2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-inducement-grants-nasdaq-listing-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPTX/repare-shareholders-approve-acquisition-xenotherapeutics2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-employment-inducement-grant-january-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-inducement-grants-nasdaq-listing-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-fda-orphan-drug-designation-endoxifen-dmd2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-inducement-grants-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HKPD/cellyan-biotechnology-nasdaq-bid-price-deficiency2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-atopic-dermatitis-trial-results2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-inducement-grants-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-inducement-grant-nasdaq-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-inducement-grant-nasdaq-rule-56352026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-8-8-million-offering2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-epcoritamab-phase-3-results-dlbcl-trial2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-topline-results-epcoritamab-phase-3-trial2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/vaximm-appoints-sebastien-wieckowski-cso2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-emerging-growth-conference-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/precision-platforms-disrupt-2026-tumor-landscape2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-warrants-exercise-4-64-million2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-inducement-grants-january-20262026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-release-results-q4-2025-webcast2026-01-19T14:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/enhertu-pertuzumab-eu-validation-first-line-treatment2026-01-19T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-merck-collaboration-oncology-therapies2026-01-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-chikungunya-vaccine-update2026-01-19T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-update-chikungunya-vaccine-ixchiq2026-01-19T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/nmpa-accepts-illuccix-application-prostate-cancer2026-01-20T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-fy-2025-guidance-gozellix-launch2026-01-20T21:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-fda-resubmission-ankteva-bladder-cancer2026-01-20T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-achieves-fy-2025-guidance-revenue-growth2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-orphan-drug-designation-ipf2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sofetabart-mipitecan-fda-breakthrough-designation2026-01-20T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-launches-inpefa-sotagliflozin-uae2026-01-20T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-conference-call-february-20262026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-phase-3-trial-lpcn-1154-postpartum-depression2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-synchrony-s1-prefillable-syringe-launch2026-01-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/new-consensus-recommends-papzimeos-first-line-treatment2026-01-20T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-license-agreement-pfizer-matrix-m2026-01-20T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-postpones-reverse-stock-split2026-01-20T12:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-merck-long-term-survival-mrna-keytruda-combo2026-01-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-nasdaq-anniversary-opening-bell-20262026-01-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-dealflow-discovery-conference-20262026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-analyst-day-january-20262026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-phase-2-study-vyd2311-long-covid2026-01-20T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-preliminary-full-year-2025-business-update2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-orphan-drug-designation-japan-dyne-1012026-01-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-soquelitinib-atopic-dermatitis-trial2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-nda-bezuclastinib-rtor2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-fda-gedatolisib-advanced-breast-cancer2026-01-20T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-phase-2a-pancreatic-cancer-study2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-igalmi-label-expansion2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-advances-bbi-940-kinesin-degrader2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-neuro-pmr-study-results-portable-mri2026-01-20T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-ceo-letter-stockholders2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presentation-dealflow-discovery-conference2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-lp-284-fda-orphan-drug-designation2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-preliminary-financial-results-20252026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-fourth-quarter-full-year-2025-results2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-microsoft-ai-lung-cancer-detection2026-01-20T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fetal-focus-nipt-smfm-presentation2026-01-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q4-2025-financial-results2026-01-20T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-expands-renovocath-adoption-cancer-centers2026-01-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-breakthrough-designation-qrx0032026-01-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-presentation-dealflow-discovery-conference2026-01-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-corporation-live-earnings-webcast2026-01-20T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-health-appoints-adnan-mansour-cdo2026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-phase-2-results-ns0022026-01-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-open-market-purchases-fu-wei2026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-nasdaq-closing-bell-20262026-01-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-merck-five-year-data-intismeran-keytruda2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-bge-102-indication-expansion-dme-trial-20262026-01-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-extends-access-nuq-vet-cancer-test2026-01-20T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-cms-reimbursement-trusight-oncology2026-01-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ce-mark-tactiflex-duo-ablation-catheter2026-01-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-listing-rule2026-01-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-ateganosine-cancer-treatment-2026-milestones2026-01-20T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-customer-growth-robotic-expansion2026-01-20T15:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-secures-uk-ces-contract-steraMist2026-01-20T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-new-patent-application2026-01-20T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRNS/transcat-third-quarter-fiscal-year-2026-conference-call2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presentation-dealflow-conference-20262026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-fourth-quarter-2025-financial-results2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-gelrinc-cartilage-regeneration-mri-results2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sublingual-alprazolam-patent2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-patent-acne-treatment-australia2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMM/3m-reports-fourth-quarter-full-year-2025-results2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fetal-focus-sgnipt-smfm-presentation2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-fda-resubmission-anktiva-bladder-cancer2026-01-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q4-2025-earnings-call2026-01-20T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-advances-ateganosine-cancer-treatment2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ce-mark-tactiflex-duo-ablation-catheter-afib2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-200-million-public-offering2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-host-first-2026-stakeholder-webcast2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engn-expands-debt-facility-hercules-capital2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-fourth-quarter-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-webcast-fiscal-2026-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-announces-fourth-quarter-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-ceo-emerging-growth-conference-20262026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-warrant-exercise-proceeds2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-dividend-distribution-warrants2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-investor-day-recap-20262026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-inducement-grants-nasdaq-listing-rule-56352026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-public-offering-20262026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-proposed-public-offering-150-million2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/bioage-announces-proposed-public-offering2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-200-million-offering-medtronic-investment2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-fourth-quarter-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-lupus-optimal-care-initiative-grants2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-intranasal-foralumab-publication2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-granted-patent-alzheimers-treatment2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-va-contract-esoguard2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-patent-ht-kit-cancer-program2026-01-21T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-ypsomed-partnership-biologics-market2026-01-21T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-advances-budgetary-validation-purchase-orders2026-01-21T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-health-surpasses-100-scientific-studies2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-burixafor-phase-2-trial-tandem-meetings-20262026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERO/venus-concept-voluntary-delist-nasdaq2026-01-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/california-k12-schools-neffy-program-epinephrine2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-poster-keystone-obesity-conference2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-fda-qidp-fast-track-scy-2472026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-appoints-david-robinson-cfo2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-pricing-22-5-million-offering-common-stock2026-01-21T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-end-of-phase-2-fda-pilavapadin2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-acquired-kuva-labs2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/good-health-summit-morehouse-college2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-data-tandem-meetings-20262026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-explores-strategic-alternatives2026-01-21T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-net-sales-darzalex-20252026-01-21T11:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-q1-2026-priorities-pipeline-outlook2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/acacia-clinics-vagus-nerve-study-ecor2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-shareholder-letter-2026-objectives2026-01-21T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/concerns-topical-steroids-chronic-skin-conditions2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-tandem-meetings-20262026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-phase-2-b-supreme-study-update2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-phase-1-2-trial2026-01-21T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-appoints-sandeep-kulkarni-ceo2026-01-21T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-jama-study-alzheimers-risk-profiling2026-01-21T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-expands-medical-affairs-infrastructure-botensilimab-balstilimab2026-01-21T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-q4-full-year-2025-results2026-01-21T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-latitude-tissue-free-mrd-test-validation2026-01-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/nivf-appoints-joshua-chu-tokenization-strategy2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-appoints-marc-waldman-vp-commercial2026-01-21T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-minako-pazdera-general-counsel2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-announces-fiscal-q2-2026-results2026-01-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-clarivate-top-100-global-innovator-20262026-01-21T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/dawnzera-approval-eu-hereditary-angioedema2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-fourth-quarter-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-report-q4-full-year-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluoguide-ind-submission-fg001-registration-trial2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-exxua-launch-major-depression-treatment2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/interpace-biosciences-2025-revenue-guidance2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inducement-grants-nasdaq-listing-rule-56352026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-fourth-quarter-2025-financial-results2026-01-21T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-ceo-named-top-healthcare-technology-ceo2026-01-21T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-coimmunity-initiative-grants-vaccination-gaps2026-01-21T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/dawnzera-approved-eu-hereditary-angioedema2026-01-21T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-fortune-most-admired-companies-20262026-01-21T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-gazi-university-collaboration2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-acquires-integrity-orthopaedics-shoulder-repair2026-01-21T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-science-talent-search-2026-finalists2026-01-21T17:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-expands-medical-affairs-infrastructure-bot-bal2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-q4-2025-results2026-01-21T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-conference-call-q4-2025-results2026-01-21T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-report-second-quarter-fiscal-2026-results2026-01-21T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/companies-hiring-rd-professionals2026-01-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-fda-approves-gp2-flamingo-012026-01-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-italia-launch-expansion-portfolio2026-01-22T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-upsized-public-offering-124-million2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-upsized-public-offering2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-fourth-quarter-2025-financial-results-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/trodelvy-keytruda-phase-3-ascent-04-results2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q4-2025-earnings-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-inducement-grants-nasdaq-rule-56352026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATXS/astria-stockholders-approve-acquisition-biocryst2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-advance-conversation-early-car-t-access2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/biostem-technologies-acquisition-biotissue-wound-care2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q4-2025-results-webcast2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-fiscal-2026-first-quarter-conference-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-award-20262026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-fda-bpd-type-2a-meeting-shareholder-approval2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPCH/option-care-health-q4-2025-results-conference-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-expands-belgian-manufacturing-capacity2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-proposed-public-offering-common-stock2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-business-update-conference-call-20262026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-acquisition-integrity-orthopaedics2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-gemini-fda-approval-pathway-aki2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-22-5-million-offering2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-clinical-trial-results2026-01-22T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-financial-results-conference-call-20252026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-full-year-2025-results2026-01-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-cortigent-orion-system-nans-20262026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-phase-2-advanced-2-trial-asco-20262026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharma-partnership-runway-health-arakoda2026-01-22T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reyobiq-cnsid-commercialization-update2026-01-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-amendment-lifearc-license-teverelix2026-01-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-laurie-stelzer-board-appointment2026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-lindsey-vonn-antibodies-education2026-01-22T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-phase-3-rosella-trial-relacorilant-ovarian-cancer2026-01-22T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-gammagard-liquid-erc-us-availability2026-01-22T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/initiate-study-pathogen-inactivated-platelets-cerus2026-01-22T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-bms-collaboration-tumor-therapeutic2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-appoints-kevin-tracey-board2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-appoints-bryan-humbarger-cfo2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-q4-2025-results-conference-call2026-01-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAT/j-star-complaints-against-pwc-aicpa-pcaob2026-01-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-fda-clearance-ai-scada-brainct-ich2026-01-22T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-us-patent-pds01012026-01-22T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/sweetwater-launches-big-trip-double-ipa2026-01-22T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSIC/henry-schein-webcast-q4-2025-conference-call2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVA/sinovac-nasdaq-hearings-panel-grants-listing2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-elects-ellen-cooper-board-directors2026-01-22T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-usability-study-nasarix-allergy-blocker2026-01-22T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-italia-launch-therapeutic-cannabis2026-01-22T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-medical-italia-expansion-portfolio2026-01-22T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-phase-2b-ipf-cough-trial-results2026-01-22T17:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-quarterly-dividend-2026-meeting-details2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-report-full-year-2025-results2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-advances-vax-31-pneumococcal-vaccine-programs2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-eu-mdr-certification-navigation-software2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-q4-2025-financial-results-report2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-report-q4-2025-results-investor-conference2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-technologies-closing-public-offering2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-medtronic-tavr-investment-320-million2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-announces-fourth-quarter-earnings2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-phase-2-3-trial-atmelnant-cah2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-awards-20262026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q4-2025-financial-results2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-benefit-hf-trial-barostim-heart-failure2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIR/mirion-earnings-release-conference-call-20252026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-fda-approval-guardant360-cdx-braftovi2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-fda-clearance-ai-software2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-new-us-patent-pds01012026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-clinical-response2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-laurie-stelzer-audit-chair2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-advanced-2-trial-data-asco-symposium2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-sphere-360-catheter-ce-mark-ide-trial2026-01-23T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-research-cloud-ai-panel-design2026-01-23T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-preliminary-financial-results-20252026-01-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/fda-approves-compassionate-use-urcosimod-neuropathic-corneal-pain2026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-closes-22-5-million-offering2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-20262026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-phase-iii-vaccine-trials-skepticism2026-01-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-nasdaq-closing-bell-anniversary2026-01-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-fourth-quarter-full-year-2025-results-call2026-01-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-voluntary-delisting-tase2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-phase-1b-data-tegoprubart-kidney-transplant2026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-9-million-offering2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-business-update-2026-objectives2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-launches-s540md-slide-scanner-system2026-01-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-2-results-glioblastoma-anktiva2026-01-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMN/amn-healthcare-fourth-quarter-2025-earnings-call2026-01-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/20-million-patients-benefit-da-vinci-surgery2026-01-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-acquisition-astria-therapeutics2026-01-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-financing-14-million2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-partnership-runway-health-arakoda2026-01-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fda-approval-afrezza-label-update2026-01-26T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/prospera-test-lung-transplant-study-ntra2026-01-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-leqembi-iqlik-sbla-subcutaneous-dosing2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-boswick-symposium-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-report-3-year-data-embark-study-elevidys2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAFF/moolec-science-nasdaq-exception-compliance-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-upsized-public-offering-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-q3-2025-financial-results-business-update2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-upsized-public-offering-common-stock2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grant-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-receives-nasdaq-notification-stockholders-equity-deficiency2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-business-update-february-20262026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-exercise-warrants-11-million2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-key-dates-terms2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-s540md-slide-scanner-launch2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-2-results-recurrent-glioblastoma2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-acquisition-astria-therapeutics-hae2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-red-c-phase-3-trials-update2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/enlivex-therapeutics-nasdaq-trading2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CM/daxor-corporation-9-million-offering2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-reports-financial-results-20252026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-affera-sphere-360-ce-mark-ide-trial2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-phase-1b-data-tegoprubart-kidney-transplant2026-01-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-private-offering-senior-notes-amicus-acquisition2026-01-26T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-acquisition-ip-portfolio-gerd-device2026-01-26T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-kol-event-roluperidone2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/baylor-pancreatic-cancer-study-marker-therapeutics2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-cardamyst-etripamil-launch2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-secures-new-us-patent-novel-compound-structures2026-01-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-portfolio-update-rain-token-whitebit2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-gist-therapy2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-terminates-agreement-kowa-promotion-zoryve2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-fourth-quarter-2025-financial-results-call2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-positive-embark-results-elevidys-duchenne2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-acquisition-bluejay-therapeutics-hdv2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-phase-1-miroliverelap-results2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-patent-adc-program-aktx-1022026-01-26T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-influenza-treatment2026-01-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-phase-2-illuminate-1-trial-bipolar-depression2026-01-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-presentation-miplyffa-worlsymposium2026-01-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-redomiciliation-completion-us2026-01-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-2-nbi-1065890-tardive-dyskinesia2026-01-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-fda-type-c-meeting-hlhs-trial2026-01-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/da-vinci-5-cleared-cardiac-procedures2026-01-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-funds-note-purchase-agreements2026-01-26T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-api-stockpile-deals-details2026-01-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-hyft-technology-functional-adjacency2026-01-27T05:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-transformation-biotech-defense-industrial-consolidator2026-01-27T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-update-financing-strategy2026-01-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-ati-2138-hair-regrowth2026-01-27T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-participation-investor-conferences2026-01-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-presentation-jefferies-global-healthcare-conference2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-appoints-william-sharbaugh-board-directors2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-acquires-bluejay-therapeutics-hdv-treatment2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-positive-three-year-embark-results-elevidys2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KODK/kodak-expands-pharmaceuticals-portfolio-products2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-fourth-quarter-2025-results2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-inducement-grant-nasdaq-rule-56352026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q4-2025-results-report2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-survival-rate-sr-agvhd-treatment-update2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-announces-nuq-nets-indication-hidradenitis-suppurativa2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-mexican-patent-breast-cancer-vaccine2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-phase-1b-study-paxalisib-tnbc2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-data-presentations-actrims-20262026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-expands-focusfactor-distribution-canada2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-orphan-drug-designation-japan2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-fda-lifts-hold-magnitude-2-trial2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-leadership-appointments-cardiovascular-expertise2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-terminates-license-agreement-qilu2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-gene-therapy-trial-mertk-retinitis-pigmentosa2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-selected-for-japan-entry-acceleration-program2026-01-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-on-track-with-hcm-awareness2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-myqorzo-available-us-treatment-ohcm2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-positive-update-onvansertib-trial2026-01-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-leadership-changes-late-stage-development2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-fda-meeting-zervimesine-dlb2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-reverse-stock-split2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-dragon-ii-trial-enrollment-completed2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-2-survival-data-bctx2026-01-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q4-2025-financial-results2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-fourth-quarter-full-year-2025-results2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-advances-mrd-commercialization-timeline2026-01-27T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-ip-momentum-patent-application2026-01-27T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-capital-allocation-digital-assets2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-share-repurchase-program-benchmark2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-forte-huntingtons-disease-awareness2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/sweetwater-420-fest-2026-lineup2026-01-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-accellacare-expands-oncology-research-capabilities2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-fourth-quarter-full-year-2025-results2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-bexmarilimab-phase-i-ii-trial-sarcoma2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/strong-divitum-tka-results-jco-precision-oncology2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/biotech-veteran-virologist-joins-cancervax2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-terminates-promotion-agreement-kowa2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-miplyffa-worlsymposium-20262026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-fourth-quarter-2025-financial-results2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-redomiciliation-us-completion2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASTH/astrana-health-financial-results-conference-call-20252026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-private-offering-senior-notes-acquisition2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/prospera-guided-care-lung-transplant-study2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-files-patent-aktx-102-ceacam52026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-secures-us-patent-novel-compound-structures2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-ratutrelvir-tivoxavir-marboxil-update2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-phase-2-study-nbi-1065890-tardive-dyskinesia2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-fda-type-c-meeting-elpis-ii-hlhs2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/da-vinci-5-cleared-for-cardiac-procedures2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-positive-results-phase-1-miroliverelap2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REVB/revelation-biosciences-reverse-stock-split-20262026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-expands-ai-program-alcohol-use-disorder2026-01-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-shareholders-approve-bd-combination2026-01-27T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-financial-results-fiscal-20262026-01-27T14:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-spin-off-biosciences-diagnostic-solutions2026-01-27T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/next-generation-tablo-hemodialysis-fda-clearance-launch2026-01-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-2025-milestones-2026-strategic-initiatives2026-01-27T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-first-quarter-2026-earnings-release2026-01-27T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-tender-offer-results2026-01-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-first-commercial-sales-yartemlea2026-01-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-fourth-quarter-fiscal-year-2025-earnings-release2026-01-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-swoop-system-stroke-detection-data2026-01-27T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-btig-conference-participation2026-01-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-amendment-hercules-capital-debt-facility-fda-approval2026-01-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-fourth-quarter-2025-financial-results2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-vt-1953-phase-3-study-valuation2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-presents-digital-asset-investor-conference2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fourth-quarter-year-end-2025-results2026-01-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-declares-dividend-share-repurchase-authorization2026-01-27T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-quadruplet-regimen-approval2026-01-27T20:49:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-revenue-estimates-and-guidance2026-01-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-ultrasensitive-assays-ella-platform2026-01-28T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-nugevia-glp1-users2026-01-28T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-abstracts-tpip-pvri-2026-congress2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-imcas-2026-data-facial-injectables2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-discontinues-phase-2-kourage-trial2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-litifilimab-fda-breakthrough-therapy-designation2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-asbrs-breast-cancer-treatment-guidelines2026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-holdings-shareholder-letter-20252026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-update-20262026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-regulatory-update-ultra-rare-mps-programs2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-matt-skelton-cco2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-castanospermine-purification-license2026-01-28T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-sc247-imari-presentation-antifungal-activity2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-acceptance-clinical-data-abstract-sio-20262026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-promotes-alireza-javadi-cto2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-q4-2025-results-report2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-samit-hirawat2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-successful-type-c-fda-meeting2026-01-28T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-parkinsons-research-collaboration2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/roche-obesity-moderna-vaccine-sarepta-data2026-01-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-phase-2a-gene-expression-ipf2026-01-28T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-appoints-kylie-jimenez-cpo2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-appoints-kylie-jimenez-chief-people-officer2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-patients-show-tumor-regression-immune-activation2026-01-28T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/first-patient-dosed-accel-phase-3-study-ibsrela2026-01-28T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-pain-mitigation-pancreatic-cancer-sio-20262026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-data-presentations-worlsymposium-20262026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-completes-enrollment-aces-emb-trial-heart-transplantation2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-1-5-million-offering2026-01-28T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-launches-vitagard-mrd-infrastructure-asean-market2026-01-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-partnership-u-deliver-distribution2026-01-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-report-fourth-quarter-full-year-2025-results2026-01-28T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-fda-breakthrough-therapy-nxc-2012026-01-28T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-phase-2-study-results-il-12-immunocytokine2026-01-28T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-submission2026-01-28T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-fourth-quarter-full-year-2025-results-webcast2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-half-year-results-updates2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-pivot-to-growth-strategy-2025-results2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-acquires-woori-io-strategic-review2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-shareholder-letter-20262026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-japanese-mhlw-orphan-drug-designation2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-accelerates-ip-momentum2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-selected-for-jeap2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sublingual-clopidogrel-patent2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-dragon-ii-trial-enrollment-complete2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-fda-lifts-clinical-hold-magnitude-2-trial2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-report-fourth-quarter-full-year-2025-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GKOS/glaukos-fda-approval-idose-tr-re-administration2026-01-28T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-refutes-misleading-claims2026-01-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-75-million-offering2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-financial-results-february-20262026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-q4-2025-financial-results-release2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-announces-q2-2026-dividend2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-changes2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-upcoming-investor-events2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-quadruplet-regimen-approval-multiple-myeloma2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-declares-dividend-authorizes-share-repurchases2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-q2-results-report2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-investor-conferences-20262026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-fourth-quarter-2025-financial-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-amendment-hercules-capital-debt-facility2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-fourth-quarter-full-year-2025-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-fourth-quarter-year-end-2025-financial-results2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-phase-1-2a-study-arodimer-pa2026-01-28T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2025-financial-results2026-01-28T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-tlx591-px-prostate-cancer-japan2026-01-29T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/it-professionals-hiring-biopharma-20262026-01-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-regeneron-bayer-eylea-agreement2026-01-29T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-settlement-agreement-eylea-biosimilar2026-01-29T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-q3-fy2025-results-vyvanse-generics-impact2026-01-29T06:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-data-presentations-worldsymposium-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-quarterly-dividend-april-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-metastatic-breast-cancer-resistance2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-barda-entolimod-radiation-syndrome-discussion2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-shareholder-letter-revenue-20252026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-fda-breakthrough-nxc-2012026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-phase-2-results-pds01adc-prostate-cancer2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-new-data-imcas-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-update-key-value-drivers-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-appoints-samit-hirawat-board2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-enrollment-update-pf614-phase-3-trial2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-q4-full-year-2025-results2026-01-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/bexmarilimab-clever-1-inhibition-cancer-immunotherapy2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-veterinary-recall-hycoat-solution2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-safety-data-children-ataxia-telangiectasia2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-inducement-grant-nasdaq-rule-56352026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-btig-conference-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-ryoncil-revenue-increase-q2-20252026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-board-appointments2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-q4-fiscal-year-2025-results2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-btig-conference-participation-20262026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-pharmaceuticals-added-to-sp-600-index2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-fda-clearance-ser-252-parkinsons2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-envetec-recycling-solution-laboratory-plastics2026-01-29T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-renergen-helium-project-update2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-fourth-quarter-full-year-2025-conference-call2026-01-29T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-nimacimab-keystone-obesity-conference2026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-breadth-phase-2b-asthma-trial-kt-6212026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q2-fy262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-february-investor-conferences2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-weight-maintenance-data2026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-uspto-patents-cbgm-platform2026-01-29T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-participation-apao-20262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-btig-conference-participation-20262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-conference-call-q4-2025-results2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-collaboration-totec-pharma2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-boehringer-ingelheim-data-collaboration2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-fourth-quarter-full-year-2025-results2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/fda-acceptance-ivonescimab-summit-therapeutics2026-01-29T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/satellos-appoints-antoinette-paone-cdo-regulatory-affairs2026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/applied-therapeutics-tender-offer-extension2026-01-29T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-announces-q4-2025-financial-results-call2026-01-29T13:08:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-participate-upcoming-conferences2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-expands-board-appointment-directors2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-positive-us-study-results-linc-20262026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/terrapin-beer-co-brand-refresh-20262026-01-29T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-love-in-mind-migraine-impact-relationships2026-01-29T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/art100-completes-clinical-evaluation-budgeted-procurement2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-ibd-experts-clinical-advisory-board2026-01-29T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-japan-patent-potency-assay-methods2026-01-29T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-noble-capital-conference-20262026-01-29T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/cibolo-health-endorses-heartsciences-myoVista-insights2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-shareholder-letter-2026-trials-milestones2026-01-29T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-analyst-day-february-20262026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-early-clinical-proof-concept-apr-10512026-01-29T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-private-placement-5-6-million2026-01-29T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIO/bio-rad-fourth-quarter-full-year-2025-results2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-acquires-safe-save-medical-cell-sciences2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-warrant-inducement-7-5-million2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-report-q4-full-year-2025-results2026-01-29T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-expanding-phase-iii-gelrinc-clinical-sites2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-agreement-microsize-sublingual-aspirin2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-positive-results-phase-iii-denifanstat-acne2026-01-29T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-fourth-quarter-2025-financial-results2026-01-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pricing-private-offering-senior-notes2026-01-29T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-fda-approval-galleri-multi-cancer-test2026-01-30T00:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pricing-public-offering-private-placement2026-01-30T07:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-manufacturing-consolidation-20262026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-public-offering-common-stock2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-worldsymposium-2026-data-presentations2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-eversense-365-european-approval2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-update-on-recent-developments2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-q2-fiscal-year-2026-results2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-fourth-quarter-2025-results-conference-call2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-stock-units-warrants-employees-20262026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/alk-receives-positive-recommendation-eurne2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-announces-550-million-public-offering2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-q4-2025-financial-results2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-fda-clearance-rystiggo-freedomedge-infusion2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-seanobi-study-100-patients-enrolled2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-phase-3-neat-trial-results2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-closes-75-million-offering-common-stock2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-recordati-collaboration-mrna-3927-commercialization2026-01-30T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-3-resilient-data-tonmya2026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-fourth-quarter-full-year-2025-results2026-01-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-annual-shareholder-meeting-summary-20262026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-rd-leadership-evolution2026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q2-fy26-cash-flow-report2026-01-30T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-guggenheim-biotech-summit-20262026-01-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-reimbursement-submission-nuq-cancer-assays2026-01-30T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-acquisition-somalogic-completes2026-01-30T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-preclinical-data-nd2l2026-01-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-invests-20-million-in-quantum-scan-holdings2026-01-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-resubmits-bla-ux111-sanfilippo-syndrome2026-01-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-recordati-mrna-therapy-partnership2026-01-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-sale-somalogic-illumina2026-01-30T14:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOBT/io-biotech-corporate-update-strategic-alternatives2026-01-30T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-pricing-underwritten-offering2026-01-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/cd47-expression-predicts-response-evorpacept-advanced-breast-cancer2026-01-30T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-chmp-opinion-zynyz-scac-treatment2026-01-30T14:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-private-placement-11-million2026-01-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-phase-ii-clinical-data-mcs-82026-01-30T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-pennsylvania-manufacturing-facility2026-01-30T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-urcosimod-ascrs-presentation-20262026-01-30T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-nasdaq-minimum-bid-price-notification2026-01-30T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-fda-complete-response-letter-leniolisib-apds2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXT/sensient-announces-conference-call-january-20262026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-departure-cfo-shane-kovacs2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-presentation-imaging-dosimetry-data-mp07122026-02-02T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-sandoz-biosimilars-canada-australia-new-zealand2026-02-02T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-supply-commercialization-agreements-biosimilars2026-02-02T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-investor-relations-events-february-20262026-02-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-3d-stem-cell-organoid-culture-portfolio2026-02-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-q4-full-year-2025-results2026-02-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-signatera-cdx-fda-approval-submission2026-02-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-financial-results-q4-full-year-20252026-02-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-licenses-rare-disease-product2026-02-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-ultrasensitive-ctdna-monitoring-cancer-immunotherapy2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-fda-orphan-drug-ifx-2-0-melanoma2026-02-02T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-inducement-grants-nasdaq-rules2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-nexus-triomphe-amds-persevere-trials2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-positive-52-week-data-asc40-acne-trial2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-reaffirms-2025-revenue-guidance-strong-growth2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-new-patent-dna-polymerase-inhibitors2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-accelerate-regulatory-engagement-wve-0062026-02-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-amends-license-agreement-newsoara2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-goodrx-arakoda-partnership2026-02-02T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/eurneffy-adrenaline-nasal-spray-eu-approval2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-cannabinoid-technology2026-02-02T13:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-positive-cbeyond-phase-2a-results-nimacimab2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-injection-angiogenesis-20262026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-statins-porokeratosis2026-02-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-fda-fast-track-sonelokimab-ppp2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-15-year-anniversary-epifix-amniofix2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-financial-results-webcast-20262026-02-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-national-burn-awareness-week-20262026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-relocates-headquarters-san-jose2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-participate-conferences-february-20262026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-phase-2b-trial-halneuron2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-webcast-enzyme-transportvehicle-programs2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-share-repurchase-program2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-positive-results-integument-infant-trial-zoryve2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fda-complete-response-anaphylm2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-btig-conference-participation-20262026-02-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-fda-accepts-nda-zanzalintinib-mcrc2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-allia-moveo-fda-clearance-ce-mark2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-q1-results2026-02-02T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-td-cowen-conference-20262026-02-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-interim-co-ceos-appointment2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-funds-vt-1953-phase-3-study2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-2-car-nk-cell-therapy-trial2026-02-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-sale-short-read-sequencing-assets2026-02-02T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-peer-reviewed-research-difs-technology2026-02-02T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-scope-summit-2026-concussion-treatment2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/polaryx-therapeutics-nasdaq-listing-plyx2026-02-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DLHC/dlh-fiscal-2026-first-quarter-results2026-02-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-nasdaq-bell-ringing-20262026-02-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GROUP/astrazeneca-begins-trading-nyse2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/ambry-genetics-one-millionth-test-rna-diagnostic-accuracy2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-bio-neuroscience-conference-amsterdam2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-car-t-therapy-approval2026-02-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-expands-insulin-delivery-solutions2026-02-02T14:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-precision7-contact-lens-canada2026-02-02T14:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-bla-filing-ost-her2-osteosarcoma2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-phase-2-calma-trial-enrollment2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/sparrow-appoints-carlo-incerti-board-directors2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/fruzaqla-reimbursement-ontario-mcrc2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-novartis-partnership-mayzent-ms-canada2026-02-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-grants-new-employees-inducement-plan2026-02-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-inducement-grants-nasdaq-rule-56352026-02-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-spin-off-record-date2026-02-03T02:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-instituto-butantan-chikungunya-vaccine-brazil2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-instituto-butantan-pilot-vaccination-brazil2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-2026-financial-guidance-rare-disease-pipeline2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/biontech-multi-modality-vs-moderna-mrna-pipeline2026-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADXN/addex-preclinical-data-mglu7-nams-anxiety-treatment2026-02-03T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/datroway-priority-review-tnbc-treatment2026-02-03T07:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/preciseonco-consortium-awarded-eur-14-9-million-ihi-grant2026-02-03T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/osrx-licensing-availability-compounded-ophthalmic-medications2026-02-03T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-inducement-grants-nasdaq-rule-56352026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-632-million-public-offering2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-inducement-grants-nasdaq-rule-5635c42026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/protara-therapeutics-inducement-grants-february-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-flow-cytometry-mrd-myeloma-test2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-us-names-approval-car-t-therapy2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-expands-access-insulin-delivery-solutions2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-wylie-oaks-texas2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-timber-ridge-wisconsin2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-expands-arizona-operations2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-acquires-northwest-radiology-indiana2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-webinar-february-20262026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-source-healthcare-nociscan-growth2026-02-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-trofinetide-rett-syndrome-update2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/definium-therapeutics-employee-inducement-grants2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-fourth-quarter-full-year-2025-results2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-fda-breakthrough-designation2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-interim-ceo-appointment2026-02-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-guggenheim-biotech-summit-20262026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-guggenheim-biotech-summit-20262026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-expands-enabling-technology-market2026-02-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-fda-liberty-phase-3-trial-vyd23112026-02-03T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-fiscal-2026-first-quarter-results2026-02-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-participate-btig-medtech-conference-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTA/centessa-pharmaceuticals-investor-conferences-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-meai-veterans-access-therapies2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-late-breaking-results-cardiamp-hf-trial2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-fda-meeting-efzofitimod-pulmonary-sarcoidosis2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-allohome-clinical-validation-2026-tandem-meetings2026-02-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-earnings-conference-call-february-20262026-02-03T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-inducement-grants-nasdaq-rule-56352026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-leadership-transitions-oncology-pipeline2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-cardiac-catheter-af-symposium2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-fourth-quarter-full-year-2025-results2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-change-the-target-cardiovascular-care2026-02-03T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-full-year-2025-results-2026-guidance2026-02-03T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-ultra-long-acting-glp-1-ra-weight-loss-phase-2b2026-02-03T11:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-fourth-quarter-full-year-2025-results2026-02-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-2-trial-enrollment-open2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-commercial-update-arbli-launch2026-02-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-vcn-01-retinoblastoma-apao-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-third-quarter-results-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FOLD/amicus-therapeutics-worlsymposium-2026-data2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-present-investor-scientific-conferences-february2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-appoints-mayo-pujols-cto2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-fiscal-q3-2026-results-update2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-phase-1-vcn-01-retinoblastoma-apao-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-guggenheim-summit-20262026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-140-million-private-placement-financing2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-appoints-mark-kubik-cbo2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-championship-sunday-events2026-02-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-announces-revenues-and-earnings2026-02-03T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-announces-revenues-earnings-february-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-neurorestore-acd856-adpd-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/wuxi-vertex-tcell-engager-agreement2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-td-cowen-health-care-conference-20262026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-first-quarter-fiscal-year-2026-results2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-fourth-quarter-2025-results2026-02-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-leadership-team-expansion2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-phase-1-starlight-1-data-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-cardiovascular-scientific-forum-20262026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-fda-clearance-tap2d-image-enhancement2026-02-03T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-acquires-cathworks-innovation-strategy2026-02-03T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-san-diego-zoo-frozen-zoo-sequencing2026-02-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-fda-clearance-prt123962026-02-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/faces-of-natrelle-testimonial-program-launch2026-02-03T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-fda-ema-applications-upadacitinib-vitiligo2026-02-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-matthew-maletta-chief-legal-officer2026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-hyla-blood-sensor-validation2026-02-03T14:22:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-appoints-michael-p-miller-board-directors2026-02-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-healthcare-conference-taipei-20262026-02-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-fda-clearance-gtb-5550-trike2026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-fda-pre-ind-meeting2026-02-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-new-patent-tenapanor2026-02-03T13:29:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLT/cycle-pharmaceuticals-acquires-applied-therapeutics2026-02-03T13:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-fda-submission-alzheimers-blood-test2026-02-03T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-presentation-spie-medical-imaging-20262026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-neuroplasticity-psychiatric-disease2026-02-03T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-reduces-short-position-crypto2026-02-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-expands-european-commercial-footprint-switzerland2026-02-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-underwritten-offering-pricing2026-02-03T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-soteria-trial-launch-worlsymposium-20262026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-duck-flats-partnership-fda-ind-readiness2026-02-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABR/caring-brands-secures-new-patents-hair-technology2026-02-03T13:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-ketamir-2-phase-1-study-update2026-02-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/oncotype-dx-breast-recurrence-score-test-milestone2026-02-03T14:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-partnership-mounjaro-discounted-therapy2026-02-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-full-year-2025-results2026-02-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-report-q4-full-year-2025-results-investor-event2026-02-03T21:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-full-year-results-2025-webcast-notification2026-02-04T11:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/biotech-ipos-2021-current-status2026-02-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/mapi-pharma-ga-depot-ppms-actrims-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reports-full-year-2025-results-guidance-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-ultra-long-acting-glp-1-ra-weight-loss-phase-2b-trial2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-leadership-transitions-innovation-oncology2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-presentation-healthcare-conference-taipei-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-pricing-offering2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-expands-european-commercial-footprint2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-neuroplasticity-psychiatric-treatment2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/twist-bioscience-inducement-grants-nasdaq-rule-56352026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-leadership-changes-regulatory-clinical2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-fourth-quarter-2025-financial-results2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-showcases-qiasprint-connect-slas-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GH/guardant-health-investor-conferences-february-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-fourth-quarter-full-year-2025-results-investor-event2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-btig-conference-participation2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-q2-results2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-staar-study-fabry-disease2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-investor-conference-february-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-reverse-stock-split-nasdaq-compliance2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-awards-february-20262026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-upsized-ipo-pricing-announcement2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-inkt-ipf-data-keystone-symposia2026-02-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-phase-2-calliper-trial-data-actrims-20262026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-february-20262026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-q2-fiscal-2026-results2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-q4-2025-results2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-guggenheim-biotech-summit2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-reports-q4-full-year-2025-results2026-02-04T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-fiscal-2026-first-quarter-results-conference-call2026-02-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/final-apex-phase-1b-results-kodiaks-ksi-1012026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-q4-2025-financial-results-2026-guidance2026-02-04T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/devote-study-nusinersen-sma-results2026-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-investor-conferences-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-guggenheim-biotech-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-acquires-stake-arrow-aviation2026-02-04T12:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-presents-oppenheimer-healthcare-conference-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-february-investor-conferences2026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-guggenheim-biotech-summit-20262026-02-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-guggenheim-biotech-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-investor-conferences-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-february-healthcare-conferences2026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-2025-revenue-business-updates2026-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-participate-guggenheim-biotech-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-publication-ultralow-temperature-ablation-vt2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/kasey-keller-lymphoma-journey-breyanzi2026-02-04T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-genomic-alterations-gene-editing2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-cancer-phase-1-data-aacr-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-institutional-volatility-income-vault2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-locket-device-hospital-approvals2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/breckenridge-distillery-romano-beverage-distribution-illinois2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-guggenheim-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-enterabio-partnership-oral-pth-tablet2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-guggenheim-biotech-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-guggenheim-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-declares-quarterly-dividend-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-february-conferences-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-miplyffa-npc-worldsymposium2026-02-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-presentation-guggenheim-summit-20262026-02-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-guggenheim-summit-20262026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-cc-pharma-top-100-innovator-germany2026-02-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-fourth-quarter-2025-results2026-02-04T12:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-positive-ai-modeling-results-syntekabio-collaboration2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-third-quarter-results-conference-call2026-02-04T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-first-quarter-results2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-clinical-data-sio-2026-meeting2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-2025-financial-results-clinical-highlights2026-02-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/opko-enterabio-partnership-oral-pth-tablet2026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-exclusive-license-otsukas-opb-171775-gist2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-eugene-kennedy-cmo2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-stelo-smart-meal-logging-enhancements2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-srp-1005-clinical-trial-approval2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-fy2026-q3-results-conference-call2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/hologic-fda-approval-aptima-hpv-assay2026-02-04T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-next-generation-automated-solutions-slas20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-presentation-guggenheim-summit-20262026-02-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-shareholder-letter-growth-outlook2026-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-participate-investor-conferences-february-20262026-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-fda-fast-track-pelareorep-colorectal-cancer2026-02-04T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-evident-capital-tokenized-bond-launch2026-02-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-sponsors-symposium-european-hidradenitis-suppurativa2026-02-04T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-fda-fast-track-ifetroban-dmd2026-02-04T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-congressional-directive-alternative-endpoints-aud2026-02-04T14:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-anito-cel-tandem-presentation-20262026-02-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-exclusive-distribution-agreement-summit-products2026-02-04T15:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-2026-q2-financial-results2026-02-04T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q4-2025-results-announcement2026-02-04T23:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-regains-nasdaq-compliance2026-02-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACLX/arcellx-anito-cel-late-breaking-presentation-tandem-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-fiscal-year-2026-q3-results-update2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-presents-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-ultralow-temperature-ablation-vt2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-quarterly-dividend-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-fourth-quarter-2025-revenue-updates2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXG/pharosai-10x-genomics-cancer-research-ai-spatial-biology2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/ambrys-contributions-to-maves-support-patient-reclassifications2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/lumicell-appoints-cheryl-blanchard-board-directors2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-investor-conferences-february-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COR/cencora-fiscal-2026-first-quarter-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q4-2025-financial-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-pivot-insulin-patch-pump-milestone2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-appoints-ori-gon-cfo2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-clinical-data-tamp-therapy-sio-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-eugene-kennedy-chief-medical-advisor2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-reiterates-full-year-2025-financial-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/acarix-eu-mdr-certification-cadscor-system2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-q3-results-conference-call-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-canada-pr-ajovy-pediatric-migraine-approval2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-avt80-entivio-study-results2026-02-05T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-positive-results-avt80-biosimilar-entivio2026-02-05T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-q4-2025-financial-results-release2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-inducement-awards-nasdaq-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-guggenheim-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2026-q3-results-earnings-call2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-february-2026-investor-conferences2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-q4-2025-results-growth-pillars2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q4-2025-financial-results-call2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q4-2025-results-announcement2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-inducement-grant-nasdaq-rule-56352026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-guggenheim-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fourth-quarter-2025-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-acquisition-update-renal-therapeutic-program2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STE/steris-fiscal-2026-q3-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OLMA/olema-oncology-investor-conferences-february-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-acquires-dual-targeting-car-t-assets2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-report-2025-results-business-update2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-february-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-attend-health-care-conferences2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-q4-full-year-2025-financial-results-call2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-guggenheim-biotech-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-guggenheim-summit-20262026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPO/enpro-fourth-quarter-year-end-2025-earnings-release2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-participate-guggenheim-biotech-summit-20262026-02-05T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-q4-2025-results2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-investor-conferences-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-burixafor-stem-cell-mobilization-multiple-myeloma2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-guggenheim-biotech-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-investor-conferences-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-2026-shareholder-letter2026-02-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-year-end-report-20252026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-2a-ind-amendment-ttx-mc1382026-02-05T13:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-guggenheim-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-fourth-quarter-full-year-2025-results-call2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-fourth-quarter-2025-results2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-fourth-quarter-2025-financial-results2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-addresses-market-rumor-no-crypto-assets2026-02-05T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-endoxifen-duchenne-muscular-dystrophy2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-fireside-chat-guggenheim-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-fourth-quarter-2025-earnings-call2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-announces-475-million-offering-nasdaq-iinn2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-2-million-offering2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-guggenheim-biotech-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-appoints-richard-kyle-board2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-guggenheim-biotech-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-mark-voll-cfo2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/pro-familia-profound-medical-sonalleve-procedures2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-guggenheim-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-oppenheimer-conference-20262026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-launches-neurocare-ai-virtual-clinic2026-02-05T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-announces-q4-2025-results2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-oncology-conference-20262026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-investor-conferences-february-20262026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovarian-cancer-study-update2026-02-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/uwe-heartsciences-ecg-education-center2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-canadian-patent-cachexia-treatment2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-guggenheim-biotech-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-present-upcoming-conferences-february-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-guggenheim-summit-20262026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q4-2025-financial-results-conference-call2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-extends-access-program-zervimesine2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-liver-transplant-success2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-participate-guggenheim-biotech-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-fourth-quarter-2025-financial-results2026-02-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-inducement-grants-nasdaq-rule-56352026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-report-financial-results-february-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-guggenheim-biotech-summit-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-participate-february-investor-conferences2026-02-05T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-investor-conferences-20262026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-positive-year-end-interim-clinical-progress2026-02-05T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-health-canada-authorization-livmarli-tablet2026-02-05T13:51:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-health-canada-authorization-livmarli-pfic2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-launches-discovery-platforms-slas20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-q4-2025-earnings-release-webcast2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q4-2025-results-conference-call2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-pert-consortium-research-fund-pulmonary-embolism2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-participate-investor-conferences2026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-launches-omnipod-5-middle-east2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-reports-fourth-quarter-full-year-2025-results2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q4-full-year-2025-results2026-02-05T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-soundhealth-collaboration2026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INNV/innovage-senior-care-capitol-advocacy2026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-proenzyme-therapy-pancreatic-cancer2026-02-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-board-appointments-20262026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fiscal-q2-2026-revenue-growth2026-02-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q4-2025-results-conference-call2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/locket-suture-retention-device-scripps-conference-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-reverse-stock-split-february-20262026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-announces-private-placement-funding2026-02-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-guggenheim-summit-20262026-02-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-bitgo-collaboration-solana-strategy2026-02-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-epigenetic-modulation-cancer-aging2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-health-canada-approval-enflonsia-rsv-prevention2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-q3-fiscal-2026-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-participate-webinar-webull-financial2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-supports-mikaela-naylon-act-reauthorization2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-webinar-participation-webull-financial2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-webinar-participation2026-02-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/fda-accelerates-oncolytics-biotech-cancer-treatment2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMCL/omnicell-fy-2025-financial-results2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-q4-2025-earnings-date-revenue-growth2026-02-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-financial-results-q4-fy-20252026-02-05T21:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-launches-cost-savings-program-trumprx2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-cardiac-catheter-study2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-reports-fourth-quarter-annual-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-ipo-pricing-announcement2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-announces-pricing-initial-public-offering2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-fiscal-2026-first-quarter-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/tralesinidase-alfa-potential-treatment-sanfilippo-syndrome2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-quarterly-preferred-stock-dividend2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-ipo-closing-additional-shares2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ind-clearance-btk-degrader-apg-32882026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/amtagvi-real-world-data-advanced-melanoma2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COEP/coeptis-shareholder-approval-z-squared-merger2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-report-fourth-quarter-full-year-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-investor-conferences-february-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-investor-conferences-march-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q4-full-year-20252026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-guggenheim-biotech-summit-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q4-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-full-year-2025-results2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-launches-eden-study-preeclampsia-risk-assessment2026-02-06T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-inducement-grants-nasdaq-rule-5635c42026-02-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-actrims-20262026-02-06T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-guggenheim-summit-20262026-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-positive-phase-2-brepocitinib-cutanous-sarcoidosis2026-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/priovant-positive-phase-2-results-brepocitinib-cs2026-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-clearmind-intranasal-formulation-development2026-02-06T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-corporate-updates-financial-results-q3-20252026-02-06T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-tacti-004-phase-iii-trial-enrolment2026-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-development-agreement-intranasal-meai2026-02-06T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/fda-priority-review-hympavzi-hemophilia-treatment2026-02-06T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-presents-guggenheim-biotech-summit2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-guggenheim-biotech-summit-20262026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ablation-catheters-afib-symposium-20262026-02-06T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-piper-sandler-symposium-20262026-02-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-pricing-public-offering2026-02-06T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-webinar-participation-february-20262026-02-06T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANEB/anebulo-pharmaceuticals-voluntary-delist-nasdaq2026-02-06T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q4-2025-financial-results2026-02-06T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/fda-approves-yescarta-label-update-pcnsl2026-02-06T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-eventhorizoniq-launch2026-02-06T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-milestone-2-system-integration-marketplace-activation2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISPC/ispecimen-rapid-procurement-influenza-research2026-02-06T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-special-meeting-adjournment-reconvened-meeting2026-02-06T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biologics-license-application-lecanemab-china-priority-review2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-closes-94-million-offering-private-placement2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-inducement-grants-nasdaq-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-inducement-awards-february-20262026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-inducement-grant-nasdaq-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-nasdaq-listing-rule-56352026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/pendopharm-yorvipath-approval-hypoparathyroidism2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q4-2025-financial-results-call2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-q4-2025-financial-results2026-02-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-first-quarter-fiscal-2026-results2026-02-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-inhale-1st-study-afrezza-pediatric-diabetes2026-02-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-fourth-quarter-2025-results-call2026-02-09T11:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-rita-johnson-greene-cfo2026-02-09T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-canadian-patent-namodenoson-obesity-therapy2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-upcoming-conferences-20262026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-adam-rogers-ceo-appointment2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NOTV/inotiv-q1-fy-2026-financial-results-update2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-appoints-scientific-advisory-board2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-trial-update2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-completes-enrollment-4front-1-phase-3-trial2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-secures-vendor-approval-clalit-health-services2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-fda-ide-approval-ocs-heart-trial2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-presents-upcoming-investor-conferences2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-launch-ychant-japan-molluscum-contagiosum2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/klinikum-fuerth-robotic-heart-arrhythmia-program2026-02-09T13:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-fda-feedback-sgt-003-duchenne2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-board-composition-changes-20262026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-inducement-grants-nasdaq-rule-56352026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-rmat-designation-kb707-nsclc2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-promotes-kate-rochlin-president-coo2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-dod-funding-bioengineered-blood-vessels2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-quellimmune-therapy-pediatric-akd2026-02-09T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-appoints-geno-germano-chairman-board2026-02-09T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-communications-grant-recipients-20262026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-investor-conferences-20262026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-positive-safety-results-cmnd-1002026-02-09T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-participate-immuno-oncology-360-conference2026-02-09T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-fiscal-2026-q1-results-update2026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-guggenheim-biotech-summit-20262026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-appoints-michael-stansky-board-directors2026-02-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-sponsors-nad-health-conference2026-02-09T13:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-launches-readyfix-fleet-management-solution2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-appoints-experts-advisory-board2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-presentation-td-cowen-oppenheimer-conferences2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-phase-3-trial-vdphl01-hair-loss2026-02-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-eb103-presentation-tandem-meetings2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/chemspeed-sciy-self-driving-laboratory-platform2026-02-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-positive-results-phase-3-ameluz-pdt2026-02-09T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-advances-in-ogm2026-02-09T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-piper-sandler-symposium-20262026-02-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMDA/omada-health-q4-2025-results-conference-call2026-02-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-advances-onp-002-concussion-therapy2026-02-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-appoints-christopher-miglino-ceo2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-phase-2-moonstone-trial-results2026-02-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-acquire-orna-therapeutics-cell-therapies2026-02-09T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-expands-global-ip-protection-australian-patent2026-02-09T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-completes-combination-bd-biosciences-diagnostic-solutions2026-02-09T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-biosciences-diagnostic-solutions-spin-off2026-02-09T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-acquisition-generation-bio2026-02-09T14:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-phase-3-sigma-trial-safusidenib2026-02-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-completes-combination-bd-biosciences-diagnostics2026-02-09T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-planned-departure-cfo-key-milestones2026-02-09T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-conference-call-rezolve-ad-results2026-02-09T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-regulatory-update-rgx-121-mps-ii2026-02-09T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-nyse-american-non-compliance-notice2026-02-09T22:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-full-year-2025-growth-acceleration2026-02-10T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-reappoints-ceo-roy-jakobs2026-02-10T05:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-board-appointment2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-mako-handheld-robotics-release2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-closes-acquisition-generation-bio2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-eb103-tandem-meetings-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-fda-accepts-oveporexton-narcolepsy-nt12026-02-10T08:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-extensions-fda-niehs-collaborations2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-conference-call-february-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-closes-public-offering-usd57-2-million2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMTM/amentum-reports-q1-fy2026-results-guidance2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-barclays-healthcare-conference-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/medpace-holdings-reports-q4-full-year-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-conference-call-q4-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-fiscal-q1-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-investor-meetings-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-guggenheim-summit-participation2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-frontier-space-partnership-life-sciences-research2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q4-2025-results-investor-conferences2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-closes-initial-public-offering2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-ipo-closing2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-fourth-quarter-2025-earnings-call2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-fourth-quarter-2025-financial-results-earnings-call2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-new-data-aacr-io-biomarkers-bot-bal2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-launches-unity-fetal-antigen-nipts2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-appoints-dr-ben-porter-brown-cmo2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-expanding-immunology-portfolio-aaaaai-20262026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-conference-call-fy2025-results2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-report-fourth-quarter-full-year-2025-results2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-biotoos-q4-2025-results-announcement2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-announces-110-million-offering2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-clinical-data-aaaaai-20262026-02-10T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-oveporexton-fda-priority-review-narcolepsy2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-google-cloud-ai-agents-chemistry2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-mbl-distributor-nuq-discover-japan2026-02-10T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patent-reqorsa-gene-therapy-cancer2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-gdnf-results-semaglutide-comparison2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezolve-ad-maintenance-data-rezpegaldesleukin2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-hba1c-analyser-ifcc-gold-classification2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-showcase-neffy-aaaaai-20262026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-phase-1-sep-631-aaaa-meeting-20262026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-establishes-renovocath-medical-advisory-board2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-report-fourth-quarter-full-year-2025-results2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-launch-orquick-hiv-self-test-canada2026-02-10T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-appoints-flavio-mantelli-cmo2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-appoints-david-sandoval2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-fda-clearance-teverelix-phase-2b-study2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-vincent-capone-ceo-appointment2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-fourth-quarter-2025-results2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-record-financial-results-20252026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-cordstrom-uk-marketing-authorization2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q4-2025-results-outlook-20262026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-ceo-pete-oheeron-hspan-summit-20262026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-portfolio-update-rain-token-kraken2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-transition-securities-exchange-act2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-report-fourth-quarter-full-year-2025-results2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-summit-posters-2026-aaaai2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-completes-patient-enrollment-bRTX-1002026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-fda-submission-amended-trial-protocol2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-presents-glioblastoma-summit-20262026-02-10T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-fourth-quarter-full-year-2025-results2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q4-2025-financial-results2026-02-10T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-govramp-tx-ramp-certifications2026-02-10T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-webinar-als-drug-development2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-library-preparation-kits2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-report-q4-2025-results2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-duke-collaboration-obesity-research2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-q4-2025-financial-results-announcement2026-02-10T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-phase-2a-evo301-atopic-dermatitis-results2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-edp-978-presentation-2026-aaaai2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-participate-upcoming-investor-conferences2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-fourth-quarter-full-year-2025-results2026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-participate-guggenheim-biotech-summit-20262026-02-10T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-fda-pre-submission-helix-catheter2026-02-10T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-achieves-second-who-inn-milestone2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-aprevo-lumbar-fusion-procedure2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WW/weight-watchers-pvolve-partnership-strength-workouts2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDXS/codexis-achieves-iso-9001-certification2026-02-10T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-preclinical-data-soteria-trial2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELU/celularity-receives-12-2-million-new-jersey-nols2026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-chairmans-letter-20262026-02-10T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-michael-cola-ceo2026-02-10T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-fourth-quarter-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-financial-results-march-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-fourth-quarter-2025-financial-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-duke-collaboration-clinical-research-obesity2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOYG/starlab-auxilium-biotechnologies-microgravity-research2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVMN/evommune-evo301-phase-2a-results-atopic-dermatitis2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-edp-978-aaaai-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ON/astrazeneca-results-fy-q4-20252026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-reports-q4-full-year-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-participate-guggenheim-securities-biotech-summit-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-regains-nasdaq-compliance2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q4-2025-financial-results-guidance-20262026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COO/coopervision-launches-misight-1-day-japan2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-long-term-agreement-mexico2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-fourth-quarter-full-year-2025-results2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-dividend-increase-share-repurchase-authorization2026-02-10T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-warrant-inducement-transaction-3-4-million2026-02-10T18:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-tender-offers-debt-securities2026-02-10T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-fourth-quarter-full-year-2025-results2026-02-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q4-2025-financial-results2026-02-10T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-proposed-public-offering2026-02-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-report-financial-results-february-20262026-02-10T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-february-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-private-placement-15-million2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-pricing-public-offering-275-million2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-fourth-quarter-fiscal-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-increases-dividend-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-webcast-phase-2-valiant-trial-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-refusal-to-file-fda-mrna-10102026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-vitesse-phase-3-study-presentation2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-preliminary-financial-results-q4-20252026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-q3-2026-financial-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-public-offering-common-preferred-stock2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBLL/ceribell-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-european-summit-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-report-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-inducement-grant-nasdaq-rule-56352026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-regulatory-approval-upstream-manufacturing2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-presentation-glioblastoma-summit-20262026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-q4-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/boston-life-sciences-job-openings2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-expands-mash-pipeline-licensing-agreement2026-02-11T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/seismic-consortium-secures-ih-grant-minimally-invasive-brain-treatments2026-02-11T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-2025-accomplishments-2026-outlook2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q4-2025-financial-results-earnings-call2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-leadership-changes-20262026-02-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-shero-imaging-breast-cancer-cryoablation-missouri2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-expands-lymphir-distribution-europe2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-fourth-quarter-2025-results2026-02-11T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-q1-results-clinical-progress2026-02-11T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-valiant-trial-results2026-02-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-strategic-plan-dual-targeting-car-t-assets2026-02-11T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-phase-1-trial-senti-202-aml2026-02-11T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-q4-2025-results-call2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q4-2025-results2026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-meeting-request-crl-response2026-02-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-2025-financial-results2026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/fda-refuses-review-moderna-mrna-flu-vaccine2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-investor-conferences-20262026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdex-announces-26-million-registered-direct-offering2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-proactive-disciplined-deals-ma-not-urgent2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-announces-fourth-quarter-2025-financial-results2026-02-11T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GELS/gelteq-healthy-extracts-partnership-gel-nutrition2026-02-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-board-members-stock-purchases2026-02-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/telehealth-available-dare-to-play-sildenafil-cream2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-glioblastoma-summit-20262026-02-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-positive-fda-outcome-btx-1002026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-filing-ameluz-sbcc2026-02-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-new-hae-data-aaai-20262026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-fourth-quarter-full-year-2025-results-conference-call2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-expands-adc-pipeline2026-02-11T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-20262026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/astrazeneca-awards-3-4-million-healthcare-access2026-02-11T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q4-2025-results-announcement2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-first-patient-dosed-stk-002-phase-12026-02-11T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-fourth-quarter-2025-financial-results-webcast2026-02-11T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-fda-clearance-pbgene-dmd2026-02-11T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q4-2025-results-webcast2026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-orphan-drug-status-vt-19532026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-approval-ovarian-cancer-treatment2026-02-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-pharmdx-eoc2026-02-11T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-fourth-quarter-full-year-2025-results2026-02-11T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-settlement-shareholder-litigation2026-02-11T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-patent-issuance-invocell-device2026-02-11T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-novel-serotonergic-agonists-20262026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-names-michael-cola-ceo-growth2026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-ceo-and-advances-clinical-trials2026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-ceo-appointment-michael-cola2026-02-11T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-antibody-drug-conjugate-data-sot-meeting2026-02-11T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-redeems-preferred-stock-cancels-shares2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-heartways-program-chap-certification2026-02-11T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-unite2fight-paralysis-symposium-20262026-02-11T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-upsized-public-offering-78-million2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-boehringer-ingelheim-impact-award2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-21-million-private-placement2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-launches-fda-cleared-blood-test-alzheimers2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-reports-fourth-quarter-full-year-2025-results2026-02-11T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-transition-atm-equity-offering-leerink-partners2026-02-11T15:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/biopharma-job-market-layoff-decline-20262026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-fourth-quarter-2025-earnings-announcement2026-02-11T14:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-increases-share-capital2026-02-11T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-flu-vaccine-rejection-fda2026-02-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-q3-fy2026-results2026-02-11T18:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q4-2025-financial-results2026-02-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q4-2025-financial-results2026-02-11T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-upsized-public-offering2026-02-12T03:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-q4-2025-financial-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q4-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bridgebio-oncology-inducement-grants-nasdaq-rule-56352026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-3-phase-3-trial-vax-312026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-investor-conference-presentations-february-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q4-2025-results-update2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-q3-2026-financial-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/astrazeneca-health-equity-funding-20232026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-announces-pricing-public-offering2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-underwritten-offering-pricing2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/fda-approves-novocure-optune-pax-pancreatic-cancer2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-lokahi-fda-type-c-meeting-lt-100-apitox2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-inducement-awards-february-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-investor-conferences-march-april-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-conference-call-fy-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-fourth-quarter-year-end-results-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/high-survival-rates-ryoncil-eind-program-sr-agvhd2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-board-chair-transition-freire-dorsa2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q4-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/quidelortho-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-virtual-kol-event-tx2100-hht2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-fourth-quarter-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-fourth-quarter-full-year-2025-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANL/adlai-nortye-phase-1-trial-an90252026-02-12T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/divitum-tka-prognostic-associations-breast-cancer2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fourth-quarter-2025-earnings-call2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-oppenheimer-conference-20262026-02-12T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-q4-2025-results2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-signs-supply-agreement-qkine2026-02-12T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-appoints-michele-holcomb-board-directors2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-us-notice-allowance-exon-skipping-therapy2026-02-12T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-uplizna-approval-generalized-myasthenia-gravis2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-grant-inducement-awards-nasdaq-listing-rules2026-02-12T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-joins-ihope-initiative-genomic-sequencing2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-q4-full-year-2025-results2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-redtail-platform-aacr-io-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-scientific-investor-conferences2026-02-12T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-progress-upcoming-milestones-20262026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-fourth-quarter-full-year-2025-results2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-appoints-chris-chapman-cco2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-investor-conferences-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-q4-2025-financial-results-release2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-mount-logan-award-tulsa-procedure2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-nopain-act-survey-data2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-acquires-realbotix-ai-humanoid-robotics2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/hhs-backs-prasad-moderna-flu-shot-blowback2026-02-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-corporate-updates-inflammatory-immune-diseases2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-endovascular-robotic-system-iest2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-phase-3-car-t-cell-trial-lyl3142026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-report-fourth-quarter-full-year-2025-results2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-fda-alignment-phase-2b-3-xpro1595-alzheimers2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-third-quarter-2026-update2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-appoints-david-horn-board-directors2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q4-2025-financial-results-call2026-02-12T14:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/digital-pathology-ai-her2-cancer-treatment2026-02-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-appoints-lucinda-warren-cfbo2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-2025-earnings-conference-call2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-oppenheimer-conference-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-report-q4-full-year-2025-results2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-igalmi-market-assessment2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-q2-2026-results-update2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-abstracts-accepted-american-college-psychiatrists2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-positive-phase-3-results-infigratinib-achondroplasia2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-appoints-randy-teel-ceo2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-global-patent-portfolio-expansion2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-dsmb-approval-phase-3-trial-buntanetap-alzheimers2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-virtual-investor-closing-bell-event2026-02-12T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-reports-fourth-quarter-full-year-2025-results2026-02-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-new-subsidiary-ardia2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-leadership-appointments2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-fourth-quarter-full-year-2025-results2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-earnings-call-february-20262026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q4-2025-results2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-acquires-avadel-pharmaceuticals-sleep-medicine2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-reports-fourth-quarter-results-20252026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-management-investor-conferences2026-02-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-reports-fourth-quarter-2025-results2026-02-12T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-allohome-ai-powered-ngs-surveillance-aml-mds2026-02-12T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-reports-fourth-quarter-full-year-2025-results2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-data-2026-aaai-meeting2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-reports-fourth-quarter-full-year-2025-results2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-advances-bladder-kidney-cancers-asco-20262026-02-12T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-great-place-to-work-fourth-year2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-record-bookings-2025-subscription-transition2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-inkspace-imaging-snuggle-pediatric-mri-coil2026-02-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-successful-heart-transplant-ucsf2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-phase-ii-trial-results-mcs-82026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-reports-record-revenue-growth2026-02-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HTFL/heartflow-expands-gamefilm-registry-nba-nhl-alumni2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-q4-2025-financial-results-report2026-02-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/catheter-precision-secures-financing-accelerate-growth2026-02-12T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-expands-uk-pharmaceutical-access-smartway-agreement2026-02-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-report-q4-full-year-2025-results2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-fourth-quarter-full-year-2025-results2026-02-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-announces-q4-2025-financial-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNVC/mpox-orphan-drug-designation-nv-387-nanoviricides2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-patent-sublingual-ondansetron2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-pantracer-pro-solid-tumor-therapy2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICLR/icon-plc-update-2025-earnings-investigation2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INM/inmed-reports-q2-fiscal-2026-results2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-fourth-quarter-2025-earnings-call2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-reports-q4-full-year-results-20252026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-investor-conferences-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-presentation-2026-aaai-meeting2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-allohome-ai-ngs-surveillance-aml-mds2026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-advances-bladder-kidney-cancer-treatment-asco-gu-20262026-02-12T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-flu-vaccine-rejection-breakeven-plans2026-02-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-withdraws-translarna-nda2026-02-12T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-fourth-quarter-full-year-2025-results2026-02-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-uplizna-approval-myasthenia-gravis2026-02-12T20:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-closes-private-offering-senior-notes2026-02-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-fiscal-q3-2026-results-update2026-02-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-present-march-2026-investor-conferences2026-02-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-fda-clearance-stealth-axis-surgical-system2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/ollie-bearman-joins-prenetics-im8-health2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-private-placement-commercial-stage2026-02-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-reports-first-revenue-from-lymphir2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-td-cowen-health-care-conference-20262026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-q3-2026-results-corporate-update2026-02-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-investor-conferences-20262026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-kidney-franchise-journavx-sales2026-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-private-placement-funding2026-02-13T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-wy-biotech-trimmune-financing2026-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fourth-quarter-full-year-2025-results2026-02-13T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-chi-mei-feasibility-study-apercus2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-inducement-grants-nasdaq-rule-56352026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-launches-ceo-corner-platform2026-02-13T13:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-mayo-clinic-oxygen-monitoring-collaboration2026-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-expands-puerto-rico-water-filtration-solutions2026-02-13T13:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-closes-15-million-private-placement2026-02-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-q3-2026-financial-results2026-02-13T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-new-board-member-phillip-balatsos2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/breztri-phase-iii-trials-asthma-results2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXT/sensient-technologies-q4-2025-results2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-fourth-quarter-fiscal-year-2025-results2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/alk-annual-report-presentation-20252026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reverse-stock-split2026-02-13T13:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-fourth-quarter-fiscal-year-2025-results2026-02-13T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-global-patent-protection-da-17262026-02-13T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-board-of-directors-updates2026-02-13T14:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-uplizna-amgen-gmg-treatment2026-02-13T14:34:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-investor-webinar-20262026-02-13T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-q2-fiscal-year-2026-conference-call2026-02-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-first-digital-asset-treasury-borrowing2026-02-13T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-phase-2-study-alto-101-enrollment-completed2026-02-13T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-citi-2026-oncology-summit2026-02-13T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-uplizna-approval-europe-generalized-mg2026-02-13T19:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-closes-460-million-offering2026-02-13T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-ella-platform-ce-ivd-marking2026-02-16T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-retevmo-event-free-survival-lung-cancer2026-02-16T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-discuss-2025-results-march-20262026-02-16T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-mrna-flu-shot-efficacy-wait2026-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-phase-3-trials-data-release2026-02-16T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-participate-td-cowen-health-care-conference2026-02-16T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-q4-2025-financial-results2026-02-16T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-oppenheimer-conference-20262026-02-17T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-appoints-katie-kazem-chief-legal-officer2026-02-17T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-preliminary-2025-fiscal-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-full-year-2025-results-guidance-march-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-janx0112026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-bispecific-antibody-licensing-agreement2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-financial-results-q4-20252026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-participate-investor-conferences2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/fda-accepts-iberdomide-application-bmy2026-02-17T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-braftovi-regimen-improves-survival-colorectal-cancer2026-02-17T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-comp360-phase-3-trial-success2026-02-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-fourth-quarter-2025-earnings-call2026-02-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-regulatory-engagement-saudia-arabia2026-02-17T11:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-fireside-chat-leerink-conference2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-investor-conferences2026-02-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-expands-global-ip-estate2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-q1-2026-results-update2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-report-q4-2025-results2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-nasal-epinephrine-powder-aaai-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-oppenheimer-conference-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-pociredir-sickle-cell-trial-data2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-oppenheimer-conference-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CING/cingulate-closes-12-million-private-placement2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q4-2025-financial-results-update2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-preclinical-data-cue-4012026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-upcoming-investor-conferences2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q4-2025-results-call2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-kol-event-vonaprument-geographic-atrophy2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-2025-financial-results2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-sale-insighta-tencent-70-million2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-fourth-quarter-full-year-2025-results-call2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-rewalk-exoskeleton-aetna-coverage-expansion2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/vtak-acquires-strategic-stake-flyte2026-02-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-private-placement-strategic-update2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/briumvi-long-term-efficacy-relapsing-ms2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-spl026-phase-2a-trial-results2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-fourth-quarter-full-year-2025-results2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-european-commission-approval-myorzo2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-centurion-one-capital-conference-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/brainsway-change-ads-ratio2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-fourth-quarter-2025-earnings-release2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-launches-spinach-pufferz-vape2026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-td-cowen-conference-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-oppenheimer-conference-20262026-02-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-proliant-launch-recombinant-human-albumin2026-02-17T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVL/corvel-great-place-to-work-certification-20262026-02-17T12:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-dcat-week-20262026-02-17T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-oppenheimer-conference-20262026-02-17T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-obesity-breakthrough2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-positive-results-sol-1-trial2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/ataibeckley-participate-investor-conferences-march-20262026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-elevate-44-201-study-dose-escalation2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-path-new-drug-application-nrx-1002026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-cyc-126-phase-2-study-update2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-launches-pharmapack-kits2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-settles-sunosi-patent-litigation2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-fourth-quarter-full-year-2025-results-webcast2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-present-upcoming-investor-conference2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q4-2025-results2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-expands-executive-team-appointments2026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-participate-investor-conferences-20262026-02-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-symon-ii-study-enrollment-20262026-02-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-fourth-quarter-2025-financial-results-call2026-02-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q4-2025-results-business-update2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/duvakitug-phase-2b-maintenance-results-uc-cd2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-barda-expansion-ai-ultrasound2026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fourth-quarter-full-year-results-20252026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-successful-primate-study-oncotox-aml2026-02-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-investor-call-february-20262026-02-17T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-hiv-treatment-prevention-data-croi-20262026-02-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-td-cowen-conference-20262026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-fda-approval-wakix-pediatric-narcolepsy2026-02-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALC/alcon-launches-total30-multifocal-toric-lens2026-02-17T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASI/masimo-acquired-by-danaher-for-180-per-share2026-02-17T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-fourth-quarter-full-year-2025-results2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/clinical-utility-bioaffinity-technologies-cypath-lung-test2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/viiv-healthcare-hiv-innovation-croi-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVTY/revvity-investor-conferences-20262026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-positive-data-rlyb116-phase-1-study2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/scribe-therapeutics-lilly-collaboration-milestone2026-02-17T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-participate-investor-conferences-20262026-02-17T14:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-phase-1-database-lock-ameluz2026-02-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-shareholder-meeting-results2026-02-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRI/gri-bio-ceo-marc-hertz-virtual-investor-segment2026-02-17T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-oppenheimer-conference-20262026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-brian-piper-appointment-cfo2026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDXS/codexis-td-cowen-health-care-conference-20262026-02-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-fiscal-2026-q2-results2026-02-17T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-appoints-bram-verstockt-clinical-advisory-board2026-02-17T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-public-offering-pricing2026-02-17T13:44:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-japanese-patent-annamycin2026-02-17T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-selects-cro-soteria-phase-2-trial2026-02-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-key-executive-appointments2026-02-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/strata-skin-sciences-308-nm-excimer-laser-psoriasis2026-02-17T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-arc-ecr-2026-showcase-ai-capabilities2026-02-17T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-acquire-masimo-corporation2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approves-rybrevant-faspro-monthly-dosing2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-next-gen-microflow-lc-columns2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-td-cowen-conference-20262026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sublingual-meclizine-patent2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-secures-composition-protection-igc-ad12026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-investor-conferences-march-20262026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-dr-robert-redfield-advisor2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-q4-full-year-2025-financial-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-tumor-cell-mortality-tnbc2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-appoints-key-executives-strategic-transformation2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-q2-fy2026-results-corporate-update2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-participation-investor-conferences-20262026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-q3-fiscal-2026-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-2025-fourth-quarter-results2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-ucsf-collaboration-nktr-0165-ms2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-eu-authorization-mnexspike-vaccine2026-02-17T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-leerink-partners-conference-20262026-02-18T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-follow-on-offering-pricing2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-fourth-quarter-2025-call2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-150-million-public-offering2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-fourth-quarter-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-oppenheimer-conference-participation2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/fda-expands-evo-icl-age-indication2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-td-cowen-healthcare-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q4-fy2025-results-update2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-fourth-quarter-financial-results-20252026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-participate-td-cowen-health-care-conference2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-inducement-grants-nasdaq-listing-rule-56352026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-report-fourth-quarter-full-year-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-financial-results-webcast-time-change2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-presents-td-cowen-health-care-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-submits-european-marketing-authorization-tlx101-px2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-share-repurchase-program2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-financial-results-business-update-march-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-closing-private-placement-financing2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-first-patient-phase-2-givastomig-gastric-cancer2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-investor-conferences-february-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-leerink-2026-conference2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-q4-2025-financial-results-guidance-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-investor-day-march-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-public-offering-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-buy-back-program-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-phase-1a-results-zp98302026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DSGN/design-therapeutics-investor-conferences-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-presentation-leerink-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-licenses-syn-020-rasayana-therapeutics2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-citizens-life-sciences-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-appoints-sidney-braun-ceo-liora2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-inducement-grants-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-investor-conferences-20262026-02-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-ascend-phase-1-2-trial-cr-0012026-02-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-participation-barclays-global-healthcare-conference2026-02-18T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-carlsberg-exclusive-brewing-partnership2026-02-18T12:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-conference-call-march-20262026-02-18T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-2025-financial-results-update2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-citi-2026-oncology-summit2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-oppenheimer-conference-20262026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-report-fourth-quarter-2025-results2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-appoints-dr-greenhawt-cmo2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-q4-2025-results-investor-conferences2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADVB/advanced-biomed-announces-reverse-stock-split2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-report-fourth-quarter-year-end-2025-results2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-appoints-michael-campbell-cco2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-fourth-quarter-2025-financial-results-call2026-02-18T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-experts-als-platform2026-02-18T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-participate-march-2026-investor-conferences2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-oppenheimer-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-executive-appointments2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pbgene-dmd-presentation-mda-conference2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-virtual-kol-event-sat-3247-dmd2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-reports-fourth-quarter-full-year-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q4-2025-results-guidance-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-positive-fda-meetings-ta-ert-sanfilippo2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-ekterly-first-line-therapy-pediatric-hae2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-mayo-clinic-ai-drug-discovery-collaboration2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NPO/enpro-reports-fourth-quarter-full-year-2025-results2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-fda-review-influenza-vaccine2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVM/celsci-fiscal-first-quarter-2026-results2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/vyome-positive-preclinical-results-uveitis2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-authorization-europe-bladder-cancer2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-q4-2025-financial-results2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-financial-services-launch2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-us-patent-zunveyl-dosing-regimens2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-acquires-faeth-therapeutics2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/gsk-arexvy-rsv-risk-reduction-study2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-investor-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-td-cowen-health-care-conference2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TWST/twist-bioscience-investor-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-raymond-james-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-q4-fy-2025-results-im8-revenue-growth2026-02-18T14:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-biocom-conference-20262026-02-18T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-fourth-quarter-full-year-2025-results2026-02-18T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-corporate-update-half-year-results2026-02-18T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-20252026-02-18T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-pharmaceuticals-appoints-david-pyott-board2026-02-18T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SILO/silo-pharma-notice-allowance-japan-spc-152026-02-18T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-miracle-trial-preliminary-results2026-02-18T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/vietnam-approves-biomericas-ez-detect-nationwide-distribution2026-02-18T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSKN/johns-hopkins-dermatology-xtrac-laser2026-02-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-phase-2-trial-sclc2026-02-18T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/pluri-china-patent-immune-cell-expansion2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-great-place-to-work-certification-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-oppenheimer-conference-20262026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-investor-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-apr-1051-clinical-activity-update2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-ecco-congress-spy003-presentations2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-participate-upcoming-conferences2026-02-18T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAGX/jaguar-health-special-stock-dividend2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-barda-discussions-entolimod-march-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-inducement-grants-nasdaq-rule-56352026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q4-2025-results-call2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-patent-expansion2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-oppenheimer-conference-20262026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KLTO/klotho-neurosciences-patent-claims-australia2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-fda-breakthrough-designation-head-neck-cancer2026-02-18T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluo-guide-webcast-february-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-phase-ii-beam-x-trial-bexmarilimab-aml2026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-q4-fy2025-results-march-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-financial-results-20252026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-2025-revenue-outlook-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-licenses-phase-1-drug-candidate-otsuka-gist2026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-upcoming-conferences-march-20262026-02-19T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-fy-2025-results2026-02-20T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-venclexta-acalabrutinib-combination-cll2026-02-20T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-prefunded-warrants-exercised2026-02-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-leerink-partners-conference-20262026-02-20T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/henriette-mersebach-steps-down-alk-rd2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-public-offering-pricing2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-participate-oppenheimer-td-cowen-conferences2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-announces-reverse-share-split2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-redtail-platform-bites-aacr-io-20262026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/high-dose-inhaled-nitric-oxide-antimicrobial-therapy2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-phase-3-versatile-003-trial-amendment2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-financial-results-webcast-20262026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-pedmark-head-neck-cancers2026-02-20T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-data-2026-aaaai2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-fourth-quarter-full-year-2025-results2026-02-20T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-td-cowen-health-care-conference2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-launches-anktiva-saudi-arabia2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-pricing-public-offering2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-td-cowen-conference-20262026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-presentation-td-cowen-conference2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/calquence-venetoclax-approval-chronic-lymphocytic-leukemia2026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-cell-gene-live-event-20262026-02-20T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-virtual-investor-webinar-february-20262026-02-20T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-acquires-strategic-stake-in-sarborg2026-02-20T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-nyse-warning-letter2026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-investor-conferences-20262026-02-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-virtual-investor-day-march-20262026-02-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-compliance-nasdaq-requirements2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fourth-quarter-earnings-conference-call2026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-transactions-managerial-employees2026-02-20T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-virtual-investor-closing-bell2026-02-20T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-opendoor-ownership-increase2026-02-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences-february-20262026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALK/annual-general-meeting-alk-abello-20262026-02-20T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-409th-consecutive-quarterly-dividend2026-02-20T16:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-fda-approval-bysanti-milsaperidone2026-02-20T22:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABVX/abivax-obefazimod-ecco-20262026-02-21T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-ulcerative-colitis-long-term-data2026-02-21T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/sickle-cell-gene-therapies-casgevy-lyfgenia-traction2026-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presentation-td-cowen-healthcare-conference2026-02-23T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-arcellx-anito-cel-potential2026-02-23T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-biocidal-product-approvals2026-02-23T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-bexmarilimab-poster-presentation-bsh-20262026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-dr-theodora-ross-cdo2026-02-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-amended-healthcare-royalty-agreement2026-02-23T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-appoints-ryan-maynard-cfo2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-patents-reqorsa-gene-therapy-cancer2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-fda-qidp-designation-ap-sa022026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-testing-capabilities-diagnostic-accuracy2026-02-23T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-participate-upcoming-investor-conferences2026-02-23T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quantum-leap-energy-necsa-collaboration2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-launches-bioflex-3d-bioprinting-kit2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-board-directors-election2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-emerging-growth-conference-20262026-02-23T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-participate-46th-annual-td-cowen-health-care-conference2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-td-cowen-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-q4-2025-financial-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q4-2025-results2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-conference-call-webcast-2025-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-participation-march-investor-conferences2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-investor-conferences-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-investor-conferences-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-2025-financial-results-announcement2026-02-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-oppenheimer-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-oppenheimer-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-investor-conferences-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-sol-1-data-macula-society-meeting2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-march-investor-conferences2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-investor-conferences-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-fda-clearance-ind-phase-2-dare-hpv2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-presentations-aaaai-20262026-02-23T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-td-cowen-health-care-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-participate-march-conferences2026-02-23T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-2-momentum-trial-cemsidomide2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-bb-301-abstract-acceptance2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-financial-results-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-investor-webinar-march-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-march-investor-conferences2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q4-2025-results-update2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-appoints-dr-paeger-board-directors2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-presents-at-healthcare-investor-conferences2026-02-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-participate-upcoming-investor-conferences2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-oppenheimer-conference-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-td-cowen-conference-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-american-heart-month-prioritize-therapies-cvd2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-croi-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-seralutinib-phase-3-prosera-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-business-update2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-licenses-miudella-hormone-free-iud2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-refinance-senior-secured-debt2026-02-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-agbt-2026-spatial-biology-advancements2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-td-cowen-conference-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-700-percent-revenue-growth-anktiva2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-investor-conferences-20262026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-advances-functional-proteomics-timsomni-mass-spectrometry2026-02-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-2-luspatercept-results2026-02-23T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-evolves-human-health-structure2026-02-23T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-appoints-dr-eisner-dr-nirula-board2026-02-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-oppenheimer-conference-20262026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-compuflo-advisor-program-launch2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-participation-world-adc-summit2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-nasdaq-extension-compliance2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYOJ/ryojbaba-participation-guardian-girls-aikido-project2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGLC/bionexus-gene-lab-governance-restructuring2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-acceptance-dtx401-gsdia2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-sells-prv-205-million2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-investor-conferences-20262026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-fda-policy-reduction-trial-burden2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-investor-conferences-20262026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-congressional-support-deep-brain-neurostimulation2026-02-23T13:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-leerink-partners-conference-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/syncardia-total-artificial-heart-training-houston2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-fourth-quarter-2025-financial-results2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-present-march-investor-conferences2026-02-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-adjourn-special-meeting-stockholders2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-preclinical-testing-rig-i-immunotherapy2026-02-23T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-investor-conferences-20262026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/zepbound-tirzepatide-multi-dose-kwikpen-available2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-dr-conejo-garcia-keynote-sctr-retreat2026-02-23T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-novaseq-x-advancements-data-quality-output2026-02-23T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-launches-im8-daily-ultimate-essentials-pro2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-highres-lightning-talk-nvidia-gtc2026-02-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ice-secret-trial-results2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-pali-2108-ecco-20262026-02-23T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-amends-financing-agreement2026-02-23T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-webinar-xpro1595-alzheimers-strategy2026-02-23T14:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-arcellx-car-t-therapy2026-02-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-prv-sale2026-02-23T14:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-investor-conferences-march-20262026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-investor-conferences-20262026-02-23T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-olga-anczukow-sab2026-02-23T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-2-trial-ampligen-durvalumab2026-02-23T13:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-td-cowen-health-care-conference2026-02-23T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-webcast-healthcare-conference-20262026-02-23T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-fda-approval-smart-capsule2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-investor-conferences2026-02-23T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reimbursement-milestone-ama-cpt-code2026-02-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YMAT/j-star-exclusive-distribution-agreement-pssb2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-pacific-backbone-infrastructure2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-ama-cpt-code-femaseed-intratubal-insemination2026-02-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-reports-q4-2025-results-guidance-20262026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-td-cowen-health-care-conference2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/avenue-therapeutics-exclusive-license-atx-04-pompe-disease2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-scientific-industry-events2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-march-2026-investor-conferences2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-neo-conference-20242026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-announces-quarterly-dividend-20262026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-expands-collaboration-pathai-digital-pathology2026-02-23T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-invest-380-million-north-chicago-manufacturing2026-02-23T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-td-cowen-health-care-conference2026-02-23T21:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-presents-barclays-global-healthcare-conference-20262026-02-23T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-fourth-quarter-full-year-2025-results2026-02-23T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-abstracts-aacr-annual-meeting-20262026-02-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/successful-readout-sinergy-trial-signatera-mrd-treatment2026-02-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-participate-investor-conferences2026-02-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-corporate-update-q4-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-1-results-vir-5500-prostate-cancer2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-casdatifan-hif-2a-inhibitor-kidney-cancer-data2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-presentation-leerink-partners-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-td-cowen-conference-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-dr-soon-shiong-milken-summit-cancer-20352026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-presents-td-cowen-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-participate-td-cowen-health-care-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-financial-results-q4-20252026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-sciences-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-fourth-quarter-2025-earnings-call2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-conferences-march-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-participate-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-pauses-enrollment-linnet-trial2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-conference-call-selva-trial-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARA/tara-002-complete-response-rate-bladder-cancer2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-fg-3246-enzalutamide-asco-gu-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investor-conferences-march-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-inducement-grant-nasdaq-rule-56352026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-si-bone-distribution-agreement2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-fda-clearance-nexsys-pcs-persona-plus2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-full-year-2025-financial-results-update2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-oppenheimer-conference-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-francois-nader-appointment2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-participate-2026-canaccord-genuity-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-updated-earnings-call-dates2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-reports-q4-full-year-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-report-fourth-quarter-full-year-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-q4-2025-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q4-2025-financial-results2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-presentation-td-cowen-conference2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-investor-conferences-march-20262026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIBN/si-bone-reports-record-financial-results-q4-20252026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-march-investor-conferences2026-02-24T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-investor-conferences-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-td-cowen-health-care-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q4-2025-results2026-02-24T11:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-investor-conferences-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-investor-conferences-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-presents-bio-investment-growth-summit2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-investor-conferences-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SHC/sotera-health-revenue-growth-2026-outlook2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-reports-q4-2025-results-and-2026-guidance2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-positive-results-phase-3-selva-study-qtorin-rapamycin2026-02-24T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-march-investor-conferences2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-halo-clarity-trial-fda-submission-insomnia2026-02-24T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-investor-conferences-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-voyager-platform-launch-us-hupo-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/mainz-biomed-presentation-ddw-20262026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-expert-dtx-launch-accelerate-discovery2026-02-24T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-fda-breakthrough-designation-nomlabofusp2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q4-2025-results2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-march-investor-conferences2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRYS/krystal-biotech-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q4-2025-results2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-covid-19-antibody-protection-study2026-02-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q4-fy25-results-updates2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-positive-results-til-cell-therapy-sarcomas2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-present-td-cowen-health-care-conference2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-updated-clinical-data-mrt-2359-enzalutamide2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-business-highlights-financial-results-20252026-02-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-phase-1b-pioneer-trial-results2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-fourth-quarter-full-year-2025-results2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-us-patent-pan-kras-inhibitor-eras-40012026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-outpatient-bva-diagnostic-program-tennessee2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-td-cowen-conference-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-stockholder-letter-cnmau8-2026-catalysts2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-td-cowen-conference-20262026-02-24T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-q4-2025-results-and-update2026-02-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-report-fourth-quarter-full-year-2025-results2026-02-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-advancements-in-hemato-malignancies2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-clarity-phase-3-trial-solriamfetol2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXGN/axogen-reports-fourth-quarter-full-year-2025-results2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-at-587-hepatitis-e-croi-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARVN/arvinas-reports-q4-2025-results-corporate-update2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-thad-huston-cfo-appointment2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-business-update-clinical-progress2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q4-2025-results-conference-call2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-lpga-partnership-digestive-health2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-pharmaceuticals-q4-2025-results2026-02-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-march-conferences2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANNX/annexon-biosciences-td-cowen-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-investor-conferences-20262026-02-24T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-phase-1b-trial-ati-052-asthma2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-phase-1-trial-nlrp3-inhibitor2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-raymond-james-conference-20262026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-q4-2025-results-2026-guidance2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HIND/livechain-acquires-humanyze-ai-hr-analytics2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRC/atricure-participate-citizens-life-sciences-conference2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESTA/establishment-labs-leadership-transition-growth2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-2025-financial-results2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-march-2026-events2026-02-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZOM/diality-appoints-peter-donato-cfo2026-02-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-investor-conferences2026-02-24T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNBX/bnb-plus-corp-new-orders-lineadna-genetic-medicine2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/ttfields-therapy-coverage-bc-cancer2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-investor-conferences-march2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OFIX/orthofix-reports-q4-2025-results-and-2026-guidance2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-upcoming-presentations-mda-conference-20262026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-noetik-collaboration-tissue-models2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-td-cowen-46th-annual-health-care-conference2026-02-24T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-td-cowen-healthcare-conference-20262026-02-24T11:39:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-strategic-progress-diversification-fuels-success2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-investor-conferences-20262026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/tampa-general-hospital-adopts-liberty-robotic-system2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-phase-2-results-cad-1005-hit2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-global-protection-thermostem2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-patent-notice-allowance-feeding-tube2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-sarborg-expansion-bacteria-agrochemicals2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-barclays-healthcare-conference-20262026-02-24T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-explores-strategic-options-helomics-business2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-fda-fast-track-aky-11892026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-board-appointments2026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-freda-lewis-hall2026-02-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-new-product-innovations-acfas-20262026-02-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-participate-upcoming-investor-conferences2026-02-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-financial-results-20252026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/acd440-orphan-drug-status-eu2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VMD/viemed-healthcare-year-end-2025-earnings-call2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMPH/amphastar-fda-approval-ipratropium-bromide-hfa2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-participate-march-2026-investor-conferences2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-md-anderson-clinical-trial-atr-042026-02-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-present-march-2026-investor-conferences2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/minimed-launches-ipo-roadshow2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-dnastack-global-federated-hifi-dataset2026-02-24T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-participate-investor-conferences-march2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-registration-programs-scac-crc2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q4-2025-results2026-02-24T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-presentation-td-cowen-conference2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-expands-us-operations-greenwood-indiana2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYGN/myriad-genetics-2026-asco-gu-conference2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-3-ateganosine-nsclc2026-02-24T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-nosedives-late-stage-failure-pah-program-uncertainty2026-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-positive-results-phase-3-paridiprubart-study2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-japanese-marketing-approval-alphadart2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-mda-conference-20262026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/max-homa-arcutis-free-to-be-me-campaign2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-oppenheimer-conference-20262026-02-24T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-march-investor-conferences2026-02-24T14:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-exercises-warrants-3-million2026-02-24T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-launch-elevidys-japan2026-02-24T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-decipher-data-asco-gu-symposium-20262026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q4-2025-results-call2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-participate-bank-america-animal-health-summit2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-td-cowen-conference2026-02-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-exclusive-distribution-agreement-rmr-ortho2026-02-24T15:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approved-allergic-fungal-rhinosinusitis2026-02-24T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/dentsply-sirona-burkhart-dental-partnership-expansion2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-announces-q4-2025-financial-results2026-02-24T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-risorius-eeg-digital-biomarkers-partnership2026-02-24T13:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-bouygues-uk-drug-testing2026-02-24T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-launches-synchfix-evt-syndesmotic-fixation2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-launches-ai-insights-breast-cancer-signature2026-02-24T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-trupath-genome-genomic-insight2026-02-24T17:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-td-cowen-health-care-conference2026-02-24T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-td-cowen-health-care-conference2026-02-24T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-fda-approval-imaavy-waiha-treatment2026-02-24T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-investor-conferences-march2026-02-24T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-investor-conferences-20262026-02-24T22:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-accelerates-ht-001-trial-enrollment2026-02-24T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-2025-financial-results-update2026-02-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-2025-financial-results-guidance2026-02-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-full-year-2025-results2026-02-24T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-investor-conferences-march-20262026-02-24T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/puretech-present-leerink-partners-healthcare-conference2026-02-25T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-prices-private-placement-convertible-notes2026-02-25T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluoguide-annual-report-fiscal-year-20252026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/fluoguide-q4-2025-report2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-pricing-public-offering2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-proposed-public-offering2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-q4-2025-results-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABCL/abcellera-reports-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-td-cowen-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TEM/tempus-reports-fourth-quarter-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-td-cowen-health-care-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-share-repurchase-program2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/fda-approves-pfizer-braftovi-colorectal-cancer2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-phase-2-results-business-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-appoints-new-board-members2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-investor-conferences-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-td-cowen-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-full-year-2025-financial-results-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTA/azenta-participate-raymond-james-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-fourth-quarter-2025-financial-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-td-cowen-health-care-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/day-one-reports-q4-2025-results-and-2026-outlook2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-public-offering-common-stock2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-fourth-quarter-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-q4-2025-results-guidance-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SUPN/supernus-announces-record-financial-results-20252026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-proposed-public-offering2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-q4-2025-results-business-update2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-td-cowen-conference-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-investor-conferences-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-ser-252-parkinsons-trial2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-pharma-td-cowen-health-care-conference2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-march-2026-investor-conferences2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-march-2026-investor-conferences2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-strategic-alternatives2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q4-full-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-reports-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-fourth-quarter-fiscal-year-2025-results2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q4-2025-results-announcement2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZVRA/transpire-bio-appoints-laduane-clifton-cfo2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-capital-increase-employee-warrant-exercise2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-reports-hy26-results-strategic-reset2026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-reports-q4-full-year-2025-results-2026-guidance2026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-inducement-grants-nasdaq-rule-56352026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-q4-2025-financial-results2026-02-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFST/lifestance-reports-fourth-quarter-full-year-2025-results2026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-investor-conferences-march-20262026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-launches-elevidys-gene-therapy-japan2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-1-trial-ide0342026-02-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-fda-acceptance-imsiidolimab-gpp2026-02-25T12:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conferences-20262026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/fda-accepts-viatris-snda-mr-141-presbyopia2026-02-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDHL/joint-commercialization-redhill-talicia-launch2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-talicia-promotion2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-early-tender-results-upsize-offer-cap2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-acquires-ai-powered-exoskeleton-for-stroke-recovery2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-march-20262026-02-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-march-investor-conferences2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-redeem-1-trial-results-tpst-20032026-02-25T12:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-investor-conferences-march-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-nasal-foralumab-biomarker-data2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-td-cowen-conference-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-march-investor-conferences2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-new-cpt-code-reyobiq2026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-upcoming-investor-conferences2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-conferences-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-conferences-march-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-td-cowen-conference-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-acceptance-phentolamine-presbyopia2026-02-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-investor-conferences-march2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-q4-2025-financial-results-update2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-td-cowen-conference-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-corporation-q4-2025-financial-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-fourth-quarter-full-year-2025-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-td-cowen-conference-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conferences-20262026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-financial-results-conference-call2026-02-25T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-phase-3-barzolvolimab-chronic-spontaneous-urticaria2026-02-25T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-ogm-impact-oncology-therapy2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-march-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-td-cowen-conference-20262026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AURA/aura-biosciences-investor-conferences-20262026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-td-cowen-conference-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-march-investor-conferences2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/amarin-reports-q4-2025-financial-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-ceo-corner-publication-strategy2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-investor-dinner-mar-a-lago2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-leerink-partners-2026-healthcare-conference2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-investor-conferences-20262026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/YDES/yd-bio-yc-biotech-partnership-dual-core-regulatory-platform2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CURX/curanex-operational-update-regulatory-milestones2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-citizens-life-sciences-conference2026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-reports-fourth-quarter-full-year-2025-results2026-02-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-inducement-grants-nasdaq-56352026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-participate-investor-conferences2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-expands-robotic-filling-platform-support2026-02-25T13:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-ceo-letter-shareholders-20262026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-participate-canaccord-genuity-conference2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-commercial-momentum-multi-pillar-execution2026-02-25T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launch-minimed-go-smart-mdi-system2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-multiomics-cancer-breakthroughs2026-02-25T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-secures-financing-commitment2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-participation-investor-conferences-march-20262026-02-25T13:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-q4-2025-financial-results-release2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-extends-rights-offering-subscription-period2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-study-bamc2026-02-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-participate-leerink-partners-healthcare-conference2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-withdrawal-petition-patent2026-02-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-reports-2025-results-outlook2026-02-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-financial-results-q4-20252026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-investor-conferences2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-q4-2025-financial-results2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-cellscape-xr-launch-spatial-proteomics2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-acquires-drug-discovery-assets-charles-river2026-02-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-ceo-succession-plan-announcement2026-02-25T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-fourth-quarter-2025-results2026-02-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-125-million-public-offering2026-02-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-2025-revenues-increase-30-percent2026-02-25T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STSS/sharps-technology-the-tie-collaboration-solana2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDXS/codexis-fourth-quarter-fiscal-year-2025-results2026-02-25T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-first-readers-shipped2026-02-25T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-launch-onetest-longevity-blood-test2026-02-25T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-strategic-alternatives-review2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/zimmer-biomet-aaos-2026-annual-meeting2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-td-cowen-conference2026-02-25T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-reports-fourth-quarter-full-year-2025-results2026-02-25T18:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-tender-offers-pricing-announcement2026-02-25T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-td-cowen-conference-20262026-02-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-q4-2025-financial-results-update2026-02-26T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-eckert-ziegler-development-agreement2026-02-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-investor-conferences-2025-results2026-02-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-validation-study-cypath-lung2026-02-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-full-year-2025-financial-results2026-02-26T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-adapt-oculus-trial-results2026-02-26T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-fourth-quarter-2025-results-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CARL/carlsmed-reports-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-75-million-offering2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-announces-record-fourth-quarter-full-year-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-vykat-xr-launch-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-participate-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-fourth-quarter-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-record-financial-results-20252026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/terns-pharmaceuticals-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-presents-at-march-2026-healthcare-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-fourth-quarter-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-reports-fourth-quarter-2025-results-guidance2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-presentation-td-cowen-health-care-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPRX/catalyst-pharmaceuticals-record-financial-results-20252026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-investor-conferences-march-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHE/chemed-fourth-quarter-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-phase-3-trials-doravirine-islatravir-hiv2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-fda-approval-desmoda2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-q4-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-phase-2b-trial-results-stem-cell-therapy2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-participate-td-cowen-healthcare-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-participate-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-march-2026-conference-presentation2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-beacon-study-enrollment2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-leerink-2026-conference2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-year-end-report-20252026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-public-offering-pricing2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-upsized-public-offering2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-upsized-public-offering2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/fda-approves-numelvi-jak-inhibitor-dogs2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-increases-quarterly-dividend2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTMD/biote-fourth-quarter-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SDGR/schrodinger-reports-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCYT/veracyte-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q4-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-q4-2025-financial-results-pipeline-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INVA/innoviva-reports-fourth-quarter-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-reports-q1-fiscal-year-2026-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STAA/staar-surgical-4-million-icls-sold2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-reports-q4-full-year-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-fourth-quarter-year-end-2025-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q4-2025-financial-results2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-financial-results-2025-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-update-pending-acquisition-alcon2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-upcoming-conferences-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/viiv-healthcare-lotivibart-hiv-treatment-data2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/viiv-healthcare-pipeline-data-hiv-treatment-therapies2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-bictegravir-lenacapavir-hiv-treatment2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-third-quarter-results-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-participate-investor-conferences-march-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-tender-offers-pricing2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-reports-q4-2025-results-corporate-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-q4-full-year-2025-financial-results-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-td-cowen-conference-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-participate-march-2026-investor-conferences2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEO/neogenomics-launches-radar-st-mrd-testing2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-2025-results-outlook2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/immuno-oncology-investments-accelerate-pipeline-catalysts-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IART/integra-lifesciences-q4-2025-results-guidance2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENOV/enovis-fourth-quarter-full-year-2025-results2026-02-26T11:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q4-fy-2025-results-release2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-financial-results-2025-update2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONC/beone-medicines-q4-2025-financial-results2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVAH/aveanna-fourth-quarter-2025-earnings-release2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FTRE/fortrea-reports-q4-full-year-2025-results-guidance-20262026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-fourth-quarter-full-year-2025-results2026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-reports-q4-2025-results-guidance-20262026-02-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-fourth-quarter-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-investor-conferences-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-reports-fourth-quarter-full-year-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q4-2025-results-muscular-dystrophy2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-orforglipron-superior-blood-sugar-control2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-fy2025-financial-results2026-02-26T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-fourth-quarter-full-year-2025-results2026-02-26T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-dividend-policy-2026-quarterly-announcement2026-02-26T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-year-end-2025-results-corporate-update2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-pipeline-progress-milestones-financial-results2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-korean-patent-photocurable-dermal-filler2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-positive-opinion-orphan-drug-sgx9452026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-q4-2025-financial-results2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q4-2025-results-update2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-reports-fourth-quarter-full-year-2025-results2026-02-26T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-vibrant-trial-aaaai-20262026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q4-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-reports-q4-2025-results-briumvi-guidance2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-phase-1-allohatrial-fda-clearance2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-james-mackaness-retirement-jennifer-fulk2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q4-2025-results-update2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-2026-investor-day-strategic-plan2026-02-26T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMVP/rezatapopt-phase-1-results-published-nejm2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q4-2025-results-guidance2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q4-2025-results-updates2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q4-fiscal-year-2025-results2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-reports-fourth-quarter-full-year-2025-results2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-td-cowen-conference-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-reports-fourth-quarter-full-year-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q4-2025-financial-results-update2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-presentation-upcoming-conferences2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-leerink-partners-healthcare-conference2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q4-2025-earnings-call2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-remains-1-pivotal-cohort-completion2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-merck-hiv-pills-phase-3-data2026-02-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-leerink-partners-2026-conference2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-reports-2025-results2026-02-26T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-reports-fourth-quarter-full-year-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-financial-results-20252026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-day-3-highlights2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-infoods-ibs-real-world-data2026-02-26T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-reports-2025-financial-results-business-update2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-conference-call-march-20262026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-full-year-2025-results2026-02-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-fourth-quarter-2025-financial-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-4th-quarter-2025-results-announcement2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q4-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q4-2025-results-update2026-02-26T11:58:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-mda-conference-20262026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-introduces-sensus-link-advanced-capabilities2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-reports-fourth-quarter-results-20252026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endras-taeus-liver-device-consistency-clinical-study2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-enrollment-pivotal-trial-anktiva-bcg2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-sells-chromadex-business-lgc2026-02-26T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-progress-financial-results-20252026-02-26T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-acquisition-celyn-therapeutics-assets2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/olezarsen-fda-priority-review-severe-hypertriglyceridemia2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-reports-q4-2025-financial-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/systimmune-bms-positive-phase-iii-results-iza-bren2026-02-26T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-reports-2025-financial-results-outlook-20262026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-q4-2025-financial-results2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-warrant-exercise-funding2026-02-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-2026-sir-annual-meeting-abstract-acceptance2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/netherton-now-recognizes-rare-disease-day2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-present-bio-investment-growth-summit2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-fourth-quarter-2025-results2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-financial-results-business-update2026-02-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-phase-1-trial-scy-2472026-02-26T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-naloxone-formulation-study-results2026-02-26T13:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-training-day-tht-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLSN/yoolie-park-joins-solesence-as-vp-brand-partnerships2026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-leerink-healthcare-conference-20262026-02-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-reports-q4-2025-results2026-02-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JYNT/joint-corp-report-2025-results-conference-call2026-02-26T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/good-supply-cannabis-spring-lineup-canada2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-reports-fourth-quarter-full-year-2025-results2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-phase-2a-results-emp-01-social-anxiety2026-02-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-nominates-cunniff-burke-board2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-evaluates-acquisition-sciometrix-digital-care-management2026-02-26T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-q4-2025-results2026-02-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/us-patent-office-sun-pharma-patent-unpatentable2026-02-26T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-prafulla-gokhale2026-02-26T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-participate-investor-conferences-march-20262026-02-26T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-report-q4-full-year-2025-results2026-02-26T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-fembloc-mdsap-certification-global-access2026-02-26T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-partners-viuhealth-autoimmune-dataset2026-02-26T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-investor-conferences-march-20262026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DGX/quest-diagnostics-benjamin-beauvalot-appointment2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/lineage-cell-therapeutics-q4-2025-results-update2026-02-26T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-year-end-fourth-quarter-2025-results2026-02-26T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/jnj-pasritamig-docetaxel-prostate-cancer-study-results2026-02-26T19:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-mda-conference-2026-presentations2026-02-26T21:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-2026-citizens-conference2026-02-26T21:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q4-2025-financial-results2026-02-26T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-financial-results-q4-2025-announcement2026-02-26T23:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-participate-investor-conferences2026-02-26T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/jpm26-conference-insights-san-francisco2026-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-march-2026-investor-conferences2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GENB/generate-biomedicines-ipo-pricing-announcement2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/ryoncil-profits-substantial-growth-pipeline2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIR/vir-biotechnology-investor-conferences-march-20262026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-report-q4-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/natera-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-reports-financial-results-20252026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSNL/personalis-reports-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UNDER/definium-therapeutics-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-fda-breakthrough-therapy-ngn-401-rett-syndrome2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-q4-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-achieve-1-study-interim-readout2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVR/anteris-reports-2025-financial-results-corporate-update2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-march-2026-investor-conferences2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-participate-march-2026-investor-conferences2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-transformation-saentra-forge-strategic-expansion2026-02-27T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inducement-grants-nasdaq-rule-5635c42026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-investor-conferences-20262026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRX/amneal-reports-fourth-quarter-full-year-2025-results2026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-closing-144-million-public-offering2026-02-27T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-q4-2025-results2026-02-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-q4-2025-financial-results-business-update2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGNY/progyny-fourth-quarter-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-university-hospital-essen-promise-pet-collaboration2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-regains-nasdaq-compliance2026-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-tax-valuation-allowance-impact-q4-results2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-eu-approval-chronic-spontaneous-urticaria2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-participate-march-investor-conferences2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-symposium-2026-highlights-advancements-ogm2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-reports-record-financial-results-20252026-02-27T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-q4-2025-results-and-update2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-vtama-phase-3-atopic-dermatitis-sleep-improvement2026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-business-update-fy-20252026-02-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-dawnzera-data-2026-aaaai-meeting2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGON/cg-oncology-2025-financial-results-business-updates2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-rare-disease-day-commitment2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/zusduri-achieves-complete-responses-eortc-risk-groups2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-advancing-renovocath-adoption-cancer-centers2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-participate-upcoming-investor-conferences2026-02-27T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRM/medirom-partnership-tools-for-humanity-expansion2026-02-27T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OPK/opko-health-jefferies-biotech-summit-20262026-02-27T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/treace-medical-concepts-q4-full-year-2025-results2026-02-27T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-positive-opinion-ema-mavorixafor2026-02-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-olumiant-chmp-approval-adolescents-alopecia-areata2026-02-27T13:11:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-whole-genome-sequencing-rare-disease-testing-florida2026-02-27T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-gene-therapy-phase-1-2-data2026-02-27T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-update-expiration-20262026-02-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-paclitaxel-bevacizumab-ovarian-cancer2026-02-27T15:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/signatera-mrd-data-asco-gu-bladder-preservation2026-02-27T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/padcev-keytruda-bladder-cancer-trial-results2026-02-27T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-padcev-improves-survival-muscle-invasive-bladder-cancer2026-02-27T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-route-79-duchenne-scholarship-program-20262026-02-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFSA/profusa-withdraws-s1-registration-statement-offering2026-02-27T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-commercial-launch-rwd-platform-palantir2026-02-27T13:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-reports-fourth-quarter-full-year-2025-results2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-mcombriax-positive-opinion-ema2026-02-27T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-announces-full-year-2025-results-business-updates2026-02-27T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-approves-biomarin-palynziq-adolescents-pku2026-02-28T01:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-summit-trial-aaaai-20262026-02-28T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-welireg-adjuvant-therapy-rcc-results2026-02-28T15:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/welireg-lenvima-advanced-renal-cell-carcinoma-results2026-02-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-verekitug-phase-2-vibrant-trial-results2026-03-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEPN/septerna-positive-phase-1-data-sep-6312026-03-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-positive-data-aaaai-20262026-03-01T14:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/investor-education-webinar-tlx2026-03-02T12:56:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-protagonist-fda-accepts-rusfertide-nda2026-03-02T07:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-phase-3-transcend-trial-data2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-vibrant-trial-verekitug-aaaai-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-phase-3-vitesse-study-aaaai-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/keytruda-welireg-adjuvant-therapy-rcc-trial-results2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/welireg-lenvima-advanced-renal-cell-carcinoma-trial-results2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/biocytogen-first-patient-dosed-phase-1-trial-ide0342026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-approves-biomarins-palynziq-for-adolescents-with-pku2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-participate-2026-leerink-healthcare-conference2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-share-repurchase-plan-announcement2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDNA/caredx-inducement-grants-nasdaq-rule-5635c42026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/fda-approves-yuviwel-achondroplasia-treatment2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inducement-grants-nasdaq-rule-56352026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-nasdaq-delist-hearing-request2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-management-td-cowen-health-care-conference2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-phase-3-hero-trial-pause2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-reports-q4-2025-results-update2026-03-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-acquires-cl-273-celyn-therapeutics2026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/ralinepag-reduces-clinical-worsening-risk-pah2026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-aln1003-preclinical-data-obesity2026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-royalty-pharma-250-million-financing2026-03-02T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-corporate-update-financial-results-20252026-03-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-fourth-quarter-2025-results2026-03-02T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-acquires-gleamer-radiology-ai-solutions2026-03-02T10:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-city-of-hope-phase-ii-trial-bexmarilimab2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VACH/veraxa-biotech-merger-approval-vach2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-full-year-2025-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PULM/pulmatrix-terminates-merger-cullgen-alternative-opportunities2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-collaboration-shirley-ryan-abilitylab-rewalk2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bdx-surgiphor-1000ml-fda-clearance-surgical-safety2026-03-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-participate-investor-conferences2026-03-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-leerink-partners-conference-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-zusduri-launch-financial-results-20252026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/urogen-refinanced-term-loan-agreement-pharmakon2026-03-02T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-reverse-share-split-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SION/sionna-therapeutics-q4-2025-financial-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REPL/replimune-present-upcoming-investor-conferences2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QURE/uniqure-2025-financial-results-company-updates2026-03-02T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-upsized-public-offering-20262026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/deucrictibant-data-aaaai-20262026-03-02T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-igor-studies-aaos-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-phase-3-limelight-enrollment-completion-ocu4002026-03-02T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-fda-lift-clinical-hold-magnitude-trial2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-amber-faust-appointment2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-appoints-susan-rodriguez-cso2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-bio-summit-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ISRG/intuitive-expands-investment-footprint-europe2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-participate-investor-conferences-march-20262026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-regains-nasdaq-compliance2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-reports-full-year-2025-financial-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-leerink-partners-2026-healthcare-conference2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-first-patients-dosed-phase-3-duravyu-dme2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-financial-results-20252026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-acquires-us-rights-to-hemangeol2026-03-02T12:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-appoints-pete-ligotti-cco-nxt-41x-launch2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q4-2025-financial-results2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-participate-investor-conferences2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-advancing-zervimesine-dlb-psychosis2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-leerink-global-healthcare-conference2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-evaluates-strategic-options-shareholder-value2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-msa-awareness-month-20262026-03-02T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APLS/apellis-announces-mikael-dolsten-board-directors2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pipeline-progress-2025-results2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/icosapent-ethyl-reduce-it-hospitalizations-death2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-investor-conferences-20262026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-present-leerink-partners-healthcare-conference2026-03-02T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGIO/agios-pyrukynd-approved-thalassemia-uae2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-125-million-share-repurchase-initiative2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-candid-merger-agreement2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-tg-therapeutics-azer-cel-milestone2026-03-02T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-acquires-neogen-animal-genomics-business2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-sale-genomics-business-zoetis2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-sebetralstat-patient-satisfaction-data2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XERS/xeris-biopharma-record-performance-2025-guidance-20262026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-optune-lua-reimbursement-approval-japan2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-investor-conferences-20262026-03-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NIVF/newgen-signs-mou-women-web3-hong-kong-health-initiative2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-fourth-quarter-full-year-2025-results-update2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q4-2025-results-update2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-barostim-outcomes-tht-20262026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-us-patent-fibroblast-cell-therapy-osteoporosis2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-fourth-quarter-2025-results-conference-call2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-leadership-artificial-heart-therapy2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-12-lox-inhibitor-expansion2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-march-investor-conferences2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-q4-2025-financial-results-call2026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-march-conferences-20262026-03-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-inzymes-non-animal-dairy-enzyme-commercialization-20262026-03-02T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-present-leerink-partners-2026-conference2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-prof-joshua-brown-cmo2026-03-02T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SI/shoulder-innovations-appoints-drew-hykes-board2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-march-2026-investor-conferences2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-reports-fourth-quarter-2025-results2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-egm-results-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-restricted-stock-units-warrants-grant-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-barzolvolimab-phase-2-data-aaaai-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMAT/lemaitre-participate-investor-conferences-march-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-signs-amendment-pincell-option-agreement-feng-application2026-03-02T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-finalizes-companion-spine-transactions2026-03-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-50-percent-enrollment-nephro-crrt-trial2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNTH/lantheus-fda-tentative-approval-pnt20032026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-2026-annual-meeting-corporate-update2026-03-02T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/ascendis-pharma-td-cowen-health-care-conference2026-03-02T13:43:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-positive-results-phase-3-affirm-study-skyrizi2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-prosense-cryoablation-breast-fibroadenomas-study2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-launches-colorectal-cancer-study2026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-participate-investor-conferences-march-20262026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PALI/palisade-bio-investor-conferences-march-20262026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-buyback-program-20262026-03-02T14:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-phase-3-trial-ampligen-pancreatic-cancer2026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/lucent-diagnostics-life-line-screening-partnership2026-03-02T13:33:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-q3-fy-2026-results-call2026-03-02T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-foundation-12-million-hiv-prevention-initiative2026-03-02T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALUR/allurion-appeal-nyse-delisting-compliance-plan2026-03-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-acquires-brewdog-global-craft-beverage-platform2026-03-02T15:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-financial-results-march-20262026-03-02T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-investor-conferences2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/alan-walshe-appointed-general-manager-takeda-canada2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-positive-recommendation-amvuttra-reimbursement2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-appoints-lynne-kelley-cmo2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-acquires-cullgen-targeted-protein-degradation2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-investor-conferences-march-20262026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-prof-joshua-brown2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-aln1003-obesity-treatment-data2026-03-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-participation-scientific-conference2026-03-02T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-financial-results-20252026-03-02T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-global-sleep-survey-20262026-03-03T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/sherpa-research-consortium-ai-assistive-technologies2026-03-03T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-pricing-public-offering2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-cfo-speak-barclays-global-healthcare-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-april-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-announces-dividend-march-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-ceo-speak-leerink-partners-2026-healthcare-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-re-examination-trofinetide-rett-syndrome2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-investor-conferences-march-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-corporation-full-year-fourth-quarter-2025-results2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-financial-results-q4-full-year-20252026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVNS/avanos-medical-presentation-2026-citizens-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-public-offering-common-stock2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-correction-announcement-march-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-q4-2025-results2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/nuvation-bio-fourth-quarter-2025-results-update2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYTK/cytokinetics-participate-march-2026-investor-conferences2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-investor-conferences-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SENS/senseonics-q4-2025-financial-results2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-rule-56352026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-presentation-leerink-healthcare-conference2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-q4-2025-financial-results-guidance2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-leerink-partners-conference-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGRY/surgery-partners-q4-2025-results-guidance-share-repurchase2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-appointment-richard-kender-ceo2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-q4-2025-financial-results-conference-call2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-rotator-cuff-repair-aaos-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-participate-march-2026-investor-conferences2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-uplisting-nasdaq-global-select-market2026-03-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q3-2026-results2026-03-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-acquires-corstasis-enbumyst-nasal-spray2026-03-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q4-2025-financial-results-call2026-03-03T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-sevasemten-mda-conference-20262026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-present-leerink-partners-healthcare-conference2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-2025-financial-results-clinical-updates2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-executives-open-market-share-purchases2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-investor-conferences-march-20262026-03-03T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRIO/dario-health-oral-glp1-therapy-support2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-phase-3-trial-triesence-cataract-surgery2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-fda-fast-track-sle2026-03-03T13:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-diagnostic-platform-asthma-therapy2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-participate-upcoming-investor-conferences2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-regulatory-update-tabelecleucel2026-03-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-chopin-trial-results-lancet-oncology2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-reports-q4-2025-results-outlook-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-leerink-conference-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q4-2025-results2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-citizens-life-sciences-conference2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-fourth-quarter-full-year-2025-results2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-leerink-global-healthcare-conference-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-march-investor-conferences2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-tumor-growth-inhibition2026-03-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-wisconsin-clinic-progyny-network2026-03-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-investor-conferences-20262026-03-03T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-partners-with-total-clean-air2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-ceo-shareholder-update-20262026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-present-multiple-investor-conferences2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FULC/fulcrum-therapeutics-leerink-partners-conference2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYOJ/ryojbaba-global-labor-support-agreement2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-fourth-quarter-2025-results-conference-call2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-molteni-collaboration-ad04-europe2026-03-03T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-appoints-raghunathan-global-sales-vp2026-03-03T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-showcase-alzheimers-treatment-20262026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-corporation-2025-fiscal-year-results2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardias-late-breaking-results-cardiamp-hf-trial2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-leerink-partners-2026-conference2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/insight-molecular-diagnostics-graftassuredx-fda-submission2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-presentations-adpd-2026-conference2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-john-fowler-appointment2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-march-investor-conferences2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRME/prime-medicine-reports-2025-financial-results2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-investor-conferences-march-20262026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-phase-1a-1b-arq-234-atopic-dermatitis2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERT/certara-simcyp-simulator-asciminib-cml-trials2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-potential-impact2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-keybanc-forum-presentation2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-distribution-agreement-imperial-imaging2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/embrace-your-sparkle-paris-hilton-campaign-coll2026-03-03T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-participate-roth-conference-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-financial-results-conference-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-citizens-conference-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-keybanc-healthcare-forum2026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-leerink-global-healthcare-conference2026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-q4-2025-financial-results-report2026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-march-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-lonvoguran-ziclumeran-aaaai-20262026-03-03T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-secondary-offering-class-a-common-stock2026-03-03T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/brepocitinib-fda-acceptance-priority-review-dermatomyositis2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-q4-2025-results-business-highlights2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-leerink-partners-2026-conference2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-2026-leerink-partners-conference2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-phase-3-bpl-003-trd2026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-investor-conferences-march-20262026-03-03T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-phase-3-cypress-study-failure2026-03-03T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAZ/transcode-secures-royalty-free-license-oncolytic-immunotherapy2026-03-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-fda-hearing-hetlioz-jet-lag-disorder2026-03-03T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-leerink-partners-2026-conference2026-03-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBM/psyence-biomed-export-npx-5-australia-phase-iib-trial2026-03-03T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-operational-stability-geopolitical-event2026-03-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-presents-leerink-partners-conference2026-03-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-diagnostic-platform-asthma-therapy2026-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-business-update-call-phase-2a-data-vis-1012026-03-03T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XGN/exagen-participate-investor-conferences2026-03-03T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-microsize-sublingual-alprazolam2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-mpar-technology-publication2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-leerink-partners-conference-20262026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/sherpa-consortium-ai-technologies-brain-cancer-treatments2026-03-03T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cfo-thierry-pieton-investor-conferences2026-03-03T15:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-q4-full-year-2025-results-business-update2026-03-03T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AORT/artivion-oppenheimer-conference-participation-20262026-03-03T21:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-presentation-ubs-global-consumer-retail-conference2026-03-03T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-2025-revenue-growth2026-03-03T22:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-reports-financial-results-20252026-03-03T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-holdings-q4-2025-financial-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QSI/quantum-si-reports-q4-full-year-2025-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-appoints-jonathan-poole-board2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-presentation-leerink-conference-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNM/immunome-reports-2025-financial-results-business-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-fy-2025-results-pipeline-progress2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-inducement-grants-nasdaq-listing-rule-56352026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-advances-oral-epetraborole-phase-2-study2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-2025-financial-results-business-highlights2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-blackstone-400-million-agreement-duvakitug2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-tonmya-poster-aapm-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-grand-opening-new-headquarters2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-fourth-quarter-2025-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-webcast-citizens-life-sciences-conference-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-q4-2025-financial-results-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VXRT/vaxart-upcoming-conference-calls-2025-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-march-2026-investor-conferences2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-leerink-partners-2026-conference2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q4-2025-financial-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-q4-2025-financial-results-update2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-leerink-partners-conference-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-update-business-separation-financial-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNN/smith-nephew-aaos-2026-showcase-robotics2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-colorectal-cancer-screening-success2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-2025-financial-results-announcement2026-03-04T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-fourth-quarter-full-year-2025-results2026-03-04T08:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/radnet-acquisition-gleamer-conference-call2026-03-04T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-rembra-ct-ecr-2026-launch2026-03-04T09:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/alzecure-pharma-presentation-stora-aktiedagarna2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-financial-statements-20252026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-annual-report-20252026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-leerink-conference-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presentations-mda-conference-20262026-03-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-present-leerink-2026-healthcare-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-fireside-chat-leerink-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-fda-approval-new-manufacturing-facility2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-announces-reverse-stock-split2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q4-2025-financial-results-update2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-participate-citizens-life-sciences-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-fireside-chat-barclays-conference2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-citizens-life-sciences-conference2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/moderna-win-covid-19-patent-spat-roivant2026-03-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-participate-march-investor-conferences2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fiscal-year-fourth-quarter-2025-results2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-ai-infrastructure-biotech2026-03-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-inducement-grants-nasdaq-rule-56352026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-collaboration-tampa-general-hospital2026-03-04T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-regains-compliance-nasdaq-listing-requirements2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-announces-q4-full-year-2025-results2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-report-financial-results-march-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-phase-3-trial-neflamapimod-dementia-lewy-bodies2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-clinical-trial-approval2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-financial-results-20252026-03-04T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fites-namodenoson-phase-2a-pancreatic-cancer-study2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-therapies-shareholder-letter-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-present-additional-data-fortify-trial-20262026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-appoints-daniel-claassen2026-03-04T12:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/ardelyx-participate-investor-conferences-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-progresses-development-commercial-launch-foundation-model2026-03-04T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-srnt-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-investor-conferences-20262026-03-04T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/radoff-jec-group-open-letter-seer-independent-directors2026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-clearcardio-partnership-12-lead-ecg-technology2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RBOT/vicarious-surgical-delisting-notice-nyse2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-inducement-grants-nasdaq-rule-5635c42026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-vybrance-north-american-meeting2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-revenue-growth-fiscal-year-20252026-03-04T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-positions-transformational-growth2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-inducement-grant-nasdaq-rule-56352026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-ama-policy-radiation-protection2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLOV/clover-health-first-payer-cms-aligned-network2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-phase-3-protocol-eb613-osteoporosis2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-business-update-q4-full-year-2025-results2026-03-04T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-jefferies-biotech-summit-20262026-03-04T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-appoints-new-leaders2026-03-04T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-fermbox-launch-recombinant-dnase-i2026-03-04T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RDNT/deephealth-comprehensive-ai-solutions-ecr-20262026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q4-full-year-2025-results2026-03-04T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-phase-1-ketamir-2-dosing-completed2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-highlight-obesity-metabolic-therapies-forum2026-03-04T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-openai-api-ht-kit-oncology2026-03-04T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-phase-1-data-lymphir-carl-t-therapy2026-03-04T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-participate-investor-conferences2026-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-top-abstract-crt-20262026-03-04T13:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-rights-offering-results2026-03-04T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-dr-mary-yamashita-medical-advisor2026-03-04T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-exercise-warrants-4-million-proceeds2026-03-04T15:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-gallup-award-20262026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/akeso-inovio-clinical-collaboration-gbm-therapy2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-health-systems-ceo-appointment2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-ama-session-growth-plans2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-conference-call-fy-2025-results2026-03-04T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-q2-dividend2026-03-04T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-secondary-offering-pricing2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-fourth-quarter-year-end-2025-financial-report2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-participation-2026-citizens-life-sciences-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-fourth-quarter-year-end-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-fourth-quarter-full-year-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-regulatory-updates-freedom22026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-reports-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q4-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XNCR/xencor-ultomiris-royalty-revenue-forecast-change2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inducement-grants-nasdaq2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-citizens-life-sciences-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOK/zorevunersen-dravet-syndrome-potential-modification2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VMD/viemed-healthcare-record-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-march-2026-investor-conferences2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/castle-biosciences-ss0-2026-decisiondx-melanoma2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-second-quarter-dividend2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-closes-30-million-offering2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q4-2025-financial-results-update2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-business-highlights-financial-results-20252026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-indomo-acne-treatment-agreement2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-leerink-partners-2026-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-investor-conferences-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLLN/billiontoone-reports-q4-2025-results-raises-guidance2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-q4-2025-financial-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-march-2026-investor-events2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-employee-inducement-awards-march-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-2025-financial-results-update2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-advances-iliac-artery-treatment-eu2026-03-05T07:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-participate-upcoming-investor-conferences2026-03-05T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-employer-connect-launch-obesity-coverage-options2026-03-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-coffee-microcaps2026-03-05T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STTK/shattuck-labs-q4-2025-financial-results2026-03-05T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-reports-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KURA/kura-oncology-q4-2025-financial-results2026-03-05T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-sma-data-mda-sma-europe-conferences2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/quantum-leap-energy-appoints-nate-salpeter-cto2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-q4-full-year-2025-results2026-03-05T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-report-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-annual-special-meeting-shareholders-20262026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-financial-results-update-march-20262026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-2025-financial-results-update2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RGEN/repligen-corporation-march-conferences-20262026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launch-amniofix-thyroid-shields2026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/mediwound-reports-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-phase-2-sknjct-003-results2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q4-2025-financial-results2026-03-05T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-q4-2025-financial-results-declaration-trial-updates2026-03-05T12:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-michael-mina-cmo2026-03-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-full-year-2025-financial-results-update2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-2025-financial-results-business-update2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-2025-annual-report-delay2026-03-05T13:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-participate-investor-conferences-march-20262026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRMD/cormedix-q4-2025-financial-results-update2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COLL/collegium-present-new-real-world-data-painconnect-20262026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-2025-financial-results-update2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BVS/bioventus-fourth-quarter-full-year-2025-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRTX/biorestorative-participate-be-well-show-20262026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-bxcl501-opioid-withdrawal-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-mhra-registration-hp-detect-commercial-sales2026-03-05T13:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-business-progress-q4-2025-results2026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-symposium-parkinsons-disease-adpd-20262026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-alnylam-research-collaboration-cardiovascular-disease2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-wve-006-ats-conference-presentation2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PACB/pacbio-appoints-chris-gibson-board-directors2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-sarborg-us-provisional-patent-ai-signature-agent2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-phase-1-2-trial-cywc628-diabetic-foot-ulcers2026-03-05T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-fda-enrollment-save-registry2026-03-05T13:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CURX/curanex-forms-scientific-advisory-board2026-03-05T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HELP/helus-pharma-phase-2-results-hlp004-gad2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-appoints-justin-renz-cfo2026-03-05T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-fourth-quarter-2025-financial-results-call2026-03-05T12:04:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-tango-clinical-collaboration-eras-00152026-03-05T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-q4-2025-financial-results2026-03-05T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/alliance-genomic-discovery-expansion-regeneron2026-03-05T14:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-christopher-hite-board2026-03-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-business-update-2025-results2026-03-05T14:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-promotion-mas-matsuda-executive-vice-president2026-03-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-tenaya-genetic-heart-disease-targets2026-03-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-time-lapse-incubation-technology-wisconsin2026-03-05T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMIX/autonomix-medical-best-innovation-competition-crt-20262026-03-05T13:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-board-transition-hezi-levy2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHIO/phio-participates-renmark-virtual-roadshow2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-march-2026-investor-conference2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-ai-digital-leadership-himss-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/hls-therapeutics-launches-nilemdo-canada2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-participate-march-2026-investor-conferences2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCK/mckesson-cfo-transition-britt-vitalone-kenny-cheung2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLN/silence-therapeutics-business-achievements-2025-results2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-azure-clinical-program-update2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-phase-2-study-dm199-preeclampsia2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-oppenheimer-conference-20262026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-first-patient-enrollments-heart-attack-study2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-tibusure-study-design-presentation2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/hls-therapeutics-launches-nilemdotm-canada2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/herantis-pharma-2025-report-release2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-annual-report-2025-correction2026-03-05T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-present-leerink-partners-2026-healthcare-conference2026-03-05T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-revello-stent-ce-marking-eu2026-03-05T19:19:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-fda-approval-tecvayli-darzalex-multiple-myeloma2026-03-05T20:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZTR/azitra-cancels-special-meeting-stockholders2026-03-05T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-cash-dividend-fy-20262026-03-05T21:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-investor-conferences-20262026-03-05T21:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-report-fourth-quarter-full-year-2025-results2026-03-05T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/minimed-announces-ipo-pricing2026-03-06T00:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-presents-pharma-discovery-bio-europe-spring-20262026-03-09T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/waters-ares-g3-rheometer-launch2026-03-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-korean-patent-breast-cancer-vaccine2026-03-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-positive-results-phase-1-abbv-295-study2026-03-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/asbrs-resource-guide-cryotherapy-breast-cancer-iccm2026-03-09T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-scientific-conferences2026-03-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-collaboration-als-trial2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-rinvatercept-data-mda-conference2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-ibezapolstat-clinical-trial-recurrent-cdi2026-03-09T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRAY/first-ever-dental-dedicated-mri-fda-clearance2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-positive-topline-data-phase-3-x-tole2-study2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERU/veru-phase-2b-plateau-clinical-trial-enobosarm-semaglutide2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-leadership-diversified-growth-strategy2026-03-09T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-tn-301-preclinical-data-mda-20262026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TGTX/briumvi-reduces-relapse-mri-activity-ms2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-completes-private-placement-growth2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-neffy-commercialization-update-20252026-03-09T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-2025-financial-results-update2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-160-million-private-placement2026-03-09T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-phase-2-ndv-01-bladder-cancer-data2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/olatorepatide-obesity-treatment-phase-3-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-tenacia-collaboration-rap-2192026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q4-2025-financial-results2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-investor-call-captain-trial-outcomes2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-q4-full-year-2025-results2026-03-09T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNKD/mannkind-afrezza-data-at-atted-20262026-03-09T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q4-2025-financial-results2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-positive-phase-2-skincare-study2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-phase-3-development-plan-canvuparatide2026-03-09T14:21:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-closes-50-million-tranche-appointment2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-oversubscribed-private-placement2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-share-buyback-program-update2026-03-09T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLTO/galecto-name-change-damora-therapeutics-blood-disorders2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-q4-2025-results-updates2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-participate-iaccess-virtual-alpha-conference-20262026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-financial-results-webinar-march-20262026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-phase-3-captivate-trial-update2026-03-09T11:09:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-go-decision-captiavate-trial-claseprubart2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-present-new-data-cue-401-wirm-20262026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-i31-slnb-study-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q4-2025-financial-results2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-phase-1b-study-cdi-988-norovirus2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-financial-results-march-20262026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presents-new-data-aua-20262026-03-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-q4-full-year-2025-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-positive-phase-2b-results-acne2026-03-09T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-supports-lifes-a-polyp-foundation-fap2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-bell-potter-summit-20262026-03-09T11:25:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-ras-inhibitors-research2026-03-09T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-zevaskyn-commercial-launch-update2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ns002-phase-2-study-presentation2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-eventhorizoniq-subscription-launch2026-03-09T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-advances-bla-submission-fabry-disease2026-03-09T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-expands-skin-health-ecosystem2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-robert-lenz-board-directors2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-presentation-life-sciences-investor-forum2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-private-lending-pool-hyperlend2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-bim-iol-system-phase-1-2-results2026-03-09T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-end-of-phase-2-fda-meeting-ipf-cough2026-03-09T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-opens-palm-beach-clinic2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYNB/kyntra-bio-fourth-quarter-full-year-2025-results2026-03-09T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WGS/genedx-acmg-2026-abstracts-presentation2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-2025-financial-results-updates2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-fda-fast-track-pbgene-dmd2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-board-changes-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-npulse-vybrance-thyroid-nodule-study2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-40-million-private-placement-financing2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-dale-hooks-cco2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-stock-repurchase-authorization2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENGN/engene-reports-q1-2026-financial-results-business-update2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-successor-2-mezigdomide-results2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-phase-2-study-tilrekimig-atopic-dermatitis2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-ai-insights-pancreatic-cancer-therapy2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/koselugo-approved-canada-plexiform-neurofibromas-nf12026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-ost-her2-type-b-pre-bla-meeting2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INM/inmed-update-pharmaceutical-development-programs2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-resubmission-sbla-fda-anktiva-bcg-nmibc2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-visara-positive-results-vis-101-phase-2a-study2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-protalix-elfabrio-eu-approval-four-week-dosing2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-acquires-biocare-medical-pathology-solutions2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AZN/enhertu-priority-review-her2-positive-breast-cancer2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-deliver-trial-results-dmd2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-phase-3-harmonia-trial-z-basivarsen-dm12026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/fda-approves-sotyktu-for-active-psoriatic-arthritis2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-zymyz-approval-advanced-scac2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIM/aim-immunotech-closing-rights-offering2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-regulatory-update-molbreevi-autoimmune-pap2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-acquisition-kuva-labs2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-inducement-grants-nasdaq-rule-56352026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-nasdaq-5635c42026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-nasdaq-ntla2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-reverse-stock-split-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-grants-inducement-awards2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-inducement-awards-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-announces-bbo-11818-preclinical-data-cancer-discovery2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGNY/progyny-executives-investor-conferences-march-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-mda-conference-20262026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DAWN/servier-day-one-acquisition-oncology-portfolio2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-240-million-private-placement2026-03-09T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-david-ramsay-interim-cfo2026-03-12T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-conference-call-20252026-03-12T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-q4-2025-financial-results2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-water-tower-research-podcast2026-03-12T15:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-global-patent-expansion-vanoglipel2026-03-12T14:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-clinical-trial-update-endoxifen2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-japanese-patent-codx-pcr-platform2026-03-12T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/freestyle-libre-technology-type-2-diabetes-management2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/freestyle-libre-technology-improves-glucose-management2026-03-12T08:54:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-voxzogo-early-treatment-achondroplasia2026-03-12T14:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-manufacturing-process-cld-4012026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/los-angeles-life-sciences-growth2026-03-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-maxim-group-strategic-opportunities2026-03-12T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XOMA/xoma-royalty-fourth-quarter-full-year-2025-results2026-03-12T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-reverse-stock-split2026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-financial-results-conference-call2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-rollout-glucose-monitoring-system-brazil2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-full-year-2025-results2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-clearmind-patent-weight-loss-therapy2026-03-12T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-sls009-aml-trial-enrollment2026-03-12T12:35:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-fourth-quarter-2025-results2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-positive-phase-3-dtx301-otc-deficiency2026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-presents-roth-conference-20262026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-year-end-2025-results2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-hydros-robotic-system-launch2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-2025-financial-results2026-03-12T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-2025-financial-results-update2026-03-12T12:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-fourth-quarter-2025-results-update-call2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-stifel-2026-cns-forum2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-financial-results-march-20262026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-q4-2025-financial-results2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-q4-2025-financial-results2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-2025-financial-results-conference-call2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPSC/century-therapeutics-2025-financial-results2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-report-full-year-2025-results-march-19-20262026-03-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q4-full-year-2025-results2026-03-12T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-financial-results-business-update-20252026-03-12T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-ad-pd-2026-fda-update2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-advances-burn-treatment-fibroblast-spheroid-technology2026-03-12T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-fda-clearance-ind-dare-hpv2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-presentations-adpd-2026-conference2026-03-12T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-2025-financial-results-highlights2026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope-3-data-2026-mda-conference2026-03-12T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q4-2025-financial-results2026-03-12T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-abstract-adpd-20262026-03-12T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BJDX/bluejay-abstract-accepted-saem-20262026-03-12T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q4-2025-financial-results2026-03-12T21:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-q4-full-year-2025-results2026-03-12T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-ceo-retirement-and-successor-appointment2026-03-12T21:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CURX/curanex-expands-scientific-advisory-board2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-report-2025-financial-results-conference-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-fourth-quarter-full-year-2025-results-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-deramiocel-dmd-mda-conference-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-expands-global-reach-argentina-clearance2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/extraordinary-general-meeting-izafe-group2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-saentra-forge-ceo-appointment-italian-academy2026-03-13T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-q4-year-end-2025-update-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-fourth-quarter-2025-results-conference-call2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-ceo-retirement-and-new-appointment2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-report-financial-results-q4-20252026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-reports-revenue-growth-fy20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q4-2025-financial-results-update2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-public-offering-747-million2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-q4-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-719-million-offering2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ERAS/erasca-reports-q4-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-fourth-quarter-full-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-year-end-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q4-2025-financial-results-update2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-annual-business-update-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capso-vision-financial-results-release-march-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q4-2025-financial-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q4-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-2025-financial-results-updates2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-q4-full-year-2025-financial-results-report2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-q4-2025-financial-results-update2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-fourth-quarter-fiscal-year-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-2025-results-2026-milestones2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KZR/enodia-therapeutics-acquisition-kezar-assets2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-reports-financial-results-20252026-03-13T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-recommends-shareholders-vote-for-consolidation2026-03-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-financial-results-20252026-03-13T10:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-2025-financial-results2026-03-13T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-ticker-change-nasdaq-qucy2026-03-13T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-total-artificial-heart-btv2026-03-13T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q4-2025-financial-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/indivior-prices-upsized-convertible-senior-notes-offering2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-march-20262026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STVN/stevanato-group-keybanc-virtual-healthcare-forum2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-ceo-transition2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-stifel-2026-cns-forum2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-revenue-growth-20252026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-financial-results-20252026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SANA/sana-biotechnology-type-1-diabetes-study-results2026-03-13T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-shareholder-approval-oramed-partnership2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/tacti-004-phase-iii-study-discontinued2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/graftassure-assay-superiority-study-imdx2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-financing-ra-capital-management2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-inducement-awards-nasdaq-rule-56352026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-hong-kong-patent-depression-therapy2026-03-13T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-2025-financial-results2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-2025-revenue-cypath-lung2026-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-strategic-progress-clinical-development2026-03-13T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-new-brain-wave-biomarkers-adhd2026-03-13T11:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/captain-trial-tulsa-vs-robotic-prostatectomy2026-03-13T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SBC/sbc-medical-q4-full-year-2025-results2026-03-13T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADTX/aditxt-acquires-ignite-proteomics-cancer-care2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-reports-fourth-quarter-year-end-2025-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-participation-stifel-2026-cns-forum2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-eu-mdr-certification-freedom60-infusion-pump2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-nk-cell-production-milestone2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-reports-2025-financial-results2026-03-13T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-zervimesine-dlb-adpd-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-q3-2026-results-update2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-q4-full-year-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-inducement-awards-nasdaq-rule-56352026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-public-offering-common-stock2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-financial-results-20252026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRMD/iradimed-participate-38th-annual-roth-conference2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMRN/reduce-it-data-acc-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-participate-roth-conference-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-participate-upcoming-investor-meetings2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-corporate-updates-fiscal-year-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-participate-roth-conference-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-clearmind-patent-depression-therapy2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/new-data-approach-trial-transcon-cnp-achondroplasia2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRON/cronos-group-speak-38th-roth-conference2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-phase-ii-covalent-111-results-diabetes2026-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-regulatory-milestone-saudi-arabia2026-03-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-lsi-usa-26-summit-presentation2026-03-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYPH/cypherpunk-reports-full-year-2025-financial-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-veritas-genetics-preventive-genomics-consortium2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-ai-insights-platinum-resistance-ovarian-cancer2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-2025-annual-results-conference-call2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HALO/fda-approves-tecvayli-darzalex-faspro-multiple-myeloma2026-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-q4-2025-financial-results-update2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-bioequivalence-ketamine-application2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-update-recurrence-rate2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-q4-2025-earnings-call2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q4-2025-financial-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRFS/grifols-chronos-platform-parkinsons-disease2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-agreement-global-preclinical-cro2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-nsclc-trial-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-henry-brem2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-launches-sancuso-website2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-sonicare-world-oral-health-night2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-fda-response-reproxalap-dry-eye2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-appoints-kevin-lobo-board-directors2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IQV/iqvia-ai-platform-launch-nvidia2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-patents-psychedelic-therapies2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASRT/assertio-reports-fourth-quarter-full-year-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CERS/cerus-appoints-vivek-jayaraman-ceo2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-financial-results-20252026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-announces-cfo-transition2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-enrollment-endeavor-cohort-8-elevidys-gene-therapy2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VREX/varex-successful-debt-refinancing2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-corporate-update-fiscal-2025-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-new-data-cardio-pulmonary-pipeline-acc262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-phase-3-results-20252026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-120-million-financing2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MASS/908-devices-sidoti-small-cap-conference-20262026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-reports-2025-financial-results2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-reports-business-progress-financial-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-accelerates-cardiac-catheter-program2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-positive-topline-phase-2-results-atirmociclib2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-at-roth-conference-20262026-03-17T13:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASND/transcon-hgh-turner-syndrome-trial-results2026-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/imc-strategic-entry-cyber-drone-interception2026-03-17T13:37:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-q4-2025-earnings-release-webcast2026-03-17T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-2025-financial-operational-results2026-03-17T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-reports-q4-2025-results2026-03-17T11:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-osa-study-oral-anatomy-correlation2026-03-17T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-q4-2025-results2026-03-17T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-dan-reuvers-ceo2026-03-17T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-fda-pdufa-fee-waiver-d-plex100-nda2026-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MYNZ/quantum-cyber-strategy-trump-administration-cybersecurity2026-03-17T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-roth-conference-participation2026-03-17T12:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-financial-results-webcast-march-20262026-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-financial-results-platform-expansion2026-03-17T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-submits-marketing-authorization-symvess-israel2026-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-license-hcw11-006-trimmune2026-03-17T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-nmpa-priority-review-hydronidone2026-03-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q4-2025-results2026-03-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-clear-outcomes-acc-20262026-03-17T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EPRX/eupraxia-phase-1b-2a-resolve-trial-eosinophilic-esophagitis2026-03-17T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/national-survey-correctional-facilities-opioid-treatment2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-gardasil-eurogin-congress-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/clinical-utility-signatera-anal-rectal-cancers2026-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-fourth-quarter-2025-earnings-call2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-q3-fiscal-2026-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MGRX/mangoceuticals-lawsuit-clarity-ventures2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-andrew-ratz-cto2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q4-2025-results-corporate-update2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-q4-2025-results2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-keybanc-capital-markets-forum2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-presents-new-data-aacr-annual-meeting2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-aacr-2026-posters2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-aacr-2026-adc-portfolio2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-muzastotug-aacr-2026-presentations2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-aacr-annual-meeting-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-prt13722-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMA/imagene-bio-inducement-grants-nasdaq-rule-56352026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ads-ratio-change2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-missing-screenings-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-aacr-2026-presentations2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-aacr-2026-oncology-candidates2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-aacr-presentation-cldn18-22026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-aacr-2026-botensilimab-balstilimab-colorectal-cancer2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1500-millones-mujeres-pruebas-preventivas-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-aacr-annual-meeting-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-transparency-notification-bank-of-america2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-bank-of-america-transparency-declaration2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/arrrivent-preclinical-posters-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-aacr-2026-presentation-kinesin-degrader2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-zidesamtinib-aacr-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-missing-preventive-tests-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-lack-essential-screenings2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOLX/1-5-billion-women-lack-essential-screenings-holx2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-aacr-2026-abstracts2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVMD/revolution-medicines-aacr-2026-presentations2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MESO/mesoblast-rd-day-april-20262026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/nccn-guidelines-update-anktiva-bcg-nmibc2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-research-agreements-nad-plus2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-aacr-annual-meeting-20262026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-abstracts-sgo-2026-avutometinib-defactinib2026-03-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-250-million-offering2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-poster-presentations-aacr-20262026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-new-data-aacr-annual-meeting2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCR/immunocore-kimmtrak-2026-aacr-presentation2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NNNN/anbio-biotechnology-keybanc-healthcare-forum2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMRX/immuneering-2026-aacr-annual-meeting-atebimetinib-data2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-operational-progress-altai-capital2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-full-year-2025-financial-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-pricing-public-offering-common-stock2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-aacr-annual-meeting-20262026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-aacr-2026-preclinical-data2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptar-announces-gael-touya-ceo-transition2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVBP/aarvik-therapeutics-aacr-2026-adc-molecules2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-abstracts-sgo-2026-ovarian-cancer2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FLGT/fulgent-genetics-acquisition-bako-stratadx2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXAS/exact-sciences-aacr-2026-mrd-mced-data2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q4-2025-financial-results-update2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-inducement-grants-nasdaq-rules2026-03-18T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-10-million-public-offering2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-q4-2025-financial-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-20252026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-bio-europe-spring-20262026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-full-year-2025-results-highlights-milestones2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBOT/bbot-announces-presentations-aacr-annual-meeting-20262026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-barda-funding-deepview-system2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-kathy-turner-board2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-full-year-2025-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-participate-38th-annual-roth-conference2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/red-light-holland-kala-bio-pex010-clinical-development2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-abstracts-ascrs-2026-annual-meeting2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-university-buffalo-sjogrens-syndrome2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-report-q4-2025-results2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-virtual-investor-event-niyad-crrt2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-labcorp-collaboration-precision-oncology-testing2026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-glp1-obesity-program-irb-approval-phase-12026-03-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-iba-cyclotron-manufacturing-expansion2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-choisit-cyclone-kiube-iba-production-us2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-2025-financial-results-conference-call2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-2025-financial-results-business-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-financial-results-q4-2025-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-presents-roth-conference-20262026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q4-2025-results-business-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-board-constitution-restricted-stock-units-warrants2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-annual-general-meeting-20262026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-20-million-offering2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-phase-i-study-lag-3-agonist-autoimmune-diseases2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-gtx-104-presentation-data-asah2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q4-2025-financial-results2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-reports-2025-results-miracle-trial-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-fda-action-animal-testing2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-reports-q4-fiscal-year-2025-results2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRIS/curis-fourth-quarter-2025-business-update2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-launches-national-chemical-defense-consortium2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-hybrite-clinical-summary-expert-opinion2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-hotswap-launch-aferetica-partnership-isicem-20262026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSRH/woori-io-signs-nda-sinopharm-china-market2026-03-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-cardamyst-launch-update2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-new-roles-20262026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-kol-webinar-ras-mutated-colorectal-cancer2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/deucrictibant-efficacy-safety-h%20hereditary-angioedema2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-financial-results-conference-call-20262026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-fourth-quarter-2025-results-needham-conference2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/autophagy-failure-alzheimers-disease-avxl2026-03-20T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-lung-nodule-biomarker-study2026-03-20T12:06:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capsovision-announces-14-million-private-placement-financing2026-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-next-gen-emperor-heart-technology-acc-20262026-03-20T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-iba-cyclone-manufacturing-expansion-us2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardias-2025-financial-results-conference-call2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATR/aptars-unidose-nasal-delivery-phase-ii-study-inna0512026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-full-year-2025-results-business-update2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-quantiFERON-tb-prevention-data2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZURA/zura-bio-full-year-2025-financial-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-fda-approval-imcivree-acquired-obesity2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-reports-q4-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-releases-q1-2026-aide-memoire2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AND/teva-conference-call-first-quarter-2026-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-roth-conference-20262026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-reports-q4-full-year-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-report-financial-results-march-20262026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLSN/solesence-fourth-quarter-full-year-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SABS/sab-bio-closes-85-million-offering2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGMO/sangamo-therapeutics-2025-earnings-call2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-virtual-rd-day-kidney-disease-pipeline2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-2025-financial-results-update2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-q4-2025-financial-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-year-end-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-year-end-2025-financial-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-q4-full-year-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-q4-2025-financial-results-conference-call2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-gpsai-study-improving-cancer-diagnosis2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-expands-south-asia-distribution2026-03-20T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acquisition-exact-sciences-march-20262026-03-20T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-phase-2b-studies-aad-20262026-03-20T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENSG/ensign-group-quarterly-dividend-announcement2026-03-20T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-gpsai-study-misdiagnosis-cancer2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QGEN/qiagen-announces-form-20-f-annual-report-filing-2025-results2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-present-new-ekterly-data-angioedema-conference2026-03-20T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/pantherx-selected-exclusive-pharmacy-imcivree-expansion2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/real-world-leqembi-treatment-persistence-adpd-20262026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-long-term-treatment-persistence-adpd-20262026-03-20T16:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTLB/xtl-biopharmaceuticals-ads-ratio-change2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DHR/danaher-first-quarter-2026-earnings-call2026-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-investor-events-darovasertib-results2026-03-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-conference-call-apex-trial-data2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-investor-relations-events-darovasertib-results2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTA/prothena-data-parkinsons-alzheimers-adpd-20262026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-presentation-ebmt-2026-ta-tma-treatment2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-opdivo-approval-hodgkin-lymphoma2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IOVA/iovance-inducement-grants-nasdaq-rule-5635c42026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GS/zevra-therapeutics-cfo-inducement-grant2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-annual-general-meeting-may-20262026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inducement-grants-nasdaq-rule-56352026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-approval-macau-nmibc2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-report-2025-financial-results-conference-call2026-03-23T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-webcast-phase-2-trial-data-ocu4102026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTX/avalos-2025-financial-results-business-updates2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-approves-effexor-japan-generalized-anxiety-disorder2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIOA/new-data-long-term-treatment-lecanemab-2026-ad-pd-congress2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-fourth-quarter-full-year-2025-results2026-03-23T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-enrollment-milestone-miracle-trial2026-03-23T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-positive-results-phase-3b-encore-arikayce2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/craig-tendler-leads-tuhura-vista-program-aml2026-03-23T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-omniasecure-fda-approval-defibrillation-lead2026-03-23T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-phase-1-renergen-helium-project-drilling-completed2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-pipeline-business-updates-2025-results2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-phase-3-trial-fda-approval2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-epicapture-prostate-cancer-test-results2026-03-23T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-private-placement-funding2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tp-03-approval-china-demodex-blepharitis-tars2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-share-reclassification2026-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-senti-202-innate-killer-conference2026-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-pharmaceuticals-closes-10-million-offering2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-closing-10-million-private-placement2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-unbuzzd-clinical-trial-publication2026-03-23T12:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-business-update-q4-2025-results2026-03-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-leadership-appointment-jennifer-mcdonough2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRCT/eau-guidelines-upgrade-aquablation-therapy-bph2026-03-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-1-opus-2-phase-3-trials2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-reverse-stock-split-20262026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-2026-acc-presentations2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-cfo2026-03-23T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-annual-general-meeting-20262026-03-23T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-launch-choriofix-advanced-wound-care2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-novo-nordisk-phase-1-study-lx98512026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-commercial-site-transfer-agreement2026-03-23T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-2025-financial-results-update2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/national-viagra-day-women-claim-turn2026-03-23T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q4-2025-results2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-q4-2025-results-business-update2026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/biodexa-global-early-access-erapa-fap-patients2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q4-2025-results-update2026-03-23T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-attr-cm-acc-presentation-20262026-03-23T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-valneva-lyme-disease-vaccine-phase-3-results2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/hybryte-treatment-results-us-cutaneous-lymphoma-workshop2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-aacr-2026-presentations2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-300-million-offering2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-annual-meeting-shareholders-20262026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-public-offering2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMED/globus-medical-board-departure2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-pricing-oversubscribed-offering2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IONS/ionis-zilganersen-fda-priority-review-alexander-disease2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-valneva-lyme-disease-vaccine-efficacy-phase-32026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-joenja-approval-japan-apds2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-photonova-spectra-fda-clearance2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-fourth-quarter-2025-results2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/insitro-bristol-myers-squibb-collaboration-expansion2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-initiates-coverage-zacks2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-ouro-medicines-t-cell-engager2026-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-bullous-pemphigoid-japan2026-03-24T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-medtech-leader-european-patent-office-20252026-03-24T08:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-evolving-into-saentra-forge-strategic-options2026-03-24T07:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-q1-2026-aide-memoire-availability2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-approval-japan-bullous-pemphigoid2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q4-fiscal-year-2025-results-webcast2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-gilead-collaboration-t-cell-engager-autoimmune2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-2025-financial-results-presentation2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-world-vaccine-congress-20262026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q4-2025-financial-results2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-fourth-quarter-full-year-2025-results2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STRO/sutro-biopharma-2025-financial-results-highlights2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRZN/surrozen-reports-q4-2025-results-business-update2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTX/context-therapeutics-reports-2025-results2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-elcc-2026-lung-cancer-portfolio2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-elcc-2026-lung-cancer-data2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QDEL/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-pricing-public-offering2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-2025-results-regulatory-progress2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-reports-q4-2025-results-and-guidance2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-cellsentials-consumerlab-approval2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-private-placement-ra-capital2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-full-year-2025-results-call2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/alnylam-advances-attr-cm-care-collaboration-viz-ai2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMPS/compass-pathways-q4-full-year-2025-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGNE/neurogene-reports-full-year-2025-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-phase-2-armada-trial-results-ocu4102026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-ip-patent-portfolio2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-phase-3-sentry-trial-myelofibrosis-results2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-partners-with-mlb-striking-out-cancer2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/john-stamos-jodie-sweetin-cologuard-campaign2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ASPI/asp-isotopes-quantum-leap-bristol-laser-facility2026-03-24T11:41:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-usclc-workshop-2026-lymphir2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-partnership-avance-clinical-australia2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEMD/aethlon-medical-advances-final-cohort-oncology-trial2026-03-24T13:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RZLT/rezolute-update-congenital-hyperinsulinism-fda-meeting2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-investor-summit-conference-20262026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-jeffrey-munsie-appointment2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-sotagliflozin-presentations-acc-20262026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q4-2025-financial-results2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-fast-company-innovative-companies-20262026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-year-end-2025-results-update2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-2025-financial-results-conference-call2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-acquires-ouro-medicines-galapagos-partnership2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q4-2025-financial-results2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAMP/camp4-appoints-michael-maclean-board-directors2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q4-2025-results-business-updates2026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/2020-biolabs-rokit-healthcare-ckd-prediction-agreement2026-03-24T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-debt-financing-rain-token-updates2026-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-liberty-robotic-system-publication2026-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-dairy-industry-mexico2026-03-24T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-add-on-offering-senior-unsecured-notes2026-03-24T12:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEED/envue-medical-expands-presence-michigan-health-system2026-03-24T12:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-adc-toxicity-detection-models2026-03-24T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-haus-agreement-silhouette2026-03-24T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMS/ams-financial-results-conference-call-20252026-03-24T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-compliance-nasdaq-filing-requirement2026-03-24T10:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATAI/atai-beckley-joins-crsp-index-s-p-benchmark-indices2026-03-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-roth-conference-20262026-03-24T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/spago-nanomedical-tumorad-abstract-presentation2026-03-24T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-im8-superpower-supplementation-partnership2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-advances-key-regulatory-milestones2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-dpyd-testing-colorectal-cancer-awareness2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-appoints-meir-peleg-cfo2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INMD/inmode-presentation-needham-healthcare-conference-20262026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-webcast-may-5-conference-call2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-receives-uae-regulatory-clearance2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TMO/thermo-fisher-acquisition-clario-holdings2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-pre-clinical-results-catheter2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-merit-medical-agreement-viaverte-system2026-03-24T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-ht-001-positive-data2026-03-24T13:13:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trial-sil2042026-03-24T13:46:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-acquire-20-percent-colugo-stake2026-03-24T12:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-investor-summit-conference-20262026-03-24T15:18:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-ceo-pay-bump-20252026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-congress-bipartisan-legislation-aud2026-03-24T13:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRVA/privia-health-2026-hfma-map-award-revenue-cycle-excellence2026-03-24T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-research-collaboration-spain2026-03-24T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-2025-financial-results-highlights2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-conference-call-2025-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-q4-full-year-results-20252026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-2025-business-highlights-financial-results2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-nasdaq-minimum-bid-requirement2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRPT/sarepta-clinical-data-sirna-pipeline-fshd1-dm12026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-financing-avenue-capital2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-shareholders-approved-share-consolidation2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HROW/harrow-pricing-50-million-offering-senior-notes2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-employment-inducement-grants2026-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering-350-million2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-pricing-public-offering2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-employment-inducement-grants-march-20262026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MEDP/medpace-holdings-first-quarter-2026-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-q4-2025-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-fourth-quarter-full-year-2025-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q4-2025-results-and-2026-guidance2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-fourth-quarter-results-20252026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-2025-financial-results2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-join-cac-mid-60-sbf-120-indices2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-ana-sodium-reduction-initiative2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-addresses-short-seller-report2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-acquire-terns-pharmaceuticals-hematology-pipeline2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TERN/merck-acquire-terns-pharmaceuticals-hematology-pipeline2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-pharmaceuticals-fiscal-year-2025-results-update2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVXL/anavex-withdraws-blarcamesine-eu-application2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-geekwire-deal-of-the-year2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-virtual-investor-event-april-20262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-announces-reverse-stock-split2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-q4-2025-financial-results-announcement2026-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-ships-diagnostic-materials-india-tuberculosis-studies2026-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-comet-suite-spatial-biology2026-03-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-vicki-goodman-cmo2026-03-25T11:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-appoints-jane-wright-mitchell-clo2026-03-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-full-year-2025-results2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-reports-q4-2025-results-highlights2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-phase-2-horizon-trial-mze8292026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-phase-2-data-ovarian-cancer2026-03-25T12:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSCS/heartsciences-myvista-insights-epic-toolbox-designation2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-ouro-buy-johnson-johnson-approval2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDAP/edap-reports-record-hifu-revenue-20252026-03-25T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-phase-1b-trial-cemsidomide-elranatamab2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-2025-financial-results2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APUS/inscobee-apimeds-new-board-appointment2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TOMZ/tomi-environmental-solutions-binary-ionization-technology-approval2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-full-year-2025-results2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVF/invo-fertility-reverse-stock-split-march-20262026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-update-qrx003-netherton-syndrome2026-03-25T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-fda-feedback-abp-450-biosimilar2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTAK/flyte-hops-vision-jet-private-aviation2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-nova-2-trial-lb-102-schizophrenia2026-03-25T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-statement-media-speculation2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-declaration-rumeur-medias2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-oncology-studies-aacr-20262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLPH/talphera-abstracts-aki-crrt-20262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-jessica-chutter-board2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-showcase-cardiology-portfolio-acc262026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIVN/livanova-first-quarter-2026-results-announcement2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-strategic-alternatives-review2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-2025-financial-results2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-detection-early-stage-cancers2026-03-25T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-positive-results-icesecret-study-kidney-cancer2026-03-25T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/new-york-life-sciences-job-opportunities2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-realbotix-ericsson-6g-trial2026-03-25T16:47:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GHRS/gh-research-phase-2b-results-mebufotenin-trd2026-03-25T15:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-fda-approval-avlayah-hunter-syndrome2026-03-25T15:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-webinar2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRXH/srxh-health-solutions-hedges-defi-portfolio-investment-gold2026-03-25T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-advances-ns002-pivotal-study2026-03-25T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-glaucoma-market-expansion2026-03-25T11:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-full-year-2025-financial-results2026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-brands-third-quarter-results-april-20262026-03-25T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/philips-intrasight-plus-launch-coronary-interventions2026-03-25T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-executive-leadership-appointments2026-03-25T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-new-contracts-for-smallpox2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-closes-public-offering2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-full-year-2025-results2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-q4-2025-results-corporate-update2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-executive-team-appointments2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-ernennung-von-fuehrungspersonal2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-announces-executive-appointments2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/fda-approves-corcepts-lifyorli-ovarian-cancer2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-fiscal-year-2025-earnings-call2026-03-25T21:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q4-2025-financial-results2026-03-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q4-2025-financial-results-update2026-03-25T22:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-q4-2025-results-and-highlights2026-03-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-2025-financial-results-business-updates2026-03-25T21:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-2025-financial-results-business-updates2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-share-consolidation2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-annual-report-fiscal-year-20252026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-appoints-jesper-hoiland-head-strategy2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2025-annual-report-10-k2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2025-financial-results2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-annual-meeting-stockholders-virtual-format2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-new-executive-appointments2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-nominations-haute-direction2026-03-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-full-year-2025-results-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-annual-meeting-2026-virtual-format2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGEN/oragenics-receives-audit-opinion-going-concern2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q4-2025-financial-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-annual-report-20252026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRTC/glyphallo-first-triglyceride-mimetic-prodrug2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-full-year-2025-results-update2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-reverse-stock-split-nasdaq-compliance2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-2025-annual-report2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-jesper-hoiland-strategy-appointment2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-financial-results-20252026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-fourth-quarter-full-year-2025-results-webinar2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CELC/celcuity-reports-q4-full-year-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-full-year-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q4-full-year-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROK/prokidney-appoints-greg-madison-cco2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-first-quarter-2026-results-conference-call2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-roluperidone-olanzapine-trial-sirs-20262026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-fourth-quarter-2025-results2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-q4-2025-results-eq504-update2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFWD/lifeward-strategic-partnership-oramed2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-secures-new-contracts-smallpox2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-2025-financial-results-business-highlights2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-expand-personalized-nutrition-acquisition-bioniq2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-fda-approval-plasma-collection-center-san-antonio2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-q4-2025-financial-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-financial-results-20252026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-financial-results-corporate-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-phase-3-vanquish-2-trial-completion2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-investor-analyst-day-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-phase-2-panova-4-trial-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-orphan-drug-designation-sgx945-behcets-disease2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-appoints-ron-andrews-board2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-pivotal-trial-anktiva-bcg-nmibc2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXR/daxor-blood-volume-analysis-validated-sccm-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-2026-aspire-higher-scholarship-program2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-4-million-offering2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-esophageal-cancer2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-openclaw-ai-drug-discovery2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-ai-insights-brain-metastases-risk2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLGN/collplant-biotechnologies-2025-financial-results-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-rain-update-ai-agent-interface-prediction-market2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-eu-consortium-cardio-oncology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-acquires-bbb-delivery-technology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-announces-fourth-quarter-full-year-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLNO/soleno-therapeutics-securities-fraud-lawsuit2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-first-quarter-2026-earnings-call2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-chmp-positive-opinion-imcivree2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-q4-2025-results2026-03-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-vitiligo-program-update-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volition-abstract-risk-stratification-lung-cancer-elcc2026-03-26T13:17:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-glow2-phase-3-results-diabetic-retinopathy2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-year-end-2025-financial-results2026-03-26T13:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-consensus-recommendations-tardive-dyskinesia2026-03-26T13:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-positive-phase-1-data-wve-0072026-03-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-insurance-coverage-nevada2026-03-26T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-3-development-strategy-verekitug2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-1-study-tnx-19002026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-phase-iii-tiger-pac-trial-milestone2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-phase-2-clinical-trial-lucid-ms2026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q4-20252026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-launches-security-subsidiary-israel-investment2026-03-26T12:48:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-business-update-skinject-study2026-03-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBOT/emory-healthcare-robotic-endovascular-procedures2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LGND/ligand-expands-business-development-team2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-new-agreements2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-appoints-rick-mcelheny-business-development2026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GERN/geron-appoints-new-board-members2026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-virtual-rd-day-april-20262026-03-26T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-year-end-2025-results-update2026-03-26T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIFF/firefly-partnership-department-war-ptsd-tbi2026-03-26T11:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-cytisinicline-receptor-selectivity2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHG/fda-clears-philips-ai-solution-heart-valve-repair2026-03-26T13:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-q4-fy2025-results-conference-call2026-03-26T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-european-ip-patent-grant2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CDT/cdt-expands-tapinarof-ip-portfolio-patent-filings2026-03-26T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-reports-2025-financial-results2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLRY/tilray-popsicle-adult-beverages-launch2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGMB/agomab-us-patent-agmb-447-ipf-treatment2026-03-26T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q4-2025-results-guidance-20262026-03-26T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FIRST/faron-pharmaceuticals-new-cto-appointment2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/fda-approves-lifyorli-relacorilant-cort2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-participate-world-vaccine-congress-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VALN/valneva-participation-world-vaccine-congress-20262026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-leadership-eu-consortium-cardio-oncology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-strategic-cro-evaluation-clinical-research2026-03-26T16:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-2025-highlights-update2026-03-26T13:23:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-leads-eu-ihi-consortium-cardio-oncology2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-reports-2025-financial-results-clinical-progress2026-03-26T13:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-vinia-no-1-resveratrol-brand-us2026-03-26T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-leads-eu-funded-ihi-consortium2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-role-consortium-cardio-oncology-eu2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-2025-annual-report-shareholders-meetings2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-2025-annual-report-and-general-meetings2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-public-offering-403-million2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-full-year-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-offerings-convertible-notes-common-stock2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-public-offering-common-stock2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-reports-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-reports-q4-2025-earnings-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q4-2025-results-business-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-graftassuredx-fda-review-q4-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-ceo-resignation-appointment-robert-goodman2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capso-vision-reports-q4-full-year-2025-results2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-fiscal-2025-results-update2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-phase-3-apollo-trial-bitopertin-epp2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-share-consolidation-delay2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-host-march-2026-webcast-bot-bal2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-announces-results-annual-special-meeting-shareholders2026-03-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-concurrent-public-offerings-20262026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-positive-chmp-opinion-joenja-apds-treatment2026-03-27T06:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-march-2026-stakeholder-webcast-bot-bal2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLP/simulations-plus-q2-fiscal-2026-earnings-call2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-corporate-update-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-record-revenues-financial-results-q4-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-reports-2025-financial-results-business-update2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/STOCK/dbv-technologies-2025-annual-report-filing2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-phase-3-apollo-trial-bitopertin2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVB/eisai-nuvation-bio-taletrectinib-ema-approval2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-concurrent-public-offerings2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-2025-financial-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-2025-financial-results-business-update2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-nominates-gino-santini-board-directors2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-business-update-q4-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CV/capsovision-q4-full-year-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-fourth-quarter-full-year-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-submits-graftassuredx-fda-review-q4-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-reports-financial-results-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-financial-results-20252026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGP/spyglass-pharma-fourth-quarter-full-year-2025-earnings2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CRNX/crinetics-submission-marketing-authorization-brazil-palsonify2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-2025-financial-results-updates2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-announces-q4-2025-financial-update2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-reports-q4-2025-results2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZEAL/zealand-pharma-annual-general-meeting-2026-resolutions2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-advances-cro-evaluation-revenue-growth2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-compass-consortium-cardio-oncology2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-fda-approval-pd-l1-ihc-22c3-esophageal-carcinoma2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-quilt-2-005-trial-results-20262026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-first-oncology-injectable-self-administration2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-reports-2025-financial-results-progress2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDIT/editas-medicine-broad-institute-patent-decision2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-approval-kresladi-pediatric-lad-i2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-upsized-public-offering2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-patent-india-psychedelic-compounds2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/irenic-letter-teleflex-board-acquirors2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/profound-medical-texas-prostate-100th-tulsa-procedure2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-announces-75-million-private-placement-tcgx2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-reports-financial-results-20252026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-lawsuit-skincure-oncology2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-q4-full-year-2025-results2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/ivonescimab-phase-iii-studies-elcc-20262026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-mcs2-clinical-benefits2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/york-space-systems-new-contract-update2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/first-tracks-biotherapeutics-secures-145-million-private-placement2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-spin-off-first-tracks-biotherapeutics2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANAB/anaptys-announces-stock-repurchase-plan-business-update2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIL/instil-bio-reports-q4-full-year-2025-results2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-fda-approval-neffy-age-requirement2026-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-2025-financial-results2026-03-27T12:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-phase-1b-trial-data2026-03-27T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-150-million-private-placement2026-03-27T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-fourth-quarter-year-end-2025-results2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-financial-results-20252026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GCTK/glucotrack-fda-ide-filing-q2-20262026-03-27T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-igalmi-approval-outpatient-setting2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADMA/adma-biologics-refutes-culper-research-allegations2026-03-27T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-annual-report-conference-call2026-03-27T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AIDX/maryland-fire-departments-cancer-screenings-onetest2026-03-27T12:31:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-signs-binding-offer-sophia-high-tech2026-03-27T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-2025-financial-results-envee-system2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LTRN/fda-clearance-ind-star-001-pediatric-cns-trial2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-approval-kresladi-leukocyte-adhesion2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MNPR/monopar-reports-fourth-quarter-full-year-2025-results2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-commitment-value-maximizing-strategies2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ebglyss-lebrikizumab-atopic-dermatitis-results2026-03-27T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-aad-2026-immune-mediated-skin-diseases2026-03-27T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-2026-dermatology-meeting2026-03-27T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-positive-data-phase-2-urticaria-studies2026-03-27T14:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-private-placement-11-million2026-03-27T14:40:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACRS/aclaris-ati-2138-aad-2026-results2026-03-27T14:10:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-nova-1-trial-results-sirs-20262026-03-27T16:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-mhra-ema-australian-tga-meetings2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SMMT/ivonescimab-data-phase-iii-elcc-20262026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OGN/organon-vtama-cream-atopic-dermatitis-analysis2026-03-27T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TFX/teleflex-open-strategic-alternatives2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-2026-annual-meeting-date2026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-financial-results-update-20252026-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-2025-financial-results-update2026-03-27T21:12:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-data-acc-20232026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-momentum-trial-presentation-acc-20232026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-litifilimab-phase-2-results-cle2026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-phase-3-sonelokimab-hidradenitis-suppurativa-results2026-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-phase-2b-results-aad-20262026-03-28T17:36:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JNJ/icotyde-one-year-results-plaque-psoriasis2026-03-28T15:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/champion-af-study-watchman-flx-device2026-03-28T15:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/hi-peitho-trial-boston-scientific-ekos-superior-treatment2026-03-28T15:38:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-povorcitinib-hidradenitis-supurativa-aad-20262026-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-positive-data-povorcitinib-hidradenitis-suppurativa2026-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INCY/incyte-povorcitinib-hidradenitis-suppurativa-aad-20262026-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-securities-fraud-lawsuit2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-lawsuit-securities-violations2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-presents-phase-2-data-nbtxr3-lung-cancer2026-03-30T06:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/bms-phase-3-scout-hcm-trial-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-winrevair-phase-2-cadence-trial-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TAK/takeda-zasocitinib-psoriasis-phase-3-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CORT/corcept-momentum-trial-acc-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-cuts-risk-major-cardiovascular-events2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/taltz-zepbound-superior-efficacy-psoriatic-arthritis-obesity2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-phase-3-sonelokimab-results-hidradenitis-suppurativa2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/valor-trial-brepocitinib-dermatomyositis-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALMS/alumis-envudeucitinib-phase-3-trials-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-hypertriglyceridemia-data2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-phase-2b-rezolve-ad-rezolve-aa-data-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/hi-peitho-trial-ekos-superior-treatment-pulmonary-embolism2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/champion-af-study-watchman-flx-device-stroke-risk-reduction2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNY/sanofi-amlitelimab-phase-3-results-atopic-dermatitis2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-broadening-data-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-phase-2-results-atopic-dermatitis-infants2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PTGX/protagonist-icotyde-phase-3-data-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMY/cobenfy-switch-study-symptom-stability2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-financial-results-20252026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-2026-annual-meeting-date-announcement2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-full-year-2025-financial-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VERA/vera-therapeutics-inducement-grants-march-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-ceo-transition-lucinda-warren2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-q4-full-year-2025-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-lb-102-cognitive-performance-sirs-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TIVC/tivic-ceo-emerging-growth-conference-april-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-positive-phase-2-data-barzolvolimab-aad-20262026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-2026-aad-meeting2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ebglyss-lebrikizumab-atopic-dermatitis-study-results2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-test-improves-risk-prediction2026-03-30T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-fda-fast-track-zw191-ovarian-cancer2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-fda-clearance-asurys-fluid-management-system2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRXP/hope-therapeutics-emobot-partnership-ai-depression-thermometer2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fda-anaphylm-meeting2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACB/aurora-executive-gender-diversity-globe-mail2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-elegrobart-phase-3-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/UTHR/united-therapeutics-teton-1-study-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-positive-phase-3-data-kid-trial2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-stat6-inhibitor-immunology20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-high-dose-spinraza-nusinersen-sma2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-plinabulin-aacr-2026-poster-presentation2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-vilobelimab-pyoderma-gangrenosum-aad-20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNSE/sensei-biotherapeutics-full-year-2025-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MANE/veradermics-reports-q4-full-year-2025-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-ai-polio-vaccine-world-congress2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PCRX/pacira-exparel-cost-care-ors-20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-apr-1051-clinical-trial-update2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-conference-call-q1-2026-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-oversubscribed-private-placement2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BFLY/butterfly-network-fda-clearance-blind-sweep-ai-tool2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-third-quarter-fy-2026-results-release2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SVRA/savara-ema-validation-marketing-authorization-application2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-fireside-chat-hc-wainwright-march-312026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-settles-debt2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BAX/baxter-introduces-iv-verify-line-labeling-system2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/koppers-closing-bell-20th-anniversary2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-therapy-presentation2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EW/edwards-lifesciences-evoque-system-two-year-data2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-phase-1-combination-study-ide849-ide1612026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-precision-oncology-flatiron-integration2026-03-30T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-dr-robert-walker-rd-lead2026-03-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-q4-2025-financial-results-update2026-03-30T12:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-first-patient-phase-3-upstream-sjd-trial2026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/URGN/envision-trial-results-zusduri-urogen2026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-year-end-2025-financial-results2026-03-30T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SSII/ss-innovations-expands-global-opportunity-ss-mantra-approval2026-03-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-alcon-patent-infringement-verdict2026-03-30T11:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SEER/seer-patent-upheld-nano-micro-particle-enrichment2026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-reports-year-end-2025-financial-results2026-03-30T12:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RVPH/reviva-reports-full-year-2025-financial-results2026-03-30T10:05:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-fda-clearance-ux016-gne-myopathy2026-03-30T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-allucent-phase-2-trial-ms2026-03-30T11:50:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-scientific-publication-vascular-anomalies2026-03-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-adds-former-mossad-deputy-advisory-board2026-03-30T13:28:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-2025-financial-results-update-pds0101-phase-32026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-q4-2025-financial-results2026-03-30T10:53:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-phase-2-validation2026-03-30T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-bionic-intelligence-research-agent-launch2026-03-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nexicart-2-trial-enrollment-complete2026-03-30T12:45:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-positive-data-quellimmune-save-registry2026-03-30T12:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ESPR/esperion-new-data-clear-outcomes-acc-20262026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-expands-intellectual-property-portfolio2026-03-30T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-private-placement-financing2026-03-30T11:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/rademikibart-phase-3-atopic-dermatitis-results2026-03-30T11:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-positive-topline-data-rademikibart2026-03-30T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-clinical-trial-cmnd-1002026-03-30T12:32:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CANF/can-fite-vetbiolix-phase-2-osteoarthritis-study-dogs2026-03-30T11:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALNY/new-data-acc26-vutrisiran-zilebesiran2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKTS/aktis-oncology-fda-clearance-ak-2519-business-updates2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-needham-healthcare-conference-20262026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVVD/invivyd-presentation-world-vaccine-congress-washington2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-q4-2025-financial-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-cyprium-sale-priority-review-voucher2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-freedom2-study-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-full-year-2025-financial-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INGN/inogen-inc-inducement-grants-nasdaq-listing-rule2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-financial-results-20252026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IVA/inventiva-2025-results-business-update2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BBNX/beta-bionics-first-quarter-2026-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HAE/haemonetics-fda-approval-vascade-mvp-xl2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-q4-2025-results-update2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-full-year-2025-results2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-date-change-earnings-call2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-publishes-2025-annual-report2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-annual-report-20252026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-files-annual-report-sec-20252026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALVO/alvotech-2025-financial-report-20-f2026-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-prime-designation-optic-neuritis2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NTRA/signatera-mrd-breast-cancer-surgery2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-appoints-jon-congleton-board2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-full-year-2025-results2026-03-31T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLPG/galapagos-gilead-collaboration-gamgertamig-autoimmune2026-03-31T05:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPO/onward-medical-2025-results-commercial-performance-pipeline-milestones2026-03-31T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-2025-annual-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KMDA/kamada-updates-withholding-tax-cash-dividend2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-phase-1-data-lyme-disease2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquire-apellis-immunology-portfolio2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BHC/bausch-health-first-quarter-2026-results-announcement2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-phase-2-trial-epetraborole2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SRRK/scholar-rock-resubmits-bla-apitegromab-sma2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCYX/poxel-sale-pxl770-scynexis-196-million2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q4-2025-results-phase-2-advancements2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-participation-raymond-james-2026-symposium2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/soligenix-recent-accomplishments-financial-results-20252026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBRX/immunitybio-financing-global-expansion-immunotherapy2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NGEN/nervgen-pharma-2025-financial-results-business-updates2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-nxp900-aacr-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BLTE/belite-bio-annual-report-20252026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inducement-grants-nasdaq-rule-56352026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-2025-financial-results-update2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-buntanetap-historical-review-scientist2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-first-quarter-2026-earnings-call2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-needham-virtual-healthcare-conference-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-2025-financial-results-antiviral-updates2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-chinese-patent-cancer-technology2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-arrows-clinical-trial-data-pralsetinib-nsclc2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-coolmonth-2026-offers2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-needham-healthcare-conference-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EOLS/evolus-participate-needham-virtual-healthcare-conference2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-new-us-patent-evm301-drug-candidates2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TARS/tarsus-phase-2-trial-lyme-disease-prevention2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-cruise-ship-clinic-partnership2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BON/bon-strategic-partnership-tigerbone-group-health-initiatives2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INDV/cost-impact-model-sublocade-correctional-facilities2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-launch-update2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DRTS/alpha-tau-presentation-ddw-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-financial-results-20252026-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-year-end-2025-financial-results2026-03-31T14:20:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-funding-belgium2026-03-31T13:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMCC/im-cannabis-reports-2025-results-revenue-growth2026-03-31T12:55:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquires-apellis-immunology-portfolio2026-03-31T10:59:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IINN/inspira-technologies-terminates-equity-facilities2026-03-31T12:16:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DOMH/dominari-2025-revenue-surges-487-percent2026-03-31T14:07:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-names-nick-mead-vice-president-investor-relations2026-03-31T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-expands-dublin-facility-injectable-therapies2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-emerging-growth-conference-20262026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-2025-annual-report-highlights2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-announces-share-consolidation2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-briaPro-asset-purchase-soluble-cd802026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-25th-annual-needham-conference2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KIDS/orthopediatrics-participate-needham-healthcare-conference2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-q4-full-year-2025-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-inducement-grants-nasdaq-rule-56352026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-reports-2025-financial-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-q4-2025-financial-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBRX/forte-biosciences-2025-results-update2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-manufactures-cywc628-drug-product2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GLMD/galmed-pharmaceuticals-annual-report-20252026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GEHC/ge-healthcare-rejects-mini-tender-offer-potemkin2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-q4-2025-financial-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGPU/axe-compute-reports-full-year-2025-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q4-2025-results-highlights2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-global-access-program-paf2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-early-access-program-fap2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-early-access-fap-patients2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDRX/tanner-pharma-biodexa-access-program-fap2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q4-2025-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-life-sciences-achieve-1-study-results2026-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-pricing-public-offering2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-2-million-euros-funding-belgium2026-04-01T01:27:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-enabled-medication-dispensing-europe2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GMAB/genmab-orbis-investment-shareholder-announcement2026-04-01T07:24:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-2025-financial-results-updates2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACI/albertsons-fiscal-2025-earnings-release-conference-call2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OMER/omeros-reports-fourth-quarter-year-end-2025-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-business-highlights-q4-2025-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-q4-2025-financial-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-inducement-awards-nasdaq-rule-56352026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-ceo-letter-shareholders2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LH/labcorp-first-quarter-results-april-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARQT/arcutis-management-present-needham-conference2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-q4-2025-results-business-update2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-2025-financial-results-business-update2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-inducement-grants-cfo-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-simcere-sim0505-abstract-asco-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-financial-results-corporate-update-20252026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-reports-q4-2025-financial-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-phase-3-trial-roluperidone2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-2025-financial-results-highlights2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-rinzimetostat-darolutamide-phase-3-trial2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-participate-needham-healthcare-conference2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCAB/bioatla-share-consolidation-april-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-financial-results-q4-20252026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBTX/nanobiotix-business-update-full-year-2025-results2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-manufacturing-cywc628-diabetic-foot-ulcer-trial2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-oral-showcase-respiratory-innovation-summit2026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-coolmonth-announcement-20262026-04-01T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-kristin-stafford-cfo2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-regains-nasdaq-compliance-bid-price2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-completes-dosing-phase-2-3-trial-ocu410st2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-rap-219-phase-2-data-2026-aan2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-present-additional-sol-1-data-april-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALKS/alkermes-phase-3-brilliance-studies-alixorexton-narcolepsy2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BRKR/bruker-appoints-thierry-bernard-board-directors2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NVCR/novocure-first-quarter-2026-financial-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PODD/insulet-announces-q1-2026-financial-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/USNA/usana-ceo-calls-for-daily-health-routines2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HLF/herbalife-first-quarter-2026-results-announcement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-korsana-merger-agreement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-abstract-ats-2026-conference2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-phase-2-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SCNI/scinai-reports-full-year-2025-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-patient-global-phase-3-battman-trial2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-global-clinical-trial-collaboration2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VRTX/vertex-fda-approval-alyftrek-trikafta-cf2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-q4-2025-financial-results-update2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ARDX/rajani-dinavahi-appointed-cmo-ardelyx2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SYK/stryker-announces-q1-2026-financial-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-nvns-benefits-mtbi-ptsd2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COGT/cogent-biosciences-bezuclastinib-nda-gist2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-reports-q4-2025-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-bofa-securities-conference-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-cfo-transition-announcement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JANX/janux-therapeutics-development-candidate-nomination2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/A/agilent-biotek-cytation-9-launch2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-fulcrum-vt-study-results-hrs-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PROF/incision-free-mri-guided-prostate-treatment-sir-20262026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VIVS/vivosim-announces-4-million-public-offering2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hungary-approves-ht-001-trial-expansion2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCTH/delcath-systems-sir-2026-meeting2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-breast-imaging-software-update2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-logic-gated-car-design2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-breast-cancer-vaccine-phase-22026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-domicile-change-nevada2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XAIR/beyond-air-expands-commercial-access-lungfit-ph2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-acquires-view-point-medical2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/APYX/renuvion-wins-newbeauty-award-minimally-invasive-skin-tightener2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-enabled-medication-dispensing-system-europe2026-04-01T10:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-aacr-2026-presentation2026-04-01T12:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-nasal-anti-cd3-cognition-aging2026-04-01T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ind-application-lucid-ms2026-04-01T12:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-participate-scientific-conference2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/XRTX/xortx-share-consolidation-effective-date2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-based-medication-distribution-europe2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ai-medication-dispensing-europe2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-european-medication-dispensing-ai-system2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-2-million-offering2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDLN/medline-hirc-member-choice-awards-supply-chain-achievement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RMD/resmed-third-quarter-fiscal-2026-earnings-release2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-philip-vickers-appointment2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SGHT/sight-sciences-ascrs-2026-presentations2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-proposed-public-offering-common-stock2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-participate-needham-healthcare-conference2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GILD/gilead-extends-tender-offer-acquire-arcellx2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ALGN/align-technology-q1-2026-results-announcement2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-us-patent-alpha-1062-traumatic-brain-injury2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-phase-2-alto-101-results2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-inducement-grants-nasdaq-rule-56352026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VOR/vor-bio-inducement-grant-nasdaq-rule-5635c42026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-2-million-euro-funding-belgium2026-04-01T16:26:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-foundayo-glp1-pill-weight-loss2026-04-01T16:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TLX/telix-appoints-david-gill-non-executive-director2026-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CLDX/celldex-pricing-300-million-public-offering2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-battman-phase-3-study-first-patient-enrolled2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-batman-trial-success2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-battman-trial-success-mss-pmmr-cancer2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-battman-phase-3-study-enrollment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-3-battman-study-enrollment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-3-battman-trial-bot-bal-cancer2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-patient-battman-trial2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-iii-battman-trial-recruitment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/roivant-brepocitinib-lpp-phase-2b-3-trial2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IMVT/immunovant-phase-3-batoclimab-thyroid-eye-disease-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANGO/angiodynamics-fiscal-year-2026-q3-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ROIV/priovant-brepocitinib-lpp-phase-2b-3-trial2026-04-02T09:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHVS/pharvaris-reports-q4-2025-results-business-update2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PHAR/pharming-group-2025-annual-report-filing2026-04-02T05:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/merck-phase-2b-3-trial-mk-87482026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRK/european-commission-approves-keytruda-ovarian-carcinoma2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-sales-growth-q1-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-pricing-public-offering-70-million2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-agent-797-asgct-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-patent-buntanetap-neurological-injuries2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SNGX/positive-results-hybrite-comparative-study-ctcl2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-raymond-james-symposium-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-ogm-outperforms-traditional-methods-multiple-myeloma2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-international-preparedness-conferences2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-fda-fast-track-cdi-988-norovirus2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-board-transition-mark-pavao2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-strengthens-executive-team2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-new-treatment-center-zevaskyn-new-york2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CAI/caris-chromoseq-launch-myeloid-malignancies2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-ceo-early-breast-cancer-detection2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DXCM/dexcom-first-quarter-2026-earnings-release2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ZTS/zoetis-webcast-conference-call-q1-2026-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-private-placement-bvf-partners2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-public-offering-pricing2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-regains-nasdaq-compliance2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-board-changes-david-king-nomination2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-fda-accelerated-approval-cardiamp-system2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CODX/comira-manufacturing-facility-saudia-arabia2026-04-02T14:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRE/prenetics-giannis-antetokounmpo-partnership2026-04-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-1154-postpartum-depression-results2026-04-02T13:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PSTV/plustherapeutics-highmark-coverage-cnside-assay2026-04-02T11:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ONCO/onconetix-realbotix-ai-humanoid-robot-delivery-update2026-04-02T12:30:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MRNA/pfizer-biontech-halt-covid-vaccine-trial-slow-enrollment2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDXG/mimedx-sponsor-advanced-wound-care-conferences2026-04-02T13:15:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VCEL/vericel-barda-award-nexobrid-development2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FBLG/fibrobiologics-closes-3-million-public-offering2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/HOTH/hoth-therapeutics-closing-2-million-offering2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-vascular-anomalies-issva-20262026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CADL/candel-therapeutics-inducement-grants-nasdaq-rule-5635c42026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-award-nasdaq-rule-56352026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/CNMD/conmed-announces-first-quarter-2026-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VSTM/verastem-oncology-inducement-grants-nasdaq-rule-56352026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-needham-virtual-healthcare-conference2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q1-2026-results2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-inducement-awards-nasdaq-rule-56352026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q1-2026-results-announcement2026-04-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/EVGN/evogene-nasdaq-minimum-bid-price-notification2026-04-02T21:01:00.000Zmonthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-foundayo-orforglipron-lly2026-04-02T17:03:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-kempen-life-sciences-conference2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-needham-conference-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/KALV/kalvista-inducement-grants-nasdaq-listing-rule-56352026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MLAB/mesa-labs-quarterly-dividend-april-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-inducement-grants-april-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/REGN/trinetx-regeneron-collaboration-health-records-research2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-nasdaq-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-award-april-20262026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NERV/minerva-leadership-transition-jim-oconnor2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-zovegalisib-vascular-anomalies-presentation2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RXST/rxsight-participate-needham-healthcare-conference2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-nyse-american-compliance-plan2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDWD/medi-wound-barda-contract-vericel-nexobrid2026-04-03T04:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-phase-ii-study-agent-797-aacr-20262026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-phase-ii-study-bot-bal-aacr-20262026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-inducement-grant-karen-basbaum2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/AVTR/avantor-first-quarter-2026-earnings-report2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/GSK/trump-tariff-drugmakers-impact-gsk2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BCRX/biocryst-inducement-grants-nasdaq-rule-5635c42026-04-03T11:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-board-changes2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-dnl593-grn-ftd2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-nasdaq-notifications-minimum-bid-price2026-04-03T15:02:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-inducement-grants-nasdaq-ikt2026-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/IBO/impact-biomedical-going-concern-audit-opinion-20252026-04-03T17:52:00.000Zmonthly0.5